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Abstract 
 
This thesis principally focuses on the development of a novel series of asymmetric iminium ion 
organocatalysts, based on the pyrazolidin-3-one template. Also described is the development of 
a novel asymmetric Steglich rearrangement with pyrazolyl carbonates. 
 
The pyrazolidin-3-one framework has been identified as a potentially effective new scaffold for 
iminium ion organocatalysis. The development of a synthetic route to racemic pyrazolidinone 
catalysts is outlined which allows for systematic variation of key substituents. The influence of 
these groups on reactivity and diastereoselectivity in the Diels-Alder reaction of 
(E)-cinnamaldehyde and cyclopentadiene is described and an optimised catalyst identified. 
A method for the resolution of a simple pyrazolidinone precursor was then investigated in order 
to access an enantioenriched catalyst for asymmetric reaction. Resolution was achieved by 
amide coupling to a chiral acid, chromatography to separate the subsequent diastereoisomers 
and acid cleavage. The initial enantioenriched catalyst gave modest enantioselectivity in the 
Diels-Alder reaction.  
The diastereoisomeric intermediates in the resolution process were themselves identified as 
active and enantioselective iminium ion organocatalysts. In general, one diastereoisomer was 
superior in terms of enantioselectivity, indicating a ‘matching’ of the two catalyst stereocentres. 
An optimised asymmetric diastereoisomeric catalyst derived from a trifluoromethyl-substituted 
pyrazolidinone and Cbz-protected proline gave good diastereo- and enantioselectivities in 
Diels-Alder reactions with a range of aryl aldehydes. Mechanistic investigations with this 
compound then found that fast ring-opening occurs under catalysis conditions creating a new 
chiral hydrazide which was catalytically active at catalyst loadings as low as 1 mol%.  
Also explored was the Steglich rearrangement of structurally related pyrazolyl carbonates. 
Rearrangement was observed with a range of Lewis base organocatalysts, with N-heterocyclic 
carbenes (NHCs) generally superior. Chiral NHCs were also effective in an asymmetric 
reaction, particularly with methyl substituted pyrazolyl carbonates. 
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Chapter 1: Introduction 
 
This chapter outlines the rationale and literature precedent behind the development of a new 
series of iminium ion organocatalysts based on a pyrazolidin-3-one core. The concept of 
organocatalysis and its subfields are discussed, with particular emphasis on enamine and 
iminium ion catalysis. The Diels-Alder reaction, commonly employed as a model reaction for 
novel iminium catalysed processes, is introduced and a selection of modern activation methods 
outlined. Pyrazolidin-3-ones and some recent applications of such compounds as substrates are 
then discussed followed by a rationale of their potential as catalysts, supported by related 
literature examples. 
 
1.1 Organocatalysis 
The area of organocatalysis continues to draw great interest from the synthetic research 
community since the term was popularised by MacMillan in 2000,
1
 although many reports 
concerning the use of organic molecules as catalysts pre-date this. Organocatalysis can be 
defined as the use of substoichiometric amounts of an organic molecule, that does not contain a 
metal atom, in order to accelerate chemical reactions.
2
 Enzymes, many of which are composed 
entirely of amino acid chains, are excellent examples of such an approach. Such molecules are 
capable of catalysing specific reactions with high yields and enantioselectivity.
3
 The absence of 
any metal atoms in organocatalysis may provide several advantages over conventional catalytic 
methods. Many metals useful for catalysis, such as palladium, have a low natural abundance 
and are therefore costly to obtain. These metals are often toxic and their inclusion in a catalyst 
leads to a complex with high molecular weight. In addition, organocatalytic reactions are 
generally tolerant of air and water and easy to perform.
4
 
The term organocatalysis covers a large spectrum of different reactions and this area has been 
extensively reviewed.
3,4,5 
Methods of organocatalytic activation can be broadly classified as 
Brønsted acid, Brønsted base, Lewis acid and Lewis base catalysis (Figure 1.1).
3
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Figure 1.1: Simplified organocatalytic cycles. 
This review will be primarily focused on Lewis base catalysis, in particular iminium ion 
activation. A brief overview of the other major sub-divisions of organocatalysis are outlined in 
the following sections. 
 
1.1.1 Brønsted acid catalysis 
Brønsted acid catalysis simplistically involves initial proton transfer to an acceptor molecule 
that is then activated to further chemistry.
6
 The majority of Brønsted acid catalysts contain 
either a urea, thiourea or phosphoric acid moiety.
7
 More recent studies have also found that 
carboxylic acids can be employed, as in the report of Maruoka et al. on the use of di-acid 3 for 
the addition of diazoacetates to Boc-protected imines (Figure 1.2).
8
 Proton transfer to imine 1 
accelerates addition of the nucleophile with the chiral anion controlling the face of attack to 
give products in high ee (95 % for the given example). Subsequent publications have 
significantly extended this methodology through the use of in situ generated azomethine 
imines.
9
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Figure 1.2: Brønsted acid catalysed addition of diazoacetate 2 to imine 1  
(R = 2,6-dimethyl, 4-tert-butylphenyl) 
 
1.1.2 Brønsted base catalysis 
One of the first examples of chiral organic Brønsted base catalysis, where the first step is 
activation of the substrate by deprotonation, was described by Wynberg and Helder in 1975 
with the conjugate addition of nitrosulfones to !,"-unsaturated ketones using quinine.10 Recent 
developments have frequently focused on the use of bifunctional catalysts that activate both 
nucleophiles and electrophiles to enhance and control bond-forming processes.
11
 A recent 
example comes from Connon and co-workers who described the conjugate addition of 
malonates to nitroalkenes catalysed by a cinchona alkaloid modified to include a thiourea unit 
(Figure 1.3).
12
 The quinuclidine tertiary amine acts as the Brønsted base to activate dimethyl 
malonate 6 and the thiourea activates the nitroalkene 5 by hydrogen bonding. 8 is derived from 
the C(9)-epimer of the naturally occurring alkaloid but performed substantially better than the 
parent alkaloid and gave addition products with excellent enantioselectivities. The activity of 
the catalyst was such that loading could be taken down to as little as 0.5 mol% in the example in 
Figure 1.3. 
5
6
7
N
H
NH
N
O
NHS
CF3F3C
NO2S
O
O
O
O
NO2S
O
O
O
O
8
9
N
H
H
N
NS
N
O
O
H
H
O
O
O
O
S8 (0.5 mol%)
toluene
(92 %, 94 % ee)
0 °C
 
Figure 1.3: Addition of 5 to 6 catalysed by 8 
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1.1.3 Lewis acid catalysis 
Lewis acid catalysis proceeds by the activation of a substrate by electron donation to a 
catalyst.
13
 An organocatalytic example was reported by Ko!ovsk" et al. (Figure 1.4).
14
 Chloride 
displacement from allylsilane 10 by N-oxide catalyst 11 creates a Lewis acidic intermediate that 
activates and orientates benzaldehyde 9 cis to the allyl unit, as shown. This cyclic transition 
state then provides (S)-allyl alcohol 12 in high ee. Inclusion of tetrabutylammonium chloride 
increased both reaction rate and enantioselectivity.  
Ph H
O
9 10
Cl3Si
N N
O
11
DCM, -60 °C
(7 mol%)
Bu4NI (1 eq)
(i-Pr)2NEt (1 eq)
(78 %, 90 % ee)
Ph
OH
12
Si O
Ph
H
Cl
Cl
N
N O
Cl
 
Figure 1.4: Sakuri-Hosomi-type allylation catalysed by chiral N-oxide 11 
 
1.1.4 Lewis base catalysis 
Lewis base catalysis represents the largest of the subfields within organocatalysis.
15
 One of the 
key reasons for this is the wide range of different reactive intermediates which fall into this 
category, these include N-heterocyclic carbene, ammonium enolate, acyl-ammonium and sulfur 
ylide catalysis.
3
 However, this chapter focuses on the two related subfields of enamine and 
iminium ion catalysis, which utilise amines to promote reactivity. These two areas share a 
common substrate activation pathway, as shown in Figure 1.5. Condensation of a secondary 
amine with a carbonyl group leads to an iminium ion. If this species contains a suitable 
enolisable proton on the !-carbon, deprotonation can generate an enamine. The formation of the 
enamine significantly alters the reactivity in relation to the starting carbonyl, making the 
compound nucleophilic at the !-carbon. 
H R
O
H R
N
N
H
H
N
if R =
-H2O
enamineiminium
-H
+H H
 
Figure 1.5: Reactive species of iminium ion and enamine catalysis 
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1.1.4.1 Enamine catalysis 
An early example of enamine catalysis is the Hajos-Parrish-Eder-Sauer-Wiechert reaction, 
reported in the early 1970’s.
16 
This intramolecular aldol reaction yields bicyclic alcohol 18, a 
useful intermediate in steroid synthesis, from triketone 13 (Figure 1.6). The reaction is catalysed 
by the amino acid (S)-proline 14 in high yield and enantioselectivity. It is proposed that 
condensation of (S)-proline 14 with triketone 13 leads to enamine intermediate 15. The high 
stereocontrol observed in this reaction can be rationalised by it proceeding through a highly 
ordered six-membered ring transition state 16.
17
 The hydrogen-bond interaction between the 
ketone and the stereodirecting carboxylic acid leads to preferential formation of one enantiomer 
of the product 18, after hydrolysis of iminium ion intermediate 17. 
O O
O
N
H
CO2H
(20 mol%)
O
OH
O
13
14
18
16
(99 %, 93 % ee)
O
O
N
O
HO
DMF
N O
O
15
CO2H
17
O
OH
N
O
O
-H2O
+H2O
tautomerisation
 
Figure 1.6: Hajos-Parrish-Eder-Sauer-Wiechert reaction 
In one of the first examples of ‘modern’ organocatalysis, the intermolecular variant of this 
reaction, between acetone 19 and a small range of aldehydes, was reported.
18,19
 (S)-Proline 14 is 
again used as the catalyst (Table 1.1). Competing side reactions, such as self-aldolisation, are 
suppressed by the use of an excess of acetone 19 (20 % by volume). Notably, yield and 
enantioselectivities are heavily dependent on the nature of the aldehyde substrate. For example, 
use of benzaldehyde gave aldol product in 62 % yield with a 72 % ee (entry 1). However, 
!-branched aliphatic aldehydes (entries 2 and 3) each gave their respective aldol products in 
greater than 80 % yield and greater than 95 % ee. The high enantioselectivity observed in these 
reactions has been rationalised by the reaction proceeding via the cyclic transition state shown 
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6 
in Table 1.1. In this model, preferential approach of the aldehyde to the enamine is controlled 
by hydrogen-bonding between the aldehyde carbonyl and the carboxylic acid of the enamine. 
This mode of activation has been widely expanded to other processes including Mannich
20
 and 
amination reactions.
21
 
O
N
H
CO2H
(10-30 mol%)
14
H R
O
R
O OH
19
O
H
N
O
H
R
H ODMSO
or DMF
 
Entry R Yield (%) % ee 
1 
 
62 72 
2 
 
97 96 
3 
 
85 >99 
Table 1.1: Aldol reaction catalysed by (S)-proline 14 
 
1.1.4.2 Iminium ion catalysis 
Enamines are formed from deprotonation of an intermediate iminium ion species but iminium 
ions themselves can also be used as reactive intermediates. Formation of an iminium ion from a 
carbonyl group generates a molecule with a lower LUMO energy, relative to the starting 
carbonyl. This increases the electrophilic nature of the carbonyl group and has an orthogonal 
influence to enamine formation, which converts the carbonyl into a nucleophile. Iminium ion 
catalysis has proven to be one of the most fruitful areas of organocatalysis research and has 
been applied to a range of reactions such as Friedel-Crafts alkylation and Michael reactions.
22
 
For example, conjugate addition of methyl or benzyl malonates to "-aryl, !,"-unsaturated 
aldehydes can be catalysed by (S)-proline derived amine 20 (Table 1.2).
23
 In this protocol, the 
reaction of (E)-cinnamaldehyde with dimethyl malonate (entry 1) gives an 85 % yield of 
Michael addition product with high enantioselectivity (94 % ee). A range of "-aryl, 
!,"-unsaturated aldehydes are tolerated, with reactions normally proceeding with good yield 
and high enantioselectivity. 
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H
O
R1
CO2R
2R2O2C
H
O
R1
CO2R
2
CO2R
2
N
H OTMS
Ar
20
(10 mol%)
EtOH
Ar
 
Entry R1 R2 Yield (%) % ee 
1 
 
Me 85 94 
2 O
H  
Bn 95 86 
3 
S  
Bn 83 92 
Table 1.2: Organocatalytic conjugate addition of malonates to !,"-unsaturated aldehydes (Ar = 3,5-(CF3)2-C6H4) 
It is believed that reaction proceeds through the iminium ion intermediate shown in 
Figure 1.7.
24
 Minimisation of steric interactions between the stereodirecting group and the 
olefinic substituent leads to preferential formation of the (E)-isomer of iminium ion B. 
Preferential addition of the malonate anti to the stereodirecting group leads to the configuration 
observed in the products. 
E-isomer B
favoured
Z-isomer A
disfavoured B only
N OTMS
ArAr
R1
H
substrate approach
N OTMS
ArAr
H
R1
H H
H
O
R1 CO2R
2R2O2C
H
O
R1
CO2R
2
CO2R
2
N
H OTMS
ArAr
-H2O, +H
+H2O, -H
disfavoured
steric interaction
20
 
Figure 1.7: Potential geometries of iminium ion intermediates derived from catalyst 20 (Ar = 3,5-(CF3)2-C6H4) 
 
1.2 The Diels-Alder cycloaddition 
The Diels-Alder reaction is a [4+2] cycloaddition of a diene and a dienophile wherein two new 
carbon-carbon bonds are formed in a concerted manner.
25,26
 The reaction has found great 
synthetic utility because it enables rapid access to highly useful cyclohexene-type structures. 
Furthermore, it can potentially lead to the formation of up to four new stereocentres in a 
controlled manner.
22
 The reaction produces two diastereoisomeric products that can be 
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classified as either exo or endo. There has been a great deal of research into methods to achieve 
rate acceleration and induce asymmetry in such reactions, such as molecular recognition,
27
 
Lewis acid catalysis
25,28
 and a number of organocatalytic approaches.
2,3,22
 Examples of each of 
these methods are described in the following sections. 
 
1.2.1 Molecular recognition 
In an example of molecular recognition, the reaction between furan 21 and maleimide 22a 
resulted in only 4 % conversion to product in 5 hours (Figure 1.8).
29
 The product was produced 
as a mixture of diastereoisomers, exo- and endo-23a, in a ratio of 2:1, respectively. A 
significant rate acceleration was observed in the reaction of 21 with 22b, where the ester group 
has been replaced with a carboxylic acid, with 80 % conversion in the same time. Additionally, 
only the exo-adduct exo-23b was observed in this case.  
N N
H
O O
N N
H
O
N
RO
O
O
O
O H
H
N
O
OR
O
O
CHCl3
N N
H
O
N
RO
O
O
O
O H
H
21
22
a R = Me
b R = H exo-23 endo-23  
Figure 1.8: Recognition mediated Diels-Alder cycloaddition 
Furan 21 and maleimide 22b have been designed with complementary recognition sites on their 
respective side chains (Figure 1.9). These hydrogen-bond interactions bring the reactants 
together and orientates them for reaction thereby providing a rate acceleration relative to the 
unmediated model system of 21 and 22a. 
N N
O
OO
21 (diene)
22b (dienophile)
H
H
N
O
O
O
 
Figure 1.9: Molecular recognition of furan 21 maleimide 22b 
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1.2.2 Lewis acid catalysis 
A range of Lewis acids, such as aluminium trichloride, are capable of catalysing Diels-Alder 
cycloadditions (Figure 1.10).
25
 In the reaction of anthracene 25 with dimethyl fumarate 24, the 
uncatalysed reaction requires a temperature of 101 ºC for 3 days to give full conversion to 26.
30
 
The introduction of aluminium trichloride gives complete conversion in 2 h at room 
temperature. The coordination of the Lewis acid to the carbonyl of the electron-deficient 
dienophile 24 lowers the LUMO energy relative to the uncoordinated olefin, bringing it closer 
to the HOMO energy of the electron-rich anthracene 25. By reducing this energy gap, addition 
is accelerated, leading to an increase in reaction rate.  
MeO
O
CO2Me
MeO2C
AlCl3
rt, 2 h
25
24 26
OMe
O
AlCl3
MeO
O
OMe
O
 
Figure 1.10: Lewis acid catalysed Diels-Alder cycloaddition of anthracene 25 with dimethyl fumarate 24 
Chiral Lewis acids, such as 29, have been developed that promote enantioselective Diels-Alder 
cycloadditions (Figure 1.11).
31
 In the example below, the chiral diazaaluminolidine 29 catalyses 
the addition of diene 27 to 28 to give only the endo diastereoisomer of acryloyl oxazolidinone 
30 in 93 % yield and with 96 % ee. It has been noted as a general feature of Lewis acid-
catalysed Diels-Alder reactions that, of the two possible diastereoisomers, the endo 
diastereoisomer is usually favoured.
32
 
BnO O
N
O
O
N
Al
N
Ph Ph
29
(10 mol%)
CH2Cl2, -78 
oC
NO
O
O
BnO
30
(93 %, 96 % ee)
2827
Tf Tf
 
Figure 1.11: Diels-Alder reaction catalysed by chiral diazaaluminolidine 29 
 
1.2.3 Organocatalysis 
Organic Brønsted acids can achieve the same LUMO-lowering effects as Lewis acid catalysis 
via hydrogen-bonding interactions with the dienophile and enantioselective variations utilising 
this activation mode have been developed.
6,33
 An example is shown in Scheme 1.12 where 
Chapter 1: Introduction 
 
 
 
10 
TADDOL derivative 33 catalyses the reaction of amino siloxydiene 31 with methacrylaldehyde 
32 to give Diels-Alder adduct 34, which was not isolated (Figure 1.12).
34
 Instead, reduction and 
desilylation gave the cyclohexenone 35 in 91 % ee and 83 % total yield over the 3 steps. 
TBSO
N O
H 20 mol%
toluene, -80 oC
TBSO
N
O
i) LiAlH4, Et2O,
   -78 oC to rt
O
OH
O
O
OH
OH
Ar Ar
Ar Ar
33
353431 32
ii) HF-CH3CN,
    0 oC to rt
(83 %, 91 % ee)  
Figure 1.12: Diels-Alder reaction catalyst by TADDOL derivative 33 (Ar = 1-naphtyl) 
 
1.2.3.1 MacMillans imidazolidinones 
In 2000, MacMillan et al. postulated that a similar LUMO-lowering effect could be achieved 
using iminium ion catalysis.
1
 Computational studies led to the design of imidazolidinone 
catalyst 36, which successfully catalysed the cycloaddition of a small range of both aliphatic 
(entry 1) and aryl (entries 2 and 3) !,"-unsaturated aldehydes with cyclopentadiene (Table 1.3). 
Reactions proceeded with high yield and excellent levels of enantioselectivity, though little 
diastereoselectivity for the exo or endo diastereoisomers. For example, the reaction of 
cyclopentadiene with (E)-cinnamaldehyde (entry 2) showed only a small preference for the exo 
diastereoisomer (exo:endo 57:43), but gave the exo product in 93 % ee. The reaction of 
acrylaldehdye and crotonaldehyde with a small range of dienes was also described. 
Interestingly, the addition of 5 % water (by volume) was found to increase both reaction rate 
and enantioselectivity.
22
 Later investigations into this effect by Tomkinson and co-workers 
found the addition of water increased the concentration of free aldehyde over its dimethyl 
acetal, increasing reaction rate.
35
 The rate of catalyst hydrolysis from the products was also 
increased thereby reducing retro Diels-Alder reactions that led to lower enantioselectivity. 
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R
N
H
N
O
Ph
O
H
36
CHO
R
+
MeOH-H2O (19:1)
R
CHO
HCl
(5 mol%)
exo-(2S) endo-(2S)
S
S
 
Entry R Yield (%) exo: endo exo % ee  
1 
 
81 50:50 84 
2 
 
99 57:43 93 
3 
O  
85 50:50 91 
Table 1.3: Diels-Alder reaction catalysed by imidazolidinone 36 
In order to achieve high enantioselectivity in this process, both the iminium ion geometry and 
the face of substrate attack must be controlled. It has been established that the preferred 
conformation of the reactive iminium ion species is (E)-isomer B as shown in Figure 
1.14.
1,36,37,38 
The gem-dimethyl substitution forces the iminium ion to adopt a geometry such 
that steric interactions with these methyl groups are minimised i.e. the (Z)-isomer A is 
disfavoured and (E)-isomer B favoured. The stereodirecting benzyl group then directs substrate 
approach to the iminium ion. Gas-phase DFT calculations
36
 and analysis of the iminium ion in 
both the solid and solution phase
37
 have shown the preferred conformation of the molecule 
places the benzyl substituent over the imidazolidinone ring, blocking the upper face as drawn. 
Preferential diene attack anti to the stereodirecting group leads to the experimentally observed 
Diels-Alder adducts exo-(1S,2S,3S,4R)-38 and endo-(1R,2S,3S,4S)-38.
39
 
Ph
O
H
36 substrate approach
E-isomer B
favoured
Z-isomer A
disfavoured
CHO
Ph
+
Ph
CHO
B only
-H2O, +H
+H2O, -H
OR
disfavoured
steric interaction
N
H
N
O
Ph
exo-(1S,2S,3S,4R)-38
endo-(1R,2S,3S,4S)-38
N
N
Ph H
E
OPh
N
N
H
OPh
Z
Ph
H
S
S
37
 
Figure 1.14: Reaction pathway for MacMillan's first generation imidazolidinone 36 
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Subsequent work by MacMillan et al. showed that imidazolidinone 36 could act as an iminium 
ion organocatalyst for several other reactions such as nitrone addition
40
 and the Friedel-Crafts 
alkylation of pyrroles.
41
 The synthetic utility of this methodology has been shown by its 
application to the synthesis of natural products such as (+)-Hapalindole Q
42
 and Eunicellin 
(Figure 1.15).
43
 
(+)-Hapalindole Q
NCS
NH
O
OAc
AcO
H H
AcO
AcO
Eunicellin  
Figure 1.15: Natural products synthesised using imidiazoldinone 36 catalysis 
 
1.2.3.2 Other catalysts  
Since the first publications using imidazolidinones as organocatalysts, a number of compounds 
with markedly different structures have been applied to the iminium-ion promoted Diels-Alder 
reaction.
44
 Catalyst 39 (the perchlorate salt of compound 20, described in Section 1.1.4) was 
initially successfully employed in toluene
45
 but neat reaction in the presence of water was found 
to be superior in terms of both rate and enantioselectivity (selected examples in Table 1.4).
46
 
The cycloaddition of cyclopentadiene and a range of !,"-unsaturated aldehydes proceeded with 
excellent enantioselectivity and high exo diastereoselectivity (97 % exo ee, 80:20 exo:endo with 
cinnamaldehyde, entry 1). Selected reactions of an aldoester and acrolein with different dienes 
were also reported (entries 2 and 3). Jørgensen et al.
47
 and others
44
 have extended the scope of 
similar diarylprolinol silyl ether catalysts to hetero-Diels-Alder reactions, although these 
operate via enamine intermediates. 
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R
O
H
39
water, 4 °C
(5 mol%)
N
H OTMS
ArAr
Diels-Alder 
products
HClO4
diene
 
Entry Diene R Product Yield (%) % ee 
1a S
 
Ph CHO
Ph
(exo:endo 80:20)
S
 
93 
(exo: endo) 
(80:20) 
84 (exo) 
2 S
 
CO2Et 
CHO
CO2Et
S
 
89 93 
3b S
 
H R
CHO
 
72 91 
Table 1.4: exo-Selective Diels-Alder reaction catalysed by 39 (Ar = 3,5-(CF3)2-C6H4) 
a) Reaction at RT; b) 10 mol% catalyst used 
A five-membered ring is not a prerequisite for catalytic activity, however, as exemplified by 
acyclic catalyst 40 (Figure 1.16).
48
 Maruoka et al. showed that a binaphthyl amine could be 
used to perform an iminium catalysed reaction with high enantioselectivity and excellent exo 
diastereoselectivity (93:7 exo:endo for the reaction of (E)-cinnamaldehyde 37 and 
cyclopentadiene). The main limitations of this methodology were the need for extended reaction 
times and a lack of reactivity with dienes other than cyclopentadiene (both cyclohexadiene and 
1,3-pentadiene gave only traces of cycloadduct product).  
Ph
O
H
40
PhCF3, -20 °C, 120 h
(12 mol%)
exo-(2R)-38 endo-(2R)-38
p-TsOH (20 mol%)
(80 %)
(93:7 exo:endo) (92 % ee) (91 % ee)
37
NHMe
NHMe
4-t-Bu-C6H4
4-t-Bu-C6H4
Ph
CHO
+
CHO
Ph
R
R
 
Figure 1.16: exo-Selective Diels-Alder reaction catalysed by 40 
Recently, the first examples of enantioselective cycloadditions catalysed by primary amines 
have been reported.
49
 Catalyst 42, derived from phenylalanine, was developed specifically for 
challenging !-acyloxyacroleins, such as 41 (Figure 1.17).50 Such aldehydes are inactive with 
MacMillan’s secondary amine imidazolidinone catalysts.
51
 
Chapter 1: Introduction 
 
 
 
14 
N
N
H
NH2
Ph
42
EtNO2, rt
(10 mol%)
C6F5SO3H (27.5 mol%)
(quant.)
(90 % ee)
41
O
H(4-MeOC6H4)O
O
CHO
O(4-MeOC6H4)
O
43
 
Figure 1.17: Diels-Alder reaction catalysed by primary amine 42  
The observed enantioselectivity in this process was attributed to the creation of a pseudo 
5-membered transition state by hydrogen bonding of the iminium ion to other amine groups in 
the catalyst (Figure 1.18). This in situ ordering of the catalyst structure helps to favour the 
(Z)-iminium geometry, with the diene substrate approaching from the opposite face to the 
adjacent benzyl stereodirecting group. 
N
Y
H
Bn
N
H
X N
X
H
N
H
Bn
N
H
X N
X
H
Y
E-isomer B
disfavoured
Z-isomer A
favoured
disfavoured
steric interaction  
Figure 1.18: Origin of stereoselectivity with catalyst 42 
 
1.2.3.3 Mechanistic studies 
Although great strides have been made in the development of new catalysts, the field of 
iminium ion organocatalysis is still at an early stage in terms of understanding the mechanistic 
intricacies of different catalysts. This has begun to be addressed by the use of computer 
modelling and isolation of reactive intermediates.
36,37
 It was originally postulated by MacMillan 
et al. that both the iminium ion formation step and the carbon-carbon bond forming step 
influence the overall rate of reaction with imidazolidinone catalyst 36 (Section 1.2.3.1).
1
 
However, a kinetic study of the iminium ion catalysed Diels-Alder reaction of 
(E)-cinnamaldehyde 37 and cyclopentadiene was later reported by Tomkinson and 
co-workers.
52
 Trifluoromethyl pyrrolidine 44 was identified as an effective catalyst (10 mol%, 
93 % conv. after 6 h, exo:endo 68:32) which allowed the reaction to be followed by a 
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combination of 
1
H and 
19
F NMR spectroscopy The hexafluorophosphate salt of pyrrolidine 44 
provided an isolatable (E)-iminium ion intermediate 45 that could be analysed by X-ray 
crystallography and allowed the rates of both iminium ion formation and the cycloaddition step 
to be studied independently (Figure 1.19).  
The study showed that, for this reaction, the rate-determining step was the cycloaddition step 
which was approximately six times slower than iminium ion formation. It was found that the 
key factor was the Arrhenius parameter A, which is ten orders of magnitude smaller for step B, 
and this was attributed to the stricter steric requirements necessary for cycloaddition over 
iminium ion formation. In addition, the presence of the electron withdrawing trifluoromethyl 
moiety adjacent to the reactive centre served to lower the LUMO energy of the iminium ion 
intermediate, leading to acceleration of the kinetically significant cycloaddition step. 
44
Ph
O
H
37
exo-46
+
-H2O, +H
45
Ph
N
H
CF3
Ph
H
N CF3
Ph
N H
CF3
endo-46
+H2O, -Hstep A step B
exo-38
+
Ph
CHO
Ph
CHO
endo-38
PF6
N
H
F3C
HPF6
 
Reaction 
Step 
k293 
(x10
-3 
dm
3
 mol
-1
) 
Ea /kJ mol
-1
 A /s
-1
 
A 2.65 100 5.89 x 10
14
 
B 0.374 45.1 4.14 x 10
4
 
Figure 1.19: Kinetic parameters for Diels-Alder reaction catalysed by pyrrolidine 44  
The Diels-Alder cycloaddition remains one of the most powerful methods for the synthesis of 
complex ring structures. As a result of its synthetic utility, it is unsurprising that the Diels-Alder 
reaction has become something of a benchmark transformation by which to evaluate new 
asymmetric organic catalysts.
22 
The potential for iminium ion organocatalysts with a range of 
structures to effectively accelerate reactions and control stereoselectivity is also now well 
established.  
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1.3 Pyrazolidin-3-ones 
This report focuses on the pyrazolidin-3-one framework and its use as both a catalyst and a 
substrate in organocatalysed reactions. The following section outlines selected recent 
applications of pyrazolidinones as reaction substrates. 
 
1.3.1 Pyrazolidin-3-ones as substrates  
Pyrazolidin-3-ones are 5-membered ring heterocycles containing two adjacent nitrogen atoms 
and a carbonyl at the three position. Two examples of commercially used pyrazolidin-3-ones 
are Phenidone, used as a photographic developer, and Edaravone which is sold as a 
neuroprotective agent (Figure 1.20).
53
  
Edaravone
N
NH
O
Ph
N
N
O
Ph
Phenidone  
Figure 1.20: Commercially used pyrazolidino-3-ones Phenidone and Edaravone 
Azomethine imines are 1,3-dipolar compounds readily derived from pyrazolidin-3-ones by 
condensation with an aldehyde.
54
 They have recently found substantial application in catalysed 
[3+2] cycloadditions with a range of suitable partners.
55
 A recently reported example also 
showed their potential utility as electrophiles, in this case under attack by 
trimethyl(trifluoromethyl)silane (Figure 1.21).
56
 Reaction proceeds under phase transfer 
conditions, using chiral alkaloid catalyst 50. The subsequent products can be readily converted 
to valuable trifluoromethylated amines, such as 49, by treatment with Raney nickel and acid. 
toluene/CH2Cl2
50 (10 mol%)
(94 %)
Me3SiCF3, KOH
(90 % ee)
N
N
O
Ph
N
NH
O
PhF3C
48
Br
50
NH
OH
N
CF3
CF3
i) Raney-Ni, 180 °C 
(73 %)
(98 %)
ii) HCl (conc.), reflux
NH2
PhF3C
(90 % ee)
49
-50 °C
47
 
Figure 1.21: Phase transfer catalysis using 50 and conversion of products to trifluoromethylated amine 49 
Sibi and co-workers have reported the use of pyrazolidinone crotonate dipolarophiles in 
enantioselective Lewis acid catalysed Diels-Alder reactions (Figure 1.22).
57
 The pyrazolidinone 
acts as a template for the active copper/ligand complex and this leads to a locking in the 
configuration of the previously configurationally labile N(1)-benzyl substrate.  
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Favoured
N
N
R
O O
M
*L L*
N
N
R
O
O
N
N
R
O O
M
*L L*
ML*2
pyrazolidinone 
crotonate  
Figure 1.22: Chiral relay from chiral ligands to N(1) pyrazolidinone substituent 
This newly created stereocentre then acts in concert with the chiral ligands to direct the 
approach of a diene to the dienophile. Catalysis results for a series of templates with copper 
triflate and bisoxazoline 51 are outlined in Table 1.5. For oxazolidinone 52 (entry 1) and an 
N(1)-unsubstituted pyrazolidinone (entry 2), enantioselectivity is poor due to the absence of 
chiral relay. However, enantioselectivity improves markedly when an N(1)-benzyl substituent is 
employed (entry 3) and increases with increasing steric bulk in the chiral relay group (entry 4). 
The same principle has subsequently been applied to cycloadditions of pyrazolidinone 
crotonates with nitrones, nitrile oxides and conjugate additions with hydroxylamines and 
radicals.
58
 
O
Z
51
DCM
(16 mol%)
N
N
R
exo-(2R) endo-(2R)
+
O Z
O
Z
N
OO
N
Cu(OTf)2 (15 mol%)
Z =
O
O
N
O
OR
52  
Entry Z exo:endo endo % ee 
1 52 13:87 23 
2 R = H 5:95 8 
3 R = Ph  7:93 71 
4 
R =
 
10:90 92 
Table 1.5: Diels-Alder cycloaddition using pyrazolidinone templates 
The same research group were then able to modify this methodology to obtain enantioenriched 
pyrazolidinones by kinetic resolution (Figure 1.23). The copper/bisoxazoline 54 complex 
showed excellent selectively for the (R)-enantiomer of pyrazolidinone crotonate 53 which 
underwent Diels-Alder reaction thereby leaving (S)-55 with 98 % ee, eventually isolated in 
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40 % yield. The Diels-Alder adduct endo-(2R)-56 could be cleaved with lithium 
p-methoxybenzyloxide to access the (R)-enantiomer in 70 % ee.
59
 
54
DCM
(5.5 mol%)
(40 %)
Cu(OTf)2 (5 mol%)
(98 % ee)
N
OO
N
N
N
O
O
N
N
O
O
53
+
O N
N
Ph
O
PhPh
(56 % conv.)
(S)-55 endo-(2R)-56
(S = 34)
 
Figure 1.23: Kinetic resolution of 53 
 
1.3.2 Pyrazolidin-3-ones as potential iminium ion organocatalysts  
While extensive progress has been made in the development of highly stereoselective iminium-
ion promoted reactions, there is significant potential for improvement in many areas, notably in 
reaction diastereoselectivity, lowering catalyst loading and reducing reaction time. In addition, 
new catalysts may help to improve our understanding of iminium ion reaction mechanisms. 
Hence, there remains a need for the development of new selective and efficient organocatalytic 
methods, in order to build on those already established. 
This report focuses on the pyrazolidin-3-one framework (Figure 1.24) as this possesses the 
potential to act as an effective iminium ion organocatalyst. It shares a number of similarities to 
MacMillan’s imidazolidinone catalyst 36, also shown in Figure 1.24; both frameworks possess 
a nitrogen atom with a lone pair capable of acting as a nucleophile, essential for formation of 
the reactive iminium ion. In both cases, this nitrogen is held within a constrained 
five-membered ring that can be adorned with stereodirecting groups. While imidazolidinone 36 
contains a gem-dimethyl moiety at the C(2) position, this structural motif could be included in 
the pyrazolidinone backbone at C(4), fixing the orientation of any adjacent stereodirecting 
groups present.
60
 Furthermore, the introduction of this gem-dimethyl group blocks any possible 
enolisation at the C(4) position of the catalyst. 
N
H
N
O
R
1
1
5
4
3
2 1
5
4
3
2
Imidazolidinone 36
N
H
N
O
Ph
R2
Pyrazolidin-3-one  
Figure 1.24: Pyrazolidin-3-one framework and imidazolidinone 36 
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Despite their structural similarity, the pyrazolidinone scaffold contains several features that 
differentiate it from imidazolidinone 36 and may potentially lead to enhanced rate acceleration 
and possibly high levels of enantioselectivity in catalysis. There are two sites available for 
substitution, namely at N(2) and C(5). It was envisaged that C(5) substitution would primarily 
be useful for introducing a stereodirecting group. Such a group could control the face of attack 
on an iminium ion intermediate, in analogy to the benzyl group at C(5) of imidazolidinone 36. 
However, the N(2) position, adjacent to the nucleophilic centre, may also be derivatised. It is 
anticipated that substitution here would give a defined transoid (E)-iminium geometry by 
disfavouring the (Z)-iminium (A and B in Figure 1.25). The nature of the substituent could also 
be used to control the steric and electronic environment of the adjacent nucleophilic centre. 
Using these principles, it should be possible to fine tune catalytic properties by variation of the 
substituents, allowing scope for the development of a highly efficient and stereoselective 
organocatalyst. Also possible are the two cisoid iminium conformations C and D however these 
are likely to be sterically disfavoured compared to the transoid conformations (related catalysts 
have been found to be exclusively in the transoid conformation).
37,52
  
N
N
O
R
2R1
N
N
O
R2R
1
Ph
H
Ph
H
HH
disfavoured
steric interaction
E Z N
N
O
R
2
R
1
N
N
O
R
2
R1
H H
E Z
Ph Ph
H H
Transoid Cisoid
A B C D
 
Figure 1.25: Proposed pyrazolidinone derived iminium ions  
At the outset of research, the rate-determining step for iminium ion Diels-Alder cycloadditions 
had not been established. MacMillan had postulated that both iminium ion formation and the 
cycloaddition step were important.
22
 Hence, a further feature of the pyrazolidinone framework, 
which made it attractive as an organocatalyst was the potential for increasing catalyst 
nucleophilicity by the !-effect. This may result in accelerated iminium formation and 
potentially an increase in reaction rate. The source of this effect is outlined in the next section.  
 
1.3.2.1 The !-effect 
Nucleophiles such as HOO
-
, HONH2 and N2H4 that contain a heteroatom possessing a lone pair 
of electrons adjacent to their nucleophilic site are often considered as exceptional 
nucleophiles.
61
 The presence of this adjacent lone pair leads to an increase in the rate of 
Chapter 1: Introduction 
 
 
 
20 
nucleophilic attack on electrophiles, in comparison to related structures containing no such lone 
pair. One plausible rationalisation for this effect uses frontier molecular orbital theory. It states 
that overlap of the orbital containing the electrons on the nucleophilic atom and the lone pair on 
the adjacent heteroatom will cause a splitting in energy levels of the molecular orbitals of the 
molecule.
61
 This leads to the HOMO being raised in energy, relative to the unsubstituted 
nucleophile, and, therefore, the nucleophilicity increases. A schematic example of this analysis 
using the peroxide anion is shown in Figure 1.26.  
HOMO
HO O
OHO
 
Figure 1.26: !-Effect on the HOMO of the peroxide anion 
Increasing catalyst nucleophilicity was a strategy employed by MacMillan in order to increase 
the rate of iminium ion formation with his second generation imidazolidinone catalysts.
62
 
Hence, it would be anticipated that the presence of the !-effect would be beneficial to iminium 
ion formation with a structurally related pyrazolidinone catalyst. For the pyrazolidinone 
framework, the presence of the lone pair on the N(2) atom could potentially give rise to 
increased nucleophilicity at N(1) and so increase the rate of iminium ion formation. 
 
1.3.2.2 Related catalyst architectures 
The reactivity of hydrazides as organocatalysts was elegantly presented in a series of papers by 
Tomkinson and co-workers.
63,64,65
 They examined the cycloaddition of (E)-cinnamaldehyde 37 
and cyclopentadiene, catalysed by a series of cyclic and acylic hydrazides (Table 1.6). 
Dimethylamine gave only a 22 % yield after 48 h (entry 1). Introduction of an adjacent nitrogen 
in N,N’-dimethylhydrazine led to a rate acceleration and this was attributed to enhanced catalyst 
nucleophilicity due to the !-effect (entry 2). Interestingly, the introduction of a "-electron 
withdrawing group was found to give a significant further rate acceleration (entry 3). 
Incorporation of this hydrazide ester group into a 5-membered ring led to a large drop in 
reactivity (entry 4) but expansion to a six-membered ring gave a catalyst with 90 % conversion 
in just 3 h (entry 5). Calculations on a selection of these compounds indicated a correlation of 
reactivity with the ELUMO value of the respective iminium ions, consistent with cycloaddition 
being the rate-determining step.
52,66 
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+
MeOH-H2O 
(19:1)Ph
O
H
exo-38 endo-38
Ph
CHO
+
37
(10 mol%)
Ph
CHO
HClamine
 
Entry Structure Time (h) Yield (%) exo: endo 
1a N
H  
48 22 62:38 
2a N
H
H
N
 
72 48 32:68 
3 N
H
H
N OEt
O  
6 90 66:37 
4 
N
H
N
CO2Et
 
24 38 67:33 
5 
N
H
N
CO2Et
 
3 90 68:32 
Table 1.6: Diels-Alder reaction catalysed by acyclic amines 
a) 5 mol% water added 
An asymmetric pyrazolidinone catalyst derived from camphorsulfonic acid was described by 
Ogilvie and co-workers (entry 1, Table 1.7).
67
 Optimal catalyst performance was observed in 
water alone, giving Diels-Alder adducts exo-(2R)-38 and endo-(2R)-38 in 96 % yield and an 
exo:endo ratio of 65:35. exo-(2R)-38 was produced with 90 % ee. A combination of 
1
H NMR 
spectroscopic analysis and theoretical calculations on the key iminium intermediate 57 led to 
the introduction of an (R)-!-methylbenzyl N-protecting group which gave improved diastereo- 
and enantioselectivity (entry 2).
68
 The introduction of a second stereocentre was designed to 
increase conformational control by disfavouring a (Z)-geometry in the C=N bond of the key 
iminium ion intermediate 57 (the favoured (E)-geometry is displayed in the figure). Use of the 
alternative (S)-!-methylbenzyl N-protecting group led to a decrease in enantioselectivity (entry 
3). A related system derived from (+)-pugelone was recently described by Bach.
69
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H2O, RT
Ph
O
H
(20 mol%)
exo-(2R)-38 endo-(2R)-3837
Ph
CHO
+
CHO
Ph
NH
NO
CF3SO3H  (0.2 eq)
R
N
NO
Ph
E
Ph
57
R
R
 
Entry R Yield (%) exo: endo exo % ee 
1 
Ph  
96 65:35 90 
2 
Ph
R
 
94 74:26 95 
3 
Ph
S
 
55 65:35 74 
Table 1.7: Asymmetric Diels-Alder reaction catalysed by chiral pyrazolidinone  
Lee and co-workers initially reported a structurally related sulfonyl hydrazide, also derived 
from camphor sulfonic acid, for the same reaction.
70
 However, reaction with ketones was found 
to be limited so a second-generation catalyst 59 was designed incorporating a primary, rather 
than secondary, hydrazine (Figure 1.27).71 59 showed much improved reactivity with a range of 
ketones, such as 58.  
C(O)CH3
Ph
+
Ph
C(O)CH3
S
S
exo-(2S)-60 endo-(2S)-60
Ph
O 59
toluene:THF (4:1)
(20 mol%)
TfOH (16 mol%)
(70 %)
(2:98 exo:endo)
(88 % ee)
58
N
SO2
NH2
-20 °C, 48 h
 
Figure 1.27: Asymmetric Diels-Alder reaction catalysed by chiral sulfonyl hydrazide  
The first example of a chiral acyclic hydrazide catalyst was recently reported (Figure 1.28).
72
 
Di-hydrazide 61 was found to catalyse Diels-Alder reactions with good enantioselectivity, 
though, in the majority of cases, little diastereoselectivity. 
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N NN
H
O
N
H
Ph Ph
Ph
O
H
61
CHO
Ph
+
DMF, 0 °C
Ph
CHO
(5 mol%)
S
S
exo-(2S)-62 endo-(2S)-62
HCl (50 mol%)
(82 %)
(56:44 exo:endo) (76 % ee) (87 % ee)
37
 
Figure 1.28: Diels-Alder reaction catalysed by hydrazide 61 
 
1.4 Aims and objectives  
The pyrazolidin-3-one framework contains a number of structural features that suggest it will be 
an effective source of iminium ion organocatalysts.  
N
H
N
O
R1
5 2
R2
- Control iminium geometry
- Tune steric and electronic properties
Nucleophilic N atom for 
iminium formation
Stereodirecting 
group
Block enolisaton
 
Initial aims were to: 
i) Develop a robust synthetic route to racemic series of pyrazolidinones capable of 
introducing a variety of potential substituents at C(5) and N(2). 
ii) Find suitable conditions and test these compounds as catalysts of the Diels-Alder 
cycloaddition. 
iii) Use this information to design a highly reactive, diastereo- and enantioselective 
asymmetric pyrazolidinone catalyst. 
iv) Investigate the mechanism of action to gain insight into iminium catalysed processes. 
N
H
N
O
R1 R2
+
Ph
O
H
exo-38 endo-38
Ph
CHO
+
37
(X mol%)
Ph
CHO
solvent
acid co-catalyst 
(0.X eq)
Chapter 2: Racemic iminium ion organocatalysis 
 
 
 
24 
Chapter 2: Racemic iminium ion organocatalysis 
 
This chapter details the establishment of a synthetic route to access a small range of potential 
organocatalysts based upon the pyrazolidin-3-one template, utilising and elaborating on a route 
previously developed within the group.
73
 A series of N(2)-benzyl substituted pyrazolidinones 
were targeted with either methyl, phenyl, iso-propyl or trifluoromethyl substitution at the C(5) 
position (Figure 2.1). A series of C(5)-methyl substituted pyrazolidinones were also targeted 
with varying N(2) substituents bearing both alkyl and electron-withdrawing groups. In addition, 
methods for the introduction of a gem-dimethyl group at C(4) were evaluated and the synthesis 
of a pyrazolidinone with gem-dimethyl substitution at C(4) described. These catalysts were then 
tested for activity in the Diels-Alder cycloaddition of (E)-cinnamaldehyde and cyclopentadiene 
with particular focus on substitution patterns that led to enhanced reaction rate. These results led 
to the design of catalysts 114 and 115 which had t
1/2
 values of approximately 1 h. The substrate 
scope of the 114 catalysed reaction was also delineated. 
R2 = Bn, Me, Ts, Tf, 
        CO2Bn, COPh
R1 = Me, Ph, 
        i-Pr, CF3 N
H
N
O
R1 R2
1
2
34
5
 
Figure 2.1: Pyrazolidinones targeted as potential organocatalysts  
 
 
2.1 Prior work undertaken in Smith group 
This section describes limited previous research carried out within the Smith group by 
Scott Phillips concerned with the design of a simple synthetic route to differentially protected 
pyrazolidin-3-ones, with particular reference to the introduction of substitution at both C(5) and 
N(2). Such a route should allow rapid access to a range of such compounds for testing as 
potential iminium ion organocatalysts. 
The initial synthetic pathway investigated toward this scaffold is shown retrosynthetically in 
Figure 2.2. A pyrazolinone could be synthesised from the condensation of mono-substituted 
hydrazines with an appropriate "-keto-ester, followed by cyclisation. Reduction of the imine 
functionality would then give the desired pyrazolidinones.  
N
H
N
O
R1 R
2
R1
O
H2NNHR
2
OEt
O
reduction
N
N
O
R1 R2
 
Figure 2.2: Initial retrosynthesis of pyrazolidinone scaffold 
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Pyrazolinone 64 was readily accessed from "-keto-ester 63 however the product proved 
completely resistant to both standard reducing agents (i.e. NaBH4, LiAlH4, hydrogenation) and 
others previously effective for structurally analogous substrates such as 
Superhydride (LiBEt3H) and sodium cyanoborohydride (Scheme 2.1).
67,74
 
64
i)
(85 %)
N
N
O
Ph Ph
OPh
OEtO
ii)
N
H
N
O
Ph Ph
6563  
Scheme 2.1: Reagents and conditions: i) phenylhydrazine, EtOH, reflux; ii) NaBH4, EtOH, rt, or LiAlH4, THF, 
0 ºC, or LiBEt3H, CH2Cl2, -78 ºC to rt, or NaCNBH3, acetic acid-MeOH (2:1), rt. 
An alternative route to the desired pyrazolidinone scaffold was envisaged utilising the conjugate 
addition of hydrazines to !,"-unsaturated esters (Figure 2.3). Such compounds could potentially 
be accessed in just a single step from an !,"-unsaturated ester and a mono-substituted hydrazine 
(route A). Alternatively, hydrazine itself would give a mono-substituted pyrazolidinone (route 
B). The increased nucleophilicity of the N(1) position of a pyrazolidinone over the N(2) 
position could then be exploited to selectively introduce a protecting group at N(1), followed by 
selective N(2) functionalisation and protecting group removal. 
H2NNHR
2
H2NNH2
Selective N(1)
over N(2)
deprotection
Route
A
Route
B
N
H
N
O
R1 R2 N
N
O
R1 R2
N
H
NH
O
R1
P
O
OEt
R1
 
Figure 2.3: Alternative retrosynthesis of pyrazolidinone scaffold 
The successful use of mono-substituted hydrazines would allow the most rapid access to the 
desired pyrazolidinone motif and this route was examined first. The reaction of ethyl crotonate 
66 with methylhydrazine gave a 50:50 mixture of pyrazolidinones 67 and 68, indicating an 
insufficient difference in nucleophilicity between the two nitrogens of methylhydrazine for 
effective regiocontrol (Scheme 2.2). When phenylhydrazine was used instead, only the 
uncyclised intermediate 69 could be isolated. Attempts to promote cyclisation of 69 by 
refluxing in toluene were unsuccessful, yielding only the oxidation product 70. 
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i)
6667 68
+
O
OEtN
H
N
O
N
NH
O
69 70
iii)O
OEtNH
PhHN
ii) O
OEtN
PhN
 
Scheme 2.2: Reagents and conditions: i) methylhydrazine, MeOH, reflux; ii) phenylhydrazine, MeOH, reflux; 
iii) toluene, reflux. 
Due to the issues of regioselectivity and the formation of undesired oxidation products, this 
route was not investigated further. Instead, attention turned to using hydrazine itself to access 
the desired pyrazolidinone architecture (Scheme 2.3). Formation of the pyrazolidinone ring by 
the conjugate addition/cyclisation of ethyl crotonate 66 with hydrazine hydrate, following the 
method of White et al. proceeded smoothly
75
 and subsequent N(1)-Boc protection took place 
selectively at N(1), as desired, to give compound 72 (Scheme 2.3).
76
 
N
NH
O
Boc
71
N
H
NH
O
O
OEt
66
ii)i)
(75 %)(95 %)
72  
Scheme 2.3: Reagents and conditions: i) hydrazine hydrate, EtOH, reflux; ii) di-tert-butyl dicarbonate, Na2CO3, 
dioxane-H2O, rt. 
From 72, it was hoped to selectively introduce functionalisation at N(2) through reaction with 
an appropriate electrophile (Figure 2.4). However, the pyrazolidinone framework contains two 
potential nucleophilic centres. In addition to the N(2) position, reaction at the oxygen on C(3) 
would also be possible, giving rise to undesired side-products. (This regioselectivity issue will 
be further explored in Section 2.3.1).  
Reaction at O Reaction at N(2)
72
N
NH
O
Boc
N
N
O
Boc
N
N
O
Boc
E
E
 
Figure 2.4: Potential products of attempted N(2) derivatisation (E = electrophile) 
Pleasingly, treatment of 72 with potassium carbonate, followed by iodomethane, showed 
exclusively N(2)-methylation to give the known compound 73 in 85 % yield (Scheme 2.4),
76
 
although the final step, N-Boc deprotection to give the desired amine 67, was not attempted.  
N
NH
O
Boc
72
i)
(85 %) N
N
O
Boc
73
N
H
N
O
67  
Scheme 2.4: Reagents and conditions: i) CH3I, DMF, K2CO3, rt. 
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In summary, at the outset of experimental work a number of methods towards the synthesis of 
N(2) substituted pyrazolidinones had previously been evaluated within the Smith group. The 
successful route utilised hydrazine itself in the conjugate addition/cyclisation reaction with ethyl 
crotonate to give the pyrazolidinone framework, which could be elaborated to selectively 
introduce substitution at N(1) and N(2). However, the application of this route to the desired 
catalysts was not fully delineated.  
 
2.2 Synthesis of N(2)-benzyl substituted pyrazolidinones  
2.2.1 Completion of synthetic protocol development 
On commencement of the project, the first task was to finish evaluation of the synthetic route 
partially explored in-house and so establish a reliable route to the desired pyrazolidinones. The 
initial target was C(5)-methyl, N(2)-benzyl compound 76 (Scheme 2.5). By this route, 76 would 
be accessed from previously synthesised N(1)-Boc protected compound 72 and so the synthesis 
of 72 was successfully repeated in order to obtain more material. It had previously been 
established that compound 72 could be readily methylated at N(2) and it was found that 
analogous reaction conditions could also be employed to introduce a benzyl protecting group at 
N(2), leading to compound 74. This route proved amenable to large scale synthesis, with 19.3 g 
(21.0 ml) of ethyl crotonate 66 yielding 19.9 g of intermediate compound 74 in 3 steps with 
41 % overall yield. A crystal structure obtained of compound 74 confirmed direct N-benzylation 
had been achieved (Figure 2.5). 
   
N
N
O
Boc
74
Bn
74  
Figure 2.5: Molecular representation of the single crystal structure of 74 
N-Boc-deprotection with trifluoroacetic acid proceeded smoothly but gave amine salt 75 as a 
thick oil containing significant amounts of residual acid, which could not be readily removed 
under high vacuum (similar issues were also encountered when tetrafluoroboric acid was used). 
To overcome this, 75 was treated with triethylamine to generate the free amine 76 and 
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neutralise the excess acid. This gave the desired C(5)-methyl substituted pyrazolidinone 76 
which could be taken on for testing in catalysis. 
N
NH
O
Boc
71
N
H
NH
O
O
OEt
66
ii)i)
72
iii)
(41 %,
over 3 steps)
N
N
O
Boc
74
Bn
iv)
75
CF3COOH
76
(76 %)
N
H
N
O
Bn
N
H
N
O
Bn
 
Scheme 2.5: Reagents and conditions: i) hydrazine hydrate, EtOH, reflux; ii) di-tert-butyl dicarbonate, Na2CO3, 
dioxane-H2O, rt; iii) benzyl bromide, DMF, K2CO3, rt; iv) TFA, CH2Cl2, rt, then NEt3, CH2Cl2, rt. 
 
2.2.2 Expansion to other N(2)-benzyl derivatives   
With a synthetic route established, further investigation targeted the synthesis of N(2)-benzyl 
pyrazolidinones bearing a phenyl, iso-propyl and trifluoromethyl substituent at C(5). Each of 
these compounds could be readily accessed from the appropriate !,"-unsaturated ester by 
making use of the general synthetic route established in the synthesis of 76. This would then 
allow the effect of the C(5) group on catalysis to be examined independently of other 
substitution on the ring. 
The only required !,"-unsaturated ester not commercially available was iso-propyl ester 78 
(Scheme 2.6) but this was readily accessible from a stereoselective Wittig reaction of 
iso-butyraldehdye and phosphorane 77 ((E):(Z) ratio of >20:1 as judged by 
1
H NMR 
spectroscopic analysis of the crude product residue).
77
 Due to the relatively high volatility of 78, 
the crude material was not fully isolated but was partially purified by passing through a silica 
plug, to remove residual triphenylphosphine oxide, and then directly treated with hydrazine 
hydrate to give pyrazolidinone 79 in 87 % overall yield. 
N
H
NH
O
79
i)
(87 %)
77 78
O
OEt
O
Ph3P
OEt
 
Scheme 2.6: Reagents and conditions: i) iso-butyraldehdye, CH2Cl2, 0 ºC to rt, then hydrazine hydrate, EtOH, 
reflux. 
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With the necessary starting materials in hand, !,"-unsaturated esters 78, 81 and 82 were 
derivatised using the chemistry developed with C(5)-methyl catalyst 76 (Scheme 2.7). Reflux 
with hydrazine hydrate in ethanol proceeded smoothly with trifluoromethyl ester 82 but reaction 
with ethyl cinnamate 81 produced a mixture of ester 81, pyrazolidinone 83 and a significant 
quantity of a structurally related by-product 80 in the ratio 11:56:33 (81:83:80). The structure of 
by-product 80 has not been unambiguously determined but was hypothesised from the 
1
H NMR 
spectrum to correspond to one of the two structures shown in Figure 2.6, which would result 
from either mono (80a) or di-addition (80b) of hydrazine to ethyl cinnamate 81. A second 
reflux in toluene resulted in full conversion of intermediate 80 to pyrazolidinone 83 with the 
structure of 83 confirmed by mass spectrometry and X-ray crystallography (Figure 2.7). 
OPh
OEtNH
H2N
mono-addition di-addition
ba
OPh
HNNH
H2N NH2
 
Figure 2.6: Potential structures of by-product 80 
    74
HN
N
H
O
Ph
83
 
Figure 2.7: Molecular representation of single crystal structure of 5-phenylpyrazolidin-3-one 83 
N(1)-Boc protection with all pyrazolidinones proceeded smoothly, though C(5)-trifluoromethyl 
compound 87 required a modified work-up due to its unusually high water solubility. Selective 
N(2)-benzylation of compounds 85-87 was in all cases straightforward and subsequent 
N(1)-Boc deprotection with trifluoroacetic acid, followed by washing with saturated 
sodium bicarbonate solution liberated the free amines 91-93 with good yields. Compounds 
91-93 could then be taken on for testing. 
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N
NH
O
R
Boc
N
H
NH
O
R
OR
OEt
ii)i)
iii)
N
N
O
R
Boc
Bn
iv)
N
H
N
O
R Bn
81 R = Ph 
78 R = i-Pr 
82 R = CF3
83 R = Ph 
79 R = i-Pr (87 %)a 
84 R = CF3
85 R = Ph
86 R = i-Pr (51 %)
87 R = CF3 (35 %, 2 steps)
88 R = Ph (25 %, 3 steps)
89 R = i-Pr (41 %)
90 R = CF3
91 R = Ph (97 %)
92 R = i-Pr (67 %)
93 R = CF3 (50 %, 2 steps)  
Scheme 2.7: Reagents and conditions: i) hydrazine hydrate, EtOH, reflux then toluene, reflux (80 only); ii) di-tert 
butyl dicarbonate, Na2CO3, dioxane-H2O, rt; iii) benzyl bromide, DMF, K2CO3, rt; iv) TFA, CH2Cl2, rt then 
saturated NaHCO3 solution, CH2Cl2.  
a) Yield from phosphorane 77 
The structure of C(5)-trifluoromethyl catalyst 93 was confirmed by X-ray crystallographic 
analysis (Figure 2.8). 
   93
N
H
N
O
F3C Bn
 
Figure 2.8: Molecular representation of single crystal structure of 93 (the unit cell contains two molecules of 93 
but for clarity only one is shown) 
 
2.3 Alternative substitution at N(2) 
In addition to exploring the effect of substitution at C(5), it was hoped that catalyst activity 
could be further optimised by elaboration of the N(2) position. A small range of catalysts were 
targeted with a common methyl substituent at C(5) and a range of N(2) substitution 
encompassing N-alkyl and electron withdrawing groups (Figure 2.9). This would simplify 
comparison across the series and allow the effect of N(2) substitution to be evaluated in 
isolation from other substituent effects.  
R2 = Me, Bn, Ts, Tf, 
        CO2Bn, COPhN
H
N
O
R2
1
2
34
5
 
Figure 2.9: Structure of potential N(2) substituted pyrazolidinone catalysts 
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The synthesis of N(2)-benzyl substituted catalysts has already been described (see Section 
2.2.1) and a method for the introduction of a methyl group at the N(2) position of compound 72 
had been partially established in-house, though not fully delineated (see Section 2.1). 
Compound 72 was treated with potassium carbonate and iodomethane, as before, to give the 
N(2)-methylated compound 73, albeit in lower yield than previously reported (Scheme 2.8). 
N-Boc-deprotection of the N(1) position, followed by multiple extractions of the aqueous phase 
with dichloromethane gave a 55 % yield of 67. 
N
NH
O
Boc
i) ii)
72 73 67
(53 %) (55 %)N
N
O
Boc
N
H
N
O
 
Scheme 2.8: Reagents and conditions: i) CH3I, DMF, K2CO3, rt; ii) TFA, CH2Cl2, rt, then 
saturated NaHCO3 solution, CH2Cl2. 
Similarly to C(5)-trifluoromethyl catalyst 93, we were interested in the effect of 
electron-withdrawing substituents at the N(2) position. Corey et al. had reported that a triflate 
group could be selectively introduced at nitrogen on structurally related imidazolidin-2-one 94, 
despite the potential for O-triflation (Scheme 2.9).
78 It was hoped to use this method as a general 
route for the introduction of electron-withdrawing substituents at the N(2) position, starting 
with the tosyl functional group.  
i)
(92 %)
94
NHHN
O
Ph Ph
NHN
O
Ph Ph
Tf
95  
Scheme 2.9: Reagents and conditions: i) NEt3, CH2Cl2, then triflic anhydride, -78 ºC to rt. 
Treatment of compound 72 with triethylamine, followed by addition of tosyl chloride led to 
complete consumption of starting material to give a single product that could be isolated in 
46 % yield (Scheme 2.10). However, rather than N(2)-tosylation, the product was identified as 
the O-tosylated material 96. The regioselectivity of the process was proven by 
15
N NMR (see 
Section 2.3.1) and by obtaining the crystal structure of 96 (Figure 2.10). Further corroboration 
came from examination of the 
1
H NMR spectra where a significant downfield shift of the 
C(4)H2 protons of 96 (3.26 and 2.61 ppm) was observed in comparison to those of compound 
72 (2.92 and 2.14 ppm). This effect has been observed in analogous systems and is consistent 
with O functionalisation.
79
 A combination of 
1
H and 
15
N NMR were used to establish the 
regioselectivity of further N(2) functionalisation reactions. 
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N
NH
O
Boc
72
2.14 ppm
2.92 ppm
H
H
N
N
OTs
Boc
96
2.61 ppm
3.26 ppm
H
H
72  
Figure 2.10: Molecular representation of the single crystal structure of O-tosyl compound 96 and 
1
H NMR shifts 
of the C(4)H2 protons of 96 and starting material 72 
In an attempt to facilitate N(2) substitution, the base was changed to sodium hydride but, again, 
full conversion of 72 to exclusively 96 was observed (Scheme 2.10). Potassium carbonate in 
DMF had previously been shown to selectively introducing alkyl groups at nitrogen (see 
Sections 2.1). However, in a reaction with tosyl chloride, only the O functionalised compound 
96 was again observed in the crude reaction mixture by 
1
H NMR spectroscopic analysis 
(Scheme 2.10). 
i)
N
N
OTs
Boc
96
N
NH
O
Boc
72  
Scheme 2.10: Reagents and conditions: i) NEt3, CH2Cl2, then tosyl chloride, -78 ºC to rt (46 %),  
or NaH, CH2Cl2, then tosyl chloride, -78 ºC to rt, or tosyl chloride, DMF, K2CO3, rt. 
To allow direct comparison of the inherent selectivity of pyrazolidinones in this reaction, the 
electrophile was changed to triflic anhydride in order to mimic conditions previously employed 
by Corey (Scheme 2.11). As expected, using triethylamine as base in this reaction resulted in 
complete conversion of starting material to the O-triflyl product 97, isolated in 52 % yield. The 
base was changed to n-BuLi and this still resulted in selective O functionalisation but with 
reduced reaction conversion (90 %). These results suggest that reaction at oxygen is a general 
feature of the chemistry of pyrazolidinones when using sulfur centered electrophiles. 
i)
N
N
OTf
Boc
97
N
NH
O
Boc
72  
Scheme 2.11: Reagents and conditions: i) NEt3, CH2Cl2, then triflic anhydride, -78 ºC to rt (52 %), or n-BuLi, 
CH2Cl2, then triflic anhydride, -78 ºC to rt. 
In a further attempt to facilitate N(2) substitution, it was decided to change to carbon-centered 
electrophiles.
79
 Using benzyl chloroformate as the electrophile, analysis of the 
1
H NMR 
spectrum of the crude reaction mixture showed 81 % conversion of starting material to 
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O functionalised compound 98 when using triethylamine as base (Scheme 2.12).
78
 98 was 
unstable on exposure to silica and could not be isolated by column chromatography, returning 
only parent compound 72. Therefore, 98 was characterised as the crude reaction product. 
However, performing the same reaction with sodium hydride as base allowed for exclusive N(2) 
functionalisation, with the product 99 isolated in 41 % yield after chromatography on silica. The 
benzyl carbonate group could also be selectively introduced at nitrogen using the precedented 
potassium carbonate/DMF conditions, as judged by 
1
H NMR spectroscopic analysis of the 
crude reaction mixture. However, as sufficient material was already available, 99 was not 
isolated in this case. 
N
NH
O
Boc
7298
ii)
99
i)
N
N
OCO2Bn
Boc
N
N
O
Boc
CO2Bn
 
Scheme 2.12: Reagents and conditions: i) NEt3, CH2Cl2, then benzyl chloroformate, -78 ºC to rt; 
ii) NaH, CH2Cl2, then benzyl chloroformate, -78 ºC to rt (41 %), or benzyl chloroformate, DMF, K2CO3, rt. 
With benzoyl chloride as the electrophile, the use of triethylamine as base gave quantitative 
conversion to O-benzoyl compound 100 (Scheme 2.13). As with O-benzyloxycarbonyl 
carbonate 98, 100 was not stable to column chromatography so was characterised from the 
crude reaction product. Interestingly, the use of sodium hydride as base also gave exclusively 
reaction at oxygen with this electrophile. However, refluxing 100 in toluene gave clean 
rearrangement to the desired N(2)-benzoyl compound 101 in an isolated yield of 45 % from 
72.
79
 Alternatively, 101 could be accessed directly using n-BuLi as base, albeit with low 
conversion (50 %), giving 23 % isolated yield of 101 after column chromatography. The 
regiochemistry of 101 was confirmed by obtaining the crystal structure (Figure 2.11). 
N
NH
O
Boc
72100
iii)
101
i)
N
N
OCOPh
Boc
N
N
O
Boc
COPh
ii)
 
Scheme 2.13: Reagents and conditions: i) NEt3, CH2Cl2, then benzoyl chloride, -78 ºC to rt, or NaH, CH2Cl2, then 
benzoyl chloride, -78 ºC to rt; ii) toluene, reflux (45 % from 72); iii) n-BuLi, CH2Cl2, then benzoyl chloride, -78 ºC 
to rt (23 %). 
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Figure 2.11: Molecular representation of single crystal structure of 101 
With N(2)-benzyloxycarbonyl and N(2)-benzoyl compounds 99 and 101 in hand, 
N-Boc deprotection of both substrates with trifluoroacetic acid, followed by basic work-up gave 
the amines 102 and 103, respectively, in good yield (Scheme 2.14). 
i)
N
N
O
Boc
C(O)R
102 R = OBn (78 %)
103 R = Ph    (86 %)
N
H
N
O
C(O)R
99 R = OBn
101 R = Ph  
Scheme 2.14: Reagents and conditions: i) TFA, CH2Cl2, rt, then saturated NaHCO3 solution, CH2Cl2. 
In summary,
 
a route to the synthesis of a range of substituted pyrazolidin-3-ones, utilising the 
conjugate addition/cyclisation of hydrazine to an !,"-unsaturated ester as the key step, was 
developed. This synthetic route was applied to the synthesis of a small range of compounds 
with a common N(2)-benzyl substituent and either methyl, phenyl, iso-propyl or trifluoromethyl 
substitution at C(5). It was found that carbon-centered electrophiles could be used to introduce 
different substituents at the N(2) position while  sulfur-centered electrophiles gave exclusively 
functionalisation of the oxygen at C(3). 
 
2.3.1
 
Identification of regioselectivity of O or N(2) functionalisation by
 15
N
 
NMR 
spectroscopic analysis
 
15
N NMR spectroscopy was used to confirm the regiochemistry of several of the above 
products.
80,81
 
15
N Chemical shifts for a selection of oxygen and nitrogen functionalised 
compounds were obtained experimentally by 
1
H,
15
N HMBC and also calculated at the 
B3LYP/6-31G* level of theory (Table 2.1). In the case of N functionalised compounds 85, 74, 
99 and 101 (entries 1, 2, 5 and 6), the N(2) atom has three substituents and shows sp
3
 character, 
while in O-functionalised compounds 96 and 98 (entries 3 and 4), the N(2) atom has two 
substituents and sp
2
 character. This change results in O-functionalised compounds showing a 
significant downfield shift of the corresponding 
15
N resonance relative to N-substitution by 
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around 140 ppm, allowing the N(2) chemical shift to be used as a simple diagnostic tool. In 
contrast, there is no change in the hybridization of N(1) in all compounds and therefore its 
15
N chemical shift variation is only marginal (29 ppm). Compounds 96 (entry 3) and 98 (entry 
4) are structurally similar to cyclic hydrazones and the chemical shift of the N(2) nitrogens is 
consistent with the imine nitrogen of a hydrazone moiety.
80
 The calculated values are slightly 
overestimated with an average deviation of 11.7 ppm but, nonetheless, there is good agreement 
between the experimental and theoretical data.
 
N
N
OR'
R
Boc
N
N
O
R
Boc
R'/H
N-functionalised O-functionalised
2
1
2
1
 !N  295-296 ppm
!N 155-156 ppm!N  127-137 ppm
!N 147-184 ppm
 
Experimental (ppm) B3LYP/6-31G* (ppm) 
Entry Compound Structure 
N(1) N(2) N(1) N(2) 
1 85 
N
NH
O
Ph
Boc  
127 147 139.9 147.7 
2 74 
N
N
O
Bn
Boc  
136 156 143.8 171.6 
3 96 
N
N
OTs
Boc  
156 295 170.1 311.7 
4 98 
N
N
OCO2Bn
Boc  
155 296 165 298 
5 99 
N
N
O
CO2Bn
Boc  
137 166 146.5 183.8 
6 101 
N
N
O
COPh
Boc  
136 184 145 201.1 
Table 2.1: 
15
N NMR experimental and theoretical data for selected compounds 
 
2.3 Dimethylation of catalyst precursors 
A variation to the standard pyrazolidinone architecture previously discussed is the introduction 
of a gem-dimethyl group at the C(4) position of the heterocyclic system (Figure 2.12). It was 
envisaged that these groups would fix the orientation of any adjacent stereodirecting groups 
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present.
60
 This may aid stereoselectivity in reactions using enantiomerically pure catalysts and 
facilitate efficient transfer of chiral information from the catalyst to the substrate. Furthermore, 
the introduction of a gem-dimethyl group blocks any possible enolisation at C(4) of the catalyst. 
N
H
N
O
R2
1
2
34
5
 
Figure 2.12: Structure of potential gem-dimethyl substituted pyrazolidinone catalyst 
It has been reported by Davies et al. that #-butyrolactones, such as 104, could be either mono- 
or dialkylated (105 and 106, respectively) by treatment with differing quantities of KHMDS and 
iodomethane. Monoalkylation proceeded with high levels of diastereoselectivity (Scheme 
2.15).
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i) ii)
(64 %)
104 106
O
O
N
Bn
Ph
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O
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Bn
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O
O
N
Bn
Ph
(71 %)
(dr >98:<2)
 
Scheme 2.15: Reagents and conditions: i) 1.2 eq KHMDS, -78 ºC, THF, then 5.0 eq CH3I, -78 ºC to rt; ii) 5.0 eq 
KHMDS, -78 ºC, THF, then 10 eq CH3I, -78 ºC to rt. 
Conditions for monomethylation were applied to substrate 74 and this resulted in a mixture of 
residual starting material, monomethylated product 107 and a small amount of the dimethylated 
compound 108 in the ratio 40:48:12 (74:107:108), as judged by 
1
H NMR spectroscopic analysis 
(Scheme 2.16). The monomethylated product was a mixture of diastereoisomers in the ratio 
90:10, however, the relative configuration within these diastereoisomers (either syn or anti) was 
not unambiguously established. The quoted yield of 21 % is the isolated yield of the major 
diastereoisomer of 107 as the minor diastereoisomer could not be separated by column 
chromatography from dimethylated compound 108. 
i)
N
N
O
Boc
Bn
74
N
N
O
Boc
Bn
107
(21 %) N
N
O
Boc
Bn
108
+
 
Scheme 2.16: Reagents and conditions: i) 1.2 eq KHMDS, -78 ºC, THF, then 5.0 eq CH3I, -78 ºC to rt. 
Although the dimethylated compound 108 was only obtained in small amounts in this reaction, 
it was encouraging that dimethylation was possible under conditions only intended for 
monomethylation. To increase conversion to dimethylated product, the reaction was repeated 
with an increased excess of both KHMDS and iodomethane (5.0 and 10 equivalents, 
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respectively) in an attempt to force full alkylation (Scheme 2.17). However, analysis of the 
1
H NMR spectrum of this crude reaction mixture again showed a mixture of starting material 
74, monomethylated material 107 and dimethylated product 108 in the ratio 27:44:29 
(74:107:108). Hence, this mixture was retreated with the same conditions as before and, with 
this extra encouragement, an improved 74:107:108 ratio of 8:11:81 was achieved. The final 
isolated yield, after purification, was significantly lower than this (26 %), presumably indicating 
some unspecified decomposition under these relatively forcing conditions. These reactions have 
not been repeated and require further optimisation. 
With this material in hand, it was then possible to N-Boc-deprotect substrate 108 by treatment 
with trifluoroacetic acid and liberate the free amine 109 by basic work-up in high yield 
(Scheme 2.17). Compound 109 was taken on for further testing. 
i)
N
N
O
Boc
Bn
74
N
N
O
Boc
Bn
108
(26 %)
ii)
N
H
N
O
Bn
109
(96 %)
 
Scheme 2.17: Reagents and conditions: i) 5.0 eq KHMDS, -78 ºC, THF, then 10 eq CH3I, -78 ºC to rt, then 
5.0 eq KHMDS, -78 ºC, THF, then 10 eq CH3I, -78 ºC to rt; ii) TFA, CH2Cl2, rt, then saturated NaHCO3 solution, 
CH2Cl2. 
 
2.4 Testing of pyrazolidinones as organocatalysts 
2.4.1 Proof of concept reactions  
Having developed a synthetic route to a variety of pyrazolidin-3-ones, verification of their 
ability to act as organocatalysts in the Diels-Alder reaction of (E)-cinnamaldehyde 37 and 
cyclopentadiene was tested. C(5)-methyl, N(2)-benzyl compound 76 was used as a model 
catalyst and tested with a selection of conditions employed with related literature catalysts 
(Table 2.2). All reactions were carried out at 20 mol% catalyst loading ([0.19 M] catalyst 
concentration) and analysed after 42 h by 
1
H NMR spectroscopy. The first set of conditions, 
triflic acid as co-catalyst in water, mimicked those of Ogilvie and Lemay (entry 1).
67
 Turnover 
was observed but reaction was sluggish, giving only 22 % conversion in 42 h. Markedly 
improved conversion was observed using hydrochloric acid as co-catalyst in methanol, in 
analogy to conditions employed by Tomkinson et al. (entry 2).
64
 The use of triflic acid with 
methanol gave a further small improvement in turnover (entry 3). In all cases, the catalysts 
showed significant exo diastereoselectivity. It should be noted that reactions in methanol 
resulted in the formation of a mixture of the dimethyl acetals 110, exo-111 and endo-111 and 
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the corresponding aldehydes (Figure 2.13). Hence, analysis by 
1
H NMR spectroscopy was 
preceded by hydrolysis with trifluoroacetic acid to give only the respective aldehydes.  
Ph
O
H
37
Ph
+
exo-111 endo-111
Ph
Ph
CHO
+
exo-38 endo-38
CHO
Ph
O
O
OO
Ph
110
O
O
H
H
MeOH
MeOH
 
Figure 2.13: Equilibria of dimethyl acetals to aldehyde 
For entries 2 and 3, conversion is also represented by a t
1/2 
value (time to reach 50 % 
conversion). These were obtained by taking reaction aliquots that were then hydrolysed before 
analysis by 
1
H NMR spectroscopy to establish conversion and the ratio of diastereoisomeric 
products exo-38 and endo-38. This ratio of diastereoisomers remained essentially constant for 
all reactions in this report that were analysed by this method and so only a single value is given 
in all cases.  
76
+
Ph
O
H
37 exo-38 endo-38
Ph
CHO
+
CHO
Ph
N
H
N
O
Bn
solvent
(20 mol%)
acid (0.2 eq)
42 h  
Entry Solvent Acid Conversion (%) t1/2 (h) exo: endo 
1 water CF3SO3H 22 - 63:47 
2 MeOH HCl 48 45 74:26 
3 MeOH CF3SO3H 65 40 72:28 
Table 2.2: Solvent and acid screen with catalyst 76 
On the basis of the above results, it was decided to employ methanol as solvent and triflic acid 
as co-catalyst for subsequent studies into the effect of the catalyst architecture on reactivity and 
diastereoselectivity. A reaction without pyrazolidinone catalyst was then run to establish the 
rate of background reaction (Figure 2.14). Interestingly, triflic acid in isolation was found to be 
a more active catalyst than in combination with 76, giving a t
1/2
 of 10 h and a markedly different 
diastereoselectivity of 14:86 exo:endo. This result indicated that triflic acid itself was not 
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available to catalyse the cycloaddition in the presence of a pyrazolidinone, potentially as a result 
of iminium formation. 
CF3SO3H  
(0.2 eq)
+
Ph
O
H
37 exo-38 endo-38
Ph
CHO
+
CHO
Ph
MeOH
 
t
1/2
 10 h, exo:endo 14:86 
Figure 2.14: Background reaction of triflic acid in methanol 
 
2.4.2 Model studies 
Having established that pyrazolidin-3-ones can catalyse the Diels-Alder cycloaddition of 
(E)-cinnamaldehyde and cyclopentadiene, the next stage was to investigate how substitution on 
the pyrazolidinone ring influenced the reaction in terms of reaction rate and diastereoselectivity. 
Reactions were monitored by reaction sampling, hydrolysis and analysis by 
1
H NMR 
spectroscopy to obtain t
1/2 
values. The reaction conditions of 20 mol% [0.19 M] catalyst loading 
and 20 mol% triflic acid in methanol were used consistently. 
 
2.4.2.1 C(4) and C(5) substitution 
Figure 2.15 outlines t
1/2
 values and diastereoselectivities observed with a range of C(4) and C(5) 
substituted catalysts all carrying a common N(2)-benzyl substituent. The introduction of a 
gem-dimethyl group at C(4) (catalyst 109) gave a significant rate acceleration over 
C(4)-unsubstituted compound 76 with t
1/2
 reduced to 5 h. However, this acceleration came at the 
expense of diastereoselectivity, with the endo diastereoisomer only marginally preferred to the 
exo (exo:endo 46:54). 
The nature of the C(5) substituent also had a significant effect upon reaction rate. The use of 
either C(5)-phenyl or C(5)-trifluoromethyl substituted catalysts 91 and 93 gave the highest rates 
(t
1/2
 5 h and 6 h, respectively). Catalysts 76 and 92, both of which contain C(5)-alkyl 
substitution are significantly slower. The C(5) substituent also had an effect on 
diastereoselectivity. Compounds 91 and 76 displayed high selectivity for the 
exo diastereoisomer (73:27 and 72:28, respectively). In contrast, catalyst 93 showed a 
significant reversal of diastereoselectivity, favouring the endo diastereoisomer, with an 
exo:endo ratio of 35:65. 
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Ph
CHO
+
CHO
Ph
N
H
N
O
R Bn
MeOH
(20 mol%)
CF3SO3H  
(0.2 eq)
N
H
N
O
Bn
N
H
N
O
Bn
N
H
N
i-Pr
O
Bn
N
H
N
Ph
O
Bn
N
H
N
F3C
O
Bn
76
t1/2 = 40 h
exo:endo = 72:28
109
t1/2 = 5 h
exo:endo = 46:54
92
t1/2 = 30 h
exo:endo = 44:56
91
t1/2 = 5 h
exo:endo = 73:27
93
t1/2 = 6 h
exo:endo = 35:65  
Figure 2.15: Variation of C(4) and C(5) substitution and on reaction rate and diastereoselectivity 
 
2.4.2.2 N(2) substitution 
In order to explore the effects of N(2) substitution, testing of a range of racemic C(5)-methyl 
substituted pyrazolidinones bearing both alkyl (Me, Bn) and electron-withdrawing groups 
(CO2Bn, COPh) at the N(2) position were evaluated (Figure 2.16). In the N(2)-alkyl series, the 
reaction catalysed by the N(2)-methyl substituted catalyst 67 gave a greater rate of reaction 
relative to the N(2)-benzyl substituted compound 76. It had been shown in analogous systems 
that the introduction of a "-electron withdrawing group, with respect to the reactive amine 
centre, led to a significant improvement in the observed reaction rate.
63,64
 This also proved to be 
a general feature of the pyrazolidinone motif with the most effective catalysts in this series, in 
terms of reaction rate, being compounds 102 and 103. Of these, compound 102 displayed the 
highest turnover of all the catalysts tested to date, with the reaction reaching 50 % conversion in 
2 h. Compounds 102 and 103 also displayed similar levels of diastereoselectivity, favouring the 
exo diastereoisomer by ratios of 63:37 and 59:41, respectively. Compound 67 showed a small 
selectivity for the endo diastereoisomer (44:56 exo:endo), in contrast to the other catalysts 
tested in this series. 
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exo:endo = 44:56
103
t1/2 = 2 h
exo:endo = 59:41
102
t1/2 = 2 h
exo:endo = 63:37  
Figure 2.16: Variation of N(2) substitution and on reaction rate and diastereoselectivity 
 
2.4.2.3 Catalyst optimisation 
In an attempt to further optimise catalyst efficiencies, the incorporation of a C(5)-phenyl or 
C(5)-trifluoromethyl group, in combination with an electron-withdrawing N(2)-carboxybenzyl 
substituent, was evaluated. Following the methodology developed previously, 114 and 115 were 
prepared from 85 and 87, respectively (Scheme 2.18). 
i), ii)
N
NH
O
R
Boc
85, R = Ph 112, R = Ph (38 %)
N
H
N
O
R
114, R = Ph (68 %)
CO2BnN
N
O
R CO2Bn
Boc
iii)
87, R = CF3 113, R = CF3 115, R = CF3 (42 %, 2 steps)  
Scheme 2.18: Reagents and conditions: (i) NaH, CH2Cl2, then benzyl chloroformate, #78 ºC to rt; (ii) toluene, 
reflux; (iii) TFA, CH2Cl2, rt then saturated NaHCO3 solution, CH2Cl2. 
The regiochemistry of the N(2)-carboxylation of 85 was confirmed by 
15
N NMR spectroscopy 
(Figure 2.17). The chemical shifts for both Boc-protected 112 and final catalyst 114 were 
obtained and found to be in good agreement with calculated values.  
N
N
O
Ph CO2Bn
Boc
112
!N  169 (182.6)
 !N  133 
(150.0)
N
H
N
O
Ph CO2Bn
114
!N  167 (184.6)
!N  103 
(115.0)
 
Figure 2.17: Theoretical and experimentally determined 
15
N NMR spectroscopic data (in ppm) for 112 and 114 
(theoretically determined values in parentheses) 
These compounds were subsequently evaluated as catalysts for the Diels-Alder reaction- both 
were highly active with C(5)-phenyl 114 giving the best catalytic efficiency observed within 
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this series of catalysts (t
1/2
 1 h, Figure 2.18). Modest exo diastereoselectivity was observed with 
this catalyst while C(5)-trifluoromethyl 115 showed no selectivity. 
+
Ph
O
H
37 exo-38 endo-38
Ph
CHO
+
CHO
Ph
N
H
N
O
R CO2Bn
MeOH
(20 mol%)
CF3SO3H  
(0.2 eq)
N
H
N
Ph
O
CO2Bn N
H
N
F3C
O
CO2Bn
114
t1/2 = 1 h
exo:endo = 62:38
115
t1/2 = 2 h
exo:endo = 48:52  
Figure 2.18: Variation of C(5) substitution on reaction rate and diastereoselectivity of N(2)-carboxybenzyl 
catalysts 
At the end of analysis of catalyst structure, it was found that the incorporation of an 
electron-withdrawing N(2)-carboxybenzyl group and either a C(5)-phenyl or trifluoromethyl 
unit within the pyrazolidinone template led to increased catalytic activity. Diastereoselectivity 
varied significantly, with C(5)-trifluoromethyl, N(2)-benzyl catalyst 93, in particular displaying 
significant endo diastereoselectivity, an unusual feature for an organocatalyst which normally 
show dominant exo diastereoselectivity (Figure 2.19).
48,83
 Catalysts 93 and 114 were taken 
forward for substrate screening.  
N
H
N
Ph
O
CO2BnN
H
N
F3C
O
Bn
93 114
endo 
diastereoselective
highest turnover
 
Figure 2.19: Catalysts taken forward for substrate screen 
 
2.5 Substrate screening of catalysts 93 and 114 
2.5.1 Variation of dienophile 
We began by evaluating the substrate scope of 114 in the organocatalytic Diels-Alder reaction 
with regards to the aldehyde (Table 2.3). Catalyst 114 displayed good reactivity for the 
reactions of cinnamaldehyde, 4-nitrocinnamaldehyde and hexen-2-al with cyclopentadiene, 
furnishing the desired products in good isolated yields and modest exo diastereoselectivity 
(entries 1-3). Short reaction times indicated the high reactivity of the catalyst. A longer reaction 
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time of 24 h was necessary when ester substitution was incorporated and no diastereoselectivity 
was observed (entry 4).  
114
+
R
O
H
exo endo
R
CHO
+
CHO
R
N
H
N
O
Ph CO2Bn
MeOH
(20 mol%)
CF3SO3H  
(0.2 eq)
 
Entry R Time (h) Yield (%) exo:endo 
1 Ph 7 89 62:38 
2 4-NO2-C6H4 5 73 65:35 
3 n-Pr 4 75 58:42 
4a CO2Et 24 80 50:50 
Table 2.3: Substrate tolerance of catalyst 114 in Diels-Alder reactions  
a) 5 % water added 
Catalyst 93 was also further evaluated to see whether endo diastereoselectivity was observed 
with substrates other than cinnamaldehyde (Table 2.4). An exo:endo ratio of 36:64 was also 
observed when hexen-2-al was utilised (entry 2). As expected, longer reaction times were 
required with both substrates to achieve good conversion.  
93
+
R
O
H
exo endo
R
CHO
+
CHO
R
N
H
N
O
F3C Bn
MeOH
(20 mol%)
CF3SO3H  
(0.2 eq)
 
Entry R Time (h) Yield (%) exo:endo 
1 Ph 48 50 22:78 
2 n-Pr 6 67 36:64 
Table 2.4: Testing of endo-selective catalyst 93 with a range of substrates 
 
2.5.2 Variation of diene  
We next examined the diene substrate scope of catalyst 114. It has been found that the reactivity 
of iminium ion catalysed Diels-Alder reactions with dienes other than cyclopentadiene are 
strongly dependent on a suitable substrate/ diene combination.
84,85
 The organocatalysed reaction 
between aldoester 116 and either isoprene or 2,3-dimethylbuta-1,3-diene has been reported by 
Hayashi and co-workers
45,83
 but either combination with C(5)-phenyl catalyst 114 returned only 
starting material after 24 h (Figure 2.20). A change to more reactive (E)-cinnamaldehyde 37 
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again returned only starting material with both isoprene and cyclohexadiene after overnight 
reaction. 
114
+
R
O
H
N
H
N
O
Ph CO2Bn
MeOH, 24 h
(20 mol%)
CF3SO3H  
(0.2 eq)
diene products
Ph
O
H
37
EtO2C
O
H
116
aldehyde diene
 
Figure 2.20: Unsuccessful aldehyde/diene combinations 
In an attempt to overcome this lack of reactivity, a brief solvent screen was undertaken for the 
reaction of cinnamaldehyde 37 and isoprene (Figure 2.21). The systems selected were all 
utilised by MacMillan while screening his chiral imidazolidinone catalyst, albeit with different 
substrate combinations.
1
 However, all were unsuccessful and returned unreacted aldehyde. 
114
+
Ph
O
H
37
N
H
N
O
Ph CO2Bn
solvents, 24 h
(20 mol%)
CF3SO3H  
(0.2 eq)
Ph
CHO
117
 
Solvents tested = MeOH, MeCN:H2O (95:5) or DMF:H2O (95:5) 
Figure 2.21: Solvent screening for reaction of 114 with isoprene 
As a final alternative, C(5)-trifluoromethyl catalysts 93 and 115 were tested in the reaction of 
(E)-cinnamaldehyde 37 and cyclohexadiene (Figure 2.22). In both cases, starting material was 
returned after 24 h. Due to time constraints, other conditions, such as the use of alternative 
aldehyde/ diene combinations, were not explored. 
+
Ph
O
H
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N
H
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O
F3C R
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exo-118
Ph
CHO
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CHO
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Figure 2.22: Reaction of C(5)-trifluoromethyl catalysts 93 (R = Bn) and 115 (R = CO2Bn) with 
(E)-cinnamaldehyde 37 and cyclopentadiene 
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2.6 Summary 
A route for the synthesis of racemic pyrazolidinones allowing ready access to different C(5) and 
N(2) substituent combinations was successfully developed. This chemistry was then applied to 
the synthesis of a series of N(2)-benzyl pyrazolidinones and a series of C(5)-methyl 
pyrazolidinones and these compounds screened in the Diels-Alder cycloaddition of 
(E)-cinnamaldehyde 37 and cyclopentadiene. In terms of reactivity, C(5)-phenyl or 
trifluoromethyl and N(2)-carboxybenzyl substitution were optimal. C(5)-Phenyl, 
N(2)-carboxybenzyl catalyst 114 was screened against a small range of !,"-unsaturated 
aldehydes and showed good reactivity. C(5)-Trifluoromethyl, N(2)-benzyl catalyst 93 showed 
unusual endo diastereoselectivity in the reactions of both cinnamaldehyde and hexen-1-al. 
Neither catalyst, however, gave any conversion when reaction was attempted with dienes other 
than cyclopentadiene. 
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Chapter 3: Resolution of racemic pyrazolidin-3-ones for the synthesis of a 
chiral organocatalyst 
 
This chapter details the development of a method for the synthesis of enantiomerically pure 
pyrazolidin-3-one catalysts by resolution. The amide coupling of C(5)-phenyl pyrazolidinone 83 
to a selection of chiral acids was explored using a range of conditions. The regioselectivity of 
this amide coupling was unambiguously determined by a combination of X-ray crystal structure 
data and 
15
N NMR spectroscopy. The optimal conditions found were the use of 
(R)-methylmandelic acid, two equivalents of coupling agents EDCI and HOBt, DMF as solvent 
and a delay of 5 minutes before addition of pyrazolidinone 83. The resultant diastereoisomers 
could be separated by chromatography and the acid portion removed by refluxing in 6 M 
hydrochloric acid to give enantioenriched (R)-83. (R)-83 was elaborated to catalyst (R)-114 
which was found to give diastereoisomeric products exo-(2R)-38 and endo-(2R)-38 in 48 % and 
28 % ee, respectively. 
 
3.1 Strategies for resolution of pyrazolidinone 83 
In our efforts to develop an asymmetric iminium ion organocatalyst, the initial target was 
enantioenriched compound 114 (Figure 3.1) as this was the most effective catalyst, in terms of 
reaction rate, evaluated at this stage. Two strategies were envisaged that would allow access to 
this compound, starting from the previously described racemic precursor 83. The first was to 
achieve separation via selective crystallisation of a single enantiomer using a chiral acid. The 
second would involve direct reaction with a chiral acid derivative to give a pair of 
diastereoisomeric amides, which could then be separated by column chromatography and/or 
recrystallisation. It was initially assumed that the reaction of 83 with a chiral acid derivative 
would exclusively take place through the amine nitrogen at N(1), in analogy to the selective 
reaction with di-tert-butyl dicarbonate observed in the synthesis of compound 85 (see 
Scheme 2.7). It was later established that the major product in nearly all cases was the 
corresponding N(2)-functionalised analogue shown. This will be discussed in detail in 
Section 3.3.3.4.  
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Figure 3.1: Strategies for resolution of compound 83 
 
3.2 Resolution of pyrazolidinone 83 by crystallisation of a chiral salt  
The first method investigated was selective crystallisation using a chiral acid. When a racemic 
mixture of a basic compound is treated with a chiral acid, a pair of diastereoisomeric salts are 
formed (Figure 3.2). As diastereoisomers, these two salts have different physical properties and, 
therefore, it may be possible to selectively crystallise one over the other with high levels of 
selectively.
86
 Subsequent neutralisation should return the parent compound in enantioenriched 
form.  
N
H
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Ph
N
H
NH
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Ph
HX*
HX*
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+
separate by 
crystallisation
N
H
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O
Ph
HX*
base
N
H
NH
O
Ph
(R)-83  
Figure 3.2: Resolution of compound 83 by selective crystallisation of diastereoisomeric salts 
In order to find a suitable set of conditions for the selective crystallisation of one enantiomer of 
compound 83 it was first necessary to establish which chiral acids were capable of protonating 
83 and thus form a salt. Figure 3.3 shows the chiral acids tested for salt formation with 
compound 83 by the addition of one equivalent of acid to one equivalent of 83 in deuterated 
chloroform. Of these, only (+)-camphor sulfonic acid 124 and (-)-1,1'-binaphtyl-2,2'-diyl 
hydrogenphosphate 125 were sufficiently strong acids to protonate 83, as judged by chemical 
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shift changes in the 
1
H NMR spectra. 
MeHO2C
OH
CO2H
HO2C
OH
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PhHO2C
OH
PhHO2C
OAc
O
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O
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P
O
OH
119 120 121
125124123  
Figure 3.3: Compounds tested for salt formation with 83 
These two acids were then tested in a small range of solvents, such as diethyl ether and THF, in 
order to ascertain whether it was possible to crystallise a salt composed of a single enantiomer 
of 83 (Scheme 3.1). Half an equivalent of acid was used in this case in order to encourage the 
crystallisation of one enantiomer and not a mixture of diastereoisomeric salts. Unfortunately, no 
crystallisation was observed either at room temperature or on cooling to 0 ºC. This method of 
resolution was not advanced further. 
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Scheme 3.1: Reagents and conditions: i) 0.5 eq (+)-camphor sulfonic acid 124 or (-)-1,1'-binaphtyl-2,2'-diyl 
hydrogenphosphate 125, diethyl ether or THF, 0 ºC to rt. 
 
3.3 Resolution of pyrazolidinone 83 by formation of diastereoisomeric amides 
3.3.1 Initial investigations 
As an alternative to selective crystallisation, it was envisaged that compound 83 could also be 
resolved by coupling to a single enantiomer of an appropriate chiral acid or acid derivative. 
Column chromatography and/or recrystallisation of the resultant diastereoisomers, followed by 
cleavage of the acid, would then give both enantiomers of 83 in enantioenriched form. Two 
such strategies tentatively explored were the coupling of 83 to (1S)-menthyl chloroformate and 
(R)-!-methylbenzyl isocyanate. In both cases a mixture of diastereoisomeric products were 
obtained, as judged by 
1
H NMR spectroscopic analysis. However, in both cases no separation of 
the products could be observed by TLC analysis and these routes were not explored further. The 
mixtures of diastereoisomeric products were not characterised.  
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3.3.2 Direct chiral acid coupling 
Another possibility was coupling of 83 to a chiral acid directly, making use of a selection of the 
many coupling agents now commercially available for the activation of acids in such amide 
bond-forming reactions.
87
 (R)-Mandelic acid 126 was initially chosen as the acid substrate for 
these reactions because it is a readily manipulated solid and was commercially available in 
enantiomerically pure form. 
The direct coupling of (R)-mandelic acid 126 with amine 83, facilitated by a range of coupling 
agents is outlined in Table 3.1. Reactions were left overnight at room temperature before 
work-up and the crude material examined by either 
1
H NMR spectroscopy or HPLC analysis to 
establish whether product formation had taken place. The majority of reaction conditions 
(entries 1-6) showed little or no conversion to products, instead giving complex mixtures of 
unidentified components. Interestingly, the combination of EDCI and DMAP in 
dichloromethane showed no evidence of product formation (entry 6) while EDCI and HOBt 
gave an isolated yield of the combined diastereoisomers of 33 % (entry 7). It was established 
from this reaction that (5S)- and (5R)-127 could be readily separated by column 
chromatography, utilising an ethyl acetate/petrol eluent system. Separation by this method gave 
clean samples of compounds (5S)- and (5R)-127 in 13 and 15 % yield, respectively, after a 
single column. The combination of PyBOP and Hunig’s base also gave (5S)- and (5R)-127, 
albeit in a lower yield of 20 % (entry 8). Hence, the reaction with EDCI and HOBt was chosen 
for further optimisation.  
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(5S)-127 (5R)-12783 126
N
H
NH
O
Ph PhHO2C
OH
N
H
N
O
Ph
O
Ph
OH
N
H
N
O
Ph
O
Ph
OH
CH2Cl2
RS
 
Entry Reagents 
Product 
Observed? 
1
a
 DCC, DMAP No 
2
b
 HATU, NEt3 No 
3
b
 HBTU, NEt3 No 
4
b
 BOP, NEt3 No 
5
b
 Cyclophos, NEt3 No 
6
a
 EDCI, DMAP No 
7
a
 EDCI, HOBt Yes (32 %) 
8
a
 PyBOP, (i-Pr)2NEt Yes (20 %) 
Table 3.1: Screening of peptide coupling conditions  
a) Analysed by 
1
H NMR spectroscopy b) Analysed by HPLC  
 
3.3.3 Optimisation 
3.3.3.1 Variation of reaction conditions using (R)-mandelic acid 126 
It was now established that racemic pyrazolidinone 83 could be coupled to chiral mandelic acid 
and the resulting diastereoisomers separated. The yield, however, was only 33 % and it was 
hoped to improve on this initial figure by optimisation of the reaction conditions. This began by 
screening to find the ideal solvent for the reaction (Table 3.2). The use of THF gave essentially 
identical yield to the use of dichloromethane (entry 2) whereas the use of DMF led to a small 
increase in yield from 32 to 40 % (entry 3). Also, for reaction in THF, addition of 126 five 
minutes after the other reagents was beneficial, with the yield increasing by 7 % (entries 2 and 
4). This was presumably due to the increased concentration of the desired activated acid 
intermediate 128 (Figure 3.4). 
Ph
OH
O
O
N
NN  
Figure 3.4: Activated acid intermediate 128 
Interestingly, increasing the time before addition of 126 to 2 h led to a large drop in yield to 
just 7 % suggesting the concentration of intermediate 128 may peak then drop-off over time 
(entry 5). Increasing the number of equivalents of acid 126, EDCI and HOBt also led to a 
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further increase in yield to 47 %, although this represents a rather modest improvement 
considering the large increase in reagents (entry 6). As the EDCI used in the reaction was the 
hydrochloride salt, the addition of triethylamine to neutralise this excess acid was also 
investigated (entry 7). The yield of 26 % showed that the addition provided no benefit to the 
reaction yield. 
83
N
H
NH
O
Ph
i) EDCI, HOBt
(5S)-127 (5R)-127126
PhHO2C
OH
N
H
N
O
Ph
O
Ph
OH
N
H
N
O
Ph
O
Ph
OH
ii)
 
Entry Solvent Equiv of 
EDCI/HOBt 
Delay (min) Yield ((5S)- and (5R)-127 
combined) (%) 
1 CH2Cl2 1 0 32 
2 THF 1 0 33 
3 DMF 1 0 40 
4 THF 1 5 40 
5 THF 1 120 7 
6 THF 2 5 47 
7
a
 DMF 1 5 26 
Table 3.2: Optimisation of amide coupling of pyrazolidinone 83 with (R)-mandelic acid 126 
a) 1 eq of NEt3 also included 
In order to further optimise reaction yield, the use of an alternative to HOBt was briefly 
explored. The screening of reaction conditions had already shown that the reaction was very 
sensitive to the coupling agents used (see Table 3.1). Hence, it was hoped that more subtle 
changes to the previously successful combination of EDCI/HOBt would yield greater returns of 
diastereoisomeric products (5S)- and (5R)-127. Ethyl 2-cyano-2-(hydroxyimino)acetate 129, 
sold commercially as Oxyma Pure, has been developed as an alternative to HOBt with a similar 
level of success in peptide couplings (Figure 3.5).
88
 
CN
N
EtO
O
OH  
Figure 3.5: Oxyma Pure 129 
Hence, the small-scale coupling of racemic 83 with (R)-mandelic acid was attempted, 
substituting Oxyma Pure 129 for HOBt, in a small range of solvents (Table 3.3). In each case, 
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the isolated yield compared unfavourably with those obtained with HOBt and this route was not 
investigated further. 
i) EDCI, 
Oxyma Pure, 
5 min
83
N
H
NH
O
Ph
(5S)-127 (5R)-127126
PhHO2C
OH
N
H
N
O
Ph
O
Ph
OH
N
H
N
O
Ph
O
Ph
OH
ii)
 
Entry Solvent Yield (%) 
1 CH2Cl2 9 
2 DMF 19 
3 THF 26 
Table 3.3: Screening of Oxyma Pure 129 in a small range of solvents 
 
3.3.3.2 Screening of alternative acid coupling partners 
The next stage of optimisation focused on variation of the acid component in the hopes of 
increasing the overall yield while maintaining efficient separation of the two diastereoisomeric 
products. There was concern that the alcoholic side-chain of the acid may give rise to 
significant side-reactions, either by acting as a nucleophile through the alcohol or conversely as 
an electrophile in SN2-type reactions (Figure 3.6a)). Hence, the choice of acids focused on 
compounds in which the alcohol of (R)-mandelic acid was either protected or removed 
altogether, while maintaining a stereocentre ! to the acid functionality. To this end, 
(R)-acetylmandelic acid 130, (R)-methylmandelic acid 131 and (S)-Naproxen 132 were 
examined as potential coupling partners (Figure 3.6b)). 
PhHO2C
OH
Nucleophilic 
attack
Attack by a 
nucleophile
HO2C
O
132
PhHO2C
OAc
131
PhHO2C
O
130
a) b)
 
Figure 3.6: a) Potential sites of side-reactions with (R)-mandelic acid; b) alternative acid substrates 
(R)-Acetylmandelic acid 130 and (S)-Naproxen 132 were each commercially available and 
(R)-methylmandelic acid 131 was readily synthesised in one step from (R)-mandelic acid 126 in 
62 % yield (Scheme 3.2). Greater than two equivalents of sodium hydride were used, leading to 
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a dianion intermediate which was then selectively methylated at the more reactive alkoxide 
position. 
126
PhHO2C
OH i)
131
PhHO2C
O
(62 %)
 
Scheme 3.2: Reagents and conditions: i) 3 eq NaH, THF, 0 ºC, then CH3I, reflux. 
Reaction of amine 83 with the two O-protected derivatives in THF gave similar yields to that of 
mandelic acid itself (Table 3.4, entries 1 and 2). When the reaction conditions were changed to 
reflect the results of the optimisation outlined in Section 3.3.3.1 i.e. DMF as solvent and 83 
added 5 minutes after the other reagents, a significant improvement in the yield from 29 % to 
53 % was observed with (R)-methylmandelic acid 131 (entry 3). A similar yield of 54 % was 
achieved when (S)-Naproxen 132 was employed under these conditions (entry 4). The use of a 
microwave reactor and elevated temperatures has been found to be beneficial in certain amide 
coupling reactions
89
 in terms of both reaction rate and yield and this was tested in this series 
utilising reaction with (S)-Naproxen 132 (entry 5). While it was found that the use of a 
microwave did allow reaction time to be reduced to just 10 minutes, it was not advantageous in 
terms of yield, which dropped slightly in comparison to the ambient reaction to 45 %. HPLC 
analysis of the reaction mixture indicated full consumption of (S)-Naproxen 132, in this case. 
N
H
N
O
Ph
O
N
H
N
O
Ph
O
R* R*+CO2H R*
83
N
H
NH
O
Ph
EDCI, HOBt
+
 
Entry Acid Products Solvent Delay (min) Yield (%) 
1 (R)-acetylmandelic 130 (5S)- and (5R)-133 THF 0 36 
2 (R)-methylmandelic 131 (5S)- and (5R)-134 THF 0 29 
3 (R)-methylmandelic 131 (5S)- and (5R)-134 DMF 5 53 
4 (S)-Naproxen 132 (5S)- and (5R)-135 DMF 5 54 
5
a
 (S)-Naproxen 132 (5S)- and (5R)-135 DMF 0 45 
Table 3.4: Screening of conditions for coupling of 5-phenylpyrazolidin-3-one 83 with different acids 
a) Reaction in a microwave reactor at temperature of 100 ºC for 10 min 
The absolute configuration and regiochemistry of (S)-Naproxen-derived diastereoisomer 
(5R)-135 was unambiguously confirmed by X-ray crystal structure analysis (Figure 3.7). 
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N
H
N
O
Ph
O
135
O
135   
Figure 3.7: Molecular representation of the X-ray crystal structure of 135. 
 
3.3.3.3 Acid chloride formation 
Also explored was the coupling of pyrazolidinone 83 with an appropriate acid chloride. 
Treatment of (R)-methylmandelic acid with thionyl chloride gave full conversion to the crude 
acid chloride 136, by 
1
H NMR spectroscopy (Figure 3.8). However, treatment of this compound 
with pyrazolidinone 83 in the presence of base gave no product after overnight reaction and 
returned only pyrazolidinone 83 and a number of unidentified products, apparently arising from 
decomposition of 136. In order to test the stability and reactivity of the acid chloride, it was also 
reacted with benzylamine. This reaction gave full consumption of starting material by TLC 
analysis after 18 h and 
1
H NMR spectroscopy of the crude reaction mixture confirmed complete 
conversion of acid chloride to amide product (the product was not isolated).  
131
PhHO2C
O
136
PhClOC
O
(5S)- and (5R)-134
N
H
N
O
Ph
O
Ph
O
137
Ph
O
H
N
O
Bn
SOCl2
 
Figure 3.8: Formation of acid chloride 136 and further reaction 
As an alternative, the acid chloride derived from (S)-Naproxen 132 was also tested. Treatment 
of 132 this time with oxalyl chloride gave 98 % conversion to the crude acid chloride, this time 
judged by HPLC analysis. However, a similar result was obtained upon treatment with 83, 
although on this occasion the parent acid was returned upon work-up. This route was not 
pursued further. 
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3.3.3.4 Regioselectivity of amide coupling 
The regioselectivity of the amide coupling of 83 to an acid had not as yet been unambiguously 
determined, although it was anticipated to proceed via the N(1) nitrogen to give compounds of 
type A (Figure 3.9). However, reaction at N(2) was also possible to give compounds of type B.  
83
N
H
NH
O
Ph
EDCI, HOBt EDCI, HOBt
N
H
N
O
Ph
O
N
NH
O
Ph
RO
CO2H R CO2H R
R
A B  
Figure 3.9: Potential regioselectivity of amide coupling of 83 
It was not possible to determine the regioselectivity of reaction from 
1
H or 
13
C NMR 
spectroscopic analysis. The X-ray crystal structure data of compound (5R)-135 (see Figure 3.7) 
showed that the product in this case was the N(2)-acylated compound. However, the generality 
of the reaction had not been established. 
15
N NMR spectroscopy had already proved an 
excellent method to determine the site of acylation for N(1)-protected pyrazolidinones (see 
Section 2.3.1). As an analysis method, it has the advantage that it can be applied to analogues 
for which X-ray crystal structure data could not be obtained (e.g. if said compound is not 
crystalline). Hence, for selected compounds the values of 
15
N chemical shifts were obtained 
experimentally by 
1
H,
15
N HMBC and, in certain cases, also calculated at the B3LYP/6-31G* 
level of theory (Table 3.5). Compounds 85 and 114 were chosen as reference compounds for 
which the regiochemistry was already established (entries 1 and 2). Analysis of this data found 
that the chemical shift of the N(1)-nitrogen was diagnostic. For 85 (entry 1), where this nitrogen 
has 3 substituents and sp
2
 character, the chemical shift is 127 ppm. When there are only 2 
substituents and the nitrogen has sp
3
 character, as with compound 114 (entry 2), the shift is 
significantly5 upfield at 103 ppm. The values of N(1) and N(2) are slightly lower than the 
calculated values, as seen previously, with an average deviation of 10.9 ppm. There is 
nonetheless good agreement between the experimental and theoretical data. 
The chemical shift for N(1) of (S)-Naproxen derived diastereoisomer (5R)-135 was found to be 
104 ppm, consistent with the N(2)-acylation already established from X-ray crystal structure 
data (entry 3). To rule out the possibility that in each case the two isolated diastereoisomers 
were, in fact, different regioisomers, the 
15
N chemical shifts of (R)-methylmandelic acid derived 
diastereoisomers (5S)- and (5R)-134 were also obtained (entries 4 and 5). These were found to 
be almost identical to those of (5R)-135, confirming that these compounds had the same 
hybridisation at each nitrogen atom. Calculations on compound (5S)-134 again showed good 
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agreement between the experiment and theory. Additional chemical shift values were obtained 
for compounds (5S)-127 and (5S)-133, one diastereoisomer for each different acid coupled to 
pyrazolidinone 83 (entries 6 and 7). Each compound gave chemical shift values consistent with 
N(2)-acylation.  
Experimental 
(ppm) 
B3LYP/6-31G* 
(ppm) Entry Compound Structure 
N(1) N(2) N(1) N(2) 
1 85 
N
NH
O
Ph
Boc  
127 147 139.9 147.7 
2 114 
N
H
NCO2BnPh
O
 
103 167 115 185 
3 (5R)-135 
N
H
N
O
Ph
O
O
R
 
104 192 - - 
4 (5S)-134 
N
H
N
O
Ph
O
OMe
Ph
S
 
104 192 115 209 
5 (5R)-134 
N
H
N
O
Ph
O
OMe
PhR
 
104 191 - - 
6 (5S)-127 
N
H
N
O
Ph
O
OH
Ph
S
 
104 189 - - 
7 (5S)-133 
N
H
N
O
Ph
O
OAc
Ph
S
 
104 190 - - 
Table 3.5: 
15
N NMR experimental and theoretical chemical shift data for selected diastereoisomers 
 
3.3.3.5 Combination 
At the conclusion of optimisation studies it was found that, in order to maximise reaction yield: 
• DMF was a better solvent for the reaction than THF  
• pyrazolidinone 83 should be added to the other reagents after 5 minutes 
• two equivalents of coupling reagents would give a small improvement  
• the use of (R)-methylmandelic acid 131 or (S)-Naproxen 132 was preferable to 
(R)-mandelic acid itself.  
With these conclusions in mind, a potential optimised reaction protocol was tested where 
two equivalents each of (R)-methylmandelic acid 131, EDCI and HOBt were employed 
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with DMF as solvent (Scheme 3.3). With this combination, the isolated yield of 
diastereoisomers (5S)- and (5R)-134 was now 73 %. A lower 48 % product yield was 
observed with (R)-acetylmandelic acid, though this still represents an improvement over 
unoptimised conditions with this acid. Interestingly, when the same protocol was applied 
using (R)-mandelic acid 126 itself, the isolated yield was poor at just 30 %. 
N
H
N
O
Ph
O
Ph
OR
N
H
N
O
Ph
O
Ph
OR
83
N
H
NH
O
Ph
i)
(5S)- and (5R)-127, R = H (30 %)
(5S)- and (5R)-133, R = C(O)CH3 (48 %)
(5S)- and (5R)-134, R = CH3 (73 %)  
Scheme 3.3: Reagents and conditions: i) 2 eq EDCI, 2 eq HOBt, 2 eq (R)-mandelic acid 126 , (R)-acetylmandelic 
acid 130 or (R)-methylmandelic acid 131, DMF, 5 min then 83. 
 
3.4 Chiral acid cleavage 
With conditions for the generation and separation of diastereoisomeric amides of 
pyrazolidinone 83 established, it was then necessary to investigate a method for the removal of 
the chiral acid and so generate enantiomerically pure pyrazolidinone 83. A survey of the 
available literature suggested a variety of potential conditions and a number were explored for 
the cleavage of (R)-mandelic acid 126 derived diastereoisomer (5S)-127.
32
 Unsuccessful 
conditions included stirring with either lithium hydroxide in aqueous hydrogen peroxide,
90
 
potassium tert-butoxide in diethyl ether,
91
 15 % aqueous KOH solution
92
 or refluxing with 
sodium nitrate in concentrated sulphuric acid.
93
 Unfortunately, all these conditions gave 
complex mixtures of products containing neither starting material nor any pyrazolidinone 83. 
On the other hand, it was found that refluxing of (5S)-127 in 6 M hydrochloric acid overnight 
gave a 47 % yield of the pyrazolidinone (S)-83, after basic work-up (Scheme 3.4).
94
  
N
H
N
O
Ph
O
Ph
OH
(S)-83
N
H
NH
O
Ph
(5S)-127
i)
(47 %)
S S
 
Scheme 3.4: Reagents and conditions: i) 6 M hydrochloric acid, reflux, 18 h. 
Subsequent examination of the crude reaction mixture by 
1
H NMR spectroscopic analysis 
identified the major by-product as cinnamic acid (83: cinnamic acid 72:28). It was theorised that 
the cinnamic acid was the result of hydrolysis of the amide bond of (S)-83, followed by 
elimination of hydrazine (Figure 3.10).  
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Figure 3.10: Hydrolysis of (S)-83 followed by elimination of hydrazine to give cinnamic acid 
This was corroborated by exposing racemic 83 to the same strong acid conditions. After 3 h, 
1
H 
NMR spectroscopy of the crude reaction mixture showed approximately 60 % conversion of 83 
to cinnamic acid. In order to minimise hydrolysis, the reaction time for the amide cleavage of 
(5S)-127 was reduced. It was found that quantitative conversion had taken place after 1 h, with 
the product (S)-83 isolated in a much improved 95 % yield (Scheme 3.5). The absolute 
configuration of (S)-83 was established by derivatisation to the known N(1)-benzyl 
pyrazolidinone (S)-138 by condensation of (S)-83 with benzaldehyde, followed by reduction 
with sodium borohydride to give (S)-138 in 68 % yield. Chiral HPLC showed the ee was >98 % 
and the absolute configuration was confirmed by comparison of the specific rotation to the 
literature value ([!]20D –125 (c = 0.9, dichloromethane), literature value [!]
20
D  –163 (c = 0.9, 
dichloromethane)).
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Scheme 3.5: Reagents and conditions: i) 6 M hydrochloric acid solution, reflux, 1 h; ii) benzaldehyde, EtOH, rt, 
overnight, then NaBH4, rt. 
Identical conditions were then applied to diastereoisomers derived from (R)-methylmandelic 
acid and (S)-Naproxen (Table 3.6). The cleavage of diastereoisomer (5R)-134 gave a lower 
yield of (R)-83 of 57 %, compared to the cleavage of diastereoisomer (5S)-127 (entry 1). When 
(S)-Naproxen derived diastereoisomer (5R)-135 was exposed to these conditions, the yield was 
particularly low at 18 % (entry 2). Clean product was isolated directly from the basic work-up, 
in this case, indicating decomposition of (5R)-135 to base labile compounds. 
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N
H
N
O
Ph
R*
O
(R)-83
N
H
NH
O
Ph
6 M HCl
!, 1 h
R
 
Entry Diastereoisomer R* Yield (%) 
1 (5R)-134 (R)-methylmandelic 57 
2 (5R)-135 (S)-Naproxen 18 
Table 3.6: Cleavage of diastereoisomers (5R)-134 and (5R)-135 
 
3.5 Synthesis and testing of enantioenriched catalyst (R)-114 
As the greatest quantity of (R)-83 was available at this time (1.43 g), this material was advanced 
to target chiral catalyst (R)-114, utilising identical chemistry to that of the achiral series 
(Scheme 3.6, see Section 2.4.2.3). Firstly, pyrazolidinone (R)-83 was selectively Boc protected 
at the N(1) position to then allow carboxybenzyl functionalisation of the N(2) position to give 
compound (R)-112 in 20 % yield from (R)-83. Boc deprotection with TFA gave catalyst 
(R)-114 in 61 % isolated yield.  
(R)-83
ii) iii)
N
NH
O
Ph
Boc
N
H
N
O
Ph
(R)-114
(20 % yield 
over 2 steps)
(61 %)
i)
(R)-85
N
N
O
Ph
Boc
(R)-112
O
OBn
O
OBn
N
H
NH
O
Ph
 
Scheme 3.6: Reagents and conditions: i) di-tert butyl dicarbonate, Na2CO3, dioxane-water, rt; ii) NaH, CH2Cl2, 
then benzyl chloroformate, -78 ºC to rt then toluene, reflux; iii) CF3COOH, CH2Cl2, rt, then saturated NaHCO3 
solution, CH2Cl2. 
Enantioenriced catalyst (R)-114 was then tested in the Diels-Alder cycloaddition of 
(E)-cinnamaldehyde 37 and cyclopentadiene and the Diels-Alder adducts exo-(2R)-38 and 
endo-(2R)-38 were isolated in 89 % yield and a 65:35 exo:endo diastereoselectivity (identical to 
that found with racemic catalyst 114)(Scheme 3.7).  
Ph
(89 %)
i)
O
H
37
Ph
CHO
+
exo-(2R)-38 endo-(2R)-38
CHO
Ph
 
Scheme 3.7: Reagents and conditions: i) 20 mol% (R)-114, 20 mol% triflic acid, cyclopentadiene, methanol, rt. 
A method for determining the enantiopurity of exo-(2R)-38 and endo-(2R)-38 was then 
investigated. There exist three major methods in the literature for the establishment of the 
enantiomeric excess of compounds exo-(2R)-38 and endo-(2R)-38: chiral GC of the parent 
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aldehydes,
1
 reduction to the corresponding alcohols followed by esterification and chiral 
HPLC
67
 and derivatisation with (R,R)-hydrobenzoin to form diastereoisomeric acetals, which 
can then be examined by 
1
H NMR spectroscopy
96
 (Figure 3.11). 
exo-(2R)-38
Ph
O
O
Ph
Ph
Ph
OBz
Ph
CHO
exo-(2R)-139 exo-(2R)-140  
Figure 3.11: Compound exo-(2R)-38, benzoylated derivative exo-(2R)-139 and (R,R)-hydrobenzoin acetal 
exo-(2R)-140 
Chiral GC of the parent aldehydes was investigated but, unfortunately, the chiral columns used 
by others to establish the enantiopurity of exo-(2R)-38 and endo-(2R)-38 were not available and 
experiments with similar columns were unable to yield full separation of all four stereoisomers 
to allow unambiguous ee determination. exo-(2R)-38 and endo-(2R)-38  were also derivatised 
to the corresponding benzoyl esters e.g. exo-(1R)-139. However, HPLC analysis of these 
compounds, using literature precedented methods, did not give full and reproducible separation 
in our hands. The parent aldehydes were also derivatised to the (R,R)-hydrobenzoin acetals 
e.g. exo-(2R)-140).
96
 The introduction of a further stereogenic centre converts each pair of 
enantiomers into diastereoisomers, giving them different physical properties and allowing their 
relative quantities to be established by 
1
H NMR spectroscopy. Examination of the peaks at 
5.57 ppm and 5.56 ppm for exo-(2R)-140 and 5.21 ppm and 5.17 ppm for endo-(2R)-140 gave 
enantiomeric excesses of 48 % and 28 %, respectively. Repeat experiments confirmed these 
values. 
 
3.6 Summary 
Several methods for the resolution of C(5)-phenyl pyrazolidinone 38 were screened, with amide 
coupling to (R)-mandelic acid 126 and column chromatography of the resulting 
diastereoisomers selected for further investigation. Optimisation of the reaction identified 
(R)-methylmandelic acid 131 as the favoured acid component along with the use of coupling 
agents EDCI and HOBt with DMF as solvent. 
15
N NMR spectroscopy was used to 
unambiguously establish that acylation was taking place on the N(2)-nitrogen. The subsequent 
diastereoisomeric products could be hydrolysed by treatment with refluxing 6 M hydrochloric 
acid for 1 h to generate enantioenriched pyrazolidinone (R)-83. This was derivatised to chiral 
catalyst (R)-114 which was employed in the Diels-Alder reaction of (E)-cinnamaldehyde 37 and 
cyclopentadiene. The bicyclic products were produced in 89 % yield, with an exo:endo ratio of 
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65:35. Derivatisation to the (R,R)-hydrobenzoin acetals ascertained that the (2R) enantiomers 
had been produced in of 48 % and 28 % ee for exo and endo products, respectively.  
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Chapter 4: Double asymmetric induction in pyrazolidinone organocatalysis 
 
This chapter outlines the development of a new series of diastereoisomeric asymmetric iminium 
ion organocatalysts. These compounds were accessed by exploiting the unexpected 
N(2)-regioselective amide coupling of pyrazolidinones to chiral acids as described in the 
previous chapter. One of each pair of these diastereoisomers was generally found to be 
markedly superior in terms of product ee in Diels-Alder processes, consistent with a “matched” 
and “mis-matched” pairing of the two stereocentres of each catalyst. A project of synthesis and 
screening of a range of different catalysts with variations in the acid component and 
C(5)-stereodirecting group was undertaken in order to maximise ee. 
 
4.1 Diastereoisomeric pyrazolidinones as asymmetric catalysts 
In the previous chapter, the regioselectivity of the coupling of pyrazolidinone 83 to a range of 
chiral acids was established unambiguously through a combination of X-ray crystal structure 
data and 
15
N NMR spectroscopy (see Section 3.3.3.4). Diastereoisomeric resolution of these 
compounds was then used to obtain enantioenriched (R)-83 for the synthesis of asymmetric 
pyrazolidinone catalyst (R)-114. However, these diastereoisomeric pyrazolidinone compounds 
themselves contain a secondary amine functionality, previously identified as being necessary 
for iminium ion formation and subsequent catalysis (Figure 4.1). Hence, we proposed these 
diastereoisomeric compounds would themselves act as iminium ion asymmetric catalysts of the 
Diels-Alder reaction. A number of features made these pyrazolidinones attractive as 
organocatalysts. Firstly, the coupled acid portion would serve as an electron-withdrawing group 
adjacent to the reactive centre, a feature previously identified to give an improved rate of 
product formation (see Chapter 2). Secondly, these diastereoisomeric catalysts could be 
accessed in just one synthetic step from the parent pyrazolidinone 83, as opposed to five steps 
for a catalyst such as (R)-114. Finally, the introduction of a second stereodirecting group from 
the chiral acid had the potential to act in concert with the C(5)-stereodirecting group through 
double diastereodifferentiation to enhance the ee of the subsequent catalysis products. 
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Figure 4.1: Rationale of diastereoisomer catalyst testing 
 
4.2 Proof of principle 
In order to establish that such diastereoisomeric compounds could act as catalysts in the 
asymmetric Diels-Alder reaction, methylmandelic acid derived diastereoisomers (5S)- and 
(5R)-134 were chosen for proof-of-principle testing (Table 4.1). The reaction of 
(E)-cinnamaldehyde 37 and cyclopentadiene in methanol was again used as a test reaction, with 
triflic acid used as co-catalyst. Both diastereoisomers (5S)- and (5R)-134 proved effective 
catalysts in terms of reaction rate, with both reactions complete by TLC within 5 hours (entries 
2 and 3). However, there was a significant difference in product ee and absolute configuration. 
Catalyst (5S)-134 gave an ee for the exo and endo diastereoisomers of 63 and 44 % ee, 
respectively. This was a modest improvement over catalyst (R)-114 (included in entry 1) but 
with the opposite absolute configuration of the bicyclic products ((2S) as opposed to (2R)). This 
reversal between catalyst (5S)-134 and (R)-114 appears consistent with the absolute 
configuration at C(5) of each catalyst. In contrast, diastereoisomer (5R)-134 gave the same 
(2R)-absolute configuration of exo- and endo-38 but diminished ee’s compared to (R)-114 
(33 and 31 % for exo and endo, respectively). These results support the theory of double 
diastereodifferentiation, with the stereocentres of (5S)-134 acting in concert to give high ee and 
the stereocentres of (5R)-134 acting in opposition to give low ee. Interestingly, the addition of a 
second stereodirecting group had no discernible effect on reaction diastereoselectivity which in 
all three cases was approximately 66:34 exo:endo. 
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Entry Catalyst Time (h) Yield (%) exo:endo exo % eea endo % eea 
1 (R)-114 7 89 66:34 48 28 
2 (5S)-134 5 77 67:33 -63 -44 
3 (5R)-134 5 81 65:35 33 31 
Table 4.1: Chiral catalysis results with diastereoisomeric catalysts (5S)- and (5R)-134 
a) negative ee refers to (2S) enantiomer 
 
4.3 Variation of acid component in diastereoisomeric catalysts 
Proof of principle testing with methylmandelic acid derived compounds (5S)- and (5R)-134 had 
shown that diastereoisomeric pyrazolidinones could act as effective iminium ion 
organocatalysts, with enhanced ee where the two catalysts stereocentres were ‘matched’ to each 
other. As several C(5)-phenyl diastereoisomeric pyrazolidinones were already in hand 
(synthesis described in Chapter 3), we next analysed the effect of different chiral acid groups on 
enantioselectivity (Figure 4.2). One further pair of diastereoisomers, maintaining C(5)-phenyl 
substitution and incorporating an N-carboxybenzyl-protected (Cbz) proline, were targeted to 
expand catalyst structural diversity. The synthesis of these two compounds and their subsequent 
testing alongside a range of different C(5)-phenyl diastereoisomeric pyrazolidinones is outlined 
in the following sections. 
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Figure 4.2: Compounds for C(5)-phenyl diastereoisomeric catalyst series 
 
4.3.1 Synthesis of N-Cbz proline catalysts (5S)- and (5R)-142 
Following the procedure of Berger et al.,
97
 treatment of L-proline 14 with benzyl chloroformate 
in aqueous base gave full conversion to 141, as judged by 
1
H NMR spectroscopic analysis 
(Scheme 4.1). 141 was used directly and coupled to pyrazolidinone 83 in 30 % overall yield. 
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N-Cbz proline 141 and its derivatives are known to give rotamers when analysed by 
1
H NMR 
spectroscopy and this appeared to be the case with diastereoisomers (5S)- and (5R)-142.
98
 
Variable temperature experiments with compound (5S)-142 showed line-broadening at elevated 
temperatures, consistent with rotamers, but the coalescence temperature was too high to be 
reached during analysis to achieve definitive confirmation.
99
  
N
CO2Bn
HO
O
N
H
HO
O
i)
+
(5R)-142
N
H
N
O
Ph
O
N
N
H
N
O
Ph
O
N
(5S)-142
CO2Bn CO2Bn
14114
(30 %)
RS
 
Scheme 4.1: Reagents and conditions: i) benzyl chloroformate, NaOH (aq.), then EDCI, HOBt, DMF, 5 min then 
83, 18 h. 
As neither (5S)- nor (5R)-142 were crystalline solids, 
15
N NMR spectroscopy was used to 
confirm the regioselectivity of the amide coupling. Figure 4.3 shows the experimentally and 
theoretically determined values for compound (5S)-142. As before, the calculated values are 
slightly overestimated but there is overall good agreement between the experimental and 
theoretical data, indicating that coupling has again taken place selectively at N(2). 
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Figure 4.3: Theoretical and experimentally determined 
15
N NMR spectroscopic data (in ppm) for (5S)-142 
(theoretically determined values in parenthesis) 
The absolute C(5)-configuration within (5S)-142 was determined by hydrolysis of the N-Cbz 
proline unit by refluxing (5S)-142 in 6 M hydrochloric acid solution for 1 h (Scheme 4.2). This 
gave a mixture of enantioenriched pyrazolidinone (S)-83 and N-benzyl compound (S)-138 
(likely arising from decomposition of the carboxybenzyl protecting group) in an 83:17 ratio, 
respectively.
100
 This mixture of compounds was treated sequentially with benzaldehyde then 
sodium borohydride to give exclusively (S)-138 in 33 % overall yield. The specific rotation of 
(S)-138 [!]20D –145 (c = 0.15, CH2Cl2) was consistent with the (S)-configuration at C(5) (see 
Section 3.4).
95
  
Chapter 4: Double asymmetric induction 
 
 
 
66 
+
N
H
N
O
Ph
O
N
(5S)-142
CO2Bn
N
H
NH
O
Ph
(S)-83
N
NH
O
Ph
Bn
(S)-138
N
NH
O
Ph
Bn
(S)-138
i)
(33 %)
 
Scheme 4.2: Reagents and conditions: i) 6 M hydrochloric acid, reflux, 1 h, then benzaldehyde, EtOH, rt, 
overnight, then NaBH4, rt. 
 
4.3.2 Testing of C(5)-phenyl diastereoisomeric catalysts  
With the desired catalysts in hand, the next stage was to evaluate these compounds in 
asymmetric catalysis. The analysis began by examining the influence of different chiral acid 
groups on enantioselectivity when an (R)-configuration was present at C(5) (Table 4.2). The 
results for catalysts (R)-114 and methylmandelic acid derivative (5R)-134 are also included for 
comparison (entries 1 and 2, respectively). All the compounds tested proved to be effective 
catalysts in terms of reaction rate, with the bicyclic products isolated in good to excellent yield 
(69-89 %) in all cases without the need for extended reaction times (5-22 h). In terms of 
diastereoselectivity, the catalysts were moderately exo selective with the exception of catalyst 
(5R)-142 which showed no selectivity (entry 6).  
There was significantly more variation in enantioselectivity with the change in acid, although 
nearly all were selective for the (2R)-product enantiomers shown. Mandelic acid derived 
catalyst (5R)-127 gave similar but slightly poorer ee than its methyl protected analogue 
(entry 3). Enantioselectivity was even lower with Naproxen derived catalyst (5R)-135, only 
26 % ee for exo-(2R)-38 and essentially racemic endo product (entry 5). By contrast, the highest 
ee’s of 57 % (exo) and 67 % (endo) were observed with Cbz-proline derived (5R)-142 (entries 5 
and 6).  
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Entry Catalyst Time (h) Yield (%) exo:endo exo % eea endo % eea 
1 114 7 89 66:34 48 28 
2 134 5 81 65:35 33 31 
3 127 6 86 62:38 28 22 
4 135 7 69 66:34 26 <5 
5 142 22 80 50:50 57 67 
Table 4.2: Variation in enantioselectivity of (5R)-C(5)-phenyl pyrazolidinone with change in acid component  
a) positive ee refers to (2R)-enantiomer 
The C(5)-(S)-configuration diastereoisomers were next tested and the results are outlined in 
Table 4.3. As before, catalyst reactivity was good (reaction times 4-22 h) with a modest exo 
preference. All catalysts gave the (2S)-products (as shown), in contrast to the previous series. 
The enantioselectivities of mandelic and Naproxen derived catalysts (5S)-127 and (5S)-135 
were superior to their respective diastereoisomers (compare entries 2 and 3 to Table 4.2). This 
indicates these diastereoisomers represent the stereocentre ‘matched’ configurations for these 
compounds, leading to enhanced enantioselectivity. Nonetheless, both compounds were inferior 
to methylmandelic acid derived catalyst (5S)-134 (compare to entry 1). In contrast, Cbz-proline 
catalyst (5S)-142 gave ee’s of only 27 % (exo) and -18 % (endo) (entry 4). This represents the 
‘mismatched’ stereocentre combination for this acid.  
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Entry Catalyst Time (h) Yield (%) exo:endo exo % eea endo % eea 
1 134 5 77 67:33 63 44 
2 127 6 82 62:38 54 45 
3 135 4 71 58:42 45 52 
4 142 22 82 56:44 27 -18 
Table 4.3: Variation in enantioselectivity of (5S)-C(5)-phenyl pyrazolidinone with change in acid component  
a) positive ee refers to (2S) enantiomer, negative to (2R) 
At this stage, (R)-C(5)-phenyl Cbz-proline catalyst (5R)-142 had been identified as the most 
enantioselective of those tested (Figure 4.4). We next looked to examine the influence of the 
C(5)-stereodirecting group in isolation from the choice of chiral acid and these investigations 
are described in the following sections. 
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Figure 4.4: Most enantioselective catalyst screened at this stage 
 
4.4 Variation of stereodirecting group 
With the screen of different acid groups complete, we next examined the influence of the 
stereodirecting group at C(5). In order to study the influence of this group in isolation from 
other substituent effects, (S)-Naproxen was chosen as a standard acid component and 
compounds with trifluoromethyl, methyl, benzyl and tert-butyl functionality were targeted 
(Figure 4.5). Also of interest were compounds with no stereodirecting group at C(5) as these 
would illustrate the influence of the acid component in isolation. Two compounds, one with 
gem-dimethyl substitution at C(5) and one with no substitution at all, were chosen. It was 
envisaged that all compounds could be accessed from the amide coupling of (S)-Naproxen with 
the appropriate pyrazolidinone, using the standard protocol developed in Section 3.3. 
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Figure 4.5: Targets for Naproxen-derived diastereoisomeric catalyst series 
 
4.4.1 No stereodirecting group 
The first two catalysts targeted were gem-dimethyl substituted 143 and unsubstituted 144 
(Figure 4.6). For these compounds, any stereoinduction would arise solely from the stereocentre 
derived from the chiral acid.  
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Figure 4.6: Targeted catalysts 143 and 144 
All of the catalysts in this series were envisaged to come from the amide coupling of 
(S)-Naproxen 132 with the appropriate pyrazolidinone, itself arising from condensation of 
hydrazine with an !,"-unsaturated ester. In the case of catalysts 143 and 144, the parent 
pyrazolidinones were derived from methyl 3-methyl-2-butenoate 145 and methyl acrylate 146, 
respectively (Scheme 4.3). While C(5)-gem-dimethyl pyrazolidinone 147 was isolated in near 
quantitative yield, the yield of unsubstituted pyrazolidinone 148 was disappointing at only 
10 %. White et al. have reported a very similar synthesis of 148 (using ethyl acrylate as starting 
material) and the yield in that case was also low (24 %).
75
 Nonetheless, the reaction gave 
sufficient material for the next step. The coupling of gem-dimethyl pyrazolidinone 147 
proceeded well and gave catalyst 143 in 61 % yield, with the expected regiochemistry of 143 
confirmed by 
15
N NMR spectroscopy and by obtaining the crystal structure (Figure 4.7). In 
contrast, the coupling of pyrazolidinone 148 gave a significantly lower yield of product which 
was identified as the N(1)-acylated compound 149.  
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Scheme 4.3: Reagents and conditions: i) hydrazine hydrate, EtOH, reflux then toluene, reflux (148 only); ii) 
(S)-Naproxen 132, EDCI, HOBt, DMF, 5 min then 147 or 148, 18 h. 
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Figure 4.7: Analysis of compound 143- experimentally determined 
15
N NMR spectroscopic data (in ppm) and 
molecular representation of the X-ray crystal structure. 
Evidence for the N(1)-acylation of 149 came from a number of sources. Firstly, the compound 
had very poor solubility in relatively non-polar organic solvents, such as dichloromethane. 
Good solubility could only be achieved in polar solvents such as acetonitrile and DMSO. 149 
was rotameric in the solution phase and this was confirmed by variable temperature 
1
H NMR 
spectroscopic analysis in CD3CN.
99
 In contrast, other Naproxen derived compounds in this 
series had not shown any hindered rotation in the solution phase. 
15
N NMR spectroscopic 
analysis gave a single resonance at 141 ppm and it was not possible from the 
1
H,
15
N HMBC 
spectra to unambiguously assign this chemical shift to either nitrogen atom. Theoretical 
calculations indicated that N(2)-acylated 144 would have 
15
N chemical shifts of 104.0 and 
207.5 ppm, both of which markedly differ from the single experimentally determined resonance 
(Figure 4.8a)). Calculations on N(1)-functionalised compound 149 gave chemical shifts for 
N(1) and N(2) of 147.9 ppm and 150.5 ppm (Figure 4.8b)). Taking into account the margin of 
error seen with 
15
N NMR spectroscopy on related compounds (see Sections 2.3.1 and 3.3.3.4), 
either of these values would be consistent with the experimentally determined shift of 141 ppm. 
Finally and most compellingly, an X-ray crystal structure of 149 was obtained that indicated 
N(1)-acylation. 
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Figure 4.8: Theoretically determined 
15
N NMR spectroscopic data (in ppm, values in parenthesis) for a) potential 
regioisomer 144; b) 149 and the molecular representation of the X-ray crystal structure of 149 
Despite this unexpected result, compound 149 was still of interest as an iminium ion catalyst as 
it contains a di-substituted nitrogen atom at N(2) which could (though unlikely) be utilised for 
iminium ion formation and subsequent catalysis. As this nitrogen atom was part of an amide, it 
would have lower nucleophilicity in comparison to a secondary amine and so the rate of 
iminium ion formation was likely to be slow. Nonetheless, we felt the result would be of value 
and compounds 144 and 149 were both taken forward for testing.  
 
4.4.2 Naproxen derived diastereoisomeric catalysts 
The next stage was the synthesis of a series of diastereoisomeric compounds with (S)-Naproxen 
as a common chiral acid group at N(2) and different substituents at the C(5)-position. 
C(5)-trifluoromethyl, methyl, benzyl and tert-butyl derivatives were targeted.  
The synthesis of precursors C(5)-methyl pyrazolidinone 71 and C(5)-trifluoromethyl 
pyrazolidinone 84 have already been described (see Section 2.1 and 2.2.2, respectively) and so 
the first pyrazolidinone targeted was C(5)-benzyl 153 (Scheme 4.4). In this case, the necessary 
!,"-unsaturated ester 152 was not commercially available and had to be synthesised from 
phenylacetaldehyde and phosphonate ester 151, making use of a modified Horner-Wadsworth-
Emmons reaction using methylmagnesium bromide as base, as developed by Davies and 
co-workers.
101
  
Phosphonate ester 151 was first synthesised in 99 % yield by refluxing triethyl phosphite 150 in 
ethyl bromoacetate, followed by treatment of 151 with phenylacetaldehyde to give ester 152 in 
68 % yield (Scheme 4.4). In analogy to C(5)-phenyl pyrazolidinone 83, refluxing of 152 with 
three equivalents of hydrazine hydrate in ethanol gave a 75:25 mixture of 153 and a compound 
believed to be 154, respectively. 154 was never isolated and the structure has not been 
unambiguously confirmed. However, refluxing the above mixture in toluene gave only 
pyrazolidinone 153, which was isolated in 63 % yield. 
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Scheme 4.4: Reagents and conditions: i) ethyl bromoacetate, reflux; ii) methylmagnesium bromide, THF, 0 ºC to rt 
then phenylacetaldehyde, reflux; ii) 3 eq hydrazine hydrate, ethanol, reflux then toluene, reflux. 
C(5)-tert-Butyl pyrazolidinone 156 was accessed via a similar route, using the Horner-
Wadsworth-Emmons reaction of phosphonate ester 151 and pivalaldehyde to give 
!,"-unsaturated ester 155 as exclusively the (E)-isomer by 1H NMR spectroscopic analysis of 
the crude reaction mixture (Scheme 4.5). Without purification, 155 was treated with hydrazine 
and refluxed in ethanol to give 156 in 53 % yield from 151. 
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Scheme 4.5: Reagents and conditions: i) pivalaldehyde, n-butyllithium, THF, -78 ºC to rt, then hydrazine hydrate, 
EtOH, reflux. 
With the necessary pyrazolidinones in hand, their coupling to (S)-Naproxen 132 was explored 
(Scheme 4.6). Yields were modest (15-40 %) but gave acceptable quantities of crude material 
and so no attempt was made to optimise procedures further. Separation of the diastereoisomers 
was generally challenging but achieved with a combination of column chromatography and/ or 
recrystallisation.  
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Scheme 4.6: Reagents and conditions: i) (S)-Naproxen 132, EDCI, HOBt, DMF, 5 min then 71, 84, 153 or 156, 
18 h. 
Chapter 4: Double asymmetric induction 
 
 
 
73 
The isolated diastereoisomers were normally solids amenable to the growing of single crystals 
for X-ray crystallographic analysis. X-ray crystal structures of each of the two diastereoisomers 
of the C(5)-trifluoromethyl ((5S)- and (5R)-158) and C(5)-benzyl ((5R)- and (5S)-159) 
compounds were obtained, allowing their absolute configurations to be unambiguously 
identified (Figures 4.9 and 4.10, respectively). X-ray crystal structure data could not be obtained 
for either of C(5)-tert-butyl catalysts (5S)- and (5R)-160. The absolute configurations of these 
compounds was initially assigned by their Rf values (in comparison to other compounds in the 
series) and later by comparison of results in catalysis. 
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Figure 4.9: Molecular representation of the X-ray crystal structures of (5R)- and (5S)-158 
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Figure 4.10: Molecular representation of the X-ray crystal structures of (5S)- and (5R)-159 
Despite repeated attempts, it was not possible to obtain a clean sample of C(5)-methyl 
diastereoisomer (5R)-157. The best that could be achieved was a 26:74 ((5S):(5R)) mixture of 
the two compounds arising from careful column chromatography in a diethyl ether/ petrol 
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system. Repeated chromatography or recrystallisation could not improve on this ratio. 
Formation of the hydrochloride salt of this diastereoisomeric mixture and subsequent 
recrystallisation was also attempted but, again, the same ratio was obtained. Hence, only 
diastereoisomer (5S)-157 was taken on for catalyst testing. An X-ray crystal structure of 
(5S)-157 was obtained and this confirmed the assigned (S)-C(5)-stereoconfiguration 
(Figure 4.11). 
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Figure 4.11: Molecular representation of the X-ray crystal structure of (5S)-157 
 
4.4.3 Testing of N(2)-(S)-Naproxen diastereoisomeric catalysts 
The testing of the Naproxen derived catalysts began by examining the extent of stereoinduction 
by the acid component in isolation using gem-dimethyl catalyst 143 (Figure 4.12). Diels-Alder 
products were produced with very modest selectivity for the (2S)-enantiomers of 13 % (exo) 
and 27 % (endo), meaning the catalyst is significantly less enantioselective than ‘matched’ 
catalyst (5S)-135 and consistent with the C(5) stereodirecting group being required for good 
enantioselectivity (see Table 4.3). However, the enantioselectivity is generally superior to that 
of ‘mis-matched’ catalyst (5R)-135, indicating the importance of the relative configuration of 
the two catalyst stereocentres (see Table 4.2). 
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Figure 4.12: Testing of gem-dimethyl catalyst 143 
We next examined the effect on enantioselectivity of different C(5) substituents and their 
absolute configuration. The first set of compounds tested possessed an ‘up’ configuration at 
C(5), as drawn in Table 4.4 (this represents (5R)-configuration for phenyl, tert-butyl and 
trifluoromethyl substitution, (5S)-configuration for benzyl and methyl substitution). The 
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previously reported result with phenyl substituted catalyst (5R)-135 is included for reference 
(entry 1). Efficient catalysis was observed in all cases along with general 
exo diastereoselectivity. However, enantioselectivity was generally poor, the best being benzyl 
catalyst (5S)-159 (entry 4). These results are consistent with the trend observed with phenyl 
catalysts (5S)- and (5R)-135 that the ‘up’ configuration at C(5) is mis-matched to the 
stereocentre present in Naproxen, leading to low ee’s in catalysis.  
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(0.2 eq) 
MeOH, rt
CHO
Ph
endo-(2S)-38  
Entry R Catalyst Yield (%) exo:endo exo % eea endo % eea 
1 Ph (5R)-135 69 66:34 -26 <5 
2 Me (5S)-157 73 64:36 -9 20 
3 CF3 (5R)-158 88 51:49 3 32 
4 Bn (5S)-159 82 63:37 33 44 
5 t-Bu (5R)-160 93 59:41 13 30 
Table 4.4: Variation in enantioselectivity with change in “mis-matched” stereodirecting group at C(5) 
(stereodirecting group all ‘up’ as drawn) 
a) positive ee refers to (2S) enantiomer, negative to (2R) 
The results with the corresponding ‘down’ configuration at C(5) are outlined in Table 4.5. In all 
cases, this diastereoisomer was superior to its pair in terms of enantioselectivity, consistent with 
this combination of stereocentres being ‘matched’ for high enantioselectivity. The highest 
overall enantioselectivity was achieved when a trifluoromethyl group was present with exo and 
endo diastereoisomers produced in 61 % and 71 % ee, respectively (entry 2). Interestingly, 
incorporation of a benzyl stereodirecting group, in analogy to the imidazolidinone catalysts of 
the MacMillan group (entry 3),
1
 gave no selectivity benefit compared to a phenyl substituent 
(entry 1). Similarly, the sterically bulky tert-butyl group gave no improvement in the 
enantioselectivity in comparison to phenyl (32 % exo, 40 % endo, entry 4)). Unfortunately, it 
was not possible to isolate the analogous C(5)-methyl derivative for testing. Again, 
diastereoselectivity was generally similar across the series with a small exo preference for all 
but trifluoromethyl catalyst (5S)-158 which showed the greatest endo preference (46:54 
exo:endo, entry 5).  
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Ph
O
H
+
+
exo-(2S)-3837
N
H
N
O
R
O
O
Ph
CHO
(20 mol%)
CF3SO3H 
(0.2 eq) 
MeOH, rt
CHO
Ph
endo-(2S)-38  
Entry R Catalyst Yield (%) exo:endo exo % eea endo % eea 
1 Ph (5S)-135 71 58:42 45 52 
2 CF3 (5S)-158 79 46:54 61 71 
3 Bn (5R)-159 95 58:42 39 49 
4 t-Bu (5S)-160 74 53:47 42 40 
Table 4.5: Variation in enantioselectivity with change in “matched” stereodirecting group at C(5) 
(stereodirecting group all ‘down’ as drawn) 
a) positive ee refers to (2S) enantiomer, negative to (2R) 
 
4.4.4 Amides as iminium ion organocatalysts 
The amide coupling of unsubstituted pyrazolidinone 148 with (S)-Naproxen had given rise to 
N(1)-acylated compound 149. As a secondary amide rather than a secondary amine, compound 
149 was tested to ascertain whether the nitrogen at N(2) was sufficiently nucleophilic to act as 
an iminium ion catalyst in Diels-Alder reactions (Table 4.6). In addition, two other chiral 
secondary amides, 161 and 162, were tested. These compounds represent intermediates in the 
synthesis of chiral carbene catalysts used within the group and were readily available in the 
lab.
102
 Catalyst 149 gave an isolated product yield of 88 % after 24 h reaction but low ee 
(21 % exo and 10 % endo, entry 1). In contrast, compounds 161 and 162 required 48 h reaction 
to give reasonable yields of racemic products (entries 2 and 3). The high endo 
diastereoselectivity (14:86 exo:endo in both cases) and extended reaction times indicate that the 
products are likely arising from the background reaction catalysed by the triflic acid co-catalyst 
(t
1/2 
10 h, exo:endo 14:86, see Section 2.4.1). This implies that essentially no iminium ion 
formation is taking place with these compounds and the background reaction is responsible for 
all turnover observed. With compound 149, the low but non-zero enantioselectivity implies 
some meaningful interaction between the catalyst and substrate in which stereochemical 
information is being transmitted. This may be via the formation of an iminium ion, however the 
low nucleophilicity of the amide centre makes this less likely. Another possibility is that 149 is 
acting as a hydrogen-bonding (Brønsted base) catalyst and activating trans-cinnamaldehyde by 
protonation. The mechanism of action of catalyst 149 has not been unambiguously determined 
and requires further investigation.  
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Ph
O
H +
catalyst 
(20 mol%)
N
NH
O
149
O
O
CF3SO3H 
(0.2 eq) 
MeOH, rt
161
catalysts
NH
O
Bn
162
NH
O
Ph OTBS
Ph
37
+
exo-(2S)-38
Ph
CHO
CHO
Ph
endo-(2S)-38
 
Entry Catalyst Time (h) Yield (%) exo:endo exo % eea endo % eea 
1 149 24 88 33:67 21 10 
2 161 48 71 15:85 0 0 
3 162 48 69 15:85 0 0 
Table 4.6: Catalysis with a small number of chiral amides 
a) positive ee refers to (2S) enantiomer 
 
4.5 Combination 
In terms of enantioselectivity, trifluoromethyl had been identified as the best 
C(5)-stereodirecting group and the carboxybenzyl-protected proline as the best acid component. 
Hence, a combined catalyst was targeted in the hope of maximising the enantioselectivity of the 
catalyst. The amide coupling of pyrazolidinone 84 to N-Cbz-proline 141 proceeded in low but 
acceptable yield to give diastereoisomeric compounds (5S)- and (5R)-163 (Scheme 4.7). 
Analysis of compound (5R)-163 included variable temperature 
1
H NMR spectroscopy (both 
diastereoisomers were rotameric in the solution phase)
99
 and 
15
N NMR spectroscopy to confirm 
the expected substitution pattern (Figure 4.13). 
i)
+
(5R)-163
N
H
N
O
F3C
O
N
N
H
N
O
F3C
O
N
(5S)-163
CO2Bn CO2Bn
84
(20 %)N
H
NH
O
F3C
R
S
 
Scheme 4.7: Reagents and conditions: i) (S)-N-(benzyloxycarbonyl)-proline 141, EDCI, HOBt, DMF, 5 min then 
84, 18 h. 
N
H
N
O
F3C
O
N
O
OBn
!N 184 (202.7)
!N 98
!N 86
(100.8)
(107.7)
 
Figure 4.13: Theoretical and experimentally determined 
15
N NMR spectroscopic data (in ppm) for (5R)-163 
(theoretically determined values in parenthesis) 
Chapter 4: Double asymmetric induction 
 
 
 
78 
Both diastereoisomers were tested but “matched” catalyst (5R)-163 proved the more 
enantioselective of the two compounds giving the (2R)-products in 65 % (exo) and 75 % (endo) 
ee (Table 4.7). This represents the highest enantioselectivities observed in this series. In 
addition, the catalyst proved to be significantly endo diastereoselective in a ratio of 35:65, 
which is highly unusual in the organocatalysed Diels-Alder reaction when cyclopentadiene is 
used as the diene component.  
N
H
N
O
F3C
O
N
CO2Bn
N
H
N
O
F3C
O
N
CO2Bn
(5S)-163 (5R)-163
RS
Ph
O
H +
catalyst 
(20 mol%)
CF3SO3H 
(0.2 eq) 
MeOH, rt
catalysts
Ph
CHO
+
exo-(2R)-38
CHO
Ph
endo-(2R)-3837
 
Entry Catalyst Yield (%) exo:endo exo % eea endo % eea 
1 (5S)-163 78 47:53 -30 7 
2 (5R)-163 84 35:65 65 75 
Table 4.7: Chiral catalysis results with diastereoisomeric catalysts (5S)- and (5R)-163 
a) positive ee refers to (2R) enantiomer, negative to (2S) 
 
4.6 Summary 
A new series of asymmetric iminium ion organocatalysts utilising diastereoisomeric 
pyrazolidinones were investigated. In order to explore the influence of the acid component on 
enantioselectivity, C(5)-phenyl pyrazolidinone 83 was coupled to N-Cbz proline 141 as an 
alternative series to the C(5)-phenyl catalysts previously synthesised. (S)-Naproxen 132 was 
used as a standard acid component to allow the effect of varying the C(5)-stereodirecting group 
on the pyrazolidinone ring to be investigated. A series of diastereoisomeric compounds varying 
in this substituent were synthesised from direct coupling of the appropriate pyrazolidinone to 
(S)-Naproxen 132. Also synthesised was a C(5)-gem-dimethyl derivative 143 to act as a 
reference. In catalysis, the combination of the two stereocentres was shown to have either an 
enhancing or diminishing effect in comparison to either stereocentre in isolation, depending on 
their relative configurations. Higher ee’s were observed when the two stereocentres were 
‘matched’ to each other and lower ee’s when they were ‘mis-matched’. C(5)-Trifluoromethyl, 
Cbz-proline catalyst (5R)-163 was identified as being the most enantioselective and also 
displayed an unusually high endo diastereoselectivity of 35:65 exo:endo.  
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Chapter 5: Asymmetric catalysis with optimised catalyst (5R)-163 and 
investigations into active catalytic species 
 
This chapter describes optimisation of asymmetric catalysis using C(5)-trifluoromethyl, 
Cbz-proline catalyst (5R)-163. The catalyst was then screened against a range of aldehydes with 
the (2R)-enantiomer of the products favoured. In order to rationalise this finding, an iminium 
ion derived from racemic catalyst 114 was isolated and characterised. This compound was 
found to have (Z)-geometry in the key N=C bond but also to have undergone ring-opening due 
to acid catalysed methanolysis of the pyrazolidinone ring. This led us to isolate a chiral acyclic 
hydrazide, derived from optimised asymmetric catalyst (5R)-163, which has now been 
identified as a highly active and enantioselective catalyst of the Diels-Alder reaction. This 
compound likely represents the key active catalytic species in reactions employing (5R)-163. 
 
5.1 Application of optimised catalyst (5R)-163  
5.1.1 Optimisation of reaction conditions 
With evaluation of the catalyst structure completed, the next stage was optimisation of the 
reaction conditions. This first factor examined was catalyst loading (Table 5.1). In all cases, the 
catalyst concentration was maintained at 0.19 M. Dropping the catalyst loading to 10 mol% had 
no effect on yield or enantioselectivity (entry 2). A small drop in enantioselectivity was 
observed when loading was taken down to 5 mol% (entry 3). Therefore, it was decided to 
maintain catalyst loading at 10 mol%. The ratio of exo and endo diastereoisomers was identical 
in all cases (35:65 exo:endo). 
(5R)-163
N
H
N
O
F3C
O
N
CO2Bn
Ph
O
H
+
37
(X mol%)
CF3SO3H
(0.X eq)
MeOH, rt, 18 h
Ph
CHO
+
exo-(2R)-38 endo-(2R)-38
CHO
Ph
 
Entry Loading (mol%) Yield (%) exo % ee endo % ee 
1 20 84 65 75 
2 10 85 65 73 
3 5 85 62 69 
Table 5.1: Variation of catalyst loading of catalyst (5R)-163 
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A small screen of alternative acid co-catalysts to triflic acid was next undertaken, using 
10 mol% catalyst loading (Table 5.2). Both hydrochloric and perchloric acid gave very similar 
results as co-catalysts to triflic acid (entries 2 and 3). In contrast, trifluoroacetic acid showed 
only 50 % conversion after extended (48 h) reaction, resulting in an isolated yield of 47 % 
(entry 4). Enantioselectivity was also lower. With these results, it was decided to continue with 
triflic acid as co-catalyst. Again, a diastereoisomeric ratio of 35:65 exo:endo was found for all 
examples. 
N
H
N
O
F3C
O
N
CO2Bn
Ph
O
H
+
37
(10 mol%)
(5R)-163
Ph
CHO
+
exo-(2R)-38 endo-(2R)-38
CHO
Ph
(0.1 eq)
MeOH, rt, 18 h
acid
 
Entry Acid Yield (%) exo % ee endo % ee 
1 CF3SO3H 85 65 73 
2 HCl 87 64 75 
3 HClO4 83 67 68 
4a TFA 47 60 70 
Table 5.2: Variation of acid co-catalyst 
a) Reaction time 48 h 
The final factor examined was reaction temperature (Table 5.3). Lowering the temperature to 
5 ºC maintained good reactivity and very slightly improved the ee of the endo diastereoisomer 
to 78 % (entry 2). Further reduction to -10 ºC improved the enantioselectivity further to 73 % 
(exo) and 82 % (endo) (entry 3). However, the yield was slightly reduced to 75 %. It was 
decided to keep reaction temperature at 5 ºC as a compromise between good yield and 
enantioselectivity. Once again, diastereoselectivity was unchanged at 35:65 exo:endo in all 
cases. 
Ph
O
H
+
37
Ph
CHO
+
exo-(2R)-38 endo-(2R)-38
CHO
Ph
(10 mol%)
CF3SO3H 
(0.1 eq)
MeOH, 18 h
(5R)-163
N
H
N
O
F3C
O
N
CO2Bn
 
Entry Temp Yield (%) exo % ee endo % ee 
1 RT 85 65 73 
2 5 90 65 78 
3 –10 75 73 82 
Table 5.3: Optimisation of reaction temperature 
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5.1.2 Substrate screen 
With the optimisation of reaction conditions complete, it was now possible to assess the 
substrate scope of the Diels-Alder reaction catalysed by (5R)-163. Reaction optimisation with 
(E)-cinnamaldehyde 37 had indicated that reactions should be run at 5 ºC with 10 mol% catalyst 
loading and using triflic acid as a co-catalyst. Unfortunately, lowering the temperature with 
many analogues adversely effected reaction rate and this was attributed to the low solubility of 
many of the analogues in methanol at lower temperatures. Hence, reactions were carried at 
room temperature except where aldehyde solubility allowed a lower temperature to be used.  
The results of the aldehyde screen are outlined in Table 5.4.
103
 In all cases, the ee’s of the major 
endo diastereoisomer were superior to the exo, although both followed the same trends. Yields 
were generally good, ranging from 70-86 %. Testing showed that catalysis was compatible with 
aldehydes with a range of electronic properties. The electron-donating 4-methoxy and 
electron-withdrawing 4-chloro and 4-nitro substituents were all well tolerated, giving endo ee’s 
of 77 %, 82 % and 77 %, respectively. 
Different substitution patterns were also well tolerated. 2-Nitrocinnamaldehyde, for example, 
gave 84 % ee for the endo product, the best result obtained in the series (entry 5). Bulky 
naphthyl substituents also gave good results, with 2-naphthyl and 1-naphthyl substituents giving 
endo ee’s of 79 % and 73 % ee, respectively (entries 6 and 7). However, alkyl substituents were 
less well tolerated with both n-propyl and ethyl ester substituents giving significantly lower ee’s 
than the other derivatives explored (entries 8 and 9). Diastereoselectivity was approximately 
35:65 exo:endo for the majority of derivatives tested. An exception was aldehydes with 
substituents in the 2-position, namely 2-nitrocinnamaldehyde (entry 5) and the 1-napthyl 
aldehyde (entry 7), which gave appreciably higher endo diastereoselectivity (an average of 
18:82 exo:endo for the two compounds). It should also be noted that the (2R)-enantiomer was 
preferred for all derivatives and diastereoisomers. 
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R
O
H
+
R
CHO
+
CF3SO3H 
(0.1 eq) 
MeOH, rt
(10 mol%)
CHO
R
N
H
N
O
F3C
O
N
CO2Bn
(5R)-163
R
R
 
Entry R Yield (%) exo:endo exo % ee endo % ee 
1 Ph 84 35:65 65 73 
2
a
 4-OMe-C6H4 85 35:65 72 77 
3
a
 4-Cl-C6H4 86 34:66 68 82 
4 4-NO2-C6H4 85 36:64 59 77 
5 2-NO2-C6H4 85 17:83 65 84 
6 2-Nap 88 38:62 62 79 
7 1-Nap 83 19:81 61 73 
8
a
 Pr 76 35:65 30 46 
9 CO2Et 70 47:53 3 10 
Table 5.4: Substrate tolerance of catalyst (5R)-163 in Diels-Alder reactions  
a) Reactions at 5 ºC 
During substrate screening with racemic catalyst 114, attempts to expand reaction scope to 
other dienes, other than cyclopentadiene, had proved fruitless (see Section 2.5.2). A single 
reaction, using (E)-cinnamaldehyde 37 and cyclohexadiene with catalyst (5R)-163 was explored 
(Scheme 5.1). It should be noted that this reaction cannot be realised with MacMillan’s first or 
second generation imidazolidinone catalysts.
42,85
 Reaction was very sluggish, with no 
discernible product formation by TLC analysis after 18 h. When the reaction time was extended 
to 6 days, some product formation was observed with 30 % conversion of the aldehyde to a 5:95 
exo:endo mixture of diastereoisomeric products by 
1
H NMR spectroscopic analysis. In this case, 
separation of the two diastereoisomers was possible and only the endo diastereoisomer 
endo-(2R)-118 was isolated in 30 % yield. Derivatisation to benzoyl ester endo-(2R)-164 
allowed the ee of 85 % to be determined.
104
 The specific rotation of endo-(2R)-118 was 
determined to be -35.7, confirming the absolute configuration to be (1S,2R,3R,4R) by 
comparison to the literature value of +82 ((1R,2S,3S,4S) enantiomer, >95 % ee, c 1.0, 
dichloromethane).
85
 To our knowledge, this represents the first time endo-118 has been 
synthesised using organocatalytic methods. 
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Ph
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ii)
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(30 %) (47 %)
CHO
Ph Ph
OBz
 
Scheme 5.1: Reagents and conditions: i) 10 mol% (5R)-163, 10 mol% triflic acid, cyclohexadiene, methanol, rt, 
6 days; ii) sodium borohydride, methanol, rt then benzoyl chloride, triethylamine, DMAP, dichloromethane, rt. 
 
5.2 Initial mechanistic investigations 
Catalyst (5R)-163 had been identified as an enantioselective catalyst of the Diels-Alder 
cycloaddition and screened against a range of aldehydes. The resulting adducts possessed, in all 
cases, (2R)-absolute configuration and this gives an insight into the mechanism of action. Initial 
catalyst design had proposed a transoid iminium ion with (E)-geometry for the key C=N bond 
(A in Figure 5.1) rather than (Z)-geometry (B) or either of cisoid conformations C and D. 
N
N
O
R
2R1
N
N
O
R2R
1
Ph
H
Ph
H
HH
disfavoured
steric interaction
E Z N
N
O
R
2
R
1
N
N
O
R
2
R1
H H
E Z
Ph Ph
H H
Transoid Cisoid
A B C D
 
Figure 5.1: Proposed pyrazolidinone derived iminium ions 
If such a model were applied to asymmetric catalyst (5R)-163, products with a 
(2S)-configuration would be expected, assuming the diene approaches anti to the 
trifluoromethyl stereodirecting group (Figure 5.2i)). This is not observed experimentally, with 
the observed (2R)- product configuration consistent with either a (Z)-configuration in this bond 
(Figure 5.2ii)) or the transoid conformation shown in Figure 5.2iii) (exo approach of the diene 
would also give rise to the (2R)-configuration observed in the exo product).  
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Figure 5.2: endo approach of cyclopentadiene to iminium ion of catalyst (5R)-163 a) transoid with (E)-geometry; 
ii) transoid with (Z)-geometry; iii) cisoid with (E)-geometry 
In order to ascertain which of these models best represented the active catalyst species, we 
attempted to isolate an iminium ion from an appropriate catalyst. The isolation and 
characterisation of one such compound is outlined in the following section. 
 
5.2.1 Isolation of iminium ion on model system 
We began with model studies on racemic pyrazolidinone 114 (Scheme 5.2). Initial attempts to 
prepare and isolate an iminium ion followed the method of Mayr et al. with 114 and freshly 
distilled (E)-cinnamaldehyde 37 taken up in a bi-phasic mixture of ethyl acetate and a 0.17 M 
aqueous solution of triflic acid.
105
 
1
H NMR spectroscopic analysis of the crude reaction mixture 
after 24 h showed no reaction had taken place and a 1:1 mixture of 114 and (E)-cinnamaldehyde 
37 was returned. The reaction was repeated using THF as solvent but gave the same result after 
24 h reaction.  
N
H
N
O
Ph CO2Bn
114
N
N
O
Ph CO2Bn
SO3CF3
165
ii)
Ph
 
Scheme 5.2: Reagents and conditions: i) 0.17 M triflic acid (aq.), (E)-cinnamaldehyde 37, ethyl acetate or THF, 
24 h. 
In order to improve reactivity, conditions that resembled those used in catalysis were examined. 
Following the method of Tomkinson and co-workers, the hexafluorophosphoric acid salt 166 
was isolated by treatment of 114 with hexafluorophosphoric acid in ethyl acetate, then taken up 
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in dry methanol and (E)-cinnamaldehyde 37 added (Scheme 5.3).
52
 After 3 days, 
1
H NMR 
spectroscopy of a reaction sample indicated approximately 67 % conversion of 
(E)-cinnamaldehyde to a species with peaks consistent with 167. However, attempted isolation 
of 167 by crystallisation from a hot solution of diethyl ether and dichloromethane led to 
decomposition to a complex mixture of products. The same reaction using ethanol as solvent (in 
analogy to the work of Seebach and co-workers) was also investigated but reactivity was poor 
and a complex mixture of products resulted when reaction time was extended (2 weeks).
38
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N
N
O
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PF6
Ph
 
Scheme 5.3: Reagents and conditions: i) hexafluorophosphoric acid (~65 wt. % in water), ethyl acetate; ii) 
 (E)-cinnamaldehyde 37, methanol, 3 days. 
The same method was also applied to triflate salt 168. This was isolated from 114 in 70 % yield 
then suspended with (E)-cinnamaldehyde in methanol (Scheme 5.4). Conversion to the iminium 
was again sluggish; after 3 days 
1
H NMR spectroscopic analysis of a reaction sample indicated 
only 57 % conversion of (E)-cinnamaldehyde to a compound with selected peaks consistent 
with an iminium ion. Upon extended reaction time (3 weeks), 
1
H NMR spectroscopic analysis 
of this crude mixture indicated a complex mixture of products that included a compound 
consistent with an iminium ion. Trituration of this mixture in diethyl ether and the minimum of 
dichloromethane yielded 10 mg of a yellow solid identified as the ring-opened iminium ion 169. 
Repeating this process on the filtrate gave a further 3 mg of 169, giving a 9 % yield from triflate 
salt 168.  
N
H
N
O
Ph CO2BnN
H
N
O
Ph CO2Bn
114
i) ii)
HSO3CF3
(70 %) (9 %)
169168
SO3CF3
N
H
N
CO2BnPh
O
O
Ph
 
Scheme 5.4: Reagents and conditions: i) triflic acid, dichloromethane; ii) (E)-cinnamaldehyde 37, methanol, 
3 weeks. 
Low and high-resolution mass spectrometry confirmed a methoxy group had been incorporated 
into the expected iminium ion structure and single crystal X-ray crystallographic analysis was 
used to confirm the structure in the solid phase, including the configuration of the C=N and 
Chapter 5: Asymmetric catalysis with optimised catalyst (5R)-163 
 
 
 
86 
C=C double bonds ((Z)- and (E)-configuration, respectively) and the expected transoid 
conformation of these bonds (Figure 5.3). 
    74
169
SO3CF3
N
H
N
CO2BnPh
O
O
Ph
Z
E
 
Figure 5.3: Molecular representation of the X-ray crystal structure of 169 
Control of the configuration and conformation of these bonds is crucial to achieve high 
asymmetric control in enantioselective reactions.
1
 nOe spectroscopy was used to confirm the 
solution phase molecule was consistent with that observed in the solid state (Figure 5.4). The 
correlation of H
B
 to the ortho-aromatic proton (blue arrow) on irradiation indicated the C=C 
double bond had the expected (E)-configuration. Irradiation of the H
A
 proton (red arrows) 
showed correlation to H
C
 which is also consistent with the (E)-configuration of this bond. In 
addition, this correlation is consistent with the expected transoid conformation. Finally, the 
correlation of H
A
 to the side chain CHPh proton indicated the (Z)-configuration of the N=C 
bond. 
N
H
N
CO2Bn
Ph
O
O
HA
HB
HC
H
H correlation to HB (! 7.07 ppm, dd)
correlation to HA (! 9.08 ppm, d)
 
Figure 5.4: Representation of through space correlations as determined by nOe spectroscopy  
In conclusion, a number of conditions for the isolation of an iminium ion derived from racemic 
catalyst 114 were explored, with treatment of the triflate salt 168 with (E)-cinnamaldehyde 37 
in methanol over an extended reaction time proving fruitful. The isolated compound 169 was 
found to possess a (Z)-configuration in the key N=C double bond and a transoid conformation. 
Significantly, the structure of 169 indicated that methanolysis of the pyrazolidinone ring had 
also taken place during the reaction. The implications of this finding to the mechanism of action 
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of the pyrazolidinone catalyst series and, in particular, asymmetric catalyst (5R)-163, are 
explored in the following sections. 
 
5.2.2 Analysis of ring-opening of chiral catalyst (5R)-163 
The isolation of iminium 169 under conditions similar to those used in catalysis raised the 
question of whether a similar ring-opening process was taking place during catalytic reactions 
and, if so, were any newly formed compounds also catalytically active? We set out to 
investigate this possibility with asymmetric catalyst (5R)-163 (Figure 5.5). As (5R)-163 
contains an imido group, rather than the amidocarbamate functionality present in racemic 
catalyst 114, it was envisaged that methanolysis would take place in both an endo- (Step A) and 
exocyclic (Step C) manner. Step A resembles the methanolysis observed with racemic catalyst 
114 to give the acyclic hydrazide 170. 170 also contains an amide bond which might be 
susceptible to further attack by methanol, as shown in Step B. This would give rise to 
CBz-proline methyl ester 171 and hydrazide (R)-172. Steps C and D represent the reverse of 
this process, wherein the exocyclic methanolysis takes place first to generate (R)-84 which 
would then be opened to hydrazide (R)-172 after a second methanol attack. 
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Figure 5.5: Potential methanolysis pathways of chiral catalyst (5R)-163 
Treatment of (5R)-163 with triflic acid in methanol overnight led to full consumption of starting 
material and the isolation of ring-opened compound 170 in 39 % yield (Scheme 5.5). 
Compound 170 was analysed by both 
15
N NMR spectroscopy and by single crystal X-ray 
crystallography (Figure 5.6).  
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Scheme 5.5: Reagents and conditions: i) triflic acid, methanol. 
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Figure 5.6: Theoretical and experimentally determined 
15
N NMR spectroscopic data (in ppm) for 170 
(theoretically determined values in parenthesis) and molecular representation of its X-ray crystal structure 
It was also attempted to isolate enantioenriched (R)-172 from the same reaction but the 
compound had high solubility in aqueous media and could not be retrieved after basic work-up. 
However, when racemic pyrazolidinone 84 alone was treated overnight with triflic acid in 
methanol, the triflate salt of 172 was readily isolated in high yield (Scheme 5.6). 
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Scheme 5.6: Reagents and conditions: i) triflic acid, methanol. 
In order to determine the rate of formation of these species, the methanolysis of (5R)-163 was 
carried out in deuterated methanol in an NMR tube. Reaction was carried out at 19 mM, 
identical concentration to that used with (5R)-163 at 10 mol% catalyst loading. It was found 
that the relative concentrations of all the above compounds could be readily monitored by 
19
F NMR spectroscopy (apart from CBz-proline methyl ester d3-171). A typical NMR spectra 
from the experiment is shown in Figure 5.7. 
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Figure 5.7: Typical 
19
F NMR spectra from methanolysis of (5R)-163 studies 
The relative concentrations of fluorinated compounds (5R)-163, d3-170, (R)-84 and d3-(R)-172 
were monitored over the course of 18 h and the results are represented graphically in 
Figure 5.8.
106
 The relative concentration of CBz-proline methyl ester 171 was not monitored 
and was not included in the composition values. The graph shows that the catalyst (5R)-163 is 
consumed steadily, with relative composition dropping to less than 5 % after 7 h (orange line). 
The concentration of ring-opened compound d3-170 concordantly increases to 50 % after 6 h 
then remains essentially constant over the rest of the reaction (red line), consistent with very 
slow methanolysis of d3-170 to d3-(R)-172 (Step B). In a separate experiment, when only 170 
was exposed to triflic acid and methanol, less than 5 % methanolysis of 170 was observed after 
30 h.  
The exocyclic cleavage of (5R)-163, as outlined in Step C, is also observed via the increased 
concentration of (R)-84 during the early part of the reaction (blue line). The concentration of 
(R)-84 peaks at 24 % after approximately 2.5 h then declines steadily to 3 % after 18 h. This is 
due to the subsequent conversion of (R)-84 to ring-opened compound d3-(R)-172 (as in Step D). 
As d3-(R)-172 forms from (R)-84, the concentration of d3-(R)-172 is initially low but 
accelerates markedly as the concentration of its precursor increases (green line). After 18 h, 
there has been essentially full conversion of catalyst (5R)-163 to a mixture principally 
composed of ring-opened compounds d3-170 and d3-(R)-172 (50:47:3 d3-170: d3-(R)-172:(R)-
84).  
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Figure 5.8: Triflic acid catalysed methanolysis of (5R)-163 as monitored by 
1
H NMR spectroscopy 
 
5.2.3 Application of 170 to catalysis 
We had found that several new species were being derived from catalyst (5R)-163 under 
conditions very similar to those used during catalysis. The next stage was to evaluate whether 
these compounds were themselves catalytically active and so were responsible for the observed 
turnover. This was obviously complicated by the fact that these compounds were known to 
interconvert under the reaction conditions. The exception was ring-opened hydrazide 170 which 
was straightforward to isolate and found to be resistant to further methanolysis. Hence, the 
reactivity and enantioselectivity of this component could be unambiguously determined. 
Unfortunately, it was not possible to isolate authentic samples of either enantioenriched (R)-172 
or (R)-84. Instead, racemic 84 was examined with the knowledge that interconversion to 
racemic 172 would take place under the reaction conditions. Hence, the use of racemic 84 
served as a partial measure of both compounds activity as catalysts. 
Reactions with 170 and racemic 84 were run, each with 10 mol% loading at a catalyst 
concentration of 19 mM and monitored by TLC (Table 5.5). The reaction with (5R)-163 is 
included for comparison (entry 1, full consumption of (E)-cinnamaldehyde observed within 
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4 h). Isolated 170 proved to be an effective catalyst with complete reaction also observed within 
4 h (entry 3). In contrast, the reaction with racemic 84 had not reached completion after 24 h, 
with 
1
H NMR spectroscopic analysis indicating 82 % conversion in that time (entry 2). This 
implies that 84 and its ring-opened analogue are much less active than the other potential 
catalytic species present in the reaction. Hence, these compounds were not investigated further. 
In terms of enantioselectivity, isolated catalyst 170 gave a small improvement in the 
enantioselectivity of endo-(2R)-38 over the use of (5R)-163 (entry 3). The high reactivity of 
170 led us to investigate lowering catalyst loadings. Pleasingly, the use of just 1 mol% of 170 
showed complete reaction overnight with only a fractional drop in enantioselectivity (entry 4). 
For practical reasons, this reaction was run with a tenfold dilution in catalyst concentration to 
1.9 mM. 
Ph
O
H
+
37
Ph
CHO
+
exo-(2R)-38 endo-(2R)-38
CHO
Ph
(10 mol%)
CF3SO3H 
(0.1 eq) 
MeOH
catalyst
N
H
NH
O
F3CN
H
N
O
F3C
O
N
CO2Bn
(5R)-163 17084
N
H
H
N
O
N
CO2Bn
F3C
O
O
catalysts-
 
Entry Catalyst Time (h) Yield (%) exo:endo exo % ee endo % ee 
1 (5R)-163 4 84 35:65 65 73 
2 84 24 82 (conv.) 50:50 - - 
3 170 4 81 37:63 62 81 
4a 170 18 71 35:65 60 79 
Table 5.5: Variation of catalysts 
a) 1mol% catalyst loading (1 mol% triflic acid) 
Such a low catalyst loading, while more common in transition metal-based systems, is unusual 
in organocatalysis, particularly within the sphere of iminium ion catalysis.
44
 For this reason, we 
next set out to ascertain whether the high activity of acyclic catalyst 170 would be maintained 
with different aldehydes. The results with a small range of different aldehydes are outlined in 
Table 5.6, with the endo enantioselectivity for each substrate when catalyst (5R)-163 was 
employed included for comparison (see Table 5.4). The diastereoselectivity ratios for all 
substrates were found to be approximately identical to those observed with (5R)-163 as catalyst. 
A small increase in enantioselectivity was observed in most cases, particularly so in the case of 
4-methoxycinnamaldehyde where the endo ee increased from 77 % to 86 %, the highest 
observed in this series (entry 3). The exceptions were 4- and 2-nitrocinnamaldehyde which 
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showed essentially no change in enantioselectivity when 170 was used as catalyst compared to 
(5R)-163 (entries 3 and 4).
107
 With aliphatic aldehydes, catalyst (5R)-163 had generally given 
lower enantioselectivities than with aromatic substrates. While still modest, catalyst 170 showed 
an improved endo ee with aliphatic aldehyde (E)-2-hexen-1-al of 54 %, compared to only 46 % 
with (5R)-163 (entry 6). 
170
R
O
H +
R
CHO
+
CF3SO3H 
(0.01 eq) 
MeOH, rt
(1 mol%)
CHO
R
N
H
H
N
O
N
CO2Bn
F3C
O
O
 
Entry R 
Yield 
(%) 
exo:endo 
exo % 
ee 
endo % 
ee 
endo % ee 
(cat (5R)-163) 
1 Ph 71 35:65 60 79 73 
2 1-Nap 83 21:79 62 81 73 
3
a
 4-OMe-C6H4 86 36:64 71 86 77 
4
b
 4-NO2-C6H4 91 36:64 62 75 77 
5
b
 2-NO2-C6H4 74 15:85 67 83 84 
6 Pr 90 31:69 38 54 46 
7 CO2Et 65 44:56 5 13 10 
Table 5.6: Diels-Alder reaction catalysed by 170 
a) Reactions at 5 ºC; b) 5 mol% catalyst loading 
The reaction of cinnamaldehyde and cyclohexadiene was also re-tested with 10 mol% catalyst 
170 and it was found that endo-(2R)-118 was again the major product (exo:endo 6:94) and was 
isolated in an improved 43 % yield after just 3 days with an identical enantioselectivity to that 
of (5R)-163 (Scheme 5.7).  
(85 % ee)
Ph
O
H
37
i)
endo-(2R)-118
(43 %)
CHO
Ph
 
Scheme 5.7: Reagents and conditions: i) 10 mol% 170, 10 mol% triflic acid, cyclohexadiene, methanol, rt, 3 days.  
 
5.3 Investigations into active catalyst species 
It was now clear that catalyst 170 was a highly active and enantioselective iminium ion catalyst, 
with diastereo- and enantioselectivities very similar to those found when catalyst (5R)-163 was 
used. This raised the issue of whether 170 represented the single active catalytic component 
even when catalyst (5R)-163 was employed or whether the observed turnover was as a result of 
a combination of both catalysts acting simultaneously. Unfortunately, time constraints have 
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meant that a full exploration of the relative rates of the two catalysts has not been possible. 
Preliminary investigations to establish a general trend have been undertaken and are outlined in 
the following section. 
Establishing the reaction rate of catalyst (5R)-163 is challenging due to its rapid conversion to 
catalyst 170 under the established reaction conditions. It was hoped to partially overcome this 
issue by changing to a non-nucleophilic solvent, thereby eliminating the possibility of 
nucleophilic attack on the pyrazolidinone ring. DMF was selected as an alternative solvent due 
to its similar dielectric constant (38 compared to 33 for methanol)
108
 and the results with both 
catalysts in DMF are outlined in Table 5.7. While both catalysts showed reduced reactivity 
compared to their respective reactions in methanol, catalysis by 10 mol% (5R)-163 was 
particularly sluggish, with only a 25 % yield of exo and endo products after 48 h (entry 1). In 
addition, the enantioselectivities were significantly lower than in methanol at 21 % and 38 % 
for exo and endo, respectively. By comparison, 1 mol% of catalyst 170 gave a superior yield of 
products after 24 h (40 %) while maintaining good enantioselectivity (entry 2). These results 
indicate (5R)-163 was in and of itself not an effective catalyst. 
N
H
N
O
F3C
O
N
CO2Bn
Ph
O
H
+
37
(X mol%)
(5R)-163
Ph
CHO
+
exo-(2R)-38 endo-(2R)-38
CHO
Ph
DMF, rt
CF3SO3H 
(0.X eq)
170
N
H
H
N
O
N
CO2Bn
F3C
O
O
catalyst
 
Entry Catalyst 
Rxn. Time 
(h) 
Loading 
(mol%) 
Yield (%) exo:endo exo % ee endo % ee 
1 (5R)-163 48 10 25 45:55 21 38 
2 170 24 1 40 41:59 57 69 
Table 5.7: Diels-Alder reactions catalysed by (5R)-163 and 170  
In an effort to quantify the relative rates of reaction of ring-closed catalyst (5R)-163 and 
ring-opened catalyst 170 in methanol itself, the use of competition experiments was 
investigated. For this purpose, the enantiomer of catalyst (5R)-163 was synthesised, using the 
established synthetic route, from D-proline (Figure 5.9). 
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Figure 5.9: Conversion of D-proline 14* to (5S)-163*  
It was confirmed that (5S)-163* gave the opposite absolute configuration in Diels-Alder 
adducts exo- and endo-38 ((2S) as opposed to (2R)) by performing a reaction at 10 mol% 
catalyst loading (Table 5.8, entry 1). With this in mind, a series of experiments in which varying 
mixtures of (5S)-163* and 170 (always amounting to 10 mol% in total) were used to catalyse 
the reaction of (E)-cinnamaldehyde 37 and cyclopentadiene and the results are outlined in Table 
5.7. With each catalyst favouring the opposite enantiomer of the products, the ee of the products 
served as a partial measure of the relative reaction rates of the two species. This was 
complicated somewhat by the knowledge that (5S)-163* was inevitably undergoing 
ring-opening during the experiments, leading to the formation of the enantiomeric catalyst of 
170. Nonetheless, the experiments were deemed valuable as a qualitative measure of reactivity 
(the results with acyclic hydrazide 170 are included for reference, see entry 2). 
When a 1:1 mixture of (5S)-163* and 170 was used, the observed ee of the endo 
diastereoisomer was 68 % in favour of the (2R)-enantiomer (entry 3). This was consistent with 
that catalyst 170, which favours the (2R)-enantiomer, displaying a higher rate of catalytic 
turnover than (5S)-163*. It should be noted that the ee had decreased by 13 % in comparison to 
the use of 170 only (see entry 2), indicating some contribution from (5S)-163* to catalysis. This 
is more obvious when a 9:1 mixture of (5S)-163* and 170 was employed (entry 4). The ee 
reduced substantially to 50 %, though the (2R)-enantiomer was still favoured indicating the 
dominance of 170 as a catalyst, even at 9 times lower concentration than its ring-closed 
counterpart. These results would imply that catalyst 170 is sufficiently reactive to be the major 
source of catalytic turnover even at low concentrations. Nonetheless, there is likely also a 
contribution from (5R)-163 itself.  
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Entry 
(5S)-163*:170 
(mol%) 
Yield (%) exo:endo endo % eea 
1 10:0 96 36:64 –68 
2 0:10 81 37:63 81 
3 5:5 93 38:62 68 
4 9:1 95 37:63 50 
5 9.5:0.5 92 36:64 27 
Table 5.8: Competition experiments between (5S)-163* and 170 
a) negative ee refers to (2S) enantiomer 
In order to better understand the difference in turnover rates between catalysts (5R)-163 and 
170, monitoring experiments were run in deuterated methanol and followed by 
1
H NMR 
spectroscopy. In both cases, 1-methylnaphthalene was used as a reaction standard and this 
allowed straightforward calculation of reaction concentration. In order to achieve reactions with 
rates convenient to 
1
H NMR spectroscopic monitoring, the reaction with catalyst (5R)-163 was 
run at 4 mol% catalyst loading (76 mM) and reaction with 170 at 2 mol% loading (38 mM). A 
typical 
1
H NMR spectra from the experiment is shown in Figure 5.10.  
 
Figure 5.10: Typical 
19
F NMR spectra from Diels-Alder reaction catalysed by 170 
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The concentrations of (E)-cinnamaldehyde 37 and di-CD3 acetals 110, exo-(2R)- and 
endo-(2R)-111 were monitored over the course of 4.5 h (Figure 5.11). It was found that 
(E)-cinnamaldehyde and the corresponding acetal d6-110 were present in both reaction mixtures 
at all times, in an approximately constant ratio of 1.1:1 aldehyde:acetal. By contrast, only the 
di-CD3 acetals exo-(2R)- and endo-(2R)-174 were observed and never the parent aldehydes.
106
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Figure 5.11: Equilibria of di-CD3 acetals to aldehyde in CD3OD 
Of most relevance to this discussion is the combined rate of formation of di-CD3 acetal products 
exo-(2R)- and endo-(2R)-174 and this is represented graphically in Figure 5.12. The rate of 
formation with catalyst 170 is appreciably faster than with (5R)-163- after 256 min (4.27 h), 
reaction with 4 mol% (5R)-163 reached 76 % conversion (relative to the internal standard) 
whereas catalysis with 2 mol% 170 gave 75 % conversion in just 98 min (1.63 h). 
 
Figure 5.12: Graph of % conversion (against standard) vs. time (min) for Diels-Alder reactions catalysed by 
(5R)-163 (red) and 170 (blue) 
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It is clear from this and the other experiments undertaken to date that ring-opened catalyst 170 
represents a highly reactive catalyst and is significantly more reactive than ring-closed catalyst 
(5R)-163. Catalyst 170 also retains high reactivity at low catalyst loadings and, crucially, low 
catalyst concentration. However, full characterisation of the contribution of the two species to 
catalysis under standard reaction conditions remains challenging for a number of reasons. These 
include:  
• The large variation in the concentrations of (5R)-163 and 170 over the timecourse of the 
reaction. 
• The potential for different rates of iminium formation and subsequent cycloaddition 
with each catalyst. 
Despite these obstacles, studies thus far have strongly indicated that 170 makes the dominant 
contribution to catalysis, even when present at low concentrations relative to (5R)-163.  
 
5.4 Summary 
Asymmetric reaction with catalyst (5R)-163 was optimised and the catalyst was subsequently 
screened against a range of !,"-unsaturated aldehydes. Good ee’s were obtained for a variety of 
aromatic aldehydes but aliphatic aldehydes were less selective. (5R)-163 was also found to 
catalyse the reaction of (E)-cinnamaldehyde and cyclohexadiene with low turnover but good 
enantioselectivity. The (2R)-enantiomer was preferred for all exo and endo adducts and this led 
us to investigate the geometry of the key iminium ion intermediate. Racemic catalyst 114 was 
used as a model system and an iminium ion 169 was isolated from reaction in methanol. 169 
was found to have (Z)-geometry in the key N=C bond, consistent with the observed product 
stereochemistry, but also to have undergone ring-opening due to acid catalysed methanolysis of 
the pyrazolidinone ring. Chiral catalyst (5R)-163 was found to undergo a similar methanolysis 
under the reaction conditions at a rate comparable to the rate of product formation. One of the 
methanolysis products, chiral acyclic hydrazide 170, was readily isolated and found to be a 
highly active catalyst, effective at catalyst loadings as low as 1 mol%. Competition experiments 
and 
1
H NMR spectroscopy monitoring experiments indicated that 170 likely represents the key 
active catalytic species in reactions employing (5R)-163. 
 
5.5 Future work 
Future efforts in this area would look to elucidate the mechanism of action of ring-opened 
catalyst 170. Key to this would be isolation of iminium ion 173, derived from 170, and 
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information gathered from such a structure would be invaluable in understanding how the 
acyclic structure still successfully imparts good levels of diastereo- and enantioselectivity 
(Figure 5.13a)). The implications of the isolation of 170 on the catalytic mechanism of the other 
diastereoisomeric series have also not yet been investigated. That a similar ring-opening process 
has taken place with related compounds tested seems likely but has not been unambiguously 
established (Figure 5.13b)). Isolation and testing of the respective hydrazides, such as 174 
derived from methylmandelic acid (5S)-134, may furnish new catalysts with high levels of 
reactivity/stereoselectivity. 
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Figure 5.13: a) Iminium ion derived from hydrazide 173; b) Methanolysis of (5S)-134 to 174 
With the optimal catalyst established, it could then be applied to other iminium ion processes, 
such as Friedel-Crafts alkylation (Figure 5.13).  
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Figure 5.14: Iminium ion catalysed Friedel-Crafts alkylation 
 
Chapter 6: The Steglich rearrangement of pyrazolin-3-ones 
 
 
 
99 
Chapter 6: The Steglich rearrangement of pyrazolin-3-ones 
 
The suitability of pyrazolin-3-ones as substrates in an organocatalysed O- to C- carboxyl 
transfer process was explored. A model pyrazolinone substrate with N(2)-phenyl and 
C(5)-methyl substitution underwent rearrangement to a mixture of starting material 
C(4)-carboxylate, N(1)-carboxylate and parent pyrazolinone when treated with a series of Lewis 
base catalysts. Of these catalysts, DMAP, isothiourea DHPB and a triazolium N-heterocyclic 
carbene (NHC) were tested with a series of phenyl and/or methyl substituted pyrazolinones and 
the subsequent product distributions analysed. While the NHC catalyst generally gave 
C-carboxylation, DMAP and DHPB favour N-carboxylation, particularly at short (1 h) reaction 
times. The N-carboxylates arising from three of these pyrazolinones were isolated and 
re-exposed to catalyst in order to begin to rationalise the observed product distributions. These 
results were then applied to the development of an asymmetric protocol using chiral NHCs as 
catalysts and preliminary results are presented. 
 
6.1 Introduction 
The O- to C- carboxyl group transfer of oxazolyl carbonates to the corresponding !- or 
$-carboxyazlactone, catalysed by either DMAP or PPY, was first described by Steglich and 
Höfle in 1970 (Figure 6.1).
109
 The !-carboxyazlactone product was found to be generally 
favoured unless R
2
 was a strongly electron-withdrawing substituent (e.g. R
2
 = CF3 or 
4-O2NC6H4) or the !-position was highly sterically encumbered (e.g. R
1
 = t-Bu). 
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Figure 6.1: Steglich rearrangement of 5-oxazolyl carbonates 
A basic catalytic cycle for this reaction is outlined in Figure 6.2. Attack on carbonate A by the 
catalyst (DMAP or PPY) generates a tetrahedral intermediate B which, on breakdown, gives the 
key ion pair of dienolate C and carboxylated catalyst D. Recombination of this ion-pair can 
occur at either the !- or #-positions to generate the !- or #-carboxyazlactone products, 
respectively.  
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Figure 6.2: Catalytic cycle of Steglich rearrangement of 5-oxazolyl carbonates 
More recent investigations into the Steglich rearrangement have focused on an enantioselective 
variant of this reaction.
110
 The groups of Fu,
111
 Vedejs
112
 and Richards
113
 have shown that the 
chiral DMAP or PPY derivatives, shown in Figure 6.3, induce high enantioselectivity in the 
rearrangement. Examples of other enantioselective catalyst classes include phosphines by 
Vedejs,
112
 ammonium betaines by Ooi
114
 and bicyclic imidazoles developed by Zhang.
115
 The 
Smith group have investigated N-heterocyclic carbenes
116
 and isothioureas as both racemic and 
chiral catalysts.
117
 Selected results employing both these series of catalysts are outlined in the 
following section. 
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Figure 6.3: Selected catalysts of the asymmetric Steglich rearrangement 
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6.1.1 N-heterocyclic carbenes as catalysts 
The catalytically efficient racemic carboxyl transfer of 5-oxazolyl carbonates can be achieved 
using NHC-mediated catalysis.
118,119
 For example, NHC 176, generated in situ from triazolium 
salt 175 and KHMDS as base promotes the O- to !-C-carboxyl transfer (no #-isomer observed 
in this case) with a range of substrates at low catalyst loading (0.9 mol%, Table 6.1). A slight 
excess of triazolium salt was used relative to the KHMDS in order to ensure no free base was 
present. A range of substitution patterns were readily tolerated, in particular, !-branching at 
C(4) is well tolerated in contrast to the majority of catalysts in Figure 6.3, which are unable to 
rearrange such substrates (entry 4). Crossover experiments were used to prove that the C-C 
bond forming event was irreversible.
116,120
 
N N
N
Ph
BF4
175
N O
Ar
OR1
OR
2O
N O
Ar
O
OR2
O
R1 KHMDS
(mol%)
RT, 1 h
N N
N
Ph
176
THF
(Ar = 4-MeOC6H4)
 
Entry R
1
 R
2
 Loading (mol%) [Catalyst] (mM) Yield (%) 
1 Me Ph 0.9 4 82 
2 Bn Ph 0.9 4 80 
3 Bn Me 0.9 4 82 
4
a
 t-Bu Ph 4 5 73 
Table 6.1: Rearrangement of oxazolyl carbonates by NHC 176 
a) Reaction time 2 h 
Since the initial reports on oxazolyl carbonates, work within the Smith group has employed 
alternate heterocyclic substrates such as benzofuranyl and indolyl carbonates using 
NHC-mediated catalysis.
121,122
 For the O- to C- carboxyl transfer of furanyl carbonates, both 
DMAP and NHC 176 were shown to be effective catalysts but gave differing mixtures of !- and 
#- products (Table 6.2).123 DMAP modestly favoured the !-isomer 178 (entry 1) whilst NHC 
176 favoured the #-isomer 179 with high regiocontrol (entry 2). Upon lowering the loading and 
concentration of NHC, almost complete #-selectivity was observed (entry 3). 
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Entry Catalyst Loading (mol%) [Catalyst] (mM) Ratio (!:#) 
1 DMAP 10 34 60:40 
2
a
 176 10 34 16:84 
3
a
 176 0.9 3.4 <2:>98 
Table 6.2: Treatment of furanyl carbonate 177 with DMAP and 176 at different concentrations 
a) Catalyst generated in situ from triazolium salt 175 and KHMDS 
Furthermore, independent treatment of the individual regioisomers with NHC 176 at 31 mM 
gave rise in each case to an essentially identical 15:85 !:# mixture of the two regioisomers 
(Figure 6.4). This implies that C-carboxylation under NHC catalysis in this system is reversible, 
in contrast to that observed with oxazolyl carbonates, with the #-product favoured at 
equilibrium. 
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Figure 6.4: Re-treatment of !-isomer 178 and $-isomer 179 with NHC 176 
Recently, an enantioselective variant of the O- to C- carboxyl transfer of oxazolyl carbonates 
has been investigated.
116
 A structurally diverse selection of chiral azolium catalysts were tested 
with representative examples given in Figure 6.5. Triazolium derived catalysts, such as 
184-186, gave high conversion to exclusively C-carboxylated product 181 and generally higher 
enantioselectivities (though poor) than imidazolium and imidazolinium-derived catalysts 
(e.g. 187). Imidazolinium catalysts, such as 187, produced a mixture of C-carboxylated product 
181, parent azlactone 182 and diphenyl carbonate 183 in catalysis.  
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Figure 6.5: Rearrangement of oxazolyl carbonates by chiral NHCs 
A complete and unambiguous hypothesis by which azlactone 182 and diphenyl carbonate 183 
are produced under NHC catalysis has not yet been developed. However it can be assumed that 
in situ formation of phenoxide must be occurring to produce diphenyl carbonate 183.
124
 It has 
been postulated that phenoxide could be generated from collapse of 188 and 189, which 
represent tetrahedral intermediates within the proposed catalytic cycle (Figure 6.6a)). Partial 
evidence for the role of phenoxide came from treatment of oxazolyl carbonate 181 with 
potassium phenoxide and 18-crown-6 which generated a mixture of pyrazolinone 182 and 
diphenyl carbonate 183 (Figure 6.6b)).  
N O
O OPh
O
CAT
Ph
Ar
N O
O
PhO
O
CAT
Ar
Ph
188 189 181
N O
Ar
O
OPh
O
18-crown-6
Ph
(Ar = 4-MeOC6H4)
N O
Ar
O
182
Ph
PhO OPh
O
+
183
KOPh
b)a)
THF
 
Figure 6.6: a) Tetrahedral intermediates that could act as sources of phenoxide; b) Reaction of 181 with potassium 
phenoxide 
 
6.1.2 Isothioureas as catalysts 
While investigating alternative bases for carbene generation in the above reactions, it was found 
that amidine bases could themselves act as catalysts of the Steglich rearrangement of oxazolyl 
carbonates (Figure 6.7).
124
 While 6:7 ring-fused DBU gave modest conversion to parent 
pyrazolinone and diphenyl carbonate only, changing to 6:5 ring-fused DBN resulted in a 
significant change in product distribution with !-C-carboxylate product 181 now favoured 
(181:182 90:10). These initial findings prompted investigations into related catalytic 
architectures leading to the identification of cyclic isothiourea DHPB as an efficient achiral 
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catalyst for the rearrangement of oxazolyl and furanyl carbonates.
124,125
 For example, the 
rearrangement of carbonate 181 can be realised in excellent yield with just 2 mol% catalyst 
loading. Chiral analogues of DHPB, such as 190 and 191, were then found to be highly 
enantioselective catalysts of the Steglich rearrangement.
117
 For example, the same 
rearrangement with catalyst 191 can be realised at –60 ºC in 93 % yield and 96 % ee. 
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10 mol% (-60 °C), 
93 % yield, 96 % ee
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N
S
DHPB
2 mol%, 87 % yield
(181:182 >98:<2)
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N
DBN
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N
DBU
10 mol%, > 98 % conv.
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10 mol%, 40 % conv.
(181:182 0:40)
N O
Ar
O
182
Ph
PhO OPh
O
+ +
183
N
N
SPh
190
10 mol% (-50 °C), 
96 % yield, 91 % ee
catalyst
 
Figure 6.7: Rearrangement of substrate 181 by amidines and isothioureas (Ar = 4-MeOC6H4). 
Mechanistic studies, including isolation of a carboxylated isothiouronium intermediate 192 and 
reaction monitoring, were employed to confirm the reversibility of O-carboxylation and the 
irreversibility of the key C-carboxylation step (Figure 6.8a)).
126
 DFT calculations at the 
B3LYP/6-31G(d,p) theory level were performed on the reaction transition state to rationalise 
the observed high enantioselectivities (Figure 6.8b)).
117
 In this rationale, the phenyl 
stereodirecting group is forced into a pseudoaxial position by the N-carboxyl group which is 
assumed to lie co-planar with the rest of the heterocycle. Facial selectivity on the dienolate is 
then controlled by a combination of steric factors and charge matching. 
N
N
S
OPhO
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N
N
SPh
O O
Ph
N
O
O
R
PMP N
OO
R
N
N
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Ph
O
PhO
H
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ArH
H
Cl
192
a) b)
 
Figure 6.8: a) carboxylated isothiouronium intermediate 192; b) Model of calculated reaction transition state for 
reaction with catalyst 190 
 
6.1.3 Pyrazolyl carbonates as substrates 
Given our interest in the pyrazolidinone architecture, we wished to extend this methodology to 
the O- to C- carboxyl transfer of related pyrazolyl carbonates (Figure 6.9). To our knowledge, 
substrates of this type have never been tested as substrates in Steglich-type rearrangements. 
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Figure 6.9: Generic structure of a pyrazolyl carbonate 
A recent report by Feng et al. showed that pyrazolinones could be used as carbon-centered 
nucleophiles in an yttrium-catalysed Michael addition to $-ketoesters (Scheme 6.1).127,128 The 
reaction successfully forms two new stereocentres, with excellent stereocontrol, in the presence 
of chiral ligand 196. Interestingly, it was observed that changing the metal from yttrium to 
scandium led to a reversal in the absolute configuration of the products. 
N
N
O
Ph
Bn
+
(96 % ee)
(93 %)
i)
N
N
O
Ph
BnPh
O
OEt
O
(>49:1 d.r.)
CO2Et
O
Ph
193 194 195
N N
NO N OH
Ar
H
Ar
O O
196  
Scheme 6.1: Reagents and conditions: i) 5 mol% Y(OTf)3, 5.5 mol% 196, DCM, 0 ºC, 48 h. 
(Ar = 2,4,6-trimethylphenyl) 
Although our potential catalytic system would be quite different, we were encouraged by the 
readiness of pyrazolinones to operate as carbon-centred nucleophiles (Figure 6.10). Our strategy 
would employ a similar mechanism to that observed with oxazolyl carbonates (see Figure 6.2) 
with dienolate C and carboxylate D generated in situ from pyrazolyl carbonate A. 
Recombination could then occur either !- or #- to the carbonyl to give C-carboxylate E or 
N-carboxylate F, respectively. If conditions could be found to control the regioselectivity of the 
process to favour !-enolate reactivity, this would then allow rapid access to highly 
functionalised pyrazolinones containing a quaternary stereocentre, which would be of 
significant biological interest.
129
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Figure 6.10: Proposed catalytic cycle for the Steglich-type rearrangement of pyrazolyl carbonates 
 
6.2 Proof of concept 
Initial investigations focused on establishing whether pyrazolyl carbonates were suitable 
substrates for Steglich-type rearrangement reactions. Parent pyrazolinone 198 was readily 
prepared from the commercially available ketoester 197 and phenylhydrazine (Scheme 6.2). 
Compounds such as 198 have three possible tautomeric forms: 198 (CH), 198´ (NH) and 198˝ 
(OH) and the ratio of these forms can vary with temperature, solvent etc. (Figure 6.11).
130,131
 In 
the case of pyrazolinone 198, a 5:1 mixture of tautomers 198 and 198´ was observed on 
1
H NMR spectroscopic analysis in CDCl3. 
N
H
N
O
Ph
198
N
N
O
Ph
N
N
OH
Ph
198' 198''  
Figure 6.11: Potential tautomeric forms of pyrazolinone 198 
Fortunately, the presence of these isomeric forms in solution did not appear to hinder carbonate 
formation, with model substrate 199 obtained in 97 % yield after treatment of 198 with phenyl 
chloroformate. The site of carboxylation for this, and related compounds, was established by a 
combination of 
1
H and 
13
C NMR spectroscopy and is discussed in Section 6.2.1. 
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Scheme 6.2: Reagents and conditions: i) phenylhydrazine, ethanol, reflux; ii) triethylamine, phenyl chloroformate, 
THF, 0 ºC to rt. 
Pleasingly, treatment of carbonate 199 with DMAP resulted in significant levels of 
rearrangement after just 1 h, as judged by 
1
H NMR spectroscopic analysis of the crude reaction 
mixture (Table 6.3, entry 1). The major product after this period was assigned as the 
N-carboxylate 201, making up 65 % of the reaction mixture while the desired C-carboxylate 
200 was formed in only trace quantities (5 %). In a repeat reaction, N-carboxylate 201 was 
isolated from an essentially identical mixture in 56 % yield and a crystal structure obtained to 
corroborate the assigned structure (Figure 6.12).  
   
N
N
O
Ph
O
OPh
201
201  
Figure 6.12: Molecular representation of the single crystal structure of 201 
Re-treatment of this reaction mixture with DMAP overnight, led to near completion (98 % 
conversion) and C-carboxylate 200 was now the major product (42 % isolated yield, entry 2). 
Similar product distributions were obtained after 1 h when PPY was used as the catalyst (entry 
3). The results when DHPB were used follow a similar trend but it was noted that, at longer 
reaction times, the major component was the parent pyrazolinone 198 (entries 4 and 5).  
In contrast, when the NHC 176 (generated from the appropriate triazolium salt and KHMDS) 
was used in THF, reaction was complete in just 1 h with C-carboxylate 200 as the major 
product, isolated in 65 % yield (entry 6). Levels of parent compound formation were low 
(17 %) and no N-carboxylate could be observed. In order to verify that this change in product 
distribution was due to the change in catalyst and not solvent, a reaction using DMAP as 
catalyst in THF was run (compare entries 2 and 7). It was found that levels of product 200 in 
THF were slightly lower (62 % in DCM against 45 % in THF) although this appeared to be a 
result of a lower reaction rate in THF (90 % conversion against 98 % in DCM).
132
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N N
N
PhDCM
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N
N
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199
OPh
O
Ph
N
N
O
Ph
O OPh
201200
N
N
O
Ph
PhO O
RT
N
N
O
Ph
++
198 176
 
% Ratio 
Entry Catalyst Time (h) 
199 200 198 201 
200 yield 
(%) 
1 DMAP 1 27 5 3 65  
2 DMAP o/n 2 62 25 11 42 
3 PPY 1 8 4 8 80  
4 DHPB 1 34 6 2 58  
5 DHPB o/n 6 13 64 17  
6
a,b
 176 1 0 83 17 0 65 
7
 a
 DMAP o/n 10 45 15 30  
Table 6.3: Rearrangement of pyrazolyl carbonate 199-ratio of products 
a) Reaction solvent = THF 
b) 176 derived from in situ deprotonation of triazolium salt 175 with KHMDS 
 
6.2.1 Identification of site of carboxylation 
The three isomeric products resulting from carboxylation of parent pyrazolinone 198 were 
unambiguously assigned by a combination of 
1
H and 
13
C NMR spectroscopy (Table 6.4). 
C-carboxylate 200 (entry 2) is readily identified by the upfield shift of the C(4)-methyl group 
protons, relative to both O- (entry 1) and N-carboxylates (entries 1 and 3, respectively). A 
similar upfield trend upon C-carboxylation is also evident for the chemical shift of the C(4) 
atom in 
13
C NMR spectroscopy. The O- and N-carboxylates can then be distinguished by the 
13
C chemical shift of C(3); O-carboxylate 199 has a C(3) chemical shift consistent with an enol 
ester (141.6 ppm), whereas N-carboxylate 201 has a shift consistent with a ketone (167.9 ppm). 
These trends were used to identify the site of carboxylation for all the subsequent pyrazolinone 
substrates discussed in the following section. 
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Chemical shift (ppm) 
Entry Substrate 
C(4)CH3 C(3) C(4) 
1 199 2.00 141.6 104.3 
2 200 1.73 170.4 61.6 
3 201 1.93 167.9 111.0 
Table 6.4: Selected 
1
H and 
13
C NMR chemical shifts for compounds 199, 200 and 201 
 
6.3 Substrate optimisation 
It had now been established that pyrazolyl carbonates could act as effective substrates in 
organocatalysed Steglich-type rearrangements. We next sought to investigate how other 
substituent patterns affected reactivity and regioselectivity. In particular, we focused on the 
substituents at C(5), adjacent to the reactive centre, and the substituent at N(1). To this end, 
three other pyrazolyl carbonates were prepared, using similar chemistry to that established for 
199 (Scheme 6.3). Condensation of the appropriate hydrazine with an !-methyl "-ketoester in 
refluxing ethanol proceeded successfully in each case, although 205 required a second reflux in 
toluene to give good conversion and an isolated yield of 64 %.
133
 As with N(2)-phenyl, 
C(5)-methyl compound 198, each pyrazolinone gave a mixture of CH and NH tautomeric forms 
when analysed by 
1
H NMR spectroscopy.
130,131
 In contrast, upon IR spectroscopic analysis of 
the respective solids, di-phenyl substrate 205 was assigned as the CH form while di-methyl 
substrate 203 was identified as exclusively the OH tautomer 203˝ (Figure 6.13). 
205
N
N
O
Ph Ph
N
N
OH
203''  
Figure 6.13: Tautomers 203˝ and 205˝  
With the necessary precursors in hand, straightforward carbonate formation gave the desired 
products 206–208. The structure of carbonate 207 was confirmed by crystal structure analysis 
(Figure 6.14). 
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Scheme 6.3: Reagents and conditions: i) phenylhydrazine or methylhydrazine, ethanol, reflux; ii) (for 205 only) 
toluene, reflux; iii) triethylamine, phenyl chloroformate, THF, 0 ºC to rt. 
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Figure 6.14: Molecular representation of the single crystal structure of 207 
Interestingly, it was found that dimethyl substrate 206 underwent slow (> 24 h) rearrangement 
to N-carboxylate 209 upon standing at room temperature (Figure 6.15). This necessitated 
storage of the substrate at low temperature (5 ºC), which arrested the process. In addition, it was 
found that the parent pyrazolinone 203 was removed from the reaction mixture during acidic 
work-up. Hence, for di-methyl substrate 206 an alternative work-up was used in which the 
reaction mixture was concentrated in vacuo and then analysed directly by 
1
H NMR 
spectroscopy. 
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Figure 6.15: Spontaneous rearrangement of 206 to 209 at room temperature 
Also investigated briefly was the influence of the substituent at the reactive centre (the 
C(4)-position). For related oxazolyl carbonates the formation of a quaternary stereocentre at 
carbon is not just desirable but essential for successful Steglich rearrangement and we were 
interested if this was also the case in this series.
118
 C(4)-Unsubstituted pyrazolinone 65 was 
already available as it had been synthesised previously within the group (see Section 2.1) and 
was converted to its pyrazolyl carbonate 210 in 56 % yield (Scheme 6.4). The influence of the 
methyl group at C(4) could then be inferred by comparison with the results of C(4)-methyl 
substrate 208. 
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Scheme 6.4: Reagents and conditions: i) triethylamine, phenyl chloroformate, THF, 0 ºC to rt. 
Each substrate was tested with DMAP, achiral isothiourea DHPB and the achiral NHC 176 and 
the results with each catalyst are outlined in the following section. 
 
6.3.1 Testing of substrates 
The results when each of the new substrates was treated with 20 mol% DMAP in DCM for 1 h 
are outlined in Table 6.5. Also included is the result under the same conditions for N(2)-phenyl, 
C(5)-methyl test substrate 199 (entry 1). Reactivity appeared strongly influenced by C(5) 
substitution, with C(5)-methyl substrates (entries 1 and 2) showing much higher reactivity than 
C(5)-phenyl (entries 3 and 4). In all cases, conversion was mainly to the N-carboxylate. 
DCM
20 mol% DMAP
N
N
O
R1
OPh
O
R2
N
N
O
R1 R2
O OPh
N
N
O
R1 R2
PhO O
RT, 1 h
N
N
O
R1 R2
++
R1 = Me, R2 = Me
R1 = Ph, R2 = Me
 R1 = Me, R2 = Ph 200
212
211
198
204
203
201
214
209
199
207
206
R1 = Ph, R2 = Ph 213 205 215208
C PAR NO
 
% Ratio 
Entry Substrate R
1
 R
2
 
O C PAR N 
1 199 Me Ph 27 5 3 65 
2 206 Me Me 53 0 0 47 
3 207 Ph Me 83 0 2 15 
4 208 Ph Ph 79 5 4 12 
Table 6.5: 1 h rearrangement of substrates with catalytic DMAP  
(O = O-carboxylate substrate, C = C-carboxylate, PAR = parent compound, N = N-carboxylate) 
These reaction mixtures were then re-treated with DMAP overnight (apart from di-methyl 
substrate 206 where a separate overnight reaction was run) and the results are outlined in 
Table 6.6. Di-methyl carbonate 206 showed good conversion to almost exclusively the 
N-carboxylate (entry 2). N(2)-methyl, C(5)-phenyl carbonate 207 also favoured the 
N-carboxylate but with low 38 % conversion even with the extended reaction time (entry 3). 
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Better reactivity was observed with di-phenyl substrate 208 (78 % conversion), with the major 
component being rearrangement product, isolated in 24 % yield (entry 4). 
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O OPh
N
N
O
R1 R2
PhO O
N
N
O
R1 R2
++
R1 = Me, R2 = Me
R1 = Ph, R2 = Me
 R1 = Me, R2 = Ph 200
212
211
198
204
203
201
214
209
199
207
206
R1 = Ph, R2 = Ph 213 205 215208
C PAR NO
DCM
20 mol% DMAP
RT, o/n
 
% Ratio 
Entry Substrate R
1
 R
2
 
O C PAR N 
Yield 
(%) 
1 199 Me Ph 2 62 25 11 42 (200) 
2 206 Me Me 3 0 5 92 77 (209) 
3 207 Ph Me 62 2 6 31 14 (214) 
4 208 Ph Ph 22 42 32 4 24 (213) 
Table 6.6: Overnight rearrangement of substrates with catalytic DMAP 
(O = O-carboxylate substrate, C = C-carboxylate, PAR = parent compound, N = N-carboxylate) 
In contrast, treatment of C(4)-unsubstituted 210 with DMAP overnight gave full conversion to 
parent pyrazolinone 65, as judged by 
1
H NMR spectroscopic analysis of the crude reaction 
mixture (Scheme 6.5). 65 was isolated in 54 % yield along with diphenyl carbonate 183. When 
a methyl group is present as in substrate 208, the major component was C-carboxylated product 
213 (see Table 6.6, entry 4). These results are consistent with the observation for oxazolyl 
carbonates that formation of a quaternary stereocentre at carbon is necessary for successful 
reaction with the absence of such a substituent leading only to return of the parent 
heterocycle.
118,119
 However, the results did indicate that the first step of the catalytic cycle- the 
removal of the carbonate group by the nucleophilic catalyst- was proceeding with this substrate. 
DHPB was also tested as a catalyst under identical conditions and gave rise to a similar crude 
reaction mixture. 
i)
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Ph
OPh
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Ph N
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Ph Ph(54 %) PhO OPh
O
210 65
+
183
 
Scheme 6.5: Reagents and conditions: DMAP (20 mol%), DCM, rt.  
The same substrates were next treated with 20 mol% DHPB in DCM and the results after 1 h 
are outlined in Table 6.7. The result for N(2)-phenyl, C(5)-methyl test substrate 199 is included 
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for reference (entry 1). Conversion levels were very similar to those obtained with DMAP (see 
Table 6.5) with the exception of di-methyl substrate 206 which showed almost complete 
conversion to the N-carboxylate (96 %, entry 2) compared to only 47 % with DMAP at the 
same timepoint.  
N
N
O
R1
OPh
O
R2
N
N
O
R1 R2
O OPh
N
N
O
R1 R2
PhO O
N
N
O
R1 R2
++
R1 = Me, R2 = Me
R1 = Ph, R2 = Me
 R1 = Me, R2 = Ph 200
212
211
198
204
203
201
214
209
199
207
206
R1 = Ph, R2 = Ph 213 205 215208
C PAR NO
DCM
20 mol% DHPB
RT, 1 h
 
% Ratio 
Entry Substrate R
1
 R
2
 
O C PAR N 
1 199 Me Ph 34 6 2 58 
2 206 Me Me 3 0 1 96 
3 207 Ph Me 87 0 4 9 
4 208 Ph Ph 74 1 13 12 
Table 6.7: 1 h rearrangement of substrates with catalytic DHPB 
(O = O-carboxylate substrate, C = C-carboxylate, PAR = parent compound, N = N-carboxylate) 
In all but one case, carbonate cleavage to the parent pyrazolinone was the major outcome of 
treatment with DHPB overnight (Table 6.8). The N-carboxylate 209 remained the major product 
with di-methyl substrate 206 (61 %, entry 2) but this was a reduction on the quantity observed 
after 1 h, with a concomitant increase in the parent compound. These results imply that DHPB 
is generally less efficient than DMAP at re-delivering the carboxylate moiety to either carbon or 
nitrogen, though especially to carbon.  
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N
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R1 R2
++
R1 = Me, R2 = Me
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C PAR NO
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20 mol% DHPB
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% Ratio 
Entry Substrate R
1
 R
2
 
O C PAR N 
1 199 Me Ph 6 13 64 17 
2 206 Me Me 3 0 36 61 
3 207 Ph Me 34 2 44 20 
4 208 Ph Ph 8 8 81 3 
Table 6.8: Overnight rearrangement of substrates with catalytic DHPB 
(O = O-carboxylate substrate, C = C-carboxylate, PAR = parent compound, N = N-carboxylate) 
The substrates were also treated with NHC 176 (derived from treatment of triazolium salt 175 
with KHMDS) and the results are outlined in Table 6.9. The result for N(2)-phenyl, 
C(5)-methyl test substrate 199 is once again included for reference (entry 1). Overall, NHC 
catalysis was superior in terms of both reaction rate and levels of conversion to C-carboxyl 
products compared to the other catalysts tested. The exception was di-phenyl substrate 208 
where only 33 % conversion was observed (entry 4). Reaction was extended overnight which 
significantly improved conversion though the major component was parent pyrazolinone 205 
(78 %, entry 4). The other compounds all showed good selectivity for the C-carboxylate with 
the product isolated in moderate yields (45-65 %). 
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% Ratio 
Entry Substrate R
1
 R
2
 
O C PAR N 
Yield (%) 
1 199 Me Ph 0 83 17 0 65 (200) 
2 206 Me Me 0 70 28 2 45 (211) 
3 207 Ph Me 1 83 16 0 55 (212) 
4 208 Ph Ph 67 5 28 9 - 
5
a
 208 Ph Ph 13 9 78 0 - 
Table 6.9: Rearrangement of substrates with NHC derived from triazolium 176 
(O = O-carboxylate substrate, C = C-carboxylate, PAR = parent compound, N = N-carboxylate) 
a) Overnight reaction 
The testing of substrates 206-208 with the various Lewis base catalysts showed product 
distributions were dependent on reaction time, catalyst and substrate. DMAP was an effective 
catalyst, giving either predominantly N- or C-carboxylation depending on the substrate and 
reaction time. Under DHPB catalysis, high levels of parent pyrazolinone were observed in all 
cases overnight. The high reactivity of NHC 176 led to significantly shorter reaction times (1 h 
compared to overnight reaction). C-Carboxylation was favoured for all but di-phenyl substrate 
208. 
 
6.3.2 Re-treatment of N-carboxylates  
The testing of pyrazolyl carbonates 199, 206-208 with the various Lewis base catalysts resulted 
in a range of different reactivities and product distributions. To probe the mechanism of these 
processes, the N-carboxylates 201, 209 and 214 were treated in isolation with DMAP, DHPB 
and NHC 176. Despite several attempts, it was not possible to isolate di-phenyl N-carboxylate 
215. This was due to the compound only ever being formed in trace quantities during catalysis. 
(For this reason, the assignment of this component as 215 is from the crude 
1
H NMR spectrum 
and should be considered tentative.) 
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The three isolated N-carboxylates were first treated with 20 mol% DMAP and the results are 
presented in Table 6.10. Only N-carboxylate 201 showed any significant conversion (29 %) and 
this was predominantly to C-carboxylate 200 (entry 1). This would imply that N-carboxylate 
201 represents an intermediate in the conversion of 199 to 200. For the other compounds, 
DMAP appears unable to rearrange the N-carboxylate to any significant extent (entries 2 and 3). 
R1 = Me, R2 = Me
 R1 = Me, R2 = Ph 199
206
200
211
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201
209
N
N
O
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OPh
O
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N
N
O
R1 R2
O OPh N
N
O
R1 R2
PhO O
N
N
O
R1 R2
+ +
R1 = Ph, R2 = Me 207 212 204214
C PARN O
DCM
20 mol% DMAP
RT, o/n
 
% Ratio 
Entry Compound R
1
 R
2
 
O C PAR N 
1 201 Me Ph 6 19 4 71 
2 209 Me Me 1 0 3 96 
3 214 Ph Me 2 4 2 92 
Table 6.10: Rearrangement of N-carboxylates with DMAP 
(O = O-carboxylate substrate, C = C-carboxylate, PAR = parent compound, N = N-carboxylate) 
When the same compounds were treated with DHPB, conversions were significantly higher, 
particularly with 214 where almost full conversion to pyrazolinone 204 was observed after 
overnight reaction (entry 3, Table 6.11). In all cases, the pyrazolinone was the major product. 
These results imply that DHPB is not an effective catalyst at rearranging the carboxyl group to 
carbon, regardless of the starting position (O or N). 
R1 = Me, R2 = Me
 R1 = Me, R2 = Ph 199
206
200
211
198
203
201
209
N
N
O
R1
OPh
O
R2
N
N
O
R1 R2
O OPh N
N
O
R1 R2
PhO O
N
N
O
R1 R2
+ +
R1 = Ph, R2 = Me 207 212 204214
C PARN O
DCM
20 mol% DHPB
RT, o/n
 
% Ratio 
Entry Compound R
1
 R
2
 
O C PAR N 
1 201 Me Ph 5 5 29 61 
2 209 Me Me 2 0 26 72 
3 214 Ph Me 2 0 98 0 
Table 6.11: Rearrangement of N-carboxylates with DHPB 
(O = O-carboxylate substrate, C = C-carboxylate, PAR = parent compound, N = N-carboxylate) 
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The final step was treatment with the NHC catalyst derived from triazolium salt 175 
(Table 6.12). Despite the short (1 h) reaction time, conversions were generally higher than with 
the other catalysts tested, indicating the reactivity of the active NHC catalyst. Di-methyl 
N-carboxylate 209 showed the highest conversion and this was predominantly to the 
C-carboxylate product 211 (entry 2). N(2)-phenyl, C(5)-methyl 201 also favoured 
C-carboxylation (entry 1) while N(2)-methyl, C(5)-phenyl 214 gave predominantly the parent 
pyrazolinone (entry 2). This result was unexpected as reaction with O-carboxylate 207 had 
given 83 % C-carboxylated product and none of the N-carboxylate (see Table 6.9). 
R1 = Me, R2 = Me
 R1 = Me, R2 = Ph 199
206
200
211
198
203
201
209
N
N
O
R1
OPh
O
R2
N
N
O
R1 R2
O OPh N
N
O
R1 R2
PhO O
N
N
O
R1 R2
+ +
R1 = Ph, R2 = Me 207 212 204214
20 mol% 175
RT, 1 h
THF
18 mol % KHMDS
C PARN O
 
% Ratio 
Entry Compound R
1
 R
2
 
O C PAR N 
1 201 Me Ph 0 43 21 36 
2 209 Me Me 0 63 31 6 
3 214 Ph Me 1 14 63 22 
Table 6.12: Rearrangement of N-carboxylates with NHC derived from triazolium 175 
(O = O-carboxylate substrate, C = C-carboxylate, PAR = parent compound, N = N-carboxylate) 
The testing of N-carboxylates 201, 209 and 214 with the various nucleophilic catalysts showed 
a range of reactivities dependent on both the catalyst and the substrate. DMAP showed some 
conversion with N(2)-phenyl, C(5)-methyl carboxylate 201 though generally little 
rearrangement was observed. The major product upon rearrangement in all cases with DHPB 
was the respective parent pyrazolinone. With the carbene derived from triazolium salt 175, 
dominant C-carboxylation appeared to correlate with C(5)-methyl substitution; C(5)-phenyl 
substrate 214 giving mainly parent pyrazolinone. 
 
6.4 Asymmetric Steglich rearrangement of pyrazolin-3-ones 
6.4.1 Model studies 
Attention now turned to the development of an asymmetric protocol in the hopes of producing 
rearrangement products with high levels of enantiocontrol. At this point, little was known about 
the reactivity and selectivity of pyrazolinones in such enantioselective processes and so the 
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results obtained within the group for oxazolyl carbonates were used as a guide.
116,117
 Hence, the 
examination of an enantioselective protocol began with the testing of chiral isothiourea 191, 
which was found to catalyse the rearrangement of oxazolyl carbonates with high 
enantioselectivity (Table 6.13, entry 2).
116
 Pyrazolinone 199 was initially chosen as the model 
substrate and reaction was carried out with 10 mol% catalyst loading. However, despite 
reasonable 85 % conversion overnight a mixture of products resulted, principal of which was 
N-carboxylate 201 (73 %) and only trace C-carboxylate 200 (2 %). An alternative isothiourea 
scaffold, benzotetramisole 190, was also investigated but this was found to give just 14 % 
conversion overnight with only trace product produced (entry 1). As an alternative, di-methyl 
substrate 206 was tested with catalyst 191 (entry 3). Reactivity was slightly improved (95 %) 
but no C-carboxylate product was observed, only N-carboxylate. In no case was the 
C-carboxylated product isolated.
134
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OPh
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R1 R2
O OPh
N
N
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R1 R2
PhO O
N
N
O
R1 R2
++
catalyst
(10 mol%)
RT, o/n
DCM
R1 = Me, R2 = Me
 R1 = Me, R2 = Ph 200
211
198
203
201
209
199
206
C PAR NO
N
SN
Ph
N
N
SPh
191190  
% Ratio 
Entry Substrate R
1
 R
2
 Catalyst 
O C PAR N 
1 199 Me Ph 190 82 2 12 4 
2 199 Me Ph 191 15 2 10 73 
3 206 Me Me 191 5 0 3 93 
Table 6.13: Rearrangement of pyrazolyl carbonates 199 and 206 by chiral isothiourea organocatalysts 
The poor levels of reactivity and/or product conversion observed in the initial screen of chiral 
isothioureas led us to investigate alternative modes of catalytic activation. In the racemic 
organocatalysed reaction it was established that NHCs were superior catalysts to isothioureas, 
both in terms of reactivity and product distributions. Hence, a selection of chiral triazolium-
derived NHC catalysts were tested with substrate 199 and the results are shown in Table 6.14.
135
 
Reactions were carried out in THF as before, but also in toluene, as toluene had been found to 
be the optimum solvent for high enantioselectivity in reactions with oxazolyl carbonates.
116
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Reactions were carried out at a reduced catalyst loading of 10 mol% and examined after 3 h. 
Results with the NHC derived from triazolium salt 184 were disappointing, less than 20 % 
conversion after 3 h in both solvents was observed with only trace C-carboxylate formation, the 
major component being parent pyrazolinone 198 (entries 1 and 2). More encouraging were the 
results with the NHC of oxazolidinone-derived triazolium salt 185, where greater than 
90 % conversion was observed in both solvents (entries 3 and 4). More importantly, 
C-carboxylate (–)-200 was the major component and was isolated in 55 % yield and 46 % ee in 
THF (entry 3). The yield improved to 74 % when toluene was the solvent, with no change in 
ee (entry 4). The NHC of triazolium salt 186 also proved to be effective, giving C-carboxylate 
(–)-200 in 61 % yield and 46 % ee in THF (entry 5). As with 185, changing solvent to toluene 
increased the yield, to 71 %, but here also gave a 10 % enhancement of enantioselectivity to 
56 % (entry 6). It should be noted that the absolute configuration of the C-carboxylated product 
(–)-200 has not yet been determined (the minus sign refers to the compounds optical rotation). 
N
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O
Ph
N
N
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O OPh
201200
N
N
O
Ph
PhO O
N
N
O
Ph
++
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(9 mol%)
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(10 mol%)
N N
N
Ph
BF4
186
O
Ph
N N
N
Ph
BF4
184
OTBS
Ph
Ph
N N
N
O
Ph
BF4
185  
% Ratio 
Entry Precatalyst Solvent 
199 200 198 201 
Yield (%) % ee
a
 
1 THF 82 2 12 4 - - 
2 
184 
toluene 86 3 10 1 - - 
3 THF 7 82 10 1 55 –46 
4 
185 
toluene 2 89 8 1 74 –46 
5 THF 2 87 10 1 61 –46 
6 
186 
toluene 2 87 11 0 71 –56 
Table 6.14: Rearrangement of pyrazolyl carbonate 199 by chiral NHC organocatalysts 
a)
 
+ and – signs refer to sign of the products optical rotation 
As catalyst 186 in toluene gave the best ee and good yield it was decided to focus attention on 
related morpholinone-derived catalyst architectures in an attempt to further optimise yield and 
enantioselectivity. In particular, catalysts based on the structure pioneered by Rovis were 
investigated (Table 6.15). These catalysts have found application in a range of organocatalysed 
processes, particularly in the catalytic generation of acyl anion equivalents.
136
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A small range of catalysts bearing different protecting groups on nitrogen were then tested, in 
toluene, against the model substrate. Despite the relatively small structural differences between 
each catalyst, significant differences in reactivity and enantioselectivity were observed. The 
NHCs derived from precatalysts 216 and 217 each gave 99 % conversion in 3 h with essentially 
identical levels of C-carboxylate formation (entries 1 and 2). Only in the reaction with 
precatalyst 217 (entry 2) was the product (–)-200 isolated and this gave a final yield of 61 % 
and 61 % ee. For the reaction with precatalyst 216, the ee was obtained from the crude reaction 
mixture and was slightly lower at 46 % (entry 1). Surprisingly, despite the absolute 
configuration of each catalyst being different, they give the same enantiomer as the major 
product. This could indicate that a markedly different transition state is favoured in each 
reaction, resulting in an opposite sense of stereoinduction (where each catalysts absolute 
configuration is the same).
137
 In contrast, the NHC derived from precatalyst 218 showed poor 
reactivity, with an extended reaction time of 18 h necessary to achieve 92 % conversion (entry 
3). In addition, the desired C-carboxylate (+)-200 was only a minor component of the crude 
reaction mixture (30 %), the main product being the parent pyrazolinone 198 (57 %). The 
enantiomeric excess of (+)-200 was obtained from the crude reaction mixture and found to be 
40 %, the lowest for this series of catalysts.  
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N N
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N N
N
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BF4O
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N N
N
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ClO
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% Ratio 
Entry Precatalyst 
SM P PAR N 
200 Yield (%) % ee
a
 
1 216 1 92 6 1 – –46 
2 217 1 90 8 1 61 –61 
3
b
 218 8 30 57 5 – +40 
Table 6.15: Asymmetric Steglich rearrangement of 199 
 a)
 
+ and – signs refer to sign of the products optical rotation  
b) Reaction time of 18 h 
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6.4.2 Substrate optimisation 
It had now been established that chiral triazolium NHCs were active and modestly 
enantioselective organocatalysts of the Steglich-type rearrangement of pyrazolyl carbonates. 
We next probed the scope of the reaction by varying the substitution pattern on the pyrazolyl 
carbonate to observe the effects on reactivity and enantioselectivity. We again focused on 
substitution at N(2) and C(5) and made use of the same substrates employed in the racemic 
series (see Section 6.3.1). To further explore the effects of different catalyst structure on the 
sense of enantioselectivity, each structure was treated with triazolium salts 216 and 217 and the 
results are presented below.  
The results of asymmetric catalysis with the N-phenyl chiral NHC derived from 216 are 
outlined in Table 6.16. Reactivity and enantioselectivity correlated with C(5) substitution; 
C(5)-methyl substrates 199 (entry 1) and 206 (entry 2) showed high conversion to 
C-carboxylated products and modest ee’s. In contrast, C(5)-phenyl substituted substrates 207 
(entry 3) and 208 (entry 4) required longer reaction times and gave predominantly parent 
pyrazolinone. C-carboxylates were isolated in both low yields and low enantioselectivities.  
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% Ratio 
Entry Substrate R
1
 R
2
 Time (h) 
O C PAR N 
C-carboxylate 
yield (%) 
% ee 
1 199 Me Ph 3 1 92 6 1 – 46 
2 206 Me Me 3 0 68 18 14 49 45 
3 207 Ph Me 18 5 28 64 3 10 10 
4 208 Ph Ph 96 1 8 90 1 4 <5 
Table 6.16: Rearrangement of substrates with NHC derived from N-phenyl triazolium 216 
(O = O-carboxylate substrate, C = C-carboxylate, PAR = parent compound, N = N-carboxylate) 
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With N-C6F5 triazolium 217, di-methyl 206 was again a good substrate in terms of both 
reactivity and enantioselectivity and gave an ee of 86 % (Table 6.17, entry 2). This level of 
enantioselectivity is significantly higher than the best results found with oxazolyl carbonates 
and chiral carbenes where the highest ee achieved was 50 % despite extensive optimisation.
116
 
N(2)-methyl, C(5)-phenyl substrate 207 again showed low reactivity, gave a mixture of 
products and low ee of the desired C-carboxylate (6 % ee, entry 3). However, di-phenyl 
substrate 208 showed much better reactivity than with the previous catalyst, giving 
C-carboxylate in 48 % yield, though with low enantioselectivity (entry 4). Finally, with the 
exception of di-phenyl substrate 208, N-C6F5 triazolium 217 again gave the same absolute 
configuration in the C-carboxylated products as N-phenyl 216.  
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% Ratio 
Entry Substrate R
1
 R
2
 Time (h) 
O C PAR N 
C-carboxylate 
yield (%) 
% ee 
1 199 Me Ph 3 1 90 8 1 61 61 
2 206 Me Me 3 0 72 15 13 61 86 
3 207 Ph Me 18 25 22 47 6 7 6 
4 208 Ph Ph 18 0 79 21 0 48 -20 
Table 6.17: Rearrangement of substrates with NHC derived from N-C6F5 triazolium 217 
(O = O-carboxylate substrate, C = C-carboxylate, PAR = parent compound, N = N-carboxylate) 
 
6.4.3 Preliminary mechanistic investigations 
As a preliminary step in the delineation of the reaction mechanism, the enantioenriched 
C-carboxylate (–)-211 (86 % ee) was treated with achiral NHC 176 (Scheme 6.6). After 3 h,    
(–)-211 was isolated in 66 % yield and a slightly reduced ee of 78 %. This was in contrast to 
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analogous reactions with oxazolyl carbonates in which the ee remained unchanged after 
treatment with an achiral NHC.
116
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Scheme 6.6: Reagents and conditions: i) 175 (20 mol%), KHMDS (18 mol%), toluene, 3 h, rt. 
This drop in enantioselectivity implies that carbon-carbon bond formation is a reversible 
process under catalysis with racemic NHC 176 (Figure 6.16). Crossover experiments with 
oxazolyl carbonates have shown that the first step, formation of enolate B and carboxylate C, is 
also reversible although such experiments have not yet been carried out with pyrazolyl 
carbonates. In addition, the reversibility of carbon-carbon bond formation with chiral NHCs or 
the other Lewis base catalysts examined has not yet been established.  
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Figure 6.16: Updated catalytic cycle under NHC 176 catalysis 
 
6.5 Summary 
In preliminary studies, pyrazolin-3-ones were found to be suitable substrates for the 
organocatalysed Steglich rearrangement. NHCs were generally found to be superior to DMAP 
and isothioureas in terms of both reactivity and regioselectivity for C-carboxylates over 
N-carboxylates or carbonate loss to give parent pyrazolinones. Treatment of N-carboxylates 
201, 209 and 214 showed a similar trend with NHCs again showing the greatest reactivity and 
C-carboxylate selectivity. In the asymmetric reaction, chiral NHCs based on a morpholinone 
skeleton were most enantioselective, particularly with methyl substitution at N(2) and C(5). 
Re-treatment of enantioenriched di-methyl C-carboxylate (–)-211 with an achiral NHC led to a 
small loss of ee, indicating the reversible nature of the key C-C bond-forming step. 
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6.6 Future work 
Studies with pyrazolyl carbonates have already shown that rearrangement products can be 
formed with good yields and high ee. However, there remains substantial scope for further 
optimisation of reaction conditions, for example the use of low temperatures to enhance 
enantioselectivity. NHC catalyst concentration greatly influenced product distribution with 
related furanyl carbonates but has not yet been investigated with pyrazolyl carbonates. Further 
exploration of the catalyst structure might also be instructive with the use of imidazolium and 
imidazolinium catalysts, such as 219 and 220 respectively, yet to be explored (Figure 6.17).  
 
N N
219
Ph Ph
N N
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Ph Ph
 
Figure 6.17: Example imidazolium catalyst 219 and imidazolinium 220 
Establishing optimum reaction conditions would then allow a full exploration of substrate 
scope. Preliminary studies have focused on the substitution at the N(2) and C(5) positions 
(Figure 6.18a)) but variation of the carbonate or the key C(4)-position has not been explored. 
Although some investigation of N(2) and C(5) substitution has taken place, this has focused 
exclusively on methyl and phenyl substituted pyrazolyl carbonates. While this has been fruitful, 
it is not possible from current results to attribute differences in product distributions/ 
enantioselectivities to either electronic or steric factors (or a combination of the two). 
Expansion into substituted aryl pyrazolinones e.g. 221 and 222, would allow electronic factors 
to be examined independently (Figure 6.18b)). 
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Figure 6.18: Substrates to probe effect of changing electronics on product distributions/ enantioselectivities 
In terms of enantioselectivity, it is now established that methyl substitution at N(2) and 
particularly C(5), rather than phenyl, gives higher product yields and enantioselectivities in 
reactions with chiral NHCs. However, the effect of other substitution at these, and other 
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positions, have not been explored. In addition, a priority remains determination of the absolute 
configuration of C-carboxylated products as a key step in the rationalisation of observed results 
and construction of a transition state model. Obtaining the X-ray crystal structure of a suitable 
enantioenriched product would be the most straightforward method for such a determination.  
 
Chapter 7: Experimental 
 
 
 
126 
Chapter 7: Experimental 
 
7.1 General experimental 
All reactions involving moisture sensitive reagents were performed under an atmosphere of 
argon or nitrogen using standard vacuum line techniques and with freshly distilled solvents. All 
glassware was flame dried and allowed to cool under vacuum. Temperatures of 0 ºC were 
obtained using an ice/water bath and of –78 ºC were obtained using a dry ice/acetone bath. 
Room temperature refers to 20–25 ºC. For compounds synthesised by multiple routes, only 
experimental details for the highest yielding route are included. 
All dried and purified solvents were obtained from a solvent purification system (MBraun, 
SPS-800) except for dry N,N!-dimethylformamide (DMF) which was purchased directly from 
Aldrich. Petrol refers to the fraction of petroleum ether boiling between 40 ºC and 60 ºC, 
dioxane refers to 1,4-dioxane, pH 7 phosphate buffer refers to a solution of sodium dihydrogen 
phosphate and di-sodium hydrogen orthophosphate and brine refers to a saturated aqueous 
solution of sodium chloride. Cyclopentadiene was obtained by cracking of the dimer at 170 ºC, 
after drying over MgSO4, and stored in the freezer. Catalytic runs for which isolated yields were 
obtained were carried out with aldehydes purified according to the guidelines of Perrin and 
Chai.
138
 All other reagents were used directly as supplied without further purification.  
Flash column chromatography was carried out according to the method of Still
139
 with silica gel 
60 (0.043-0.060 mm) (Merck) in the solvent system stated. A Biotage Isolera flash purification 
system was also used for chromatography where stated. Analytical thin layer chromatography 
was performed on commercially available pre-coated aluminium-backed plates (Merck silica 
Kieselgel 60 F254). TLCs were visualised either by UV fluorescence (254 nm), or by staining 
with basic KMnO4 solution. 
Optical rotations were determined using a PerkinElmer Model 341 Polarimeter, at 20.0 ºC using 
a Na/Hal lamp tuned to 589 nm and with a 100 mm path length. 
Melting points were recorded on an Electrothermal apparatus and are uncorrected. 
Microanalyses were carried out on a Carlo Erba CHNS analyser.  Infrared spectra were 
recorded on a Perkin-Elmer Spectrum GX FT-IR Spectrometer and analysed either as thin films 
between NaCl plates (thin film) or KBr discs (KBr disc) as stated. Absorption maxima (%max) 
are quoted in wavenumbers (cm
–1
) and only structurally significant peaks are quoted. 
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1
H, 
13
C and 
19
F nuclear magnetic resonance (NMR) spectra were acquired on either a Bruker 
Avance 300 (300 MHz 
1
H, 75 MHz 
13
C, 282 MHz 
19
F), a Bruker Avance 400 (400 MHz 
1
H, 
100 MHz 
13
C, 376 MHz 
19
F) or a Bruker Avance 500 (500 MHz 
1
H, 125 MHz 
13
C, 470 MHz 
19
F) spectrometer in the deuterated solvent stated. 
13
C NMR spectra were recorded with proton 
decoupling. 
15
N NMR spectra were acquired indirectly by 
1
H, 
15
N-HMBC experiments on a 
Bruker Avance 500 equipped by a 5 mm inverse tuneable double resonance probe. Chemical 
shifts (!) are quoted in parts per million (ppm) and referenced to residual solvent peaks. 
Coupling constants, J, are quoted in Hz.  The abbreviations s, d, dd, t, dt, td, tt, q, dq, quin, sext, 
desxt, sept, dsept and m denote singlet, doublet, doublet of doublets, triplet, doublet of triplets, 
triplet of doublets, triplet of triplets, quartet, doublet of quartets, quintet, sextet, doublet of 
sextets, doublet of septets and multiplet respectively. app stands for apparent and br for broad. 
The abbreviation Ar is used to denote aromatic. For compounds displaying rotamers or 
tautomers in 
1
H NMR spectroscopy, the integral ratio of the two species is given with the more 
abundant designated A and the less abundant designated B. 
Mass spectrometric (m/z) data was acquired by electrospray ionisation (ESI) or chemical 
ionisation (CI), either at the University of St Andrews Mass Spectrometry facility  or at the 
EPSRC National Mass Spectrometry Service Centre, Swansea. At the University of St 
Andrews, low and high resolution ESI MS was carried out on a Micromass LCT spectrometer.  
At the EPSRC National Mass Spectrometry Service Centre, CI MS was carried out on a 
Micromass Quattro II spectrometer.  High resolution ESI was carried out on a Finnigan MAT 
900 XLT; a Thermofisher LTQ Orbitrap XL spectrometer was used to obtain high resolution 
ESI MS for accurate mass determination but also provided fragmentation data for the 
characterisation of samples.  Values are quoted as a ratio of mass to charge in Daltons. 
Chiral HPLC was performed on Gilson apparatus, using a ChiralPak AD-H, AS-H, OD-H, or 
OJ-H or IB silica column, 0.46 cm " x 25 cm, using hexane and isopropanol as eluents.  
15
N NMR calculations were carried out by Tomas Lebl using Spartan ’08 modelling program. 
Calculations were carried out at the B3LYP level of theory using the 6-31G* basis set. 
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7.2 General experimental procedures 
General procedure A: O-functionalisation of (RS)-tert-butyl 5-methyl-3-oxopyrazolidine-1-
carboxylate 72 with triethylamine 
To a solution of (RS)-tert-butyl 5-methyl-3-oxopyrazolidine-1-carboxylate 72 (1 eq) in 
dichloromethane (0.5 M) was added triethylamine (1.1 eq). The resulting suspension was then 
cooled to 0 %C and the appropriate chloride or anhydride (1.05 eq) added. The mixture was 
allowed to warm to rt overnight. The reaction was quenched with water and extracted three 
times with dichloromethane. The combined organic layers were washed with 0.1 M aqueous 
hydrochloric acid, brine, dried (MgSO4), filtered and concentrated in vacuo. 
 
General procedure B: N(2)-alkylation of Boc-protected pyrazolidin-3-one with sodium 
hydride 
A solution of the appropriate Boc-protected pyrazolidin-3-one (1 eq) in dichloromethane 
(0.5 M) was cooled to &78 %C and sodium hydride (60 % dispersion in mineral oil, 1.1 eq) 
added. The resulting suspension was stirred for 10 min before addition of the appropriate 
chloride or anhydride (1.05 eq). The mixture was allowed to warm to rt overnight. The reaction 
was quenched with water and extracted three times with dichloromethane. The combined 
organic layers were washed with brine, dried (MgSO4), filtered and concentrated in vacuo. 
 
General procedure C: screening of aldehyde substrates under racemic catalysis  
To a suspension of catalyst (20 mol %, 0.189 mmol) in methanol (1 mL) was added triflic acid 
(17.0 µl, 0.189 mmol). After 2 min of stirring, the appropriate aldehyde (0.950 mmol) was 
added, followed by a further 15 min of stirring. Cyclopentadiene (188 mg, 2.80 mmol) was then 
added and the resulting mixture left to stir at rt. Reaction was monitored by TLC. Upon 
completion, the reaction mixture was concentrated in vacuo then hydrolysed in a chloroform 
(2 mL), water (1 mL), trifluoroacetic acid (1 mL) mixture for 2 h. Saturated sodium hydrogen 
carbonate solution (20 mL) was then added and the resulting biphasic mixture extracted with 
chloroform (2 x 20 mL). The combined organic layer were washed with brine (40 mL), dried 
(MgSO4), filtered and concentrated in vacuo. 
 
General procedure D: substrate screening with chiral iminium ion catalysts 
The appropriate catalyst (X mol%) was suspended in a solution of triflic acid in methanol 
(X mol%). After 2 min of stirring, the appropriate aldehyde (0.950 mmol) was added, followed 
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by a further 15 min of stirring. The appropriate diene (2.80 mmol) was then added and the 
resulting mixture left to stir at rt. Reaction was monitored by TLC and, upon completion, 
worked up as described in general procedure C. 
 
Procedure E: Amide coupling of pyrazolidin-3-one to a chiral acid using 1 equivalent of 
N-(3-dimelhylaminopropyl)-N'-ethylcarbodiimide hydrochloride and 1 equivalent of 
1-hydroxybenzotriazole 
N-(3-dimethylaminopropyl)-N!-ethylcarbodiimide hydrochloride (1 eq), 1-hydroxybenzotriazole 
(1 eq) and the appropriate chiral acid (1 eq) were combined in either THF or DMF (0.1 M) and 
stirred at room temperature for 15 minutes. The appropriate pyrazolidin-3-one (1 eq) was then 
added and the resultant solution stirred at rt overnight. The reaction mixture was then 
concentrated in vacuo and the resultant residue taken up in dichloromethane, washed twice with 
0.1 M hydrochloric acid solution followed by single washes with saturated sodium bicarbonate 
solution and brine before being dried (MgSO4), filtered and concentrated in vacuo. 
 
General procedure F: Derivatisation of an aldehyde to the benzoyl ester 
To a solution of the appropriate aldehyde (1 eq) in methanol (0.15 M) was added sodium 
borohydride (3 eq) and the resulting suspension stirred at room temperature for 2 h. The 
reaction mixture was concentrated in vacuo before being suspended in a mixture of water and 
brine and extracted with dichloromethane (x 2). The combined organic layers were dried 
(MgSO4), filtered and concentrated in vacuo. The resulting material was dissolved in 
dichloromethane (0. 15 M) and treated with triethylamine (1.5 eq), DMAP (1 eq) and benzoyl 
chloride (1.2 eq) then stirred at room temperature overnight. Reaction was quenched with 
saturated ammonium chloride solution and extracted with diethyl ether (x 3). The combined 
organic layers were washed with brine, dried (MgSO4), filtered and concentrated in vacuo.
48
  
 
Procedure G: Condensation of monosubstituted hydrazine with #-ketoester to give 5-pyrazolin-
3-ones 
To a solution of the required "-ketoester (1 eq) in absolute ethanol (1-1.4 M) was added the 
required monosubstituted hydrazine (1.1 eq) dropwise and the resulting solution stirred at reflux 
overnight. The suspension was then concentrated in vacuo. 
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Procedure H: O-Carboxylation of 5-pyrazolin-3-ones 
Based upon a procedure by Fu and co-workers,
95
 triethylamine (1.1 eq) was added to a stirred 
solution of the required 5-pyrazolin-3-one (1 eq) in THF (0.5-0.8 M) at 0 ºC, followed by 
addition of the required chloroformate (1.05 eq) after 15 min. The mixture was stirred at 
ambient temperature overnight. The resulting solution was poured into water and the aqueous 
phase extracted with diethyl ether (x 3). The combined organic layers were washed with 1 M 
hydrochloric acid solution, sodium hydrogen carbonate solution, brine, dried (MgSO4), filtered 
and concentrated in vacuo. 
 
Procedure I: Treatment of a pyrazolyl carbonate or N-carboxylated pyrazolin-3-one with 
DMAP or DHPB 
To a solution of the appropriate pyrazolyl carbonate or N-carboxylated pyrazolin-3-one (1 eq) in 
dichloromethane (0.1 M) was added either DMAP (20 mol%) or DHPB (20 mol%), as 
appropriate, and the mixture left to stir at rt. Reaction was quenched by the addition of 0.1 M 
hydrochloric acid solution and extracted with dichloromethane (x 3). The combined organic 
layers were washed with brine, dried (MgSO4), filtered, concentrated in vacuo and analysed by 
1
H NMR spectroscopy. Where applicable, this crude mixture was re-suspended in 
dichloromethane and treated with conditions identical to those described above. 
 
Procedure J: Treatment of a pyrazolyl carbonate or N-carboxylated pyrazolin-3-one with 
achiral carbene 176 
To a mixture of triazolium salt 175 (20 mol%) and the appropriate pyrazolyl carbonate or 
N-carboxylated pyrazolin-3-one (1 eq) in THF (0.1 M), as appropriate, was added KHMDS 
(0.5 M solution in toluene, 18 mol%) and the mixture left to stir at rt. Reaction was quenched 
by the addition of 0.1 M hydrochloric acid solution and extracted with dichloromethane (x 3). 
The combined organic layers were washed with brine, dried (MgSO4), filtered, concentrated 
in vacuo and analysed by 
1
H NMR spectroscopy.  
 
Procedure K: Treatment of a pyrazolyl carbonate with a chiral carbene 
To a mixture of the required triazolium salt (10 mol%) and the appropriate pyrazolyl carbonate 
(1 eq) in THF or toluene (0.2 M) was added KHMDS (0.5 M solution in toluene, 9 mol%) and 
the mixture left to stir at rt. Reaction was quenched by the addition of 0.1 M hydrochloric acid 
solution and extracted with dichloromethane (x 3). The combined organic layers were washed 
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with brine, dried (MgSO4), filtered, concentrated in vacuo and analysed by 
1
H NMR 
spectroscopy. 
 
Screening of racemic catalysts for t
1/2 
values 
To a suspension of catalyst (20 mol %, 0.378 mmol) in methanol (2 mL) was added triflic acid 
(35.0 µl, 0.378 mmol). After 2 min of stirring, (E)-cinnamaldehyde 37 (0.240 mL, 1.89 mmol) 
was added, followed by a further 5 min of stirring. Cyclopentadiene (370 mg, 5.60 mmol) was 
then added and the resulting mixture left to stir at rt. The reaction was monitored by taking 
samples of the reaction mixture (0.05 mL) which were concentrated in vacuo then hydrolysed in 
a chloroform (1 mL), water (0.5 mL), trifluoroacetic acid (0.5 mL) mixture for 2 h. Saturated 
sodium hydrogen carbonate solution (10 mL) was then added and the resulting biphasic mixture 
extracted with chloroform (2 x 10 mL). The combined organic layer were washed with brine 
(20 mL), dried (MgSO4), filtered and concentrated in vacuo. 
1
H NMR spectroscopy of the crude 
reaction mixture was used to establish the conversion to the products and exo:endo ratios 
through the integration of aldehyde peaks at: !H 9.93 (exo-38), 9.64 ((E)-cinnamaldehyde 37) 
and 9.60 (endo-38) which were in accordance with previously reported literature values.
63,64
  
 
Screening of chiral iminium ion catalysts 
(E)-Cinnamaldehyde 37 (0.120 mL, 0.950 mmol) and the appropriate chiral catalyst (20 mol %, 
0.189 mmol) were combined according to general procedure C. The crude material was then 
purified by column chromatography, eluting with 5 % diethyl ether in petrol to yield exo-38 and 
endo-38, with spectroscopic data in accordance with the literature.
64
 Enantiomeric excesses 
were determined by acetalisation with (+)-(R,R)-hydrobenzoin and 
1
H NMR analysis: 
(500 MHz, C6D6) exo isomers ! 5.74 (d, J 4.8, CHO2, 2R) and 5.72 (d, J 5.8, CHO2, 2S), 
endo isomers ! 5.37 (d, J 8.1, CHO2, 2R) and 5.33 (d, J 8.2, CHO2, 2S). 
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7.3 Experimental procedures 
7.3.1 Diels-Alder adducts described in Tables 2.3, 5.4 and 5.6 
exo-(1RS,2RS,3RS,4SR)-3-Phenylbicyclo[2.2.1]hept-5-ene-2-carboxaldehyde exo-38 and  
endo-(1SR,2RS,3RS,4RS)-3-phenylbicyclo[2.2.1]hept-5-ene-2-carboxaldehyde endo-38 
(Table 2.3, entry 1) 
exo-38 endo-38
Ph
CHO
+
CHO
Ph
 
(E)-Cinnamaldehyde 37 (0.120 mL, 0.950 mmol) and catalyst 114 (56 mg, 0.190 mmol) were 
combined according to general procedure C. The crude material was then purified by column 
chromatography, eluting with 5 % diethyl ether in petrol to yield the title compounds as a 62:38 
mixture of diastereoisomers, with spectroscopic data in accordance with the literature (168 mg, 
89 %).
63,64
 
Compound exo-38: !H (300 MHz, CDCl3) 9.93 (1H, d, J 2.1, CHO), 7.34–7.13 (5H, m, ArH), 
6.34 (1H, dd, J 5.8, 3.6, CHA=CHB), 6.08 (1H, dd, J 5.8, 3.3, CHA=CHB), 3.73 (1H, dd, J 5.2, 
3.4, CHPh), 3.24–3.21 (2H, m, CHCH2), 2.60 (1H, app dt, J 5.2, 2.1, CHCHO) and 1.62–1.53 
(2H, m, CH2). 
Compound endo-38: !H (300 MHz, CDCl3) 9.60 (1H, d, J 2.2, CHO), 7.34–7.13 (5H, m, ArH), 
6.42 (1H, dd, J 5.7, 3.2, CHA=CHB), 6.18 (1H, dd, J 5.7, 2.8, CHA=CHB), 3.36–3.32 (1H, m, 
CHCH2), 3.14–3.12 (1H, m, CHCH2), 3.09 (1H, dd, J 4.8, 1.5, CHPh), 2.98 (1H, ddd, J 4.8, 3.4, 
2.2, CHCHO), 1.84–1.79 (1H, m, CHAHB) and 1.65–1.63 (1H, m, CHAHB). 
 
exo-(1RS,2RS,3RS,4SR)-3-(4-Nitrophenyl)bicyclo[2.2.1]hept-5-ene-2-carboxaldehyde and 
endo-(1SR,2RS,3RS,4RS)-3-(4-nitrophenyl)bicyclo[2.2.1]hept-5-ene-2-carboxaldehyde 
(Table 2.3, entry 2) 
exo endo
CHO
+
NO2
CHO
NO2
 
4-Nitrocinnamaldehyde (168 mg, predominantly (E)-, 0.950 mmol) and catalyst 114 (56 mg, 
0.190 mmol) were combined according to general procedure C. The crude material was then 
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purified by column chromatography, eluting with 10 % diethyl ether in petrol to yield the 
product as a 65:35 mixture of diastereoisomers with spectroscopic data in accordance with the 
literature (169 mg, 73 %).
67
  
exo: !H (300 MHz, CDCl3) 9.92 (1H, d, J 1.7, CHO), 8.13–8.08 (2H, m, ArH), 7.32–7.27 (2H, 
m, ArH), 6.41 (1H, dd, J 5.7, 3.2, CHA=CHB), 6.05 (1H, dd, J 5.7, 2.8, CHA=CHB), 3.88 (1H, 
dd, J 5.0, 3.5, CHAr), 3.36–3.32 (1H, m, CHCH2), 3.27–3.33 (1H, m, CHCH2), 2.62 (1H, br d, 
J 5.0, CHCHO) and 1.62–1.60 (2H, m, CH2). 
endo: !H (300 MHz, CDCl3) 9.64 (1H, d, J 1.7, CHO), 8.19–8.14 (2H, m, ArH), 7.45–7.40 (2H, 
m, ArH), 6.44 (1H, dd, J 5.9, 3.6, CHA=CHB), 6.20 (1H, dd, J 5.7, 2.8, CHA=CHB), 3.45–3.41 
(1H, m, CHCH2), 3.22–3.18 (2H, m, CHAr and CHCH2), 2.95 (1H, ddd, J 5.0, 3.5, 1.7, 
CHCHO) and 1.78–1.68 (2H, m, CH2). 
 
exo-(1RS,2RS,3RS,4SR)-3-Propylbicyclo[2.2.1]hept-5-ene-2-carboxaldehyde and  
endo-(1SR,2RS,3RS,4RS)-3-propylbicyclo[2.2.1]hept-5-ene-2-carboxaldehyde (Table 2.3, 
entry 3) 
n-Pr
CHO
+
CHO
n-Pr
exo endo  
(E)-2-Hexen-1-al (0.110 mL, 0.950 mmol) and catalyst 114 (56 mg, 0.190 mmol) were 
combined according to general procedure C. The crude material was then purified by column 
chromatography, eluting with 2.5 % ethyl acetate in petrol to yield the product as a 58:42 
mixture of diastereoisomers with spectroscopic data in accordance with the literature (117 mg, 
75 %).
1,140 
 
exo: !H (300 MHz, CDCl3) 9.78 (1H, d, J 2.8, CHO), 6.21 (1H, dd, J 5.7, 3.1, CHA=CHB), 
6.13 (1H, dd, J 5.7, 2.9, CHA=CHB), 3.03–2.98 (1H, m, CHCH2), 2.89–2.85 (1H, m, CHCH2), 
2.28 (1H, tdd, J 7.6, 4.7, 3.1 CHCH2CH2), 1.76 (1H, ddd, J 4.7, 2.8, 1.7, CHCHO), 1.77–1.06 
(6H, m, CHCH2CH & CH2CH2) and 0.88 (3H, t, J 7.2, CH3). 
endo: !H 9.37 (1H, d, J 3.4, CHO), 6.27 (1H, dd, J 5.7, 3.2, CHA=CHB), 6.06 (1H, dd, J 5.7, 
2.8, CHA=CHB), 3.14–3.10 (1H, m, CHCH2), 2.68–2.64 (1H, m, CHCH2), 2.38 (1H, dt, J 4.4, 
3.4, CHCHO), 1.72 (1H, m, CHCH2CH2), 1.77–1.06 (6H, m, CHCH2CH & CH2CH2) and 
0.88 (3H, t, J 7.2, CH3). 
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exo-(1RS,2RS,3RS,4SR)-Ethyl 3-formylbicyclo[2.2.1]hept-5-ene-2-carboxaldehyde and  
endo-(1SR,2RS,3RS,4RS)-ethyl 3-formylbicyclo[2.2.1]hept-5-ene-2-carboxaldehyde 
(Table 2.3, entry 4) 
exo endo
CO2Et
CHO
+
CHO
CO2Et
 
Ethyl (E)-4-oxo-2-butenoate (0.120 mL, 0.950 mmol) and catalyst 114 (56 mg, 0.190 mmol) 
were combined according to general procedure C. The crude material was then purified by 
column chromatography, eluting with 15 % diethyl ether in petrol to yield the product as a 50:50 
mixture of diastereoisomers with spectroscopic data in accordance with the literature (147 mg, 
80 %).50
,141 
 
exo: !H (300 MHz, CDCl3) 9.84 (1H, d, J 0.9, CHO), 6.30 (1H, dd, J 5.6, 3.2, CHA=CHB), 6.13 
(1H, dd, J 5.6, 2.8, CHA=CHB), 4.11 (2H, d, J 7.1, OCH2), 3.42 (1H, dd, J 4.4, 3.7, CHCO2), 
3.31–3.27 (1H, m, CHCH2), 3.22–3.18 (1H, m, CHCH2), 2.83–2.81 (1H, m, CHCHO),       
1.47–1.42 (1H, m, CHACHB), 1.36–1.11 (1H, m, CHACHB) and 1.24 (3H, t, J 7.1, CH3). 
endo: !H 9.55 (1H, d, J 1.2, CHO), 6.26 (1H, dd, J 5.7, 3.3, CHA=CHB), 6.09 (1H, dd, J 5.7, 
2.6, CHA=CHB), 4.16 (2H, q, J 7.1, OCH2), 3.39–3.33 (2H, m, CHCO2 and CHCH2), 3.22–3.18 
(1H, m, CHCH2), 2.70 (1H, ddd, J 4.3, 1.2, 0.5, CHCHO), 1.69–1.65 (1H, m, CHACHB),    
1.53–1.48 (1H, m, CHACHB) and 1.27 (3H, t, J 7.1, CH3). 
 
exo-(1R,2R,3R,4S)-3-Phenylbicyclo[2.2.1]hept-5-ene-2-carboxaldehyde exo-(2R)-38 and 
endo-(1S,2R,3R,4R)-3-phenylbicyclo[2.2.1]hept-5-ene-2-carboxaldehyde endo-(2R)-38 
(Table 5.4, entry 1) 
Ph
CHO
+
exo-(2R)-38 endo-(2R)-38
CHO
Ph
 
(E)-Cinnamaldehyde 37 (0.120 mL, 0.950 mmol), triflic acid (0.190 M solution in methanol, 
0.5 mL, 95.0 µmol), catalyst (5R)-163 (10 mol%, 37.0 mg, 95.0 µmol) and cyclopentadiene 
(188 mg, 2.80 mmol) were combined according to general procedure D. The crude material was 
then purified by column chromatography, eluting with 5 % diethyl ether in petrol to yield the 
title compounds as a 35:65 mixture of diastereoisomers, with spectroscopic data identical to that 
of the racemate (159 mg, 84 %). 
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Enantiomeric excess was determined by acetalisation with (+)-(R,R)-hydrobenzoin and 
1
H NMR analysis:
67
 (500 MHz, C6D6) exo isomers ! 5.74 (d, J 4.8, CHO2, 2R) and 5.72 (d, 
J 5.8, CHO2, 2S), endo isomers ! 5.37 (d, J 8.1, CHO2, 2R) and 5.33 (d, J 8.2, CHO2, 2S). 
 
exo-(1R,2R,3R,4S)-3-(4-Chlorophenyl)bicyclo[2.2.1]hept-5-ene-2-carboxaldehyde and 
endo-(1S,2R,3R,4R)-3-(4-chlorophenyl)bicyclo[2.2.1]hept-5-ene-2-carboxaldehyde 
(Table 5.4, entry 3) 
exo-(2R) endo-(2R)
CHO
+
Cl
CHO
Cl
 
Following the method of Baldwin et al.,
142
 4-chlorobenzaldehyde (1.00 g, 7.11 mmol) in 
toluene (7 mL) was heated to 80 ºC and (triphenylphosphoranylidene) acetaldehyde (2.16 g, 
7.11 mmol) was added portionwise and the resulting mixture stirred at 80 ºC for 5 h. The 
solvent was the removed in vacuo ((E):(Z) 77:23) and the crude material purified by column 
chromatography, eluting with 25 % diethyl ether in petrol, followed by recrystallisation from 
petrol and a minimum of diethyl ether to give (E)-4-chlorocinnamaldehyde as a yellow solid, 
with spectroscopic data in accordance with the literature (330 mg, 26 %).
143
  
!H (300 MHz, CDCl3) 9.71 (1H, d, J 7.6, CHO), 7.53–7.49 (2H, m, ArH), 7.43 (1H, d, J 16.0, 
CHCHCHO), 7.41–7.39 (2H, m, ArH) and 6.69 (1H, dd, J 16.0, 7.6, CHCHO). 
(E)-4-Chlorocinnamaldehyde (172 mg, 0.950 mmol), triflic acid (0.190 M solution in methanol, 
0.5 mL, 95.0 µmol), catalyst (5R)-163 (10 mol%, 37.0 mg, 95.0 µmol) and cyclopentadiene 
(188 mg, 2.80 mmol) were combined at 5 ºC according to general procedure D. The crude 
material was then purified by column chromatography, eluting with 10 % diethyl ether in petrol 
to yield the title compounds as a 34:66 mixture of diastereoisomers, with spectroscopic data in 
accordance with the literature (187 mg, 86 %).
70
 
exo-(2R): !H (300 MHz, CDCl3) 9.90 (1H, d, J 1.8, CHO), 7.22–7.18 (2H, m, ArH), 7.08–7.05 
(2H, m, ArH), 6.35 (1H, dd, J 5.5, 3.1, CHA=CHB), 6.05 (1H, dd, J 5.5, 2.9, CHA=CHB), 
3.70 (1H, dd, J 5.0, 3.6, CHAr), 3.25–3.21 (1H, m, CHCH2), 3.19–3.16 (1H, m, CHCH2), 
2.54 (1H, app dt, J 5.0, 1.8, CHCHO) and 1.59–1.56 (2H, m, CH2). 
endo-(2R): !H (300 MHz, CDCl3) 9.59 (1H, d, J 2.0, CHO), 7.29–7.25 (2H, m, ArH), 7.22–7.18 
(2H, m, ArH), 6.41 (1H, dd, J 5.6, 3.2, CHA=CHB), 6.17 (1H, dd, J 5.6, 2.8, CHA=CHB),    
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3.38–3.32 (1H, m, CHCH2), 3.11–3.08 (1H, m, CHCH2), 3.08–3.03 (1H, m, CHAr), 2.91 (1H, 
ddd, J 5.1, 3.3, 2.0, CHCHO), 1.76 (1H, app dt, J 8.7, 1.6, CHAHB) and 1.65–1.60 (1H, m, 
CHAHB). 
Enantiomeric excess was determined by acetalisation with (+)-(R,R)-hydrobenzoin and 
1
H NMR analysis:
67
 (500 MHz, C6D6) exo isomers ! 5.66 (d, J 5.0, CHO2, 2R) and 5.64 (d, 
J 5.9, CHO2, 2S), endo isomers ! 5.31 (d, J 8.2, CHO2, 2R) and 5.25 (d, J 8.3, CHO2, 2S). 
 
exo-(1R,2R,3R,4S)-3-(2-Nitrophenyl)bicyclo[2.2.1]hept-5-ene-2-carboxaldehyde and 
endo-(1S,2R,3R,4R)-3-(2-nitrophenyl)bicyclo[2.2.1]hept-5-ene-2-carboxaldehyde 
(Table 5.4, entry 5) 
exo-(2R) endo-(2R)
CHO
+
CHO
NO2
O2N
 
 (E)-2-Nitrocinnamaldehyde (168 mg, 0.950 mmol), triflic acid (0.190 M solution in methanol, 
0.5 mL, 95.0 µmol), catalyst (5R)-163 (10 mol%, 37.0 mg, 95.0 µmol) and cyclopentadiene 
(188 mg, 2.80 mmol) were combined according to general procedure D. The crude material was 
then purified by column chromatography, eluting with 15 % ethyl acetate in petrol to yield the 
title compounds as a 17:83 mixture of diastereoisomers, with spectroscopic data in accordance 
with the literature (195 mg, 85 %).
67
  
exo-(2R): !H (300 MHz, CDCl3) 9.80 (1H, d, J 2.1, CHO), 7.72 (1H, dd, J 8.0, 1.4, ArH),  
7.46–7.30 (2H, m, ArH), 7.17 (1H, dd, J 8.0, 1.0, ArH), 6.46 (1H, dd, J 5.6, 3.0, CHA=CHB), 
6.01 (1H, dd, J 5.6, 2.9, CHA=CHB), 4.09 (1H, dd, J 5.3, 3.1, CHAr), 3.39–3.36 (1H, m, 
CHCH2), 3.30–3.25 (1H, m, CHCH2), 2.62–2.59 (1H, app dt, J 5.3, 2.1, CHCHO), 1.69–1.62 
(1H, m, CHAHB) and 1.61–1.55 (1H, m, CHAHB). 
endo-(2R): !H (300 MHz, CDCl3) 9.40 (1H, d, J 3.7, CHO), 7.82 (1H, dd, J 8.1, 1.2, ArH), 
7.61–7.51 (2H, m, ArH), 7.46–7.30 (1H, m, ArH), 6.50 (1H, dd, J 5.7, 3.3, CHA=CHB), 
6.21 (1H, dd, J 5.7, 2.8, CHA=CHB), 3.43 (1H, dd, J 5.2, 1.2, CHAr), 3.34–3.29 (1H, m, 
CHCH2), 3.14–3.10 (1H, m, CHCH2), 2.95 (1H, app dt, J 5.2, 3.7, CHCHO), 1.84 (1H, app dt, 
9.0, 1.6, CHAHB) and 1.69–1.62 (1H, m, CHAHB). 
Enantiomeric excess was determined by acetalisation with (+)-(R,R)-hydrobenzoin and 
1
H NMR analysis:
67
 (300 MHz, C6D6) exo isomers ! 5.59 (d, J 4.5, CHO2, 2R) and 5.51 (d, 
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J 5.1, CHO2, 2S), endo isomers ! 5.21 (d, J 7.6, CHO2, 2R) and 5.13 (d, J 7.6, CHO2, 2S). 
 
exo-(1R,2R,3R,4S)-3-(Naphthalen-2-yl)bicyclo[2.2.1]hept-5-ene-2-carbaldehyde and 
endo-(1S,2R,3R,4R)-3-(naphthalen-2-yl)bicyclo[2.2.1]hept-5-ene-2-carbaldehyde 
(Table 5.4, entry 6) 
exo-(2R) endo-(2R)
CHO
+
CHO
 
Following the method of Baldwin et al.,
142
 2-naphthaldehyde (1.11 g, 7.11 mmol) in toluene 
(7 mL) was heated to 80 ºC and (triphenylphosphoranylidene) acetaldehyde (2.16 g, 7.11 mmol) 
was added portionwise and the resulting mixture stirred at 80 ºC for 7 h. The solvent was the 
removed in vacuo ((Z):(E) 14:86) and the crude material purified by column chromatography, 
eluting with 60 % dichloromethane in petrol to give (E)-3-(naphthalen-2-yl)acrylaldehyde as a 
yellow solid, with spectroscopic data in accordance with the literature (210 mg, 16 %).
143
 
!H (300 MHz, CDCl3) 9.77 (1H, d, J 7.7, CHO), 8.00 (1H, s, CAr(1)H), 7.91–7.85 (3H, m, 
ArH), 7.69 (1H, dd, J 8.4, 1.7, ArH), 7.65 (1H, d, J 15.8, CHCHCHO), 7.60–7.51 (2H, m, 
ArH), and 6.84 (1H, dd, J 15.8, 7.7, CHCHO). 
(E)-3-(Naphthalen-2-yl)acrylaldehyde (173 mg, 0.950 mmol), triflic acid (0.190 M solution in 
methanol, 0.5 mL, 95.0 µmol), catalyst (5R)-163 (10 mol%, 37.0 mg, 95.0 µmol) and 
cyclopentadiene (188 mg, 2.80 mmol) were combined according to general procedure D. The 
crude material was then purified by column chromatography, eluting with 50 % 
dichloromethane in petrol to yield the title compounds as a 38:62 mixture of diastereoisomers, 
with spectroscopic data in accordance with the literature (187 mg, 86 %). 
exo-(2R): !H (300 MHz, CDCl3) 9.98 (1H, d, J 2.0, CHO), 7.82–7.72 (3H, m, ArH), 7.55 (1H, 
s, CAr(1)H), 7.49–7.37 (2H, m, ArH), 7.32 (1H, dd, J 8.6, 1.9, ArH), 6.38 (1H, dd, J 5.6, 3.1, 
CHA=CHB), 6.09 (1H, dd, J 5.6, 2.9, CHA=CHB), 3.90 (1H, dd, J 5.1, 3.5, CHAr), 3.35–3.30 
(1H, m, CHCH2), 3.30–3.23 (1H, m, CHCH2), 2.74 (1H, app dt, J 5.1, 1.8, CHCHO), 1.71–1.65 
(1H, m, CHAHB) and 1.64–1.57 (1H, m, CHAHB). 
endo-(2R): !H (300 MHz, CDCl3) 9.66 (1H, d, J 2.2, CHO), 7.82–7.72 (3H, m, ArH), 7.69 (1H, 
s, CAr(1)H), 7.49–7.37 (3H, m, ArH), 6.47 (1H, dd, J 5.7, 3.2, CHA=CHB), 6.21 (1H, dd, J 5.7, 
2.7, CHA=CHB), 3.42–3.37 (1H, m, CHCH2), 3.30–3.23 (2H, m, CHCH2 & CHAr), 3.09 (1H, 
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app dt, J 8.7, 1.8, CHCHO), 1.90 (1H, app dt, J 8.7, 1.6, CHAHB) and 1.71–1.65 (1H, m, 
CHAHB). 
Enantiomeric excess was determined by acetalisation with (+)-(R,R)-hydrobenzoin and 
1
H NMR analysis: (400 MHz, C6D6) exo isomers ! 5.81 (d, J 4.7, CHO2, 2R) and 5.78 (d, J 5.9, 
CHO2, 2S), endo isomers ! 5.44 (d, J 8.1, CHO2, 2R) and 5.39 (d, J 8.2, CHO2, 2S). 
 
exo-(1R,2R,3R,4S)-Ethyl 3-formylbicyclo[2.2.1]hept-5-ene-2-carboxaldehyde and 
endo-(1S,2R,3R,4R)-ethyl 3-formylbicyclo[2.2.1]hept-5-ene-2-carboxaldehyde (Table 5.4, 
entry 9) 
exo-(2R) endo-(2R)
CO2Et
CHO
+
CHO
CO2Et
 
Ethyl (E)-4-oxo-2-butenoate (0.120 mL, 0.950 mmol), triflic acid (0.190 M solution in 
methanol, 0.5 mL, 95.0 µmol), catalyst (5R)-163 (10 mol%, 37.0 mg, 95.0 µmol) and 
cyclopentadiene (188 mg, 2.80 mmol) were combined according to general procedure D. The 
crude material was then purified by column chromatography, eluting with 15 % diethyl ether in 
petrol to yield the title compounds as a 44:56 mixture of diastereoisomers, with spectroscopic 
data identical to that of the racemate (129 mg, 84 %). 
Enantiomeric excess was determined by derivatisation to the corresponding benzyl esters, 
following general procedure F and HPLC with ChiralPax AD-H column 
(2 % isopropanol:hexane, flow rate = 0.5 mL min
-1
, 230 nm), exo tR(2S) 19.0 min and 
tR(2R) 21.9 min, endo tR(2S) 23.3 min and tR(2R) 25.1 min.
48
 
 
exo-(1R,2R,3R,4S)-3-(Naphthalen-1-yl)bicyclo[2.2.1]hept-5-ene-2-carbaldehyde and 
endo-(1S,2R,3R,4R)-3-(naphthalen-1-yl)bicyclo[2.2.1]hept-5-ene-2-carbaldehyde 
(Table 5.6, entry 2) 
exo-(2R) endo-(2R)
CHO
+
CHO
 
Following the method of Moitessier et al.,
144
 to a suspension of (E)-3-(naphthalen-1-yl)acrylic 
acid (990 mg, 5.00 mmol) and DMF (0.0400 mL, 0.500 mmol) in dichloromethane (30 mL) was 
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added oxalyl chloride (0.65 mL, 7.500 mmol) dropwise, leading to significant gas evolution. 
The resulting mixture was stirred at room temperature for 1 h then concentrated in vacuo to a 
yellow solid which was subsequently dissolved in THF (30 mL) and cooled to –78 ºC. Lithium 
tri-tert-butoxyaluminium hydride (1.33 g, 5.25 mmol) was then added portionwise and the 
resulting mixture left to stir for 1 h. The mixture was then allowed to warm to 0 ºC and stirred 
for a further 2 h before being quenched by addition of water (30 mL). The resulting suspension 
was passed through a layer of Ceilte and the cake washed with dichloromethane (50 mL). The 
filtrate was diluted further with water (50 mL) and the resulting biphasic mixture extracted. The 
aqueous layer was washed with dichloromethane (50 mL) and the combined organic layers were 
washed with water (100 mL), brine (100 mL), dried (MgSO4), filtered and concentrated 
in vacuo. The crude material was purified by column chromatography on silica gel, eluting with 
60 % dichloromethane in petrol to give (E)-3-(naphthalen-1-yl)acrylaldehyde as a yellow solid 
with spectroscopic data in accordance with the literature (463 mg, 51 %).
145
 
mp 43–44 ˚C; !H (300 MHz, CDCl3) 9.87 (1H, d, J 7.7, CHO), 8.35 (1H, d, 
J 15.7, CHCHCHO), 8.20 (1H, d, J 8.5, ArH), 7.98–7.91 (2H, m, ArH), 7.84 (1H, d, J 7.1, 
ArH), 7.66–7.52 (3H, m, ArH) and 6.86 (1H, dd, J 15.7, 7.7, CHCHO). 
(E)-3-(Naphthalen-1-yl)acrylaldehyde (87.5 mg, 0.480 mmol), triflic acid (0.0190 M solution in 
methanol, 0.25 mL, 4.80 µmol), catalyst 170 (1 mol%, 2.00 mg, 4.80 µmol) and 
cyclopentadiene (94 mg, 2.80 mmol) were combined according to general procedure D. The 
crude material was then purified by column chromatography, eluting with 40 % 
dichloromethane in petrol to yield the title compounds as a 21:79 mixture of diastereoisomers 
(99 mg, 83 %). 
[$]20D –47.3 (c 0.5, chloroform); "max (film)/ cm
-1
 3051 (Ar-H), 2975 (C-H), 2872 (C-H), 
2815 (C-H), 2717 (C-H), 1716 (C=O), 1597 (C=C) and 1578 (Ar C=C));  
exo-(2R): !H (300 MHz, CDCl3) 9.95 (1H, d, J 1.7, CHO), 8.32 (1H, d, J 8.4, ArH), 7.89–7.84 
(1H, m, ArH), 7.76–7.70 (1H, m, ArH), 7.61–7.42 (2H, m, ArH), 7.35 (1H, t, J 7.7, ArH), 7.09 
(1H, d, J 8.4, ArH), 6.45 (1H, dd, J 5.6, 3.2, CHA=CHB), 5.82 (1H, dd, J 5.6, 3.0, CHA=CHB), 
4.58 (1H, dd, J 5.1, 3.5, CHAr), 3.37–3.33 (1H, m, CHCH2), 3.33–3.28 (1H, m, CHCH2), 
2.92 (1H, app dt, J 5.1, 1.7, CHCHO), 1.81 (1H, app dt, J 8.8, 1.5, CHAHB) and 1.62 (1H, ddd, 
J 8.8, 3.5, 1.8, CHAHB); !C (75 MHz, CDCl3) 202.6 (CHO), 139.2 (CHA=CHB), 137.6 (CAripso), 
136.2 (CAripso), 134.1 (CHA=CHB), 132.5 (CAripso), 129.1 (CAr), 127.2 (CAr), 126.2 (CAr), 
125.6 (CAr), 125.1 (CAr), 123.4 (CAr), 58.4 (CHCHO), 48.6 (CHCH2), 47.9 (CH2), 
46.0 (CHCH2) and 40.4 (CHAr). 
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endo-(2R): !H (300 MHz, CDCl3) 9.69 (1H, d, J 2.3, CHO), 8.05 (1H, dd, J 6.7, 2.5, ArH), 
7.89–7.84 (1H, m, ArH), 7.76–7.70 (1H, m, ArH), 7.61–7.42 (4H, m, ArH), 6.58 (1H, dd, 
J 5.7, 3.2, CHA=CHB), 6.22 (1H, dd, J 5.7, 2.7, CHA=CHB), 3.82 (1H, dd, J 4.9, 1.1, CHAr), 
3.44–3.38 (1H, m, CHCH2), 3.22 (1H, ddd, J 4.9, 3.5, 2.3, CHCHO), 3.20–3.17 (1H, m, 
CHCH2), 1.92 (1H, app dt, J 8.7, 1.5, CHAHB) and 1.67 (1H, ddd, J 8.7, 3.2, 1.6, CHAHB); 
!C (75 MHz, CDCl3) 203.5 (CHO), 139.1 (CHA=CHB), 136.9 (CAripso), 135.9 (CAripso), 
134.2 (CHA=CHB), 132.5 (CAripso), 129.0 (CAr), 127.3 (CAr), 126.3 (CAr), 125.8 (CAr), 
125.4 (CAr), 123.8 (CAr), 123.0 (CAr), 59.1 (CHCHO), 49.7 (CHCH2), 47.6 (CH2), 
45.7 (CHCH2) and 41.4 (CHAr); m/z HRMS (ESI
+
) C18H17O ([M+H]
+
) requires 249.1279, 
found 249.1287 (+3.0 ppm). 
Enantiomeric excess was determined by acetalisation with (+)-(R,R)-hydrobenzoin and 
1
H NMR analysis: (500 MHz, C6D6) exo isomers ! 5.79 (d, J 3.8, CHO2, 2R) and 5.77 (d, J 5.1, 
CHO2, 2S), endo isomers ! 5.51 (d, J 7.5, CHO2, 2R) and 5.43 (d, J 7.7, CHO2, 2S). 
 
exo-(1R,2R,3R,4S)-3-(4-Methoxyphenyl)bicyclo[2.2.1]hept-5-ene-2-carboxaldehyde and 
endo-(1S,2R,3R,4R)-3-(4-methoxyphenyl)bicyclo[2.2.1]hept-5-ene-2-carboxaldehyde 
(Table 5.6, entry 3) 
CHO
+
OMe
CHO
OMe
exo-(2R) endo-(2R)  
 (E)-4-Methoxycinnamaldehyde (77.0 mg, 0.480 mmol), triflic acid (0.0190 M solution in 
methanol, 0.25 mL, 4.80 µmol), catalyst 170 (1 mol%, 2.00 mg, 4.80 µmol) and 
cyclopentadiene (94 mg, 2.80 mmol) were combined at 5 ºC according to general procedure D. 
The crude material was then purified by column chromatography, eluting with 10 % diethyl 
ether in petrol to yield the title compounds as a 36:64 mixture of diastereoisomers, with 
spectroscopic data in accordance with the literature (94 mg, 86 %).
70
  
exo-(2R): !H (400 MHz, CDCl3) 9.91 (1H, d, J 2.0, CHO), 7.09–7.05 (2H, m, ArH), 6.81–6.78 
(2H, m, ArH), 6.34 (1H, dd, J 5.6, 3.2, CHA=CHB), 6.07 (1H, dd, J 5.6, 2.9, CHA=CHB), 
3.77 (3H, s, OCH3), 3.66 (1H, dd, J 5.2, 3.5, CHAr), 3.22–3.19 (1H, m, CHCH2), 3.19–3.15 
(1H, m, CHCH2), 2.53 (1H, app dt, J 5.2, 2.0, CHCHO), 1.64–1.58 (1H, m, CHAHB) and    
1.56–1.53 (1H, m, CHAHB). 
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endo-(2R): !H (400 MHz, CDCl3) 958 (1H, d, J 2.3, CHO), 7.20–7.17 (2H, m, ArH), 6.87–6.81 
(2H, m, ArH), 6.41 (1H, dd, J 5.6, 3.2, CHA=CHB), 6.16 (1H, dd, J 5.6, 2.8, CHA=CHB), 
3.79 (3H, s, OCH3), 3.33–3.29 (1H, m, CHAr), 3.08–3.04 (1H, m, CHCH2), 3.04–3.01 (1H, m, 
CHCH2), 2.94 (1H, ddd, J 5.1, 3.2, 2.3, CHCHO), 1.79 (1H, app dt, J 8.7, 1.5, CHAHB) and 
1.64–1.58 (1H, m, CHAHB). 
Enantiomeric excess was determined by acetalisation with (+)-(R,R)-hydrobenzoin and 
1
H NMR analysis:
70
 (500 MHz, C6D6) exo isomers ! 5.76 (d, J 4.9, CHO2, 2R) and 5.75 (d, 
J 7.0, CHO2, 2S), endo isomers ! 5.39 (d, J 8.2, CHO2, 2R) and 5.35 (d, J 8.2, CHO2, 2S). 
 
exo-(1R,2R,3R,4S)-3-(4-Nitrophenyl)bicyclo[2.2.1]hept-5-ene-2-carboxaldehyde and 
endo-(1S,2R,3R,4R)-3-(4-nitrophenyl)bicyclo[2.2.1]hept-5-ene-2-carboxaldehyde 
(Table 5.6, entry 5) 
exo-(2R) endo-(2R)
CHO
+
NO2
CHO
NO2
 
4-Nitrocinnamaldehyde (84.0 mg, predominantly (E)-, 0.480 mmol), triflic acid (96.0 mM 
solution in methanol, 0.25 mL, 24.0 µmol), catalyst 170 (5 mol%, 10.0 mg, 24.0 µmol) and 
cyclopentadiene (94.0 mg, 1.42 mmol) were combined according to general procedure D. The 
crude material was then purified by column chromatography, eluting with 15 % ethyl acetate in 
petrol to yield the title compounds as a 36:64 mixture of diastereoisomers, with spectroscopic 
data identical to that of the racemate (106 mg, 91 %). 
Enantiomeric excess was determined by acetalisation with (+)-(R,R)-hydrobenzoin and 
1
H NMR analysis:
67
 (500 MHz, C6D6) exo isomers ! 5.60 (d, J 5.2, CHO2, 2R) and 5.58 (d, 
J 5.9, CHO2, 2S), endo isomers ! 5.26 (d, J 8.1, CHO2, 2R) and 5.19 (d, J 8.2, CHO2, 2S). 
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exo-(1R,2R,3R,4S)-3-Propylbicyclo[2.2.1]hept-5-ene-2-carboxaldehyde and 
endo-(1S,2R,3R,4R)-3-propylbicyclo[2.2.1]hept-5-ene-2-carboxaldehyde (Table 5.6, 
entry 6) 
n-Pr
CHO
+
CHO
n-Pr
exo-(2R) endo-(2R)  
(E)-2-Hexen-1-al (0.110 mL, 0.950 mmol), triflic acid (0.0190 M solution in methanol, 0.5 mL, 
9.50 µmol), catalyst 170 (1 mol%, 4.00 mg, 9.50 µmol) and cyclopentadiene (188 mg, 
2.80 mmol) were combined according to general procedure D. The crude material was then 
purified by column chromatography, eluting with 2.5 % diethyl ether in petrol to yield the title 
compounds as a 31:69 mixture of diastereoisomers, with spectroscopic data identical to that of 
the racemate (140 mg, 90 %). 
Enantiomeric excess was determined by acetalisation with (+)-(R,R)-hydrobenzoin and 
1
H NMR analysis:
70
 (300 MHz, C6D6) exo isomers ! 5.62 (d, J 6.1, CHO2, 2R) and 5.60 (d, 
J 6.2, CHO2, 2S), endo isomers ! 5.24 (d, J 8.3, CHO2, 2R) and 5.18 (d, J 8.3, CHO2, 2S). 
 
7.3.2 Other experimental procedures 
(RS)-2,5-dimethylpyrazolidin-3-one 67 
N
H
N
O
67  
To a solution of (RS)-tert-butyl 2,5-dimethyl-3-oxopyrazolidine-1-carboxylate 73 (1.59 g, 
7.42 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (1.80 mL, 23.3 mmol) 
and the resulting solution stirred overnight at rt. TLC analysis of the crude reaction mixture 
showed incomplete reaction. Hence, further trifluoroacetic acid (0.580 mL, 7.51 mmol) was 
added and the mixture stirred overnight before concentration in vacuo. The resulting material 
was partitioned between dichloromethane (100 mL) and saturated sodium hydrogen carbonate 
solution (100 mL). The aqueous layer was washed with dichloromethane (100 mL) and the 
combined organic layers washed with brine (150 mL), dried (MgSO4), filtered and concentrated 
in vacuo to give the title compound as a colourless oil (145 mg). The aqueous layer was treated 
with triethylamine then extracted with further dichloromethane (100 mL). The organic layer 
was dried (MgSO4), filtered and concentrated in vacuo to give further material (177 mg). The 
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aqueous layer was then concentrated in vacuo and partitioned between 1M sodium hydroxide 
solution (50 mL) and dichloromethane (80 mL). The organic layer was dried (MgSO4), filtered 
and concentrated in vacuo to give further material (151 mg) (473 mg in total, 55 %). 
"max (film)/ cm
#1
 3196 (N-H), 2969 (C-H), 2927 (C-H), 1667 (C=O), 1605 and 1597 (N-H 
bend); !H (300 MHz, CDCl3) 4.12 (1H, br s, N(1)H), 3.66 (1H, app dquin, J 8.3, 6.7, C(5)H), 
3.01 (3H, s, N(2)CH3), 2.59 (1H, dd, ABX system, JAB 16.1, JAX 7.2, C(4)HAHB), 2.20 (1H, dd, 
ABX system, JBA 16.1, JBX 8.3, C(4)HAHB) and 1.24 (3H, d, J 6.4, C(5)HCH3); !C (75 MHz, 
CDCl3) 172.6 (C(3)O), 51.4 (C(5)H), 40.4 (C(4)H2), 31.4 (N(2)CH3) and 19.1 (C(5)HCH3); 
m/z (CI) 115.2 (100, [M+H]
+
); HRMS (ESI
+
) C5H11N2O ([M+H]
+
) requires 115.0866, found 
115.0865 (&0.4 ppm).  
 
(RS)-tert-Butyl 2,5-dimethyl-3-oxopyrazolidine-1-carboxylate 73 
N
N
O
Boc
73  
A solution of crude (RS)-tert-butyl 5-methyl-3-oxopyrazolidine-1-carboxylate 72 (2.92 g, 
13.6 mmol) in DMF (30 mL) was treated with iodomethane (2.80 mL, 45.0 mmol) and 
potassium carbonate (2.49 g, 18.0 mmol) and the suspension stirred at rt overnight. The reaction 
mixture was partitioned between diethyl ether (60 mL) and water (60 mL) and the resultant 
aqueous layer washed with further diethyl ether (60 mL). The combined organic layers were 
washed with brine (120 mL), dried (MgSO4), filtered and concentrated in vacuo. The material 
was then purified by column chromatography, eluting with 25 % ethyl acetate in petrol to give 
the title compound as a colourless oil with spectroscopic data in accordance with the literature 
(1.60 g, 53 %).
76 
 
!H (300 MHz, CDCl3) 4.53 (1H, app quin, J 7.0, C(5)H), 3.20 (3H, s, N(2)CH3), 2.91 (1H, dd, 
J 16.3, 8.3, C(4)HAHB), 2.00 (1H, d, J 16.3, C(4)HAHB), 1.48 (9H, s, C(CH3)3) and 1.22 (3H, d, 
J 6.8, C(5)HCH3). 
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(RS)-tert-Butyl 2-benzyl-5-methyl-3-oxopyrazolidine-1-carboxylate 74 
N
N
O
Boc
Bn
74  
To a solution of hydrazine hydrate (9.02 mL, 0.180 mol) in absolute ethanol (200 mL) was 
added ethyl crotonate 66 (21.0 mL, 0.169 mol) by dropwise addition. The resulting solution was 
stirred for 1 h at rt and then at reflux for 4 h before concentration in vacuo to give crude 
(RS)-5-methylpyrazolidin-3-one 71 (18.1 g) as a viscous yellow oil with spectroscopic data in 
accordance with the literature.
75
 Product was used without further purification. 
!H (400 MHz, CDCl3) 3.78–3.66 (1H, app dquin, J 8.7, 6.7, C(5)H), 2.48 (1H, dd, ABX system, 
JAB 16.1, JAX 7.1, C(4)HAHB), 2.12 (1H, dd, ABX system, JBA 16.1, JBX 8.7, C(4)HAHB) and 
1.22 (3H, d, J 6.3, C(5)HCH3).  
To a solution of crude (RS)-tert-butyl 5-methyl-3-oxopyrazolidine-1-carboxylate 71 (18.1 g, 
0.180 mol) in water (100 mL) was added sodium carbonate (19.1 g 0.180 mol) and dioxane 
(50 mL). A solution of di-tert-butyl dicarbonate (39.3 g, 0.240 mol) in dioxane (50 mL) was 
then added and the mixture stirred at rt for 1 h. The resulting suspension was filtered and the 
precipitate washed with chloroform. The combined organic extracts were then concentrated in 
vacuo to approximately 30 mL volume and partitioned between water (100 mL) and 
dichloromethane (100 mL). The organic extracts were washed with brine (150 mL), dried 
(MgSO4), filtered and concentrated in vacuo to give crude (RS)-tert-butyl 5-methyl-3-
oxopyrazolidine-1-carboxylate 72 (33.9 g) as a yellow solid with spectroscopic data in 
accordance with the literature.
76
 Product was used without further purification. 
!H (400 MHz, CDCl3) 9.50 (1H, br s, N(2)H), 4.38 (1H, dqd, J 9.6, 6.5, 3.3, C(5)H), 2.92 (1H, 
dd, ABX system, JAB 17.0, JAX 9.6, C(4)HAHB), 2.14 (1H, dd, ABX system, JBA 17.0, JBX 3.3, 
C(4)HAHB), 1.43 (9H, s, C(CH3)3 and 1.29 (3H, d, J 6.5, C(5)HCH3).  
A solution of crude (RS)-tert-butyl 5-methyl-3-oxopyrazolidine-1-carboxylate 72 (33.9 g, 
170 mmol) in DMF (125 mL) was treated with benzyl bromide (20.2 mL, 170 mmol) and 
potassium carbonate (23.9 g, 173 mmol) and the suspension stirred at rt for 2.5 h. The reaction 
mixture was partitioned between diethyl ether (150 mL) and water (250 mL) and the resultant 
aqueous layer washed with further diethyl ether (2 x 150 mL). The combined organic layers 
were washed with water (200 mL), brine (200 mL), dried (MgSO4), filtered and concentrated 
in vacuo. The crude material was purified by column chromatography, eluting with 25 % ethyl 
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acetate in petrol to give the title compound as a colourless solid (19.9 g, 41 %). 
"max (KBr disc)/ cm
–1
 3028 (Ar-H), 2976 (C-H), 2931 (C-H), 2871 (N-C-H), 1706 (C=O), 
1690 (C=O), 1557 (Ar C=C) and 1534 (Ar C=C); mp 90–94 ºC; !N (CDCl3) 156 (N(2)CH2Ph), 
136 (N(1)Boc); !H (400 MHz, CDCl3) 7.35–7.29 (5H, m, ArH), 5.29 (1H, d, AB system, 
JAB 14.2, CHAHBPh), 4.42 (1H, app quin, J 7.2, C(5)H), 4.39 (1H, d, AB system, JBA 14.2, 
CHAHBPh), 2.95 (1H, dd, J 16.3, 8.2, C(4)HAHB), 1.96 (1H, d, J 16.3, C(4)HAHB), 1.56 (9H, s, 
C(CH3)3) and 0.65 (3H, d, J 6.7, C(5)HCH3); !C (100 MHz, CDCl3) 171.5 (C(3)O), 
156.1 (C(O)O), 135.6 (CAripso), 129.7 (CAr), 128.4 (CAr), 128.1 (CAr), 82.6 (C(CH3)3), 
53.7 (C(5)H), 48.6 (CH2Ph), 38.1 (C(4)H2), 28.3 (C(CH3)3) and 19.7 (C(5)HCH3); m/z (CI) 
291.3 (100, [M+H]
+
); HRMS (ESI
+
) C16H23N2O3 ([M+H]
+
) requires 291.1703, found 291.1705 
(+0.7 ppm). 
 
(RS)-2-Benzyl-5-methylpyrazolidin-3-one 76 
N
H
N
O
Bn
76  
(RS)-tert-Butyl 2-benzyl-5-methyl-3-oxopyrazolidine-1-carboxylate 74 (2.84 g, 9.78 mmol) was 
stirred at rt overnight in a 1:1 mixture of trifluoroacetic acid/dichloromethane (8 mL) before 
being concentrated in vacuo. The resulting material was redissolved in dichloromethane (6 mL), 
cooled to 0 ºC before treatment with triethylamine (2.40 mL, 17.2 mmol). The resulting solution 
was stirred at rt for a further 15 min before being partitioned between water (40 mL) and 
dichloromethane (40 mL). The resultant aqueous layer was washed with dichloromethane (40 
mL) and the combined organic layers washed with brine (50 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The crude material was then purified by column chromatography, 
eluting with 5 % methanol in ethyl acetate to give the title compound as a clear yellow oil 
(1.42 g, 76 %). 
"max (film)/ cm
#1
 3202 (N-H), 3063 (Ar-H), 3031 (Ar-H), 2970 (C-H), 2925 (C-H), 
2868 (N-C-H), 1678 (C=O), 1605 (Ar C=C) and 1583 (N-H bend); !H (300 MHz, CDCl3)  
7.40–7.30 (5H, m, ArH), 4.70 (1H, d, AB system, JAB 14.6, CHAHBPh), 4.55 (1H, d, AB system, 
JBA 14.6, CHAHBPh), 4.10 (1H, br s, N(1)H), 3.69 (1H, app dquin, J 8.3, 6.7, C(5)H), 2.71 (1H, 
dd, ABX system, JAB 16.2, JAX 7.1, C(4)HAHB), 2.29 (1H, dd, ABX system, JBA 16.2, JBX 8.3, 
C(4)HAHB) and 1.25 (3H, d, J 6.4, C(5)HCH3); !C (75 MHz, CDCl3) 175.7 (C(3)O), 
139.2 (CAripso), 132.1 (CAr), 131.6 (CAr), 131.1 (CAr), 54.8 (C(5)H), 51.4 (CH2Ph), 
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43.8 (C(4)H2) and 22.1 (C(5)HCH3); m/z (CI) 191.2 (100, [M+H]
+
); HRMS (ESI
+
) C11H15N2O 
([M+H]
+
) requires 191.1179, found 191.1177 (&0.8 ppm). 
 
(RS)-5-iso-propylpyrazolidin-3-one 79 
N
H
NH
O
i-Pr
79  
To a solution of iso-butyrlaldehyde (2.17 mL, 24.0 mmol) in dichloromethane (100 mL), cooled 
to 0 ºC, was added ethyl (triphenylphosphoranylidene)acetate 77 (10.0 g, 29.0 mmol) and the 
resulting clear yellow solution stirred at rt overnight before being concentrated in vacuo. The 
crude material was then passed through a plug of silica gel, eluting with 3 % ethyl acetate in 
petrol. The resulting crude residue was then dissolved in absolute ethanol (3 mL), hydrazine 
hydrate (70.0 µL, 1.48 mmol) was added and the solution stirred for 1 h at rt and then at reflux 
for 4 h before concentration in vacuo. The crude material was purified by column 
chromatography, eluting with 5 % methanol in dichloromethane, then flushed with 20 % 
methanol in dichloromethane to give the product as a clear yellow oil (2.68 g, 87 %). 
"max (film)/ cm
#1
 3401 (N-H), 3214 (N-H), 2961 (C-H), 2931 (C-H), 2874 (N-C-H) and 
1683 (C=O); !H (300 MHz, CDCl3) 3.33 (1H, app dt, J 9.4, 7.7, C(5)H), 2.43 (1H, dd, 
ABX system, JAB 16.4, JAX 7.4, C(4)HAHB), 2.23 (1H, dd, ABX system, JBA 16.4, JBX 9.4, 
C(4)HAHB), 1.67 (1H, dsept, J 7.9, 6.5 C(5)HCH). 0.94 (3H, d, J 6.5 CH(CH3)A(CH3)B) and 
0.89 (3H, d, J 6.5, CH(CH3)A(CH3)B); !C (75 MHz, CDCl3) 177.6 (C(3)O), 65.6 (C(5)H), 
36.6 (C(4)H2), 32.5 (C(5)HCH), 19.7 (CH(CH3)A(CH3)B) and 19.6 (C(4)(CH3)A(CH3)B); 
m/z (CI) 129.1 (100, [M+H]
+
); HRMS (CI) C6H13N2O ([M+H]
+
) requires 129.1028, found 
129.1032 (+3.2 ppm). 
 
(R)-5-phenylpyrazolidin-3-one (R)-83  
N
H
NH
O
Ph
(R)-83  
(R)-2-((R)-2-Methoxy-2-phenylacetyl)-5-phenylpyrazolidin-3-one (5R)-134 (4.62 g, 
14.9 mmol) was suspended in 6 M aqueous hydrochloric acid solution (40 mL) and heated to 
reflux for 30 min. The reaction mixture was basified with 2 M sodium hydroxide solution 
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(150 mL) and extracted with dichloromethane (3 x 150 mL). The combined organic layers were 
washed with brine (300 mL), dried (MgSO4), filtered and concentrated in vacuo to give a small 
quantity of the title compound (191 mg). Hence, the aqueous phase was neutralised to pH 7 
with 37 % hydrochloric acid solution and again extracted with dichloromethane (3 x 150 mL). 
The combined organic layers were washed with brine (300 mL), dried (MgSO4), filtered and 
concentrated in vacuo to give a further 1.20 g of the title compound as a colourless solid, with 
spectroscopic data identical to 83 (1.39 g, 57 %). 
[$]20D &13.0 (c 1.0, methanol); mp 94–96 ºC. 
 
(RS)-tert-Butyl 5-iso-propyl-3-oxopyrazolidine-1-carboxylate 86 
N
NH
O
i-Pr
Boc
86  
To a solution of (RS)-5-iso-propylpyrazolidin-3-one 79 (578 mg, 4.51 mmol) in water (6 mL) 
was added sodium carbonate (503 mg, 4.75 mmol) and dioxane (3 mL). A solution of di-tert-
butyl dicarbonate (1.02 g, 4.67 mmol) in dioxane (3 mL) was then added and the mixture stirred 
at rt overnight. TLC analysis showed incomplete reaction. Hence, more sodium carbonate 
(240 mg, 2.26 mmol) and di-tert-butyl dicarbonate (490 mg, 2.24 mmol) in dioxane (1 mL) 
were added and the mixture stirred for a further 3 h. The resulting suspension was then filtered 
and the precipitate washed with chloroform. The combined organic extracts were then 
concentrated in vacuo to approximately 5 mL volume and partitioned between water (40 mL) 
and dichloromethane (40 mL). The aqueous layer was washed with further dichloromethane 
(2 x 40 mL) and then the combined organic extracts washed with brine (200 mL), dried 
(MgSO4), filtered and concentrated in vacuo. The crude material was purified by column 
chromatography, eluting with 2 % methanol in dichloromethane to give the product as an 
off-white solid (530 mg, 51 %). 
"max (film)/ cm
#1
 3171 (N-H), 3072 (N-H), 2970 (C-H), 2933 (C-H), 2877 (N-C-H), 
1698 (C=O) and 1676 (C=O); mp 80–81 ºC; !H (300 MHz, CDCl3) 4.13 (1H, ddd, J 9.8, 6.4, 
2.5, C(5)H), 2.80 (1H, dd, ABX system, JAB 17.3, JAX 9.8, C(4)HAHB), 2.23 (1H, dd, ABX 
system, JBA 17.3, JBX 2.5, C(4)HAHB), 1.84 (1H, app oct, J 6.6, C(5)HCH). 1.43 (9H, s, 
C(CH3)3) and 0.88 (6H, d, J 6.8, CH(CH3)2); !C (75 MHz, CDCl3) 170.7 (C(3)O), 
154.7 (C(O)O), 82.6 (C(CH3)3), 62.1 (C(5)H), 33.6 (C(4)H2), 32.3 (C(5)HCH), 28.3 (C(CH3)3), 
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17.9 (CH(CH3)A(CH3)B) and 17.7 (C(4)(CH3)A(CH3)B); m/z (CI) 190.3 (100, 
[M-C(CH3)3+NH4]
+
), 229.3 (35, [M+H]
+
); HRMS (ESI
+
) C11H21N2O3 ([M+H]
+
) requires 
229.1547, found 229.1547. 
 
(RS)-tert-Butyl 3-oxo-5-(trifluoromethyl)pyrazolidine-1-carboxylate 87 
N
NH
O
F3C
Boc
87  
To a solution of hydrazine hydrate (1.60 mL, 32.7 mmol) in absolute ethanol (50 mL) was 
added ethyl 4,4,4-trifluorocrotonate 82 (4.40 mL, 29.3 mmol) and the resulting solution stirred 
at reflux for 3 h before concentration in vacuo to give crude (RS)-5-(trifluoromethyl)-
pyrazolidin-3-one 84 (3.35 g) as a yellow solid. Product was used without further purification. 
An analytical sample was taken and purified by recrystallisation in hot toluene to give the title 
compound as colourless plates. 
"max (KBr disc)/ cm
#1
 3248 (N-H), 3190 (N-H), 1694 (C=O) and 1648 (N-H bend);        
mp 130–132 ºC; !F (375 MHz, CD3OD) &81.0 (3F, d, J 8.2, CF3); !H (300 MHz, CD3OD) 
4.18 (1H, dqd, J 10.3, 8.2, 2.6, C(5)H), 3.02 (1H, dd, ABX system, JAB 17.4, JAX 10.3, 
C(4)HAHB) and 2.42 (1H, dd, ABX system, JBA 17.4, JBX 2.6, C(4)HAHB); !C (75 MHz, 
CD3OD) 174.2 (C(3)O), 125.2 (q, J 279, CF3), 56.2 (q, J 31.4, C(5)H) and 31.0 (q, J 1.5, 
C(4)H2); m/z HRMS (ESI
+
) C4H9F3N3O ([M+NH4]
+
) requires 172.0692, found 172.0688 (&2.6 
ppm). 
To a solution of crude (RS)-5-(trifluoromethyl)pyrazolidin-3-one 84 (2.62 g, 17.0 mmol) in 
water (20 mL) was added sodium carbonate (1.80 g, 17.0 mmol) and dioxane (10 mL). 
A solution of di-tert-butyl dicarbonate (3.70 g, 17.0 mmol) in dioxane (10 mL) was then added 
and the mixture stirred at rt overnight. The resulting suspension was filtered and the precipitate 
washed with ethyl acetate. The combined organic extracts were then concentrated in vacuo to a 
small volume at which point the title compound began to precipitate. This solid was collected 
by filtration and washed with water. The combined filtrate was cooled to 0 ºC overnight to yield 
a second crop of the title compound which was collected by filtration and washed with further 
cold water. The combined solids were dried in a desiccator to give the title compound as a 
colourless solid (2.64 g, 35 %). 
"max (film)/ cm
#1
 3343 (N-H), 3010 (N-H), 2986 (C-H), 1717 (C=O) and 1697 (C=O);   
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mp 141–144 ºC; !F (375 MHz, CDCl3) &79.3 (3F, d, J 6.7, CF3); !H (300 MHz, CDCl3) 4.89 
(1H, dqd, J 10.6, 6.7, 2.3, C(5)H), 3.08 (1H, dd, ABX system, JAB 17.8, JAX 10.6, C(4)HAHB), 
2.64 (1H, dd, ABX system, JBA 17.8, JBX 2.3, C(4)HAHB) and 1.52 (9H, s, C(CH3)3); !C (100 
MHz, CDCl3) 168.7 (C(3)O), 154.0 (C(O)O), 124.0 (q, J 281, CF3), 84.7 C(CH3)3), 56.7 (q, 
J 34.0, C(5)H), 30.8 (C(4)H2) and 28.1 (C(CH3)3); m/z HRMS (ESI
+
) C9H14F3N2O3 ([M+H]
+
) 
requires 255.0951, found 255.0954 (+1.2 ppm). 
 
(RS) tert-Butyl 2-benzyl-3-oxo-5-phenylpyrazolidine-1-carboxylate 88 
N
N
O
Ph
Boc
Bn
88  
To a solution of hydrazine hydrate (1.45 mL, 29.8 mmol) in absolute ethanol (25 mL) was 
added ethyl cinnamate 81 (5.00 mL, 29.8 mmol) and the resulting solution stirred at reflux 
overnight. The suspension was then concentrated in vacuo and redissolved in toluene (25 mL) 
and stirred at reflux for 3 h. The resulting solution was concentrated in vacuo to give crude 
(RS)-5-phenylpyrazolidin-3-one 83 (3.62 g) as a brown solid. Product was used without further 
purification. An analytical sample was taken and purified by recrystallisation in hot toluene to 
give the title compound as an off-white solid. 
"max (KBr disc)/ cm
#1
 3234 (N-H), 3191 (N-H), 3051 (Ar-H), 3019 (C-H), 1715 (C=O), 
1664 (N-H bend) and 1599 (Ar C=C); mp 95–97 ºC; !H (400 MHz, CDCl3) 7.44–7.32 (5H, m, 
ArH), 4.84 (1H, app t, J 8.5, C(5)H), 2.85 (1H, dd, ABX system, JAB 16.2, JAX 7.6, C(4)HAHB) 
and 2.76 (1H, dd, ABX system, JBA 16.2, JBX 9.4, C(4)HAHB); !C (100 MHz, CDCl3) 
176.7 (C(3)O), 138.4 (CAripso), 129.1 (CAr), 128.6 (CAr), 126.7 (CAr), 62.0 (C(5)H) and 
38.3 (C(4)H2); m/z (ES) 185.0 (100, [M+Na]
+
), 163.2 (100, [M+H]
+
); HRMS (ESI
+
) C9H11N2O 
([M+H]
+
) requires 163.0866, found 163.0867 (+0.6 ppm). 
To a solution of crude (RS)-5-phenylpyrazolidin-3-one 83 (3.62 g, 22.3 mmol) in water (30 mL) 
was added sodium carbonate (2.37 g 22.3 mmol) and dioxane (10 mL). A solution of di-tert-
butyl dicarbonate (4.90 g, 22.4 mmol) in dioxane (10 mL) was then added and the mixture 
stirred at rt for 3 h. The resulting suspension was filtered and the precipitate washed with 
chloroform. The combined organic extracts were then concentrated in vacuo to approximately 
30 mL volume and partitioned between water (100 mL) and dichloromethane (75 mL). The 
aqueous layer was extracted with further dichloromethane (2 x 75 mL) and then the combined 
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organic extracts washed with brine (150 mL), dried (MgSO4), filtered and concentrated in vacuo 
to give crude (RS)-tert-butyl 5-phenyl-3-oxopyrazolidine-1-carboxylate 85 (4.95 g) as a yellow 
oil. Product was used without further purification. An analytical sample was taken and purified 
by column chromatography, eluting with 50 % dichloromethane in petrol, then 5 % methanol in 
dichloromethane to give the title compound as a colourless solid. 
"max (KBr disc)/ cm
#1
 3334 (N-H), 3016 (Ar-H), 2965 (C-H), 1707 (C=O) and 
1681 (C=O); mp 134–137 ºC; !N (CDCl3) 147 (N(1)Boc, 127 (N(2)H); !H (500 MHz, CDCl3) 
7.36–7.27 (5H, m, ArH), 5.33 (1H, dd, J 10.4. 3.9, C(5)H), 3.30 (1H, dd, ABX system, 
JAB 17.3, JAX 10.4, C(4)HAHB), 2.63 (1H, dd, ABX system, JBA 17.3, JBX 3.9, C(4)HAHB) and 
1.36 (9H, s, C(CH3)3); !C (75 MHz, CDCl3) 169.6 (C(3)O), 153.7 (C(O)O), 141.2 (CAripso), 
129.3 (CAr), 128.5 (CAr), 126.1 (CAr), 83.2 (C(CH3)3), 59.9 (C(5)H), 40.0 (C(4)H2) and 
28.5 (C(CH3)3); m/z (CI) 224.2 (100, [M-C(CH3)3+NH4]
+
), 263.3 (20, [M+H]
+
); HRMS (ESI
+
) 
C14H19N2O3 ([M+H]
+
) requires 263.1390, found 263.1392 (+0.7 ppm). 
A solution of crude (RS)-tert-butyl 5-phenyl-3-oxopyrazolidine-1-carboxylate 85 (4.95 g, 
18.9 mmol) in DMF (25 mL) was treated with benzyl bromide (2.25 mL, 18.9 mmol) and 
potassium carbonate (2.61 g, 18.9 mmol) and the suspension stirred at rt for 90 min. The 
reaction mixture was partitioned between diethyl ether (50 mL) and water (50 mL) and the 
resultant aqueous layer washed with further diethyl ether (2 x 50 mL). The combined organic 
layers were washed with brine (60 mL), dried (MgSO4), filtered and concentrated in vacuo. The 
material was then purified by column chromatography, eluting with 20 % ethyl acetate in petrol. 
Chromatography was then repeated, this time eluting with 15–20 % ethyl acetate in petrol to 
give the title compound as a yellow oil (2.63g, 25 %). 
"max (film)/ cm
#1
 3064 (Ar-H), 3032 (Ar-H), 2978 (C-H), 2933 (C-H), 2873 (N-C-H),        
1750–1658 (2 x C=O), 1604 (Ar C=C) and 1587 (Ar C=C); !H (400 MHz, CDCl3) 7.28–7.24 
(1H, m, ArH), 7.21–7.12 (5H, m, ArH), 7.04 (2H, t, J 7.5, ArH), 6.70 (2H, d, J 7.5, ArH), 
5.45 (1H, app d, J 9.3, C(5)H), 5.31 (1H, d, AB system, JAB 14.2, CHAHBPh), 4.59 (1H, d, AB 
system, JBA 14.2, CHAHBPh), 3.30 (1H, dd, J 16.8, 9.5, C(4)HAHB), 2.66 (1H, d, J 16.8, 
C(4)HAHB) and 1.56 (9H, s, C(CH3)3); !C (75 MHz, CDCl3) 170.5 (C(3)O), 156.7 (C(O)O), 
139.5 (CAripso), 135.7 (CAripso), 130.1 (CAr), 128.8 (CAr), 128.4 (CAr), 127.8 (CAr), 
126.1 (CAr), 83.4 (C(CH3)3), 60.2 (C(5)H), 49.2 (CH2Ph), 37.8 (C(4)H2) and 28.7 (C(CH3)3); 
m/z (CI) 353.3 (100, [M+H]
+
); HRMS (ESI
+
) C21H25N2O3 ([M+H]
+
) requires 353.1860, found 
353.1863 (+0.8 ppm). 
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(RS)-tert-Butyl 2-benzyl-5-iso-propyl-3-oxopyrazolidine-1-carboxylate 89 
N
N
O
i-Pr
Boc
Bn
89  
A solution of crude (RS)-tert-butyl 5-iso-propyl-3-oxopyrazolidine-1-carboxylate 86 (498 mg, 
2.18 mmol) in DMF (2 mL) was treated with benzyl bromide (0.260 mL, 2.18 mmol) and 
potassium carbonate (301 mg, 2.18 mmol) and the suspension stirred at rt for 60 min. The 
reaction mixture was partitioned between diethyl ether (20 mL) and water (20 mL) and the 
resultant aqueous layer washed with further diethyl ether (2 x 20 mL). The combined organic 
layers were washed with water (30 mL), brine (30 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The material was then purified by column chromatography, eluting with 
20 % ethyl acetate in petrol. Chromatography was then repeated, this time eluting with 15–25 % 
ethyl acetate in petrol to give the title compound as a crystalline yellow solid (281 mg, 41 %). 
"max (KBr disc)/ cm
#1
 3067 (Ar-H), 3035 (Ar-H), 2971 (C-H), 2928 (C-H), 2862 (N-C-H), 
1744–1661 (2 x C=O), 1602 (Ar C=C) and 1586 (Ar C=C); mp 53–56 ºC; !H (300 MHz, 
CDCl3) 7.23 (5H, app bs, ArH), 5.21 (1H, d, AB system, JAB 14.0, CHAHBPh), 4.39 (1H, d, 
AB system, JBA 14.0, CHAHBPh), 3.76 (1H, app t, J 9.3, C(5)H), 2.78 (1H, dd, JAB 16.6, 8.7, 
C(4)HAHB), 2.14 (1H, d, J 16.6, C(4)HAHB), 1.45 (9H, s, C(CH3)3), 0.88 (1H, dsept, J 10.2, 6.6, 
C(5)HCH), 0.61 (3H, d, J 6.6, CH(CH3)A(CH3)B) and 0.24 (3H, d, J 6.6, CH(CH3)A(CH3)B); 
!C (75 MHz, CDCl3) 170.9 (C(3)O), 156.6 (C(O)O), 135.7 (Aripso), 129.7 (CAr), 128.4 (CAr), 
128.2 (CAr), 82.4 (C(CH3)3), 64.1 (C(5)H), 48.6 (CH2Ph), 34.9 (C(4)H2), 30.8 (C(5)HCH), 
28.3 (C(CH3)3), 18.5 (CH(CH3)A(CH3)B) and 18.3 (C(4)(CH3)A(CH3)B); m/z (CI) 219.3 (100, 
[M-CO2C(CH3)3+NH4]
+
), 319.2 (60, [M+H]
+
); HRMS (ESI
+
) C18H27N2O3 ([M+H]
+
) requires 
319.2016, found 319.2019 (&0.8 ppm). 
 
(RS)-2-Benzyl-5-phenylpyrazolidin-3-one 91 
N
H
N
O
Ph Bn
91  
To a solution of (RS)-tert-butyl 2-benzyl-5-phenyl-3-oxopyrazolidine-1-carboxylate 88 (2.28 g, 
6.48 mmol) in dichloromethane (15 mL) was added trifluoroacetic acid (5.00 mL, 64.8 mmol) 
and the resulting mixture stirred at rt overnight. The excess acid was then quenched with 
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saturated sodium hydrogen carbonate solution (150 mL) and extracted with dichloromethane 
(2 x 100 mL). The combined organic layers were washed with brine (150 mL), dried (MgSO4), 
filtered and concentrated in vacuo to give the title compound as an off-white solid on standing 
(1.59 g, 97 %). 
"max (film)/ cm
#1
 3214 (N-H), 3062 (Ar-H), 3031 (Ar-H), 2920 (C-H), 1683 (C=O), 
1604 (Ar C=C) and 1560 (N-H bend); mp 60–62 ºC; !H (400 MHz, CDCl3) 7.26–7.18 (5H, m, 
ArH), 4.62 (1H, d, AB system, JAB 14.6, CHAHBPh), 4.58 (1H, app t, J 8.4, C(5)H), 4.51 (1H, d, 
AB system, JBA 14.6, CHAHBPh), 2.87 (1H, dd, ABX system, JAB 16.3, JAX 7.8, C(4)HAHB) and 
2.71 (1H, dd, ABX system, JBA 16.3, JBX 8.9, C(4)HAHB); !C (100 MHz, CDCl3) 171.4 (C(3)O), 
135.8 (CAripso), 135.7 (CAripso), 128.87 (CAr), 128.85 (CAr), 128.5 (CAr), 128.3 (CAr), 
128.0 (CAr), 126.5 (CAr), 58.2 (C(5)H), 48.1 (CH2Ph) and 39.3 (C(4)H2); m/z (CI) 253.2 (100, 
[M+H]
+
); HRMS (ESI
+
) C16H17N2O ([M+H]
+
) requires 253.1335, found 253.1333 (&0.9 ppm). 
 
(RS)-2-Benzyl-5-iso-propylpyrazolidin-3-one 92 
N
H
N
O
i-Pr Bn
92  
To a solution of (RS)-tert-butyl 2-benzyl-5-iso-propyl-3-oxopyrazolidine-1-carboxylate 89 
(390 mg, 1.67 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (0.500 mL, 
6.47 mmol) and the resulting solution stirred overnight at rt. TLC analysis of the crude reaction 
mixture showed incomplete reaction. Hence, further trifluoroacetic acid (0.200 mL, 1.62 mmol) 
was added and the mixture stirred for 2 h before being concentrated in vacuo. The resulting 
material was partitioned between dichloromethane (50 mL) and saturated sodium hydrogen 
carbonate solution (50 mL). The aqueous layer was washed with dichloromethane (2 x 50 mL) 
and the combined organic layers washed with brine (150 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The crude material was then purified by column chromatography, 
eluting with 50 % ethyl acetate in petrol to give the title compound as a clear yellow oil which 
solidified on standing (179 mg, 67 %). 
"max (KBr disc)/ cm
#1
 3178 (N-H), 3061 (Ar-H), 3035 (Ar-H), 2961 (C-H), 2954 (C-H), 
2880 (N-C-H), 1661 (C=O), 1602 (Ar C=C) and 1560 (N-H bend); mp 53–54 ºC; !H (400 MHz, 
CDCl3) 7.37–7.27 (5H, m, ArH), 4.64 (1H, d, AB system, JAB 14.5, CHAHBPh), 4.52 (1H, d, 
AB system, JBA 14.5, CHAHBPh), 4.07 (1H, br s, N(1)H), 3.22 (1H, app q, J 8.1, C(5)H), 2.61 
(1H, dd, ABX system, JAB 16.4, JAX 7.7, C(4)HAHB), 2.34 (1H, d, ABX system, JBA 16.4, JBX 
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8.7, C(4)HAHB), 1.61 (1H, dsept, J 7.8, 6.7, C(5)HCH), 0.91 (3H, d, J 6.7, CH(CH3)A(CH3)B) 
and 0.89 (3H, d, J 6.7, CH(CH3)A(CH3)B); !C (75 MHz, CDCl3) 172.1 (C(3)O), 136.1 (Aripso), 
128.9 (CAr), 128.4 (CAr), 127.9 (CAr), 61.3 (C(5)H), 48.1 (CH2Ph), 37.0 (C(4)H2), 
32.2 (C(5)HCH) and 19.2 (CH(CH3)2); m/z (CI) 219.3 (100, [M+H]
+
); HRMS (EI) 
C13H18N2O ([M]
+
) requires 218.1414, found 218.1413 (&0.3 ppm). 
 
(RS)-2-Benzyl-5-(trifluoromethyl)pyrazolidin-3-one 93 
Bn
N
H
N
O
F3C
93  
A solution of (RS)-tert-butyl 3-oxo-5-(trifluoromethyl)pyrazolidine-1-carboxylate 87 (1.00 g, 
3.94 mmol) in DMF (8 mL) was treated with benzyl bromide (0.50 mL, 3.95 mmol) and 
potassium carbonate (544 mg, 3.95 mmol) and the suspension stirred at rt for 2 days. The 
reaction mixture was partitioned between diethyl ether (100 mL) and water (100 mL) and the 
resultant aqueous layer washed with further diethyl ether (2 x 100 mL). The combined organic 
layers were washed with brine (150 mL), dried (MgSO4), filtered and concentrated in vacuo to 
give crude (RS)-tert-butyl 2-benzyl-5-(trifluoromethyl)-3-oxopyrazolidine-1-carboxylate 90 
(1.27 g) as a clear yellow oil. Product was used without further purification. An analytical 
sample was taken and purified by column chromatography, eluting with 15 % ethyl acetate in 
petrol, to give the title compound as a clear oil which became a colourless solid on standing. 
"max (KBr disc)/ cm
#1
 3064 (Ar-H), 3014 (Ar-H), 2985 (C-H), 1730 (C=O) and 1700 (C=O); 
mp 58–59 ºC; !F (282 MHz, CDCl3) &79.0 (3F, d, J 7.3, CF3); !H (300 MHz, CDCl3) 7.32–
7.27 (5H, m, ArH), 5.19 (1H, d, AB system, JAB 14.3, CHAHBPh), 4.77 (1H, dqd, J 10.1, 7.3, 
1.6, C(5)H), 4.58 (1H, d, AB system, JBA 14.3, CHAHBPh), 3.06 (1H, dd, J 17.5, 10.1, 
C(4)HAHB), 2.50 (1H, d, J 17.5, 1.6, C(4)HAHB) and 1.53 (9H, s, C(CH3)3); !C (75 MHz, 
CDCl3) 168.5 (C(3)O), 155.5 (C(O)O), 134.4 (CAripso), 129.8 (CAr), 128.4 (CAr), 128.3 (CAr), 
123.3 (q, J 281, CF3), 84.6 (C(CH3)3), 56.9 (q, J 33.8, C(5)H), 50.0 (CH2Ph), 30.8 (C(4)H2) and 
28.2 (C(CH3)3); m/z HRMS (ESI
+
) C16H20F3N2O3 ([M+H]
+
) requires 345.1421, found 345.1425 
(+1.3 ppm). 
Crude (RS)-tert-butyl 2-benzyl-5-(trifluoromethyl)-3-oxopyrazolidine-1-carboxylate 90 (1.04 g, 
3.02 mmol) was stirred at rt overnight in a 1:2 mixture of trifluoroacetic acid/dichloromethane 
(15 mL) before being concentrated in vacuo. The resulting material was partitioned between 
dichloromethane (100 mL) and saturated sodium hydrogen carbonate solution (100 mL). The 
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aqueous layer was washed with dichloromethane (2 x 100 mL) and the combined organic layers 
washed with brine (250 mL), dried (MgSO4), filtered and concentrated in vacuo. The crude 
material was then purified by recrystallisation from diethyl ether and the minimum quantity of 
dichloromethane to give the title compound as a colourless solid (484 mg, 50 %). 
C11H11F3N2O requires C, 54.1; H 4.5; N, 11.5 %; found C 53.9; H, 4.3; N, 11.6 %; "max (KBr 
disc)/ cm
#1
 3219 (N-H), 3068 (Ar-H), 3029 (Ar-H), 2951 (C-H), 2916 (C-H), 1700 (C=O) and 
1667 (C=O); mp 85–86 ºC; !F (282 MHz, CDCl3) &79.1 (3F, d, J 7.2, CF3); !H (300 MHz, 
CDCl3) 7.38–7.28 (5H, m, ArH), 4.92 (1H, d, AB system, JAB 14.6, CHAHBPh), 4.69 (1H, s, 
N(1)H), 4.25 (1H, d, AB system, JBA 14.6, CHAHBPh), 3.93 (1H, dqd, J 10.0, 7.2, 3.3, C(5)H), 
2.96 (1H, dd, J 17.4, 10.0, C(4)HAHB) and 2.66 (1H, d, J 17.4, 3.3, C(4)HAHB); !C (75 MHz, 
CDCl3) 168.3 (C(3)O), 135.1 (CAripso), 129.0 (CAr), 128.6 (CAr), 128.3 (CAr), 124.7 (q, J 279, 
CF3), 54.0 (q, J 32.3, C(5)H), 48.5 (CH2Ph) and 31.9 (C(4)H2); m/z HRMS (ESI
+
) C11H12F3N2O 
([M+H]
+
) requires 245.0896, found 245.0890 (+0.7 ppm).1 
 
(RS)-tert-Butyl 5-methyl-3-(tosyloxy)-4,5-dihydro-1H-pyrazole-1-carboxylate 96 
N
N
OTs
Boc
96  
(RS)-tert-Butyl 5-methyl-3-oxopyrazolidine-1-carboxylate 72 (0.991 g, 4.95 mmol) 
triethylamine (0.800 mL, 5.74 mmol) and tosyl chloride (1.00 g, 5.25 mmol) were combined 
according to general procedure A. The crude material was then purified by column 
chromatography, eluting with 15 % ethyl acetate in petrol to give the title compound as a 
colourless oil which solidified on standing (810 mg, 46 %). 
"max (KBr disc)/ cm
#1
 2987 (C-H), 2934 (C-H), 1698 (C=O), 1645 (C=N), 1596 (Ar C=C) and 
1586 (Ar C=C); mp 84–86 ºC; !N (CDCl3) 295 (N(2)COS(O)2), 156 (N(1)Boc); !H (300 MHz, 
CDCl3) 7.94 (2H, d, J 8.4, ArH), 7.36 (2H, d, J 8.4, ArH), 4.46 (1H, app dquin, J 11.0. 6.1, 
C(5)H), 3.26 (1H, dd, ABX system, JAB 17.8, JAX 11.0, C(4)HAHB), 2.61 (1H, dd, ABX system, 
JBA 17.8, JBX 5.3, C(4)HAHB), 1.49 (9H, s, C(CH3)3) and 1.34 (3H, d, J 6.3, C(5)HCH3); 
!C (75 MHz, CDCl3) 155.0 (C(O)O), 151.9 (C(4)N), 146.3 (CAripso), 132.3(CArpara), 
129.9 (CAr), 129.3 (CAr), 81.3 (C(CH3)3), 55.5 (C(5)H), 39.0 (C(4)H2), 28.4 (C(CH3)3), 
21.9 (CArparaCH3) and 20.7 (C(5)HCH3); m/z (ESI
+
) 372.2 (100, [M+NH4]
+
); HRMS (ESI
+
) 
C16H26N3O5S ([M+NH4]
+
) requires 372.1588, found 372.1593 (+1.4 ppm). 
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(RS)-tert-Butyl 3-(trifluoromethylsulfonyloxy)-5-methyl-4,5-dihydro- 
1H-pyrazole-1-carboxylate 97 
N
N
OTf
Boc
97  
To a solution of (RS)-tert-butyl 5-methyl-3-oxopyrazolidine-1-carboxylate 72 (250 mg, 
1.25 mmol) in dichloromethane (5 mL) was added triethylamine (0.700 mL, 5.00 mmol). The 
resulting suspension was then cooled to &78 ºC and triflic anhydride (0.410 mL, 2.50 mmol) 
added dropwise. The reaction mixture was stirred at &78 ºC for 2 h and 1:1 water-methanol 
added (4 mL). The reaction mixture was warmed to rt, maintained for 30 min, then diluted with 
diethyl ether (30 mL). The organic layer was washed with 0.1 M hydrochloric acid (50 mL), 
brine (50 mL), dried (MgSO4), filtered and concentrated in vacuo. The crude material was then 
purified by column chromatography, eluting with 10 % ethyl acetate in petrol to give the title 
compound as a colourless oil which solidified on standing (176 mg, 42 %). 
"max (KBr disc)/ cm
#1
 2990 (C-H), 2932 (C-H), 2873 (N-C-H), 1713 (C=O), 1635 (C=N) and 
1572 (Ar C=C); mp 41–43 ºC; !H (400 MHz, CDCl3) 4.61 (1H, app dquin, J 11.3. 6.3, C(5)H), 
3.38 (1H, dd, ABX system, JAB 17.8, JAX 11.3, C(4)HAHB), 2.70 (1H, dd, ABX system, 
JBA 17.8, JBX 5.3, C(4)HAHB), 1.52 (9H, s, C(CH3)3) and 1.42 (3H, d, J 6.3, C(5)HCH3); 
!C (100 MHz, CDCl3) 153.2 (C(O)O), 151.6 (C(4)N), 118.5 (q, J = 321, CF3), 82.4 (C(CH3)3), 
56.9 (C(5)H), 38.7 (C(4)H2), 28.4 (C(CH3)3) and 20.8 (C(5)HCH3); m/z (CI) 132.3 (100, 
[SO2CF3]
+
), 350.3 (20, [M+NH4]
+
); HRMS (ESI
+
) C10H19F3N3O5S ([M+NH4]
+
) requires 
350.0992, found 350.0991 (&0.3 ppm). 
 
(RS)-tert-Butyl 3-(benzyloxycarbonyloxy)-5-methyl-4,5-dihydro-1H-pyrazole-1-
carboxylate 98 
N
N
OCO2Bn
Boc
98  
(RS)-tert-Butyl 5-methyl-3-oxopyrazolidine-1-carboxylate 72 (1.00 g, 5.00 mmol), 
triethylamine (0.800 mL, 5.74 mmol) and benzyl chloroformate (0.75 mL, 5.25 mmol) were 
combined according to general procedure A to give crude product (1.77 g). Attempted 
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purification of this material by column chromatography led to decomposition and return of 
starting compound 72. Hence, characterisation was carried out on the crude mixture. 
"max (film)/ cm
#1
 3066 (Ar-H), 3035 (Ar-H), 2978 (C-H), 2932 (C-H), 2863 (N-C-H), 
1751 (C=O), 1725 (C=O), 1648 (C=N) and 1587 (Ar C=C); !N (CDCl3) 296 (N(2)COC(O)), 
155 (N(1)Boc); !H (300 MHz, CDCl3) 7.40–7.33 (5H, m, ArH), 5.23 (2H, s, CH2Ph), 4.54 (1H, 
app dquin, J 11.1. 6.1, C(5)H), 3.37 (1H, dd, ABX system, JAB 17.7, JAX 11.1, C(4)HAHB), 
2.68 (1H, dd, ABX system, JBA 17.7, JBX 5.0, C(4)HAHB), 1.52 (9H, s, C(CH3)3) and 1.39 (3H, 
d, J 6.3, C(5)HCH3); !C (100 MHz, CDCl3) 156.3 (C(4)N), 151.2 (OC(O)O), 134.1 (CAripso), 
129.2 (CAr), 128.9 (CAr), 128.7 (CAr), 81.6 (C(CH3)3), 71.2 (CH2Ph), 56.0 (C(5)H), 
38.1 (C(4)H2), 28.5 (C(CH3)3) and 20.7 (C(5)HCH3); m/z (ESI
+
) 357.0 (100, [M+Na]
+
); 
HRMS (ESI
+
) C17H22N2NaO5 ([M+Na]
+
) requires 357.1426, found 357.1419 (&2.1 ppm). 
 
(RS)-1-Benzyl 2-tert-butyl 3-methyl-5-oxopyrazolidine-1,2-dicarboxylate 99 
N
N
O
Boc
CO2Bn
99  
(RS)-tert-Butyl 5-methyl-3-oxopyrazolidine-1-carboxylate 72 (1.01 g, 5.04 mmol), sodium 
hydride (220 mg, 5.50 mmol) and benzyl chloroformate (0.75 mL, 5.25 mmol) were combined 
according to general procedure B. The crude material was then purified by column 
chromatography, eluting with 25 % ethyl acetate in petrol to give the title compound as a 
colourless oil (684 mg, 41 %). 
"max (film)/ cm
#1
 3066 (Ar-H), 3034 (Ar-H), 2979 (C-H), 2933 (C-H), 2874 (N-C-H), 
1799 (C=O), 1751 (C=O), 1728 (C=O) and 1587 (Ar C=C); !N (CDCl3) 166 (N(2)CO2Bn), 
137 (N(1)Boc); !H (300 MHz, CDCl3) 7.45–7.28 (5H, m, ArH), 5.36 (1H, d, AB system, 
JAB 12.3, CHAHBPh), 5.26 (1H, d, AB system, JBA 12.3, CHAHBPh), 4.42 (1H, app quin, J 7.0, 
C(5)H), 2.97 (1H, dd, J 17.1, 8.0, C(4)HAHB), 1.96 (1H, d, J 17.1, C(4)HAHB), 1.38 (9H, s, 
C(CH3)3) and 1.31 (3H, d, J 6.8, C(5)HCH3); !C (75 MHz, CDCl3) 169.9 (C(3)O), 
155.8 (N(1)C(O)O), 149.7 (N(2)C(O)O), 135.0 (CAripso), 128.7 (CAr), 128.6 (CAr), 
128.4 (CAr), 83.6 (C(CH3)3), 68.9 (CH2Ph), 53.6 (C(5)H), 39.6 (C(4)H2), 28.0 (C(CH3)3) and 
19.9 (C(5)HCH3); m/z (CI) 235.1 (100, [M–Boc+2H]
+
), 352.2 (96, [M+NH4]
+
); HRMS (ESI
+
) 
C17H26N3O5 ([M+NH4]
+
) requires 352.1867, found 352.1872 (+1.4 ppm). 
 
Chapter 7: Experimental 
 
 
 
157 
(RS)-tert-Butyl 3-(benzoyloxy)-5-methyl-4,5-dihydro-1H-pyrazole-1-carboxylate 100 
N
N
OCOPh
Boc
100  
(RS)-tert-Butyl 5-methyl-3-oxopyrazolidine-1-carboxylate 72 (250 mg, 1.25 mmol) 
triethylamine (0.200 mL, 1.38 mmol) and benzoyl chloride (0.200 mL, 1.73 mmol) were 
combined according to general procedure A to give crude product (568 mg). Attempted 
purification of this material by column chromatography led to decomposition to unidentified 
side-products. Hence, characterisation was carried out on the crude mixture. 
"max (film)/ cm
#1
 3065 (Ar-H), 2979 (C-H), 2932 (C-H), 2862 (N-C-H), 1750 (C=O), 
1642 (C=O) and 1601 (C=N); !H (300 MHz, CDCl3) 8.11–8.07 (2H, m, ArH), 7.56–7.45 (3H, 
m, ArH), 4.59 (1H, app dquin, J 11.0. 6.0, C(5)H), 3.50 (1H, dd, ABX system, JAB 17.6, 
JAX 11.0, C(4)HAHB), 2.83 (1H, dd, ABX system, JBA 17.6, JBX 4.9, C(4)HAHB), 1.54 (9H, s, 
C(CH3)3) and 1.45 (3H, d, J 6.3, C(5)HCH3); !C (100 MHz, CDCl3) 163.2 (C(O)Ph), 
157.3 (C(4)N), 134.6 (CAripso), 130.6 (CAr), 130.5 (CAr), 128.8 (CAr), 81.5 (C(CH3)3), 
55.8 (C(5)H), 38.7 (C(4)H2), 28.4 (C(CH3)3) and 20.6 (C(5)HCH3); m/z (ESI
+
) 327.1 
(100, [M+Na]
+
); HRMS (ESI
+
) C16H20N2NaO4 ([M+Na]
+
) requires 327.1321, found 327.1323 
(+0.6 ppm). 
  
(RS)-tert-Butyl 2-benzoyl-5-methyl-3-oxopyrazolidine-1-carboxylate 101 
N
N
O
Boc
COPh
101  
(RS)-tert-Butyl 5-methyl-3-oxopyrazolidine-1-carboxylate 72 (988 mg, 4.93 mmol), sodium 
hydride (225 mg, 5.63 mmol) and benzoyl chloride (0.60 mL, 5.24 mmol) were combined 
according to general procedure B. The resulting material was dissolved in toluene (15 mL) and 
refluxed for 5 h. The crude material was then purified by column chromatography, eluting with 
25 % ethyl acetate in petrol to give the title compound as a colourless solid (685 mg, 45 %). 
"max (KBr disc)/ cm
#1
 2984 (C-H), 2932 (C-H), 2863 (N-C-H), 1759 (C=O), 1727 (C=O), 
1699 (C=O) and 1596 (Ar C=C); mp 129–132 ºC; !N (CDCl3) 184 (N(2)C(O)), 136 (N(1)Boc); 
!H (300 MHz, CDCl3) 7.81 (2H, dd, J 8.4, 1.3, ArHortho), 7.57 (1H, app tt, J 7.9, 1.3, ArHpara), 
7.48–7.40 (2H, m, ArHmeta), 4.78 (1H, app quin, J 7.1, C(5)H), 3.14 (1H, dd, J 16.9, 8.3, 
Chapter 7: Experimental 
 
 
 
158 
C(4)HAHB), 2.28 (1H, d, J 16.9, C(4)HAHB), 1.40 (9H, s, C(CH3)3) and 1.39 (3H, d, J 6.4, 
C(5)HCH3); !C (100 MHz, CDCl3) 170.8 (C(3)O), 166.6 (C(O)Ph), 154.5 (C(O)O), 
133.2 (CAripso), 133.1 (CAr), 130.0 (CAr), 128.2 (CAr), 83.5 (C(CH3)3), 52.7 (C(5)H), 
39.9 (C(4)H2), 28.2 (C(CH3)3) and 20.4 (C(5)HCH3); m/z (ESI
+
) 139.2 (100, 
[H2NC(O)Ph+NH4]
+
), 305.2 (15, [M+H]
+
), 322.3 (20, [M+NH4]
+
); HRMS (ESI
+
) C16H24N3O4 
([M+NH4]
+
) requires 322.1761, found 322.1761. 
 
(RS)-Benzyl 3-methyl-5-oxopyrazolidine-1-carboxylate 102 
N
H
N
O
CO2Bn
102  
To a solution of (RS)-1-benzyl 2-tert-butyl 3-methyl-5-oxopyrazolidine-1,2-dicarboxylate 99 
(560 mg, 1.67 mmol) in dichloromethane (3 mL) was added trifluoroacetic acid (0.600 mL, 
8.09 mmol) and the resulting solution stirred overnight at rt. TLC analysis of the crude reaction 
mixture showed incomplete reaction. Hence, further trifluoroacetic acid (0.120 mL, 1.62 mmol) 
was added and the mixture stirred for 4 h before being concentrated in vacuo. The resulting 
material was partitioned between dichloromethane (30 mL) and saturated sodium hydrogen 
carbonate solution (30 mL). The aqueous layer was washed with dichloromethane (2 x 30 mL) 
and the combined organic layers washed with brine (90 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The crude material was then purified by column chromatography, 
eluting with ethyl acetate to give the title compound as a colourless oil (304 mg, 78 %). 
"max (film)/ cm
#1
 3234 (N-H), 2972 (C-H), 2927 (C-H), 1783 (C=O), 1729 (C=O), 1638 
(N-H bend) and 1583 (Ar C=C); !H (300 MHz, CDCl3) 7.47–7.42 (2H, m, ArH), 7.40–7.31 
(3H, m, ArH), 5.34 (1H, d, AB system, JAB 12.3, CHAHBPh), 5.27 (1H, d, AB system, JBA 12.3, 
CHAHBPh), 4.56 (1H, d, J 9.9, N(1)H), 3.71 (1H, app tquin, J 9.7, 6.5, C(5)H), 2.75 (1H, dd, 
ABX system, JAB 16.9, JAX 6.7, C(4)HAHB), 2.37 (1H, dd, ABX system, JBA 16.9, JBX 9.7, 
C(4)HAHB) and 1.31 (3H, d, J 6.4, C(5)HCH3); !C (100 MHz, CDCl3) 172.1 (C(3)O), 
150.0 (N(2)C(O)O), 135.1 (CAripso), 128.7 (CAr), 128.6 (CAr), 128.5 (CAr), 68.6 (CH2Ph), 
50.9 (C(5)H), 41.9 (C(4)H2) and 18.4 (C(5)HCH3); m/z (CI) 257.0 (100, [M+H]
+
); HRMS 
(ESI
+
) C12H14N2NaO3 ([M+Na]
+
) requires 257.0902, found 257.0910 (+3.2 ppm). 
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(RS)-2-Benzoyl-5-methylpyrazolidin-3-one 103 
N
H
N
O
COPh
103  
To a solution of (RS)-tert-butyl 2-benzoyl-5-methyl-3-oxopyrazolidine-1-carboxylate 101 
(457 mg, 1.50 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (0.600 mL, 
8.10 mmol) and the resulting solution stirred overnight at rt before being concentrated in vacuo. 
The resulting material was partitioned between dichloromethane (40 mL) and saturated sodium 
hydrogen carbonate solution (40 mL). The aqueous layer was washed with dichloromethane 
(2 x 40 mL) and the combined organic layers washed with brine (100 mL), dried (MgSO4), 
filtered and concentrated in vacuo to give the title compound as a clear yellow oil (263 mg, 
86 %). 
"max (film)/ cm
#1
 3224 (N-H), 3061 (Ar-H), 3029 (Ar-H), 2974 (C-H), 2931 (C-H), 
2873 (N-C-H), 1757 (C=O), 1672 (C=O), 1631 (N-H bend), 1600 (Ar C=C) and 1579 
(Ar C=C); !H (400 MHz, CDCl3) 7.65 (2H, dd, J 8.3, 1.3, ArHortho), 7.54 (1H, app tt, J 7.5, 1.3, 
ArHpara), 7.45–7.39 (2H, m, ArHmeta), 5.19 (1H, d, J 8.3, N(1)H), 3.84 (1H, app tquin, J 9.1, 6.4, 
C(5)H), 2.85 (1H, dd, ABX system, JAB 17.1, JAX 6.8, C(4)HAHB), 2.50 (1H, dd, ABX system, 
JBA 17.1, JBX 9.5, C(4)HAHB) and 1.40 (3H, d, J 6.3, C(5)HCH3); !C (100 MHz, CDCl3) 
171.9 (C(3)O), 166.7 (C(O)Ph), 133.1 (CAripso), 132.4 (CAr), 129.4 (CAr), 128.0 (CAr), 
50.2 (C(5)H), 42.1 (C(4)H2) and 18.8 (C(5)HCH3); m/z (CI) 205.1 (100, [M+H]
+
); HRMS (CI) 
C11H13N2O2 ([M+H]
+
) requires 205.0977, found 205.0978 (+0.5 ppm). 
 
(RS)-tert-Butyl 2-benzyl-4,5-dimethyl-3-oxopyrazolidine-1-carboxylate 107 
 
N
N
O
Boc
Bn
107  
To a solution of (RS)-tert-butyl 2-benzyl-5-methyl-3-oxopyrazolidine-1-carboxylate 74 
(345 mg, 1.19 mmol) in THF (5 mL), cooled to –78 ºC, was added KHMDS (0.46 M in toluene, 
3.10 mL, 1.43 mmol) and the red solution stirred for 90 min before it was treated with 
iodomethane (0.220 mL, 3.57 mmol). The mixture was stirred at –78 ºC for 3 h and then 
quenched with pH 7 phosphate buffer solution (20 mL), before being warmed to rt. The 
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biphasic solution was extracted with diethyl ether (3 x 15 mL) and the combined organic 
extracts washed with brine (30 mL) and dried (MgSO4) before being filtered through a plug of 
silica gel and concentrated in vacuo. The crude material was purified by column 
chromatography, eluting with 15 then 25 % ethyl acetate in petrol to give the product as a 
colourless oil (75 mg, 21 %). 
"max (film)/ cm
-1
 3065 (Ar-H), 3032 (Ar-H), 2976 (C-H), 2931 (C-H), 2873 (N-C-H), 
1745-1667 (2 x C=O), 1604 (Ar C=C) and 1586 (Ar C=C); !H (300 MHz, CDCl3) 
7.24-7.20 (5H, m, ArH), 5.18 (1H, d, AB system, JAB 14.2, CHAHBPh), 4.31 (1H, d, AB system, 
JBA 14.2, CHAHBPh), 3.95 (1H, q, J 6.8, C(5)H), 1.98 (1H, q, J 7.4, C(4)H), 1.47 (9H, s, 
C(CH3)3), 1.15 (3H, d, J 7.4, C(4)HCH3) and 0.55 (3H, d, J 6.8, C(5)HCH3); !C (75 MHz, 
CDCl3) 174.9 (C(3)O), 157.6 (C(O)O), 136.1 (CAripso), 130.0 (CAr), 128.7 (CAr), 128.5 (CAr), 
82.8 (C(CH3)3), 61.8 (C(5)H), 49.0 (CH2Ph), 45.4 (C(4)H), 28.6 (C(CH3)3), 19.1 (C(5)HCH3) 
and 15.8 (C(4)HCH3); m/z (CI) 305.3 (100, [M+H]
+
); HRMS (ESI
+
) C17H25N2O3 ([M+H]
+
) 
requires 305.1860, found 305.1860 (+0.2 ppm). 
 
(RS)-tert-Butyl 2-benzyl-4,4,5-trimethyl-3-oxopyrazolidine-1-carboxylate 108 
N
N
O
Boc
Bn
108  
To a solution of (RS)-tert-butyl 2-benzyl-5-methyl-3-oxopyrazolidine-1-carboxylate 74 
(268 mg, 0.923 mmol) in THF (5 mL), cooled to &78 ºC, was added KHMDS (0.46 M in 
toluene, 10.0 mL, 4.60 mmol) and the red solution stirred for 70 min before treatment with 
iodomethane (0.570 mL, 9.23 mmol). The mixture was stirred at &78 ºC for 90 min, then at rt 
for 60 min. The reaction was then quenched with pH 7 phosphate buffer solution (20 mL), the 
resulting biphasic solution extracted with diethyl ether (3 x 15 mL) and the combined organic 
extracts washed with brine (30 mL) and dried (MgSO4)  before being filtered through a plug of 
silica gel and concentrated in vacuo. 
1
H NMR showed a mixture of starting material 74, 
monomethylated material and product 108 in the ratio 27:44:29 and so the crude material was 
redissolved in THF (5 mL), cooled to &78 ºC and treated, as before, with identical amounts of 
KHMDS and iodomethane. The mixture was stirred at &78 ºC for 60 min before being quenched 
and following of the work-up procedure previously described. The crude material was purified 
by column chromatography, eluting with 10 % ethyl acetate in petrol to give the product as a 
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colourless oil (75 mg, 26 %). 
"max (film)/ cm
#1
 3065 (Ar-H), 3032 (Ar-H), 2978 (C-H), 2934 (C-H), 2871 (N-C-H),        
1747–1674 (2 x C=O) and 1605 (Ar C=C); !H (300 MHz, CDCl3) 7.24–7.20 (5H, m, ArH), 
5.15 (1H, d, AB system, JAB 14.2, CHAHBPh), 4.31 (1H, d, AB system, JBA 14.2, CHAHBPh), 
3.99 (1H, q, J 6.9, C(5)H), 1.48 (9H, s, C(CH3)3), 1.09 (3H, s, C(4)(CH3)A(CH3)B), 0.92 (3H, s, 
C(4)(CH3)A(CH3)B) and 0.42 (3H, d, J 6.9, C(5)HCH3); !C (75 MHz, CDCl3) 176.6 (C(3)O), 
157.3 (C(O)O), 136.2 (CAripso), 130.2 (CAr), 128.8 (CAr), 128.5 (CAr), 82.7 (C(CH3)3), 
65.3 (C(5)H), 49.1 (CH2Ph), 44.6 (C(4)(CH3)2), 28.7 (C(CH3)3), 24.8 (C(5)HCH3), 
18.2 (C(4)(CH3)A(CH3)B) and 15.8 (C(4)(CH3)A(CH3)B); m/z (CI) 219.2 (100, [M&Boc+2H]
+
), 
319.3 (60, [M+H]
+
); HRMS (ESI
+
) C18H27N2O3 ([M+H]
+
) requires 319.2016, found 319.2015 
(+0.2 ppm). 
 
(RS)-2-Benzyl-4,4,5-trimethylpyrazolidin-3-one 109 
109
N
H
N
O
Bn
 
To a solution of (RS)-tert-butyl 2-benzyl-4,4,5-trimethyl-3-oxopyrazolidine-1-carboxylate 108 
(142 mg, 0.446 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (0.2 mL, 
2.69 mmol) and the resulting solution stirred overnight at rt. TLC analysis of the crude reaction 
mixture showed incomplete reaction. Hence, further trifluoroacetic acid (0.2 mL, 2.69 mmol) 
was added and the mixture stirred for 2 h before being concentrated in vacuo. The resulting 
material was partitioned between dichloromethane (20 mL) and saturated sodium hydrogen 
carbonate solution (20 mL). The aqueous layer was washed with dichloromethane (2 x 20 mL) 
and the combined organic layers washed with brine (50 mL), dried (MgSO4), filtered and 
concentrated in vacuo to give the title compound as a colourless oil (94 mg, 96 %). 
"max (film)/ cm
#1
 3202 (N-H), 3064 (Ar-H), 3032 (Ar-H), 2969 (C-H), 2930 (C-H), 
2873 (N-C-H), 1678 (C=O), 1606 (Ar C=C) and 1587 (N-H bend); !H (400 MHz, CDCl3)  
7.37–7.24 (5H, m, ArH), 4.82 (1H, d, AB system, JAB 14.7, CHAHBPh), 4.34 (1H, d, AB system, 
JBA 14.7, CHAHBPh), 3.76 (1H, br s, N(1)H), 3.24 (1H, q, J 6.6, C(4)HCH3), 1.15 (3H, s, 
C(4)(CH3)A(CH3)B), 1.06 (3H, d, J 6.6, C(5)HCH3) and 0.95 (3H, s, C(4)(CH3)A(CH3)B); 
!C (100 MHz, CDCl3) 177.7 (C(3)O), 136.2 (CAripso), 128.9 (CAr), 128.2 (CAr), 127.9 (CAr), 
61.4 (C(5)H), 48.1 (CH2Ph), 43.5 (C(4)(CH3)2), 21.7 (C(4)(CH3)A(CH3)B), 
Chapter 7: Experimental 
 
 
 
162 
16.4 (C(4)(CH3)A(CH3)B) and 12.0 (C(5)HCH3); m/z (ESI
+
) 241.1 (100, [M+Na]
+
); HRMS 
(ESI
+
) C13H18N2ONa ([M+Na]
+
) requires 241.1317, found 241.1317. 
 
(RS)-1-Benzyl 2-tert-butyl 5-oxo-3-phenylpyrazolidine-1,2-dicarboxylate 112 
112
N
N
O
Ph CO2Bn
Boc
 
(RS)-1-Benzyl 2-tert-butyl 5-oxo-3-phenylpyrazolidine-1,2-dicarboxylate 85 (3.15 g, 
12.1 mmol), sodium hydride (530 mg, 13.3 mmol) and benzyl chloroformate (1.81 mL, 
12.7 mmol) were combined according to general procedure B. The resulting material was taken 
up in toluene (40 mL) and refluxed for 4 h before concentration in vacuo. The crude material 
was then purified by column chromatography, eluting with 15 then 25 % ethyl acetate in petrol 
to give the title compound as a clear yellow oil which became a colourless solid on trituration 
with petrol (1.83 g, 38 %). 
"max (KBr disc)/ cm
#1
 3064 (Ar-H), 3025 (Ar-H), 2982 (C-H), 1795 (C=O), 1733 (2 x C=O) and 
1560 (Ar C=C); mp 112–114 ºC; !N (CDCl3) 169 (N(2)CO2Bn), 133 (N(1)Boc);  !H (500 MHz, 
CDCl3) 7.44–7.28 (10H, m, ArH), 5.70 (1H, d, J 8.6, C(5)H), 5.36 (1H, d, AB system, JAB 12.3, 
CHAHBPh), 5.30 (1H, d, AB system, JBA 12.3, CHAHBPh), 3.35 (1H, dd, J 17.2, 8.6, C(4)HAHB), 
2.79 (1H, d, J 17.2, C(4)HAHB) and 1.43 (9H, s, C(CH3)3); !C (100 MHz, CDCl3) 
169.2 (C(3)O), 155.8 (N(1)C(O)O), 149.2 (N(2)C(O)O), 138.4 (CAripso), 134.9 (CAripso), 
129.1 (CAr), 128.7 (CAr), 128.6 (CAr), 128.4 (CAr), 128.2 (CAr), 125.6 (CAr), 
84.1 (C(CH3)3), 69.0 (CH2Ph), 59.7 (C(5)H), 40.1 (C(4)H2) and 28.0 (C(CH3)3); m/z HRMS 
(ESI
+
) C22H24N2NaO5 ([M+Na]
+
) requires 419.1577, found 419.1585 (+1.8 ppm). 
 
(RS)-Benzyl 5-oxo-3-phenylpyrazolidine-1-carboxylate 114 
N
H
N
O
Ph CO2Bn
114  
To a solution of (RS)-1-benzyl-2-tert-butyl 5-oxo-3-phenylpyrazolidine-1,2-dicarboxylate 112 
(1.60g, 4.04 mmol) in dichloromethane (10 mL) was added trifluoroacetic acid (1.50 mL, 
19.7 mmol) and the resulting solution stirred overnight at rt before being concentrated in vacuo. 
The resulting material was partitioned between dichloromethane (60 mL) and saturated sodium 
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hydrogen carbonate solution (60 mL). The aqueous layer was washed with dichloromethane 
(2 x 60 mL) and the combined organic layers washed with brine (100 mL), dried (MgSO4), 
filtered and concentrated in vacuo. The crude material was purified by recrystallisation from 
petrol and the minimum quantity of dichloromethane to give the title compound as colourless 
needles (816 mg, 68 %). 
C17H16N2O3 requires C, 68.9; H 5.4; N, 9.5 %; found C 68.6; H, 5.2; N, 9.5 %; "max (KBr disc)/ 
cm
#1
 3226 (N-H), 3058 (C-H), 3030 (C-H), 1739 (C=O), 1653 (N-H bend); mp 101–102 ºC; 
!N (CDCl3) 167 (N(2)CO2Bn), 103 (N(1)H); !H (300 MHz, CDCl3) 7.49–7.43 (2H, m, ArH), 
7.41–7.31 (8H, m, ArH), 5.37 (1H, d, AB system, JAB 12.2, CHAHBPh), 5.31 (1H, d, AB system, 
JBA 12.2, CHAHBPh), 4.94 (1H, bs, N(1)H), 4.75 (1H, app t, J 8.2 C(5)H), 3.05 (1H, dd, 
ABX system, JAB 17.0, JAX 7.3, C(4)HAHB) and 2.93 (1H, dd, ABX system, JBA 17.0, JBX 9.8, 
C(4)HAHB); !C (75 MHz, CDCl3) 170.7 (C(3)O), 149.8 (N(2)C(O)O), 137.3 (CAripso), 
135.1 (CAripso), 129.2 (CAr), 128.9 (CAr), 128.8 (CAr), 128.7 (CAr), 128.6 (CAr), 
126.7 (CAr), 68.7 (CH2Ph), 57.9 (C(5)H) and 41.0 (C(4)H2); m/z HRMS (ESI
+
) C17H17N2O3 
([M+H]
+
) requires 297.1234, found 297.1237 (+1.1 ppm). 
 
(R)-Benzyl 5-oxo-3-phenylpyrazolidine-1-carboxylate (R)-114 
N
H
N
O
Ph
(R)-114
CO2Bn
 
Synthesised from (R)-83 by identical means to those described for racemic 83. 
[$]20D +22.4 (c 0.25, dichloromethane); mp 123–125 ºC. 
 
(RS)-Benzyl 5-oxo-3-(trifluoromethyl)pyrazolidine-1-carboxylate 115 
N
H
N
O
F3C CO2Bn
115  
(RS)-1-Benzyl 2-tert-butyl 5-oxo-3-(trifluoromethyl)pyrazolidine-1,2-dicarboxylate 113 
(619 mg, 2.43 mmol), sodium hydride (107 mg, 2.68 mmol) and benzyl chloroformate 
(0.400 mL, 2.55 mmol) were combined according to general procedure B with a modified work-
up. In this case, the reaction was quenched with water (2 mL) and concentrated in vacuo. The 
resulting material was taken up in toluene (20 mL) and refluxed for 3 h before being cooled, 
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filtered and concentrated in vacuo to give crude product (930 mg) as a yellow oil. Product was 
used without further purification. An analytical sample was taken and purified by column 
chromatography, eluting with 10 % ethyl acetate in petrol to give the title compound as a 
colourless solid. 
"max (KBr disc)/ cm
#1
 3028 (C-H), 2984 (C-H), 1790 (C=O) and 1748 (C=O); mp 65–67 ºC; 
!F (282 MHz, CDCl3) &78.8 (3F, d, J 7.2, CF3); !H (300 MHz, CDCl3) 7.43–7.32 (5H, m, ArH), 
5.35 (1H, d, AB system, JAB 12.3, CHAHBPh), 5.30 (1H, d, AB system, JBA 12.3, CHAHBPh), 
4.42 (1H, dqd, J 9.5, 7.2, 1.3, C(5)H), 3.14 (1H, dd, J 18.2, 9.5, C(4)HAHB), 2.77 (1H, d, J 18.2, 
1.3, C(4)HAHB) and 1.38 (9H, s, C(CH3)3); !C (100 MHz, CDCl3) 167.1 (C(3)O), 
154.3 (N(1)C(O)O), 149.9 (N(2)C(O)O), 134.7 (CAripso), 128.8 (CAr), 128.7 (CAr), 
128.5 (CAr), 123.8 (q, J 281, CF3), 85.4 (C(CH3)3), 69.4 (CH2Ph), 56.2 (q, J 33.9, C(5)H), 
32.2 (C(4)H2) and 27.9 (C(CH3)3); m/z HRMS (ESI
+
) C17H23F3N3O5 ([M+NH4]
+
) requires 
406.1584, found 406.1588 (+0.9 ppm). 
A solution of crude (RS)-1-benzyl-2-tert-butyl 5-oxo-3-(trifluoromethyl)pyrazolidine-1,2-
dicarboxylate 113 (890 mg, 2.29 mmol) was stirred in a 1:2 mixture of trifluoroacetic 
acid/dichloromethane (15 mL) overnight at rt before being concentrated in vacuo. The resulting 
material was partitioned between dichloromethane (100 mL) and saturated sodium hydrogen 
carbonate solution (100 mL). The aqueous layer was washed with dichloromethane (2 x 
100 mL) and the combined organic layers washed with brine (150 mL), dried (MgSO4), filtered 
and concentrated in vacuo. The crude material was purified by recrystallisation from diethyl 
ether and the minimum quantity of dichloromethane to give the title compound as colourless 
needles (281 mg, 42 %). 
"max (film)/ cm
#1
 3261 (N-H), 3014 (Ar-H), 2935 (C-H), 1760 (C=O) and 1714 (C=O);    
mp 90–92 ºC; !F (282 MHz, CDCl3) &78.5 (3F, d, J 7.6, CF3); !H (300 MHz, CDCl3) 7.44–7.33 
(5H, m, ArH), 5.34 (1H, d, AB system, JAB 12.3, CHAHBPh), 5.32 (1H, d, J 7.9, N(1)H), 
5.30 (1H, d, AB system, JBA 12.3, CHAHBPh), 4.13–3.98 (1H, m, C(5)H), 3.07 (1H, dd, ABX 
system, JAB 18.1, JAX 9.6, C(4)HAHB) and 2.84 (1H, dd, ABX system, JBA 18.1, JBX 4.1, 
C(4)HAHB); !C (75 MHz, CDCl3) 168.3 (C(3)O), 149.5 (N(2)C(O)O), 135.9 (CAripso), 
128.8 (CAr), 128.4 (CAr), 124.1 (q, J 280, CF3), 68.9 (CH2Ph), 53.4 (q, J 32.6, C(5)H) and 
33.1 (C(4)H2); m/z HRMS (ESI
+
) C12H15F3N3O3 ([M+NH4]
+
) requires 306.1090, found 
306.1066 (+2.0 ppm). 
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endo-(1S,2R,3R,4R)-3-Phenylbicyclo[2.2.2]oct-5-ene-2-carbaldehyde endo-(2R)-118 
CHO
Ph
endo-(2R)-118
 
(E)-Cinnamaldehyde 37 (60.0 µL, 0.475 mmol), triflic acid (0.190 M solution in methanol, 
0.250 mL, 47.5 µmol), catalyst 170 (10 mol%, 20.0 mg, 47.5 µmol) and cyclohexadiene 
(140 µL, 1.43 mmol) were combined according to general procedure D. After 3 days, 
1
H NMR 
spectroscopic analysis indicated reaction had achieved 51 % conversion (exo:endo 6:94) and 
reaction was quenched as outlined in general procedure D. The crude material was then purified 
by column chromatography, eluting with 7.5 % diethyl ether in petrol to yield the title 
compound as a colourless solid with spectroscopic data in accordance with the literature 
(43 mg, 43 %).
146
 
[$]20D –35.7 (c 0.3, chloroform) (lit. [$]
20
D +82 ((1R,2S,3S,4S) enantiomer, >95 % ee, c 1.0, 
dichloromethane));
85
 mp 54–55 ˚C; !H (300 MHz, CDCl3) 9.42 (1H, d, J 1.3, CHO), 7.29–7.12 
(5H, m, ArH), 6.45 (1H, ddd, J 8.1, 6.8, 1.3, CHA=CHB), 6.12 (1H, ddd, J 8.1, 6.5, 1.2, 
CHA=CHB), 3.13 (1H, app dt, J 6.3, 2.2, CHPh), 3.03–2.98 (1H, m, CHCHCHO), 2.76 (1H, app 
dt, J 6.3, 1.5, CHCHO), 2.58–2.54 (1H, m, CHCHPh), 1.72–1.58 (2H, m, CHAHBCHCHCHO 
and CHAHBCHCHPh), 1.44–1.32 (1H, m, CHAHBCHCHCHO) and 1.07–0.94 (1H, m, 
CHAHBCHCHPh). 
 
(S)-2-((R)-2’-Hydroxy-2’-phenylacetyl)-5-phenylpyrazolidin-3-one (5S)-127 and 
(R)-2-((R)-2’-hydroxy-2’-phenylacetyl)-5-phenylpyrazolidin-3-one (5R)-127 
(5S)-127 (5R)-127
N
H
N
O
Ph
O
Ph
OH
N
H
N
O
Ph
O
Ph
OH
 
N-(3-dimethylaminopropyl)-N!-ethylcarbodiimide hydrochloride (250 mg, 1.54 mmol), 
1-hydroxybenzotriazole (208 mg, 1.54 mmol), (R)-mandelic acid (234 mg, 154 mmol) and 
(RS)-5-phenylpyrazolidin-3-one 83 (250 mg, 1.54 mmol) were combined in THF according to 
general procedure E. The crude material was purified by column chromatography, eluting 
with 25 % ethyl acetate in petrol then 50 % ethyl acetate in petrol to give title compound 
(5S)-127 as a white solid (59 mg, 13 %) and title compound (5R)-127 as a clear yellow oil 
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(67 mg, 15 %). 24 mg of mixed fractions were also collected (150 mg of compounds (5S)- and 
(5R)-127 over all fractions, 33 % combined yield). 
Compound (5S)-127 (upper spot): [$]20D –77.0 (c 0.2, chloroform); "max (KBr disc)/ cm
-1
 3422 
(O-H), 3228 (N-H), 3038 (Ar-H), 3025 (Ar-H), 2947 (C-H), 1751 (C=O) and 1686 (C=O); mp 
143–145 ºC; !N (CDCl3) 189 (N(2)C(O)), 105 (N(1)H); !H (300 MHz, CDCl3) 7.47–7.32 (10H, 
m, ArH), 6.00 (1H, s, CH(OH)), 5.17 (1H, bs, OH), 4.68 (1H, app dt, J 10.1, 7.7, C(5)H), 4.06 
(1H, d, J 7.4, N(2)H), 3.01 (1H, dd, ABX system, JAB 17.2, JAX 10.1, C(4)HAHB) and 2.90 (1H, 
dd, ABX system, JBA 17.2, JBX 7.7, C(4)HAHB); !C (100 MHz, CDCl3) 170.8 (C(O)), 170.3 
(C(O)), 138.3 (CAripso), 137.0 (CAripso), 129.2 (CAr), 129.0 (CAr), 128.9 (CAr), 128.8 (CAr), 
127.8 (CAr), 126.6 (CAr), 73.4 (CH(OH)), 58.0 (C(5)H) and 41.0 (C(4)H2); m/z HRMS (ESI
+
) 
C17H17N2O3 ([M+H]
+
) requires 297.1234, found 297.1237 (+1.1 ppm). 
Compound (5R)-127 (lower spot): [$]20 –47.3º (c 0.1, chloroform); "max (KBr disc)/ cm
-1
 3424 
(O-H), 3226 (N-H), 3058 (Ar-H), 3025 (Ar-H), 1752 (C=O) and 1700 (C=O); mp 125–126 ºC; 
!H (300 MHz, CDCl3) 7.39–7.24 (8H, m, ArH), 7.22–7.16 (2H, m, ArH), 5.96 (1H, s, 
CH(OH)), 5.41 (1H, bs, OH), 4.62 (1H, app t, J 8.0, C(5)H), 3.92 (1H, bs, N(2)H), 2.99 (1H, 
dd, ABX system, JAB 17.2, JAX 7.4, C(4)HAHB) and 2.77 (1H, dd, ABX system, JBA 17.2, 
JBX 8.9, C(4)HAHB); !C (75 MHz, CDCl3) 170.6 (C(O)), 170.0 (C(O)), 138.1 (CAripso), 
137.7 (CAripso), 129.1 (CAr), 128.8 (CAr), 127.8 (CAr), 126.5 (CAr), 73.4 (CH(OH)), 
58.2 (C(5)H) and. 41.2 (C(4)H2); m/z HRMS (ESI
+
) C17H17N2O3 ([M+H]
+
) requires 297.1234, 
found 297.1237 (+1.1 ppm). 
 
 (S)-2-((R)-2’-Acetoxy-2’-phenylacetyl)-5-phenylpyrazolidin-3-one (5S)-133 and 
(R)-2-((R)-2’-Acetoxy-2’-phenylacetyl)-5-phenylpyrazolidin-3-one (5R)-133 
N
H
N
O
Ph
O
OAc
Ph
N
H
N
O
Ph
O
OAc
Ph+
(5S)-133 (5R)-133  
N-(3-dimethylaminopropyl)-N!-ethylcarbodiimide hydrochloride (590 mg, 3.08 mmol), 
1-hydroxybenzotriazole (416 mg, 3.08 mmol), (R)-acetylmandelic acid (598 mg, 3.08 mmol) 
and (RS)-5-phenylpyrazolidin-3-one 83 (250 mg, 1.54 mmol) were combined according to 
general procedure E. The crude material was purified by column chromatography, eluting 
with 25 % ethyl acetate in petrol. Chromatography was then repeated, eluting with 20 % ethyl 
acetate in petrol to give title compound (5S)-133 as a cream solid (52 mg, 11 %) and title 
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compound (5R)-133 as a yellow amorphous solid (135 mg, 26 %). 64 mg of mixed fractions 
were also collected (251 mg of compounds (5S)- and (5R)-133 over all fractions, 48 % 
combined yield). 
Compound (5S)-133 (upper spot): [$]20D –76.1 (c 0.2, chloroform); "max (KBr disc)/ cm
-1 3237 
(N-H), 3025 (Ar-H), 2957 (C-H), 1759 (C=O), 1736 (C=O) and 1686 (C=O);        mp 181–183 
ºC; !H (400 MHz, CDCl3) 7.60–7.56 (2H, ArH), 7.42–7.34 (8H, m, ArH), 6.92 (1H, s, 
CHOC(O)), 4.65 (1H, app q, J 8.6, C(5)H), 3.42 (1H, d, J 5.1 N(2)H), 3.00 (1H, d, J 7.9, 
C(4)HAHB), 2.91 (1H, d, J 9.7, C(4) HAHB) and 2.17 (3H, s, C(O)CH3); !C (75 MHz, CDCl3) 
170.8 (C(O)), 170.6 (C(O)), 165.3 (C(O)CH3), 137.4 (CAripso) 133.0 (CAripso), 129.7 (CAr), 
129.25 (CAr), 129.22 (CAr), 129.0 (CAr), 128.9 (CAr), 126.7 (CAr), 74.5 (CHOC(O)), 57.8 
(C(5)H), 41.4 (C(4)H2) and 20.8 (C(O)CH3); m/z HRMS (ESI
+
) C19H19N2O4 ([M+H]
+
) requires 
339.1339, found 339.1342 (+0.8 ppm). 
Compound (5R)-133 (lower spot): [$]20D –37.6 (c 0.4, chloroform); "max (KBr disc)/ cm
-1 3259 
(N-H), 3064 (Ar-H), 3034 (Ar-H), 1747 (C=O), 1714 (C=O) and 1695 (C=O); mp 49–51 ºC; 
!H (400 MHz, CDCl3) 7.58–7.54 (2H, m, ArH), 7.41–7.36 (4H, m, ArH), 7.33–7.26 (4H, m, 
ArH), 6.92 (1H, s, CHOC(O)), 5.63 (1H, bs, N(2)H), 4.74 (1H, app t, J 7.9, C(5)H), 3.07 (1H, 
dd, ABX system, JAB 17.1, JAX 7.3, C(4)HAHB), 2.82 (1H, dd, ABX system, JBA 17.1, JBX 9.9, 
C(4)HAHB) and 2.18 (3H, s, C(O)CH3); !C (100 MHz, CDCl3) 170.9 (C(O)), 170.8 (C(O)), 
165.0 (C(O)CH3), 137.8 (CAripso), 132.8 (CAripso), 129.7 (CAr), 129.2 (CAr), 129.0 (CAr), 
128.9 (CAr), 128.7 (CAr), 126.6 (CAr), 74.4 (CHOC(O)), 58.2 (C(5)H), 41.7 (C(4)H2) and 20.8 
(C(O)CH3); m/z HRMS (ESI
+
) C19H18N2O4Na ([M+Na]
+
) requires 361.1159, found 361.1161 
(+2.6 ppm). 
 
(S)-2-((R)-2’-Methoxy-2’-phenylacetyl)-5-phenylpyrazolidin-3-one (5S)-134 and 
(R)-2-((R)-2’-methoxy-2’-phenylacetyl)-5-phenylpyrazolidin-3-one (5R)-134 
N
H
N
O
Ph
O
O
Ph
N
H
N
O
Ph
O
O
Ph+
(5S)-134 (5R)-134  
N-(3-dimethylaminopropyl)-N!-ethylcarbodiimide hydrochloride (14.4 g, 75.3 mmol), 
1-hydroxybenzotriazole (10.2 g, 75.3 mmol), (R)-!-methylmandelic acid (12.5 g, 75.3 mmol) 
and (RS)-5-phenylpyrazolidin-3-one 83 (12.2 g, 75.3 mmol) were combined according to 
general procedure E. The crude material was purified by column chromatography, eluting with 
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35 % ethyl acetate in petrol to give first the title compound (5S)-134 as an amorphous yellow 
solid (1.17 g, 5 %) and then title compound (5R)-134 as a cream solid (1.60 g, 7 %). 10.9 g of 
mixed fractions were also collected and subjected again to column chromatography, eluting 
with 25 % ethyl acetate in petrol to give more compound (5S)-134 (830 mg, 4 %), compound 
(5R)-134 (3.76 g, 16 %) and 5.01 g of mixed fractions (12.4 g of compounds (5S)- and (5R)-
134 over all fractions, 53 % combined yield). 
Compound (5S)-134 (upper spot): [$]20D &62.6 (c 0.5, dichloromethane); "max (KBr disc)/ cm
#1
 
3246 (N-H), 3064 (Ar-H), 3025 (Ar-H), 2927 (C-H), 1750 (C=O) and 1701 (C=O);         
mp 43–46 ºC; !N (CDCl3) 192 (N(2)C(O)), 104 (N(1)H); !H (300 MHz, CDCl3) 7.55–7.53 (2H, 
m, ArH), 7.41–7.33 (8H, m, ArH),  5.87 (1H, s, CHOCH3), 4.61 (1H, app dt, J 10.0, 7.4, 
C(5)H), 3.40 (3H, s, OCH3), 3.00 (1H, dd, ABX system, JAB 17.1, JAX 7.6, C(4)HAHB) and 
2.93 (1H, dd, ABX system, JBA 17.1, JBX 10.0, C(4)HAHB); !C (75 MHz, CDCl3) 
170.0 (N(2)C(O)), 167.2 (N(1)C(O)), 137.5 (CAripso), 135.7 (CAripso), 129.2 (CAr), 
128.9 (CAr), 128.8 (CAr), 126.7 (CAr), 81.7 (CHOCH3), 57.7 (C(5)H), 57.4 (CHOCH3) and 
41.7 (C(4)H2); m/z HRMS (ESI
+
) C18H19N2O3 ([M+H]
+
) requires 311.1390, found 311.1396 
(+1.9 ppm). 
Compound (5R)-134 (lower spot): [$]20D &1.5 (c 1.0, dichloromethane); "max (KBr disc)/ cm
#1
 
3231 (N-H), 3025 (Ar-H), 2985 (C-H), 2934 (C-H), 1744 (C=O) and 1701 (C=O);         
mp 140–144 ºC; !N (CDCl3) 190 (N(2)C(O)), 104 (N(1)H); !H (400 MHz, CDCl3) 7.52 (2H, dd, 
J 6.6, 3.2, ArH), 7.38–7.34 (3H, m, ArH), 7.31–7.27 (3H, m, ArH), 7.23–7.21 (2H, m, ArH), 
5.89 (1H, s, CHOCH3), 4.71 (1H, dd, J 9.3, 7.5, C(5)H), 3.40 (3H, s, OCH3), 3.07 (1H, dd, 
ABX system, JAB 17.1, JAX 7.5, C(4)HAHB) and 2.82 (1H, dd, ABX system, JBA 17.1, JBX 9.3, 
C(4)HAHB); !C (75 MHz, CDCl3) 169.9 (N(2)C(O)), 167.0 (N(1)C(O)), 138.0 (CAripso), 
135.4 (CAripso), 129.2 (CAr), 129.1 (CAr), 128.8 (CAr), 128.7 (CAr), 126.5 (CAr), 
81.6 (CHOCH3), 58.1 (C(5)H), 57.4 (CHOCH3) and 41.9 (C(4)H2); m/z HRMS (ESI
+
) 
C18H19N2O3 ([M+H]
+
) requires 311.1390, found 311.1393 (+0.9 ppm). 
 
(R)-2-((S)-2’-(6-Methoxynaphthalen-2-yl)propanoyl)-5-phenylpyrazolidin-3-one (5R)-135 
and (S)-2-((S)-2’-(6-methoxynaphthalen-2-yl)propanoyl)-5-phenylpyrazolidin-3-one 
(5S)-135 
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N
H
N
O
Ph
O
+
(5R)-135 (5S)-135
O
N
H
N
O
Ph
O
O
 
N-(3-Dimethylaminopropyl)-N!-ethylcarbodiimide hydrochloride (26.5 g. 138 mmol), 
1-hydroxybenzotriazole (18.7 g, 138 mmol), (S)-Naproxen (31.9 g, 138 mmol) and (RS)-5-
phenylpyrazolidin-3-one 83 (22.5 g, 138 mmol) were combined according to general procedure 
E. The crude material was purified by Biotage Isolera on silica gel, eluting with a gradient of 
10-90 % ethyl acetate in heptane to give title compound (5R)-135 as a colourless solid (7.20 g, 
14 %) and 20.9 g of mixed fractions (28.1 g of compounds (5R)- and (5S)-135 over all 
fractions, 54 % combined yield). In order to access pure compound (5S)-135, 2.02 g of mixed 
fractions were further purified by column chromatography on silica gel, eluting with 1-2 % 
ethyl acetate in dichloromethane to give 480 mg of fractions enriched in (5S)-135 and 1.50 g 
mixed fractions. These enriched fractions were further purified by column chromatography on 
silica gel, eluting with 1-2 % ethyl acetate in dichloromethane to give pure compound (5S)-135 
as a colourless oil (60.0 mg, 0.1 %). 
Compound (5R)-135 (upper spot): [$]20D +64.8 (c 1.0, dichloromethane); "max (KBr disc)/ cm
-1
 
3255 (N-H) 3050 (Ar-H), 2966 (C-H), 2956 (C-H), 1744 (C=O), 1686 (C=O), 1630 (N-H bend) 
and 1603 (Ar C=C); mp 157–160 ˚C; !N (CDCl3) 193 (N(2)C(O)), 104 (N(1)H); !H (300 MHz, 
CDCl3) 7.74–7.68 (3H, m, ArH), 7.48 (1H, dd, J 8.5, 1.8, ArH), 7.38–7.32 (5H, m, ArH), 7.10–
7.05 (2H, m, ArH), 5.04 (1H, q, J 6.9, CH(CH3)), 4.58 (1H, dd, J 10.0, 8.2, C(5)H), 3.91 (3H, s, 
OCH3), 2.95 (1H, d, J 8.2, C(4)HAHB), 2.93 (1H, d, J 10.0, C(4)HAHB) and 1.56 (3H, d, J 7.0, 
CH(CH3)); !C (75 MHz, CDCl3) 171.0 (N(2)C(O)), 169.7 (C(3)O), 157.8 (OCAripso), 137.8 
(CAripso), 135.8 (CAripso), 133.8 (CAripso), 129.5 (CAr), 129.0 (CAr), 128.7 (CAr), 127.2 (CAr), 
127.0 (CAr), 126.7 (CAr), 119.0 (CAr), 105.7 (CAr), 57.2 (C(5)H), 55.0 (OCH3), 44.2 
(CH(CH3)), 42.0 (C(4)H2) and 19.4 (CH(CH3)); m/z  HRMS (ESI
+
) C23H23N2O3 ([M+H]
+
) 
requires 375.1703, found 375.1702 (–0.3 ppm).  
Compound (5S)-135 (lower spot): [$]20D +20.8 (c 0.25, chloroform); "max (KBr disc)/ cm
-1
 
3266 (N-H) 3059 (Ar-H), 2916 (C-H), 2842 (C-H), 1744 (C=O), 1692 (C=O), 1631 (N-H bend) 
and 1604 (Ar C=C); mp 47–51 ˚C; !H (300 MHz, CDCl3) 7.72–7.68 (3H, m, ArH), 7.47 (1H, 
dd, J 8.5, 1.7, ArH), 7.28–7.21 (5H, m, ArH), 7.15–7.11 (2H, m, ArH), 5.60 (1H, d, J 6.8, 
N(1)H), 5.07 (1H, q, J 7.0, CH(CH3)), 4.66 (1H, app dt, J 9.3, 7.1, C(5)H), 3.92 (3H, s, OCH3), 
3.05 (1H, dd, ABX system, JAB 17.0, JAX 7.3, C(4)HAHB), 2.80 (1H, dd, JBA 17.0, JBX 9.3, 
Chapter 7: Experimental 
 
 
 
170 
C(4)HAHB) and 1.58 (3H, d, J 7.0, CH(CH3)); !C (75 MHz, CDCl3) 170.8 (N(2)C(O)), 
169.6 (C(3)O), 157.8 (OCAripso), 138.3 (CAripso), 135.6 (CAripso), 133.9 (CAripso), 129.5 (CAr), 
129.1 (CAripso), 129.0 (CAr), 128.6 (CAr), 127.3 (CAr), 127.1 (CAr), 126.6 (CAr), 
126.5 (CAr), 119.0 (CAr), 105.7 (CAr), 57.6 (C(5)H), 55.5 (OCH3), 44.2 (CH(CH3)), 
42.1 (C(4)H2) and 19.4 (CH(CH3)); m/z  HRMS (ESI
+
) C23H22N2O3Na ([M+Na]
+
) requires 
397.1528, found 375.1529 (+0.2 ppm). 
 
(R)-1-Benzyl-5-phenylpyrazolidin-3-one (R)-138  
N
NH
O
Ph
(R)-138
Bn
 
To a solution of (R)-5-phenylpyrazolidin-3-one (R)-83 (42 mg, 0.259 mmol) in ethanol (1 mL) 
was added benzaldehyde (0.1 mL, 1.03 mmol) and the resulting mixture left to stir at room 
temperature overnight. Sodium borohydride (49 mg, 1.30 mmol) was then added and the 
mixture stirred for a further hour. The reaction mixture was partitioned between water (5 mL), 
saturated sodium hydrogen carbonate solution (5 mL) and dichloromethane (10 mL). The 
resulting aqueous layer was extracted with further dichloromethane (3 x 10 mL). The combined 
organic layers were washed with brine (30 mL), dried (MgSO4), filtered and concentrated 
in vacuo. The crude material was purified by column chromatography, eluting with 40 % ethyl 
acetate in petrol to give the title compound as a colourless solid with an enantiomeric excess of 
95 % and spectroscopic data in accordance with the literature (33 mg, 51 %).
95,147
  
 [$]20D +168 (c 0.9, dichloromethane), lit. [!]
20
D &163 ((S)-enantiomer, c 0.90, 
dichloromethane);
34
 mp 106–109 ºC; !H (400 MHz, CDC13) 7.48 (1H, bs, N(2)H), 7.40–7.37 
(2H, m, ArH), 7.35–7.20 (8H, m, ArH), 4.15 (1H, app t, J 8.6, C(5)H), 3.95 (1H, d, AB system, 
JAB 12.9, CHAHBPh), 3.56 (1H, d, AB system, JBA 12.9, CHAHBPh), 2.90 (1H, dd, ABX system, 
JAB 16.8, JAX 8.3, C(4)HAHB) and 2.47 (1H, dd, ABX system, JBA 16.8, JBX 8.9, C(4)HAHB). 
Enantiomeric excess was determined by HPLC with Chiralpak AD-H (7 % isopropanol/hexane, 
flow rate = 1.0 mL/min, 220 nm), tR(S) 17.3 min and tR(R) 20.5 min. Absolute configuration 
determined by comparison of the optical rotation to literature value.
95
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(S)-2-((S)-1'-((benzyloxy)carbonyl)pyrrolidine-2'-carbonyl)-5-phenylpyrazolidin-3-one 
(5S)-142 and (R)-2-((S)-1'-((benzyloxy)carbonyl)pyrrolidine-2'-carbonyl)-5-
phenylpyrazolidin-3-one (5R)-142 
+
(5R)-142
N
H
N
O
Ph
O
N
N
H
N
O
Ph
O
N
(5S)-142
CO2Bn CO2Bn
 
Benzyl chloroformate (9.5 mL, 65 mmol) and 4 M sodium hydroxide solution (18.0 mL, 70 
mmol) were added dropwise simultaneously (using addition funnels) over 30 min with vigorous 
stirring to an ice-cooled solution of (S)-proline 14 (5.80 g, 50 mmol) in 2 M sodium hydroxide 
solution (30.0 mL, 60 mmol). The reaction was then left to stir at room temperature for 1 h. The 
solution was then extracted with diethyl ether (2 & 50 mL) and the aqueous layer retained and 
acidified to approximately pH 4 with 2 M HCl. The resulting solution was extracted with ethyl 
acetate (3 & 50 mL), the organic layers dried (MgSO4) and concentrated in vacuo to give crude 
(S)-N-(benzyloxycarbonyl)-proline 141 (10.1 g) as a colourless oil with spectroscopic data in 
accordance with the literature.
148
 Product was used without further purification. 
!H (300 MHz, CDCl3, rotamers A:B 1.4:1) 7.39–7.27 (A, 5H, m, ArH & B, 5H, m, ArH), 
5.18 (A, 1H, d, AB system, JAB 12.4, PhCHAHB), 5.15 (A, 1H, d, AB system, JAB 12.4, 
PhCHAHB), 5.13 (B, 2H, s, PhCH2), 4.42 (A, 1H, dd, J 8.2, 3.4, NProCH), 4.38 (B, 1H, dd, J 8.7, 
3.5, NProCH), 3.67–3.42 (A, 2H, m, NProCH2 & B, 2H, m, NProCH2) and 2.35–1.86 (A, 4H, m, 
CH2CH2 & B, 4H, m, CH2CH2). 
N-(3-Dimethylaminopropyl)-N!-ethylcarbodiimide hydrochloride (1.09 g, 5.67 mmol), 
1-hydroxybenzotriazole (766 mg, 5.67 mmol), (S)-N-(benzyloxycarbonyl)-proline 141 (1.55 g, 
6.24 mmol, added as solution in 5 mL DMF) and (RS)-5-phenylpyrazolidin-3-one 83 (1.00 g, 
5.67 mmol) were combined according to general procedure E. The crude material was purified 
by column chromatography, eluting with 40 % ethyl acetate in petrol to give title compound 
(5S)-142 as a clear yellow oil (382 mg, 17 %) and fractions containing title compound (5R)-142 
and a minor impurity (176 mg). 392 mg of mixed fractions were also collected. The fractions 
containing impure (5R)-142 were purified by further column chromatography, eluting with 
diethyl ether to give title compound (5R)-142 as a colourless oil (100 mg, 4 %) (668 mg of 
compounds (5S)- and (5R)-142 over all fractions, 30 % combined yield). 
Compound (5S)-142 (upper spot): [$]20D –82.2 (c 0.6, chloroform); "max (KBr disc)/ cm
-1
 
3248 (N-H), 3063 (Ar-H), 3033 (Ar-H), 2978 (C-H), 2955 (C-H), 2883 (C-H), 1771 (C=O), 
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1746 (C=O), 1695 (C=O), 1605 (N-H bend) and 1586 (Ar C=C); !N (CDCl3) 192 (N(2)C(O)), 
103 (N(1)H), 97.8 (NProC(O)O); !H (500 MHz, (CD3)2S(O), rotamers A:B 1.1:1) 7.46 (A, 2H, d, 
J 7.3, ArH), 7.39–7.36 (A, 4H, m, ArH & B, 4H, m, ArH), 7.33–7.27 (A, 4H, m, ArH & B, 4H, 
m, ArH), 7.24 (B, 2H, d, J 6.8, ArH), 6.54 (B, 1H, d, J 9.0, N(1)H), 6.53 (A, 1H, d, J 8.9, 
N(1)H), 5.22–5.14 (A, 1H, m, NProCH & B, 1H, m, NProCH), 5.08 (A, 2H, s, PhCH2), 5.03 (B, 
1H, d, AB system, JAB 13.1, PhCHAHB), 4.97 (B, 1H, d, AB system, JBA 13.1, PhCHAHB), 4.67 
(A, 1H, app q, J 8.3, C(5)H), 4.58 (B, 1H, br s, C(5)H), 3.53–3.38 (A, 2H, m, NProCH2 & B, 2H, 
m, NProCH2), 3.10 (B, 1H, dd, ABX system, JAB 16.9, JAX 9.0, C(4)HAHB), 3.08 (A, 1H, dd, 
ABX system, JAB 16.7, JAX 7.1, C(4)HAHB), 2.92 (A, 1H, dd, ABX system, JBA 16.7, JBX 9.6, 
C(4)HAHB), 2.81 (B, 1H, dd, ABX system, JBA 16.7, JBX 8.7, C(4)HAHB), 2.31–2.19 (A, 1H, m, 
NProCHCHAHB & B, 1H, m, NProCHCHAHB) and 1.95–1.84 (A, 3H, m, NProCHCHAHBCH2 & B, 
3H, m, NProCHCHAHBCH2); !C (100 MHz, CDCl3) 169.8 (C(3)O), 169.7 (C(3)O), 169.1 
(N(2)C(O)), 168.5 (N(2)C(O)), 155.0 (C(O)O), 154.1 (C(O)O), 137.9 (CAripso), 137.7 (CAripso), 
136.9 (CAripso), 136.8 (CAripso), 129.1 (CAr), 128.79 (CAr), 128.77 (CAr), 128.6 (CAr), 
128.5 (CAr), 128.3 (CAr), 128.2 (CAr), 128.1 (CAr), 127.9 (CAr), 126.9 (CAr), 126.7 (CAr), 
67.2 (CH2Ph), 67.1 (CH2Ph), 59.8 (NProCH), 58.7 (NProCH), 58.2 (C(5)H), 58.0 (C(5)H), 
47.4 (NProCH2), 47.0 (NProCH2), 42.0 (C(4)H2), 41.9 (C(4)H2), 30.7 (NProCHCH2CH2), 
29.8 (NProCHCH2CH2), 24.1 (NProCHCH2CH2) and 23.6 (NProCHCH2CH2); m/z HRMS (ESI
+
) 
C22H24N3O4 ([M+H]
+
) requires 394.1761, found 394.1765 (+0.9 ppm). 
Compound (5R)-142 (lower spot): [$]20D –40.3 (c 0.9, chloroform); "max (KBr disc)/ cm
-1
 
3226 (N-H), 3059 (Ar-H), 3029 (Ar-H), 2956 (C-H), 2926 (C-H), 1744 (C=O), 1708 (C=O), 
1695 (C=O) and 1605 (N-H bend); !H (300 MHz, CDCl3, rotamers A:B 1.1:1) 7.56–7.19 (A, 
10H, m, ArH & B, 10H, m, ArH), 5.40 (A, 1H, d, J 8.7, NProCH), 5.39 (B, 1H, d, J 8.5, 
NProCH), 5.17 (A, 1H, d, AB system, JAB 12.5, PhCHAHB), 5.10 (A, 1H, d, AB system, 
JBA 12.5, PhCHAHB), 5.09 (B, 1H, d, AB system, JAB 12.3, PhCHAHB), 5.03 (B, 1H, d, 
AB system, JBA 12.3, PhCHAHB), 4.75 (A, 1H, app t, J 8.8, C(5)H), 4.64 (B, 1H, app t, J 8.6, 
C(5)H), 3.74–3.49 (A, 2H, m, NProCH2 & B, 2H, m, NProCH2), 3.039 (A, 1H, d, J 8.6, 
C(4)HAHB), 3.038 (A, 1H, d, J 9.4, C(4)HAHB), 2.97 (B, 1H, dd, ABX system, JAB 17.0, JAX 7.3, 
C(4)HAHB), 2.74 (B, 1H, dd, ABX system, JBA 17.0, JBX 10.5, C(4)HAHB), 2.44–2.30 (A, 1H, 
m, NProCHCHAHB & B, 1H, m, NProCHCHAHB) and 2.08–1.89 (A, 3H, m, NProCHCHAHBCH2 
& B, 3H, m, NProCHCHAHBCH2); !C (100 MHz, CDCl3) 170.9 (C(3)O), 170.7 (C(3)O), 
169.6 (N(2)C(O)), 169.1 (N(2)C(O)), 155.0 (C(O)O), 154.2 (C(O)O), 137.6 (CAripso), 
137.5 (CAripso), 136.9 (CAripso), 129.2 (CAr), 129.1 (CAr), 129.0 (CAr), 128.9 (CAr), 
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128.6 (2 x CAr), 128.05 (CAr), 128.03 (CAr), 128.0 (CAr), 127.9 (CAr), 126.8 (CAr), 
126.6 (CAr), 67.2 (2 x CH2Ph), 60.1 (NProCH), 59.2 (NProCH), 57.8 (C(5)H), 57.4 (C(5)H), 
47.4 (NProCH2), 46.9 (NProCH2), 41.5 (C(4)H2), 41.3 (C(4)H2), 31.0 (NProCHCH2CH2), 
30.1 (NProCHCH2CH2), 24.1 (NProCHCH2CH2) and 23.5 (NProCHCH2CH2); m/z HRMS (ESI
+
) 
C22H24N3O4 ([M+H]
+
) requires 394.1761, found 394.1755 (–1.6 ppm). 
 
(S)-2-(2’-(6-Methoxynaphthalen-2-yl)propanoyl)-5,5-dimethylpyrazolidin-3-one 143 
N
H
N
O
O
143
O
 
N-(3-Dimethylaminopropyl)-N!-ethylcarbodiimide hydrochloride (1.11 g, 5.80 mmol), 
1-hydroxybenzotriazole (784 mg, 5.80 mmol), (S)-Naproxen (1.34 g, 5.80 mmol) and 
5,5-dimethylpyrazolidin-3-one 145 (662 mg, 5.80 mmol) were combined according to general 
procedure E. The crude material was purified by column chromatography on silica gel, eluting 
with 75 % diethyl ether in petrol to give the title compound as a colourless solid (1.15 g, 61 %). 
 [$]20D +20.8 (c 0.25, chloroform); "max (KBr disc)/ cm
-1
 3226 (N-H) 2967 (C-H), 2927 (C-H), 
1764 (C=O), 1747 (C=O), 1673 (N-H bend), 1633 (Ar C=C) and 1609 (Ar C=C);          
mp 109–111 ˚C; !N (CDCl3) 190 (N(2)C(O)), 117 (N(1)H); !H (400 MHz, CDCl3) 7.71–7.66 
(3H, m, ArH), 7.44 (1H, dd, J 8.6, 1.7, ArH), 7.14–7.08 (2H, m, ArH), 4.99 (1H, q, J 6.9, 
CH(CH3)), 3.90 (3H, s, OCH3), 2.53 (1H, d, AB system, JAB 16.8, C(4)HAHB), 2.45 (1H, d, 
AB system, JBA 16.8, C(4)HAHB), 1.55 (3H, d, J 7.0, ArCH(CH3)), 1.28 (3H, s, 
(C((CH3)A(CH3)B)) and 1.14 (3H, s, (C((CH3)A(CH3)B)); !C (100 MHz, CDCl3) 171.8 (C(O)), 
171.7 (C(O)), 157.7 (OCAripso), 135.9 (CAripso), 133.8 (CAripso), 129.5 (CAr), 129.1 (CAripso), 
127.2 (CAr), 127.0 (CAr), 126.5 (CAr), 119.0 (CAr), 105.7 (CAr), 55.5 (C(CH3)2), 
55.4 (OCH3), 47.9 (C(4)H2), 44.5 (CH(CH3)), 26.2 (C((CH3)A(CH3)B)), 26.1 (C((CH3)A(CH3)B)) 
and 19.4 (CH(CH3)); m/z  HRMS (ESI
+
) C19H22N2O3Na ([M+Na]
+
) requires 349.1528, found 
349.1534 (+0.6 ppm). 
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5,5-Dimethylpyrazolidin-3-one 147 
N
H
NH
O
147  
To a solution of hydrazine hydrate (2.35 mL, 48.2 mmol) in absolute ethanol (50 mL) was 
added methyl 3-methyl-2-butenoate 145 (5.30 mL, 43.8 mmol) by dropwise addition. The 
resulting solution was stirred for 1 h at rt and then at reflux for 4 h before concentration 
in vacuo to give the title compound as a colourless oil with spectroscopic data in accordance 
with the literature (4.95 g, 99 %).
75
  
!H (400 MHz, CDCl3) 7.28 (1H, br s, N(2)H), 4.08 (1H, br s, N(1)H), 2.31 (2H, s, C(4)H2) and 
1.29 (6H, s, C(CH3)2).  
 
Pyrazolidin-3-one 148 
148
N
H
NH
O
 
To a solution of hydrazine hydrate (6.20 mL, 0.130 mol) in absolute ethanol (100 mL) was 
added methyl acrylate 146 (10.4 mL, 0.120 mol) by dropwise addition causing significant heat 
evolution. The resulting solution was stirred for 1 h at rt and then at reflux for 4 h before 
concentration in vacuo. The resultant material was taken up in toluene (100 mL) and subjected 
to reflux overnight. The crude material was then purified by column chromatography on silica 
gel, eluting with 10 % methanol in dichloromethane to give the title compound as a viscous oil 
with spectroscopic data in accordance with the literature (1.05 g, 10 %).
75
  
!H (300 MHz, CDCl3) 5.26 (2H, bs, N(1)H & N(2)H), 3.50 (2H, t, J 7.7, C(5)H2) and 2.49 (2H, 
t, J 7.7, C(4)H2).  
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(S)-1-(2’-(6-Methoxynaphthalen-2-yl)propanoyl)pyrazolidin-3-one 149 
1 8
7
6
54
3
2
N
NH
O
149
O
O
 
N-(3-Dimethylaminopropyl)-N!-ethylcarbodiimide hydrochloride (1.11 g, 5.80 mmol), 
1-hydroxybenzotriazole (784 mg, 5.80 mmol), (S)-Naproxen (1.34 g, 5.80 mmol) and 
pyrazolidin-3-one 148 (500 mg, 5.80 mmol) were combined according to general procedure E. 
The crude material was purified by column chromatography on silica gel, eluting with 50 % 
diethyl ether in petrol then 5 % methanol in dichloromethane. The resultant oil was then 
triturated in diethyl ether and filtered to give the title compound as a grey solid (381 mg, 22 %). 
[$]20D +5.8 (c 0.52, chloroform); "max (KBr disc)/ cm
-1
 3190 (N-H) 2959 (C-H), 2932 (C-H), 
1716 (C=O), 1691 (C=O), 1631 (N-H bend) and 1604 (Ar C=C); mp 167–170 ˚C; !N (CDCl3) 
142; !H (400 MHz, CD3CN) 9.02 (1H, bs, (N(2)H), 7.76–7.71 (3H, m, ArH), 7.43 (1H, d, J 8.3, 
ArH), 7.24 (1H, d, J 2.5, ArH), 7.14 (1H, d, J 8.9, 2.5, ArH), 4.17 (1H, br s, C(5)HAHB), 
3.94 (1H, br s, CH(CH3)), 3.89 (3H, s, OCH3), 3.81 (1H, br s, C(5)HAHB), 2.67 (1H, br s, 
C(4)HAHB), 2.54 (1H, ddd, J 16.9, 10.2, 6.8, C(5)HAHB) and 1.45 (3H, d, J 6.9, CH(CH3)); 
!C (75 MHz, CD3CN) 170.1 (C(3)O), 166.4 (N(1)C(O)), 158.7 (OCAripso), 137.2 (CAripso), 
134.7 (CAripso), 130.1 (CAr), 129.9 (CAripso), 128.2 (CAr), 127.2 (CAr), 126.8 (CAr), 
119.8 (CAr), 106.7 (CAr), 56.0 (OCH3), 44.8 (C(4)H2), 42.6 (CH(CH3)), 31.8 (C(5)H2), and 
19.8 (CH(CH3)); m/z HRMS (ESI
+
) C17H19N2O3 ([M+H]
+
) requires 299.1390, found 299.1391 
(+0.3 ppm). 
Upon heating to 70 ˚C, the observed rotamers had almost fully coalesced: 
!H (400 MHz, CD3CN) 7.75 (2H, app d, J 8.7, CAr(4)H & CAr(8)H), 7.72 (1H, s, CAr(1)H), 
7.44 (1H, d, J 8.5, CAr(3)H), 7.24 (1H, d, J 2.4, CAr(5)H), 7.15 (1H, dd, J 8.9, 2.4, CAr(7)H), 
4.15 (1H, app q, J 8.6, C(5)HAHB), 3.99 (1H, q, J 7.0 CH(CH3)), 3.92–3.87 (1H, m, C(5)HAHB), 
3.90 (3H, s, OCH3), 2.65 (1H, m, C(4)HAHB), 2.55 (1H, ddd, J 16.9, 10.0, 6.9, C(5)HAHB), 
2.26 (1H, bs, (N(2)H) and 1.50 (3H, d, J 7.0, CH(CH3)). 
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(E)-Ethyl 4-phenylbut-2-enoate 152 
O
OEt
Ph
152  
Triethyl phosphite 150 (27.8 mL, 0.16 mol) was added slowly to ethyl bromoacetate (16.6 mL, 
0.16 mol) and the resultant solution stirred at reflux for 2 h, then cooled to rt and concentrated 
in vacuo to give ethyl 2-(diethoxyphosphoryl)acetate 151 as a clear oil, with 
1
H NMR in 
accordance with the literature (35.6 g, 99 %).
149
 
!H (400 MHz, CDCl3) 4.14 (4H, q, J 7.2, P(O)OCH2CH3), 4.10 (2H, q, J 7.0, C(O)OCH2CH3), 
2.89 (2H, d, J 21.6, P(O)CH2C(O)), 1.28 (6H, t, J 7.2, P(O)OCH2CH3) and 1.22 (3H, t, J 7.0, 
C(O)OCH2CH3). 
Methylmagnesium bromide (3.0 M solution in diethyl ether, 10.4 mL, 31.2 mmol) was added 
dropwise to a solution of ethyl 2-(diethoxyphosphoryl)acetate 151 (7.00 g, 31.2 mmol) in THF 
(250 mL) at 0 ºC before being warmed to rt. After 20 min, phenylacetaldehyde (4.0 mL, 
34.4 mmol) was added dropwise and the resulting mixture stirred at reflux for 3 h. The reaction 
was quenched with saturated ammonium chloride solution (120 mL) and the resulting biphasic 
mixture extracted with diethyl ether (200 mL). It was also necessary to add water (30 mL) in 
order to achieve efficient separation. The resulting aqueous layer was extracted with more 
diethyl ether (200 mL) and the combined organic layers were dried (MgSO4), filtered and 
concentrated in vacuo. The crude material was then purified by column chromatography, 
eluting with 5 % diethyl ether in petrol to give the product as a colourless oil, with 
spectroscopic data in accordance with the literature (3.64 g, 61 %).
101
  
!H (300 MHz, CDCl3) 7.37–7.30 (2H, m, ArH), 7.28–7.16 (3H, m, ArH), 7.12 (1H, dt, J 15.6, 
6.8, CHCHCO2), 5.83 (1H, dt, J 15.6, 1.5, CHCO2), 4.19 (2H, q, J 7.1, OCH2CH3), 3.54 (2H, 
dd, J 6.8, 1.5, PhCH2) and 1.29 (3H, t, J 7.1, OCH2CH3). 
 
(RS)-5-benzylpyrazolidin-3-one 153 
153
N
H
NH
O
Bn
 
To a solution of hydrazine hydrate (9.20 mL, 189 mmol) in absolute ethanol (120 mL) was 
added (E)-ethyl 4-phenylbut-2-enoate 152 (12.0 g, 63.1 mmol) and the resulting solution stirred 
at reflux for 90 min. The suspension was then concentrated in vacuo and redissolved in toluene 
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(120 mL) and stirred at reflux for a further 90 min. The resulting solution was concentrated 
in vacuo and purified by column chromatography on silica gel, eluting with a gradient of 
1-10 % methanol in dichloromethane to give the title compound as an off-white solid (6.96 g, 
63 %). 
"max (KBr disc)/ cm
-1
 3234 (N-H), 3165 (N-H), 3054 (Ar-H), 1698 (C=O) and 
1655 (N-H bend); mp 81–83 ˚C; !H (300 MHz, CDCl3) 7.37–7.17 (5H, m, ArH), 3.95 (1H, 
app quin, J 7.2, C(5)H), 2.98 (1H, dd, ABX system, JAB 13.8, JAX 6.9, CHAHBPh), 2.84 (1H, dd, 
ABX system, JBA 13.8, JBX 7.0, CHAHBPh), 2.55 (1H, dd, ABX system, JAB 16.4, JAX 7.2, 
C(4)HAHB) and 2.32 (1H, dd, ABX system, JBA 16.4, JBX 7.5, C(4)HAHB); !C (75 MHz, CDCl3) 
177.0 (C(3)O), 137.3 (CAripso), 129.2 (CAr), 128.8 (CAr), 127.0 (CAr), 61.0 (C(5)H), 
39.6 (C(4)H2) and 37.3 (CH2Ph); m/z  HRMS (ESI
+
) C10H13N2O ([M+H]
+
) requires 177.1022, 
found 177.1019 (–1.9 ppm). 
 
(RS)-5-(tert-Butyl)pyrazolidin-3-one 156 
156
N
H
NH
O
 
Butyllithium (2.5 M solution in hexanes, 40.0 mL, 101 mmol) was added dropwise to a solution 
of ethyl 2-(diethoxyphosphoryl)acetate 151 (22.0 g, 106 mmol)) in THF (150 mL) at –78 ºC. 
After 30 min, a solution of pivalaldehyde (10.0 mL, 92.0 mmol) in THF (150 mL) was added 
via cannula and the mixture stirred overnight. Reaction was quenched with saturated 
ammonium chloride solution (250 mL) and the resulting biphasic mixture extracted with 
dichloromethane (250 mL). The organic layer was washed with brine (250 mL), dried (MgSO4) 
and concentrated in vacuo to give crude (E)-ethyl 4,4-dimethylpent-2-enoate 155 (13.3 g) as a 
yellow oil with spectroscopic data in accordance with the literature.
150
 Product was used 
without further purification. 
!H (300 MHz, CDCl3) 6.97 (1H, d, J 15.9, CHCHCO2), 5.73 (1H, d, J 15.9, CHCO2), 4.19 (2H, 
q, J 7.1, OCH2CH3), 1.29 (3H, t, J 7.1, OCH2CH3) and 1.08 (9H, s, C(CH3)3). 
To a solution of hydrazine hydrate (5.00 mL, 101 mmol) in absolute ethanol (140 mL) was 
added crude (E)-ethyl 4,4-dimethylpent-2-enoate 155 (13.3 g, 85.1 mmol) and the resulting 
solution stirred at reflux overnight before concentration in vacuo. The crude oil was then 
purified by trituration in diethyl ether followed by filtration to give 3.68 g of the title compound 
as a colourless solid. The filtrate was concentrated in vacuo and purified by column 
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chromatography on silica gel, eluting with 8 % methanol in dichloromethane to give a further 
3.20 g of the title compound (6.68 g in total, 53 % combined yield). 
"max (KBr disc)/ cm
-1
 "max (KBr disc)/ cm
-1
 3270 (N-H), 3219 (N-H), 2958 (C-H), 2870 (C-H) 
and 1667 (C=O); mp 85–89 ˚C; !H (300 MHz, CDCl3) 4.95 (2H, bs, N(1)H and N(2)H), 
3.47 (1H, app t, J 8.6, C(5)H), 2.45 (1H, dd, ABX system, JAB 16.7, JAX 8.2, C(4)HAHB), 
2.38 (1H, dd, ABX system, JBA 16.7, JBX 8.9, C(4)HAHB) and 0.95 (9H, s, C(CH3)3); 
!C (75 MHz, CDCl3) 176.8 (C(3)O), 67.5 (C(5)H), 33.1 (C(4)H2), 33.0 (C(CH3)3) and 37.3 
(C(CH3)3); m/z HRMS (ESI
+
) C7H14N2ONa ([M+Na]
+
) requires 165.1004, found 165.1001 
(-1.7 ppm). 
 
(S)-2-((S)-2’-(6-Methoxynaphthalen-2-yl)propanoyl)-5-methylpyrazolidin-3-one (5S)-157 
and (R)-2-((S)-2’-(6-methoxynaphthalen-2-yl)propanoyl)-5-methylpyrazolidin-3-one 
(5R)-157 
N
H
N
O
O
+
(5S)-157 (5R)-157
O
N
H
N
O
O
O
 
N-(3-Dimethylaminopropyl)-N!-ethylcarbodiimide hydrochloride (1.91 g, 10.0 mmol), 
1-hydroxybenzotriazole (1.35 g, 10.0 mmol), (S)-Naproxen (2.30 g, 10.0 mmol) and (RS)-5-
methylpyrazolidin-3-one 71 (1.00 g, 10.0 mmol) were combined according to general procedure 
E. The crude material was purified by column chromatography, eluting with 80 % diethyl ether 
in petrol to give title compound (5S)-157 (220 mg, 7 %) and 590 mg of mixed fractions 
(810 mg of compounds (5S)- and (5R)-157 over all fractions, 26 % combined yield). 
Compound (5S)-157 (upper spot): [$]20D +11.3 (c 0.6, dichloromethane); "max (KBr disc)/ cm
-1
 
3249 (N-H), 2979 (Ar-H), 2955 (C-H), 2935 (C-H), 1769 (C=O), 1748 (C=O), 1669 (N-H 
bend) and 1605 (Ar C=C); mp 142–144 ˚C; !H (300 MHz, CDCl3) 7.71–7.67 (3H, m, ArH), 
7.45 (1H, dd, J 8.5, 1.8, ArH), 7.14–7.09 (2H, m, ArH), 4.98 (1H, q, J 7.0, CH(CH3)Ar), 
4.97 (1H, br s, N(1)H), 3.90 (3H, s, OCH3), 3.64–3.47 (1H, m, C(5)H), 2.67 (1H, dd, 
ABX system, JAB 17.0, JAX 6.7, C(4)HAHB), 2.41 (1H, dd, JBA 17.0, JBX 10.2, C(4)HAHB), 
1.54 (3H, d, J 7.0, CH(CH3)Ar) and 1.25 (3H, d, J 6.3, C(5)H(CH3)); !C (75 MHz, CDCl3) 
171.3 (C(O)), 171.2 (C(O)), 157.7 (OCAripso), 135.8 (CAripso), 133.8 (CAripso), 129.5 (CAr), 
129.0 (CAripso), 127.2 (CAr), 127.0 (CAr), 126.6 (CAr), 119.0 (CAr), 105.6 (CAr), 
55.4 (OCH3), 49.8 (C(5)H), 44.3 (CH(CH3)Ar), 42.2 (C(4)H2), 19.4 (CH(CH3)Ar) and 18.6 
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(C(5)H(CH3)); m/z  HRMS (ESI
+
) C18H21N2O3 ([M+H]
+
) requires 315.1547, found 315.1549 
(+0.7 ppm).  
 
(S)-2-((S)-2’-(6-Methoxynaphthalen-2-yl)propanoyl)-5-(trifluoromethyl)pyrazolidin-3-one 
(5R)-158 and (R)-2-((S)-2’-(6-methoxynaphthalen-2-yl)propanoyl)-5-(trifluoromethyl)-
pyrazolidin-3-one (5S)-158 
N
H
N
O
F3C
O
+
(5R)-158 (5S)-158
O
N
H
N
O
F3C
O
O
1
8
7
6
5
4
3
2
 
N-(3-Dimethylaminopropyl)-N!-ethylcarbodiimide hydrochloride (1.55 g, 8.11 mmol), 
1-hydroxybenzotriazole (1.10 g, 8.11 mmol), (S)-Naproxen (1.87 g, 8.11 mmol) and 
(RS)-5-(trifluoromethyl)pyrazolidin-3-one 84 (1.25 g, 8.11 mmol) were combined according to 
general procedure E. The crude material was purified by column chromatography, eluting 
with 25 % ethyl acetate in petrol then pure ethyl acetate to give impure fractions of title 
compound (5R)-158 (766 mg) and fractions of title compound (5S)-158 contaminated with 
residual  (S)-Naproxen (474 mg). The fractions of (5R)-158 were purified by recrystallisation in 
methanol and the minimum of ethyl acetate to give title compound (5R)-158 as a 
colourless solid (229 mg, 8 %). The fractions of (5S)-158 were taken up in dichloromethane 
(100 mL) and washed with saturated sodium bicarbonate solution (2 x 100 mL), brine 
(100 mL), dried (MgSO4) and concentrated in vacuo to give title compound (5S)-158 as a 
colourless solid (219 mg, 7 %) (448 mg of compounds (5R)- and (5S)-158 over all fractions, 
15 % combined yield). 
Compound (5R)-158 (upper spot): [$]20D +3.3 (c 0.6, chloroform); "max (KBr disc)/ cm
-1
 
3259 (N-H), 2938 (C-H), 1760 (C=O), 1672 (C=O), 1635 (N-H bend) and 1610 (Ar C=C); 
mp 162–165 ˚C; !F (282 MHz, CDCl3) –78.2 (3F, d, J 6.8, CF3); !H (300 MHz, CDCl3)     
7.70–7.67 (3H, m, ArH), 7.44 (1H, dd, J 8.5, 1.8, ArH), 7.15–7.09 (2H, m, ArH), 5.66 (1H, d, 
J 6.3, N(1)H), 4.99 (1H, q, J 7.0, CH(CH3)), 4.00 (1H, app dsext, J 8.8, 6.6, C(5)H), 3.90 (3H, 
s, OCH3), 3.00 (1H, dd, ABX system, JAB 17.9, JAX 8.8, C(4)HAHB), 2.91 (1H, dd, JBA 17.9, 
JBX 6.3, C(4)HAHB) and 1.57 (3H, d, J 7.0, CH(CH3)); !C (75 MHz, CDCl3) 170.8 (N(2)C(O)), 
167.0 (C(3)O), 157.8 (OCAripso), 135.1 (CAripso), 133.8 (CAripso), 129.4 (CAr), 128.9 (CAripso), 
127.2 (CAr), 126.9 (CAr), 126.8 (CAr), 124.3 (q, J 280, CF3), 119.1 (CAr), 105.6 (CAr), 
55.4 (OCH3), 52.8 (q, J 32.5, C(5)H), 43.9 (CH(CH3)), 33.8 (C(4)H2) and 19.3 (CH(CH3)); 
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m/z HRMS (ESI
+
) C18H17N2O3F3Na ([M+Na]
+
) requires 389.1089, found 389.1094 (+1.2 ppm).  
Compound (5S)-158 (lower spot): [$]20D +18.5 (c 0.5, acetonitrile); "max (KBr disc)/ cm
-1
 3292 
(N-H), 2988 (C-H), 2944 (C-H), 1757 (C=O), 1677 (C=O), 1631 (N-H bend) and 1605 (Ar 
C=C); mp 161–162 ˚C; !F (282 MHz, (CD3)2S(O)) –77.5 (3F, d, J 8.2, CF3); !H (300 MHz, 
(CD3)2S(O)) 7.78 (1H, d, J 9.0, CAr(8)H), 7.76 (1H, d, J 8.6, CAr(4)H), 7.60 (1H, d, J 1.6, 
CAr(1)H), 7.33 (1H, dd, J 8.6, 1.6, CAr(3)H), 7.27 (1H, d, J 2.4, CAr(5)H), 7.14 (1H, dd, J 9.0, 
2.4, CAr(7)H), 6.87 (1H, d, J 7.2, N(1)H), 4.88 (1H, q, J 6.8, CH(CH3)), 4.35–4.22 (1H, m, 
C(5)H), 3.86 (3H, s, OCH3), 3.25 (1H, dd, ABX system, JAB 18.3, JAX 10.1, C(4)HAHB), 2.67 
(1H, dd, JBA 18.3, JBX 2.7, C(4)HAHB) and 1.42 (3H, d, J 6.8, CH(CH3)); !C (75 MHz, 
(CD3)2S(O)) 170.7 (N(2)C(O)), 170.5 (C(3)O), 157.6 (OCAripso), 136.0 (CAripso), 
133.6 (CAripso), 129.5 (CAr), 128.7 (CAripso), 127.3 (CAr), 126.9 (CAr), 126.0 (CAr), 125.6 (q, 
J 280, CF3), 119.1 (CAr), 106.0 (CAr), 55.5 (OCH3), 51.9 (q, J 30.7, C(5)H), 43.8 (CH(CH3)), 
33.6 (C(4)H2) and 19.2 (CH(CH3)); m/z  HRMS (ESI
+
) C18H17N2O3F3Na ([M+Na]
+
) requires 
389.1089, found 389.1094 (+1.2 ppm).  
 
(S)-2-((S)-2’-(6-Methoxynaphthalen-2-yl)propanoyl)-5-benzylpyrazolidin-3-one (5S)-159 
and (R)-2-((S)-2’-(6-methoxynaphthalen-2-yl)propanoyl)-5-benzylpyrazolidin-3-one 
(5R)-159 
N
H
N
O
Bn
O
+
(5S)-159 (5R)-159
O
N
H
N
O
Bn
O
O
 
N-(3-Dimethylaminopropyl)-N!-ethylcarbodiimide hydrochloride (3.27 g, 17.0 mmol), 
1-hydroxybenzotriazole (2.30 g, 17.0 mmol), (S)-Naproxen (3.93 g, 17.0 mmol) and 
(RS)-5-benzylpyrazolidin-3-one 153 (3.00 g, 17.0 mmol) were combined according to general 
procedure E. The crude material was dissolved in diethyl ether and a minimum of 
dichloromethane, cooled to 0 ºC overnight and the resulting mixture filtered to give title 
compound (5S)-159 as a colourless solid (1.20 g, 18 %). The filtrate was concentrated in vacuo 
and taken up in diethyl ether and a minimum of methanol. 560 mg of colourless solid composed 
of a 14:86 mixture of title compounds (5S)- and (5R)-159 respectively, was collected (1.76 g of 
compounds (5S)- and (5R)-159 over all fractions, 27 % combined yield). In order to access pure 
compound (5R)-159, this mixture was subjected to recrystallisation from methanol and the 
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minimum quantity of dichloromethane to give title compound (5R)-159 as a colourless solid 
(342 mg, 5 %). 
Compound (5S)-159 (upper spot): [$]20D +31.2 (c 0.3, chloroform); "max (KBr disc)/ cm
-1
 3265 
(N-H), 3060 (Ar-H), 2976 (C-H), 2935 (C-H), 1723 (C=O), 1687 (C=O), 1630 (N-H bend) and 
1605 (Ar C=C); mp 147–148 ˚C; !N (CDCl3) 193 (N(2)C(O)), 103 (N(1)H); !H (500 MHz, 
CDCl3) 7.70–7.68 (3H, m, ArH), 7.45 (1H, dd, J 8.5, 1.3, ArH), 7.33–7.25 (3H, m, ArH), 7.16–
7.10 (4H, m, ArH), 5.19 (1H, br s, N(1)H), 4.98 (1H, q, J 6.9, CH(CH3)), 3.91 (3H, s, OCH3), 
3.69 (1H, app dq, J 9.4, 6.7, C(5)H), 2.89 (1H, dd, ABX system, JAB 13.7, JAX 6.8, CHAHBPh), 
2.83 (1H, dd, JBA 13.7, JBX 6.3, CHAHBPh), 2.64 (1H, dd, ABX system, JAB 17.0, JAX 6.9, 
C(4)HAHB), 2.55 (1H, dd, JBA 17.0, JBX 9.4, C(4)HAHB) and 1.56 (3H, d, J 6.8, CH(CH3)); !C 
(75 MHz, CDCl3) 170.9 (N(2)C(O)), 170.1 (C(3)O), 157.8 (OCAripso), 136.4 (CAripso), 135.8 
(CAripso), 133.8 (CAripso), 129.5 (CAr), 129.2 (CAr), 129.1 (CAripso), 129.0 (CAr), 127.3 (CAr), 
127.2 (CAr), 126.9 (CAr), 126.6 (CAr), 119.0 (CAr), 105.7 (CAr), 55.4 (OCH3), 55.0 (C(5)H), 
44.1 (CH(CH3)), 40.1 (CH2Ph), 39.6 (C(4)H2) and 19.4 (CH(CH3)); m/z  HRMS (ESI
+
) 
C24H24N2O3Na ([M+Na]
+
) requires 411.1685, found 411.1675 (–2.4 ppm).  
Compound (5R)-159 (lower spot): [$]20D +68.0 (c 0.5, chloroform); "max (KBr disc)/ cm
-1
 3241 
(N-H), 2970 (C-H), 2946 (C-H), 1769 (C=O), 1682 (C=O), 1629 (N-H bend) and 1604 (Ar 
C=C); mp 133–134 ˚C; !H (300 MHz, CDCl3) 7.71–7.68 (3H, m, ArH), 7.44 (1H, dd, J 8.4, 1.9, 
ArH), 7.30–7.21 (3H, m, ArH), 7.15–7.06 (4H, m, ArH), 4.99 (1H, q, J 7.0, CH(CH3)), 3.91 
(3H, s, OCH3), 3.79 (1H, app quin, J 7.3, C(5)H), 2.79 (1H, dd, ABX system, JAB 13.8, JAX 7.4, 
CHAHBPh), 2.75 (1H, dd, ABX system, JAB 17.0, JAX 7.0, C(4)HAHB), 2.70 (1H, dd, JBA 13.8, 
JBX 6.7, CHAHBPh), 2.48 (1H, dd, JBA 17.0, JBX 8.4, C(4)HAHB) and 1.54 (3H, d, J 7.0, 
CH(CH3)); !C (75 MHz, CDCl3) 170.9 (N(2)C(O)), 170.1 (C(3)O), 157.8 (OCAripso), 136.6 
(CAripso), 135.6 (CAripso), 133.8 (CAripso), 129.5 (CAr), 129.1 (CAr), 129.0 (CAripso), 128.9 
(CAr), 127.24 (CAr), 127.21 (CAr), 127.0 (CAr), 126.7 (CAr), 119.0 (CAr), 105.7 (CAr), 55.5 
(OCH3 & C(5)H), 44.1 (CH(CH3)), 40.1 (C(4)H2), 39.7 (CH2Ph) and 19.4 (CH(CH3)); m/z  
HRMS (ESI
+
) C24H25N2O3 ([M+H]
+
) requires 389.1860, found 389.1858 (–0.4 ppm).  
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(R)-2-((S)-2’-(6-Methoxynaphthalen-2-yl)propanoyl)-5-(tert-butyl)-pyrazolidin-3-one 
(5R)-160 and (S)-2-((S)-2’-(6-methoxynaphthalen-2-yl)propanoyl)-5-(tert-butyl)-
pyrazolidin-3-one (5S)-160 
N
H
N
O
O
+
(5R)-160
O
(5S)-160
N
H
N
O
O
O
  
N-(3-Dimethylaminopropyl)-N!-ethylcarbodiimide hydrochloride (5.03 g, 25.9 mmol), 
1-hydroxybenzotriazole (3.56 g, 25.9 mmol), (S)-Naproxen (6.00 g, 25.9 mmol) and 
(RS)-5-(tert-butyl)pyrazolidin-3-one 156 (3.68 g, 25.9 mmol) were combined according to 
general procedure E. The crude material was partially purified by column chromatography on 
silica gel, eluting with 60 % diethyl ether in petrol to give first 700 mg of fractions enriched in 
title compound (5R)-160 ((5R):(5S) 85:15) then 710 mg of fractions enriched in title compound 
(5S)-160 ((5R):(5S) 9:91). 2.24 g of mixed fractions were also collected ((5R):(5S) 42:58) (3.65 
g of compounds (5R)-160 and (5S)-160 over all fractions, 40 % combined yield). The fractions 
enriched in title compound (5R)-160 were further purified by column chromatography on silica 
gel, eluting with 40 % diethyl ether in petrol to give title compound (5R)-160 as an amorphous 
white solid (360 mg, 4 %) and 300 mg of mixed fractions. The fractions enriched in title 
compound (5S)-160 were further purified by dissolution in diethyl ether followed by cooling to 
0 ºC. Collection by filtration then gave title compound (5S)-160 as a colourless solid (264 mg, 
3 %).  
Compound (5R)-160 (upper spot): [$]20D –1.0 (c 0.5, chloroform); "max (KBr disc)/ cm
-1
 
3281 (N-H), 2960 (C-H), 2931 (C-H), 1744 (C=O), 1678 (C=O), 1631 (N-H bend) and 
1607 (Ar C=C); mp 45–46 ˚C; !H (300 MHz, CDCl3) 7.73–7.67 (3H, m, ArH), 7.47 (1H, dd, 
J 8.5, 1.8, ArH), 7.14–7.09 (2H, m, ArH), 5.27 (1H, br s, N(1)H), 5.04 (1H, q, J 7.0, CH(CH3)), 
3.91 (3H, s, OCH3), 3.21 (1H, dd, J 11.3, 7.6, C(5)H), 2.63 (1H, dd, ABX system, JAB 17.2, 
JAX 11.3, C(4)HAHB), 2.50 (1H, dd, JBA 17.2, JBX 7.6, C(4)HAHB), 1.56 (3H, d, J 7.0, 
CH(CH3)) and 0.92 (9H, s, C(CH3)3); !C (75 MHz, CDCl3) 170.8 (N(2)C(O)), 170.2 (C(3)O), 
157.7 (OCAripso), 135.9 (CAripso), 133.8 (CAripso), 129.4 (CAr), 129.0 (CAripso), 127.1 (CAr), 
127.0 (CAr), 126.6 (CAr), 119.0 (CAr), 105.6 (CAr), 62.3 (C(5)H), 55.4 (OCH3), 
43.9 (CH(CH3)), 35.9 (C(4)H2), 32.4 (C(CH3)3), 25.7 (C(CH3)3) and 19.4 (CH(CH3)); 
m/z HRMS (ESI
+
) C21H27N2O3 ([M+H]
+
) requires 355.2016, found 355.2015 (–0.3 ppm). 
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Compound (5S)-160 (lower spot): [$]20D +28.2 (c 0.5, chloroform); "max (KBr disc)/ cm
-1
 3290 
(N-H), 2869 (C-H), 1741 (C=O), 1679 (C=O), 1634 (N-H bend) and 1606 (Ar C=C); mp 86–87 
˚C; !H (300 MHz, CDCl3) 7.71–7.66 (3H, m, ArH), 7.46 (1H, dd, J 8.5, 1.8, ArH), 7.14–7.08 
(2H, m, ArH), 5.35 (1H, br s, N(1)H), 5.03 (1H, q, J 6.9, CH(CH3)), 3.90 (3H, s, OCH3), 3.26 
(1H, dd, J 10.1, 8.0, C(5)H), 2.58 (1H, dd, ABX system, JAB 17.2, JAX 8.0, C(4)HAHB), 2.51 
(1H, dd, JBA 17.2, JBX 10.1, C(4)HAHB), 1.56 (3H, d, J 6.9, CH(CH3)) and 0.85 (9H, s, C(CH3)3); 
!C (75 MHz, CDCl3) 170.6 (N(2)C(O)), 170.4 (C(3)O), 157.7 (OCAripso), 135.5 (CAripso), 133.7 
(CAripso), 129.4 (CAr), 129.0 (CAripso), 127.1 (CAr), 127.0 (CAr), 126.6 (CAr), 118.9 (CAr), 
105.6 (CAr), 62.7 (C(5)H), 55.4 (OCH3), 43.9 (CH(CH3)), 35.9 (C(4)H2), 32.7 (C(CH3)3), 25.7 
(C(CH3)3) and 19.4 (CH(CH3)); m/z HRMS (ESI
+
) C21H26N2O3Na ([M+Na]
+
) requires 
377.1841, found 377.1826 (–4.0 ppm). 
 
(S)-2-((S)-1'-((benzyloxy)carbonyl)pyrrolidine-2'-carbonyl)-5-(trifluoromethyl) 
pyrazolidin-3-one (5S)-163 and (R)-2-((S)-1'-((benzyloxy)carbonyl)pyrrolidine-2'-
carbonyl)-5-(trifluoromethyl)pyrazolidin-3-one (5R)-163 
+
(5R)-163
N
H
N
O
F3C
O
N
N
H
N
O
F3C
O
N
(5S)-163
CO2Bn CO2Bn
 
N-(3-Dimethylaminopropyl)-N!-ethylcarbodiimide hydrochloride (1.57 g, 8.21 mmol), 
1-hydroxybenzotriazole (1.10 g, 8.21 mmol), crude (S)-N-(benzyloxycarbonyl)-proline 141 
(1.87 g, 9.03 mmol, added as solution in 5 mL DMF) and (RS)-5-(trifluoromethyl)pyrazolidin-
3-one 84 (1.26 g, 8.21 mmol) were combined according to general procedure E. The crude 
material was purified by column chromatography, eluting with 85 % diethyl ether in petrol to 
give title compound (5S)-163 as a colourless oil (305 mg, 10 %) and fractions containing title 
compound (5R)-163 and a minor impurity (286 mg). 135 mg of mixed fractions were also 
collected. The fractions containing title compound (5R)-163 were purified by further column 
chromatography, eluting with 60 % ethyl acetate in petrol to give title compound (5R)-163 as a 
colourless foam (190 mg, 6 %) (630 mg of compounds (5S)- and (5R)-163 over all fractions, 
20 % combined yield). 
Compound (5S)-163 (upper spot): [$]20D –46.1 (c 0.6, chloroform); "max (KBr disc)/ cm
-1
 
3256 (N-H), 3064 (Ar-H), 3034 (Ar-H), 2980 (C-H), 2957 (C-H), 1786 (C=O), 1757 (C=O), 
1707 (C=O) and 1587 (N-H bend); !F (376 MHz, CDCl3, rotamers A:B 1.5:1) –78.2 (B, 3F, d, 
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J 6.5, CF3), –78.3 (A, 3F, d, J 6.6, CF3); !H (300 MHz, CDCl3, rotamers A:B 1.5:1) 7.42–7.27 
(A, 5H, m, ArH & B, 5H, m, ArH), 5.85 (A, 1H, d, J 7.2, N(1)H), 5.34–5.28 (A, 1H, m, NProCH 
& B, 2H, m, NProCH & N(1)H), 5.14 (A, 1H, d, AB system, JAB 12.6, PhCHAHB), 5.13 (B, 1H, 
d, AB system, JAB 12.1, PhCHAHB), 5.11 (A, 1H, d, AB system, JBA 12.6, PhCHAHB), 4.94 (B, 
1H, d, AB system, JBA 12.1, PhCHAHB),  4.21–4.07 (A, 1H, m, C(5)H), 3.74–3.47 (A, 2H, m, 
NProCH2 & B, 3H, m, NProCH2 & C(5)H), 3.19 (A, 1H, dd, ABX system, JAB 18.0, JAX 9.6, 
C(4)HAHB), 2.88 (A, 1H, dd, ABX system, JBA 18.0, JBX 5.2, C(4)HAHB), 2.75 (B, 1H, d, J 7.4, 
C(4)H2), 2.37–2.27 (A, 1H, m, NProCHCHAHB & B, 1H, m, NProCHCHAHB) and 2.03–1.86 (A, 
3H, m, NProCHCHAHBCH2 & B, 3H, m, NProCHCHAHBCH2); !C (100 MHz, CDCl3) 
169.6 (N(2)C(O)), 168.3 (N(2)C(O)), 168.9 (C(3)O), 168.5 (C(3)O), 155.1 (C(O)O), 
154.1 (C(O)O), 136.9 (CAripso), 136.7 (CAripso), 128.7 (2 x CAr), 128.6 (CAr), 128.3 (CAr), 
128.1 (CAr), 127.4 (CAr), 124.5 (q, J 279, CF3), 124.2 (q, J 279, CF3), 67.2 (CH2Ph), 
67.1 (CH2Ph), 59.9 (NProCH), 58.8 (NProCH), 53.3 (q, J 32.6, C(5)H), 53.2 (q, J 33.0, C(5)H), 
47.3 (NProCH2), 47.0 (NProCH2), 33.5 (C(4)H2), 33.4 (C(4)H2), 30.5 (NProCHCH2CH2), 
29.7 (NProCHCH2CH2), 24.0 (NProCHCH2CH2) and 23.4 (NProCHCH2CH2); m/z HRMS (ESI
+
) 
C17H19N3O4F3 ([M+H]
+
) requires 386.1323, found 386.1322 (+0.9 ppm). 
Compound (5R)-163 (lower spot): [$]20D –34.1 (c 0.5, chloroform); mp 50 ˚C; "max (KBr disc)/ 
cm
-1
 3240 (N-H), 3036 (Ar-H), 2985 (C-H), 2957 (C-H), 2886 (C-H), 1786 (C=O), 1761 (C=O) 
and 1701 (C=O); !N (CD3OD) 184 (N(2)C(O)), 97.6 (NProC(O)O), 86.4 (N(1)H); !F (282 MHz, 
(CD3)2S(O)), 
1
H decoupled, rotamers A:B 1.1:1) –77.3 (A, 3F, s, CF3), –77.5 (B, 3F, s, CF3); 
!H (300 MHz, (CD3)2S(O), rotamers A:B 1.1:1) 7.38–7.19 (A, 5H, m, ArH & B, 5H, m, ArH), 
6.92 (B, 1H, d, J 8.6, N(1)H), 6.89 (A, 1H, d, J 7.8, N(1)H), 5.14 (B, 1H, dd, J 8.7, 2.5, 
NProCH), 5.07 (A, 2H, s, PhCH2), 5.03 (A, 1H, dd, J 8.9, 1.9, NProCH), 4.98 (B, 2H, s, PhCH2), 
4.45–4.31 (A, 1H, m, C(5)H & B, 1H, m, C(5)H), 3.49–3.27 (A, 3H, m, NProCH2 & C(4)HAHB 
& B, 3H, m, NProCH2 & C(4)HAHB), 2.81 (B, 1H, dd, ABX system, JBA 18.3, JBX 3.1, 
C(4)HAHB), 2.78 (A, 1H, dd, ABX system, JBA 18.4, JBX 3.0, C(4)HAHB), 2.35–2.16 (A, 1H, m, 
NProCHCHAHB & B, 1H, m, NProCHCHAHB) and 1.93–1.69 (A, 3H, m, NProCHCHAHBCH2 & B, 
3H, m, NProCHCHAHBCH2); !C (75 MHz, CDCl3) 169.7 (N(2)C(O)), 169.6 (N(2)C(O)), 
169.4 (C(3)O), 169.0 (C(3)O), 154.9 (C(O)O), 154.1 (C(O)O), 136.6 (CAripso), 136.5 (CAripso), 
128.6 (CAr), 128.5 (CAr), 128.0 (CAr), 127.9 (CAr), 127.6 (CAr), 124.6 (q, J 279, CF3), 
124.5 (q, J 279, CF3), 67.2 (CH2Ph), 67.1 (CH2Ph), 59.7 (NProCH), 59.2 (NProCH), 53.3 (q, 
J 32.3, C(5)H), 53.2 (q, J 32.6, C(5)H), 47.3 (NProCH2), 47.0 (NProCH2), 33.3 (C(4)H2), 
33.1 (C(4)H2), 30.6 (NProCHCH2CH2), 29.5 (NProCHCH2CH2), 24.0 (NProCHCH2CH2) 
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and 23.0 (NProCHCH2CH2); m/z HRMS (ESI
+
) C17H22N4O4F3 ([M+NH4]
+
) requires 403.1599, 
found 403.1589 (–2.4 ppm). 
Upon heating to 100 ˚C, the observed rotamers coalesced: 
!F (282 MHz, (CD3)2S(O), 
1
H decoupled) –77.1 (3F, s, CF3); !H (300 MHz, (CD3)2S(O))   
7.36–7.26 (5H, m, ArH), 6.74 (1H, d, J 7.4, N(1)H), 5.13 (1H, d, J 9.5, NProCH), 5.05 (1H, s, 
PhCH2), 4.41–4.26 (1H, m, C(5)H), 3.49 (2H, app t, J 6.8, NProCH2), 3.30 (1H, dd, ABX 
system, JAB 18.1, JAX 9.9, C(4)HAHB), 2.75 (1H, dd, ABX system, JBA 18.1, JBX 3.6, 
C(4)HAHB), 2.36–2.21 (1H, m, NProCHCHAHB) and 1.94–1.78 (3H, m, NProCHCHAHBCH2). 
 
endo-(1SR,2RS,3RS,4RS)-3-Phenylbicyclo[2.2.2]oct-5-en-2-yl)methyl benzoate endo-164 
Ph
O Ph
O
endo-164  
Following the method of Deutsch, et al.,
151
 a solution of (E)-cinnamaldehyde 37 (0.250 mL, 
2.00 mmol), cyclohexadiene (200 mg, 2.50 mmol) and 2 crystals of hydroquinone in toluene 
(0.2 mL) in a sealed tube was flushed with nitrogen then heated at 160 ºC for 2 days. 
1
H NMR 
spectroscopic analysis indicated reaction had achieved 40 % conversion (exo:endo 67:33). The 
crude material was then purified by column chromatography, eluting with 7.5 % diethyl ether in 
petrol to yield endo-(1SR,2RS,3RS,4RS)-phenylbicyclo[2.2.2]oct-5-ene-2-carbaldehyde 
endo-118 as a colourless oil, with spectroscopic data in accordance with the literature (32 mg, 
8 %).
85
  
endo-(1SR,2RS,3RS,4RS)-Phenylbicyclo[2.2.2]oct-5-ene-2-carbaldehyde endo-118 (32.0 mg, 
0.150 mmol), sodium borohydride (17.0 mg, 0.450 mmol), triethylamine (30.0 'L, 0.216 
mmol), DMAP (18.0 mg, 0.150 mmol) and benzoyl chloride (20.0 'L, 0.175 mmol) were 
combined according to general procedure F. The crude material was purified by column 
chromatography on silica gel, eluting with 2 % diethyl ether in petrol to give the title compound 
as a colourless solid (28 mg, 58 %). 
"max (KBr disc)/ cm
-1
 2931 (C-H), 2867 (C-H), 1711 (C=O), 1658 (Ar C=C) and 1601 
(Ar C=C); mp 73–75 ˚C; !H (300 MHz, CDCl3) 7.81 (2H, dd, J 8.3, 1.4, ArH), 7.50 (1H, tt, J 
7.4, 1.4, ArH), 7.37–7.32 (5H, m, ArH), 7.27–7.19 (2H, m, ArH), 6.53 (1H, app t, J 7.4, 
CHA=CHB), 6.25 (1H, app t, J 7.3, CHA=CHB), 4.08 (1H, dd, ABX system, JAB 10.6, JAX 8.2, 
CHAHBO), 3.96 (1H, dd, ABX system, JBA 10.6, JBX 6.6, CHAHBO), 2.80–2.75 (1H, m, CHPh), 
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2.51–2.39 (3H, m, CHCHCH2O & CHCHPh), 1.74–1.68 (2H, m, CHAHBCHCHCHO & 
CHAHBCHCHPh), 1.49–1.41 (1H, m, CHAHBCHCHCHO) and 1.12–1.00 (1H, m, 
CHAHBCHCHPh); !C (75 MHz, CDCl3) 203.5 (CHO), 139.1 (CHA=CHB), 136.9 (CAripso), 
135.9 (CAripso), 134.2 (CHA=CHB), 132.5 (CAripso), 129.0 (CAr), 127.3 (CAr), 126.3 (CAr), 
125.8 (CAr), 125.4 (CAr), 123.8 (CAr), 123.0 (CAr), 59.1 (CHCHO), 49.7 (CHCH2), 47.6 
(CH2), 45.7 (CHCH2) and 41.4 (CHAr); m/z HRMS (ESI
+
) C22H26NO2 ([M+NH4]
+
) requires 
336.1958, found 336.1963 (+1.5 ppm). 
 
endo-(1S,2R,3R,4R)-3-Phenylbicyclo[2.2.2]oct-5-en-2-yl)methyl benzoate endo-(2R)-164 
Ph
O Ph
O
endo-(2R)-164  
endo-(1S,2R,3R,4R)-Phenylbicyclo[2.2.2]oct-5-ene-2-carbaldehyde endo-(2R)-118 (31.0 mg, 
0.146 mmol), sodium borohydride (17.0 mg, 0.450 mmol), triethylamine (30.0 'L, 
0.216 mmol), DMAP (18.0 mg, 0.150 mmol) and benzoyl chloride (20.0 'L, 0.175 mmol) were 
combined according to general procedure F. The crude material was purified by column 
chromatography on silica gel, eluting with 5 % diethyl ether in petrol to give the title compound 
as a colourless solid with an enantiomeric excess of 85 % (22 mg, 47 %). 
[$]20D –10.6 (c 0.5, chloroform); mp 82–84 ˚C. 
Enantiomeric excess was determined by HPLC with ChiralCel OJ-H column 
(0.5% isopropanol:hexane, flow rate = 1.0 mL min
-1
, 211 nm), tR(2S) 15.3 min and 
tR(2R) 24.7 min. 
 
(Z)-Iminium ion of (RS)-benzyl 2-(3-methoxy-3-oxo-1-phenylpropyl)hydrazinecarboxylate 
trifluoromethanesulfonate 169 
169
O
O
N
Ph
N
H
OBn
O
SO3CF3
Ph
 
To a solution of benzyl 5-oxo-3-phenylpyrazolidine-1-carboxylate 114 (100 mg, 0.337 mmol) 
in dichloromethane (1 mL) was added triflic acid (42.0 µL, 0.337 mmol) and the mixture stirred 
at room temperature for 2 h. Upon addition of petrol, 105 mg of the triflate salt 168 precipitated 
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as a colourless solid and was collected by filtration. This solid was taken up in dry methanol 
(2 mL) and (E)-cinnamaldehyde 37 (35.0 µL, 0.260 mmol) added. The resulting mixture was 
left to stir at room temperature with occasional sampling and analysis by 
1
H NMR spectroscopy 
to monitor reaction progress. After 3 weeks, the resultant dark red oil was triturated in diethyl 
ether and a minimum of dichloromethane to precipitate 10 mg of the title compound as a yellow 
solid. The filtrate was concentrated in vacuo and trituration repeated to yield a further 3 mg of 
title compound (13 mg in total, 9 %). 
"max (KBr disc)/ cm
-1
 3427 (N-H), 2925 (C-H), 2854 (C-H), 1751 (C=O), 1732 (C=O), 
1613 (N-H bend) and 1588 (Ar C=C); mp 114-116 ºC; !F (376 MHz, CD3CN) –79.9 (3H, s, 
SO3CF3); !H (300 MHz, CD3CN) 9.08 (1H, d, J 10.2, C(N)H)), 8.96 (1H, br s, NH), 8.29 (1H, 
d, J 15.4, C(N)HCHCH), 7.81 (2H, d, J 7.4, ArH), 7.73–7.68 (1H, m, ArH), 7.59–7.31 (12H, m, 
ArH), 7.07 (1H, dd, J 15.4, 10.2, C(N)HCH), 5.81 (1H, dd, J 10.1, 4.4, CHCH2), 5.07 (2H, bs, 
CH2Ph), 3.67 (3H, s, OCH3), 3.48 (1H, dd, ABX system, JAB 17.9, JAX 10.1, C(O)HAHB) and 
3.16 (1H, dd, ABX system, JBA 17.9, JBX 4.4, C(O)CHAHB); !C (125 MHz, CD3CN) 
174.1 (C(N)), 170.9 (C(O)CH3), 167.8 (C(N)CHCH), 134.0 (CAripso), 132.7 (CAripso), 
136.4 (CAr), 132.4 (CAr), 131.3 (CAr), 130.5 (CAr), 130.0 (2xCAr), 129.5 (CAr), 129.2 (CAr), 
117.0 (C(N)CH), 72.6 (CHCH2), 69.6 (CH2Ph), 52.9 (OCH3) and 34.9 (C(O)CH2); m/z HRMS 
(ESI
+
) C27H27N2O4 ([M-OTf]
+
) requires 443.1965, found 443.1966 (+0.1 ppm).  
  
(R)-Methyl 3-(2-((S)-1'-((benzyloxy)carbonyl)pyrrolidine-2'-carbonyl)hydrazinyl)-4,4,4-
trifluorobutanoate 170 
170
N
H
H
N
O
N
CO2Bn
F3C
O
O
 
To a solution of (S)-benzyl 2-((S)-3-oxo-5-(trifluoromethyl)pyrazolidine-2-
carbonyl)pyrrolidine-1-carboxylate (5R)-163 (300 mg, 0.779 mmol) in methanol (5 mL) was 
added triflic acid (0.140 mL, 1.56 mmol) and the resulting mixture stirred at rt overnight. The 
excess acid was then quenched with saturated sodium hydrogen carbonate solution (25 mL) and 
extracted with ethyl acetate (3 x 25 mL). The combined organic layers were dried (MgSO4), 
filtered and concentrated in vacuo. The crude material was purified by column chromatography 
on silica gel, eluting with 60 % ethyl acetate in petrol to give the title compound as a colourless 
solid (120 mg, 39 %). 
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[$]20D –33.2 (c 0.5, methanol); mp 90–91 ºC; "max (KBr disc)/ cm
-1
 3299 (N-H), 3271 (N-H), 
3125 (Ar-H), 3033 (Ar-H), 2986 (C-H), 2953 (C-H), 1737 (C=O), 1709 (C=O), 
1646 (N-H bend) and 1578 (Ar C=C); !N ((CD3)2S(O)) 138 (NHC(O)), 96.5 (NProC(O)O), 
65.9 (NHCHCF3); !F (376 MHz, CD3OD, rotamers A:B 1.1:1) –76.86 (B, 3F, d, J 7.7, CF3) and 
–76.89 (A, 3F, d, J 7.7, CF3); !H (300 MHz, CD3OD, rotamers A:B 1.1:1) 7.37–7.28 (A, 5H, m, 
ArH & B, 5H, m, ArH), 5.11 (B, 2H, br s, PhCH2), 5.09 (A, 2H, br s, PhCH2), 4.25–4.21 (A, 
1H, m, NProCH & B, 1H, m, NProCH), 3.93 (B, 1H, app sext, J 7.0, CHCF3), 3.80–3.68 (A, 1H, 
m, CHCF3), 3.72 (A, 3H, s, OCH3 & B, 3H, s, OCH3), 3.62–3.45 (A, 2H, m, NProCH2 & B, 2H, 
m, NProCH2), 2.69 (B, 2H, d, J 6.2, C(O)CH2), 2.61 (A, 2H, d, J 6.5, C(O)CH2), 2.31–2.13 (A, 
1H, m, NProCHCHAHB & B, 1H, m, NProCHCHAHB) and 2.04–1.86 (A, 3H, m, 
NProCHCHAHBCH2 & B, 3H, m, NProCHCHAHBCH2); !C (75 MHz, CD3OD) 174.8 (C(O)NH), 
174.7 (C(O)NH), 171.8 (C(O)OCH3), 171.6 (C(O)OCH3), 156.3 (NProC(O)O), 138.0 (CAripso), 
137.9 (CAripso), 129.5 (CAr), 129.1 (CAr), 128.9 (CAr), 128.8 (CAr), 123.6 (q, J 218, CF3), 
68.3 (CH2Ph), 60.5 (NProCH), 60.0 (NProCH), 59.6 (q, J 28.1, CHCF3), 59.4 (q, J 28.3, CHCF3), 
52.7 (OCH3), 48.0 (NProCH2), 32.9 (C(O)CH2), 32.5 (NProCHCH2), 31.4 (NProCHCH2) 
25.4 (NProCHCH2CH2) and 24.6 (NProCHCH2CH2); m/z HRMS (ESI
+
) C18H23N3O5F3 ([M+H]
+
) 
requires 418.1584, found 418.1586 (+0.4 ppm). 
 
2-(1,1,1-Trifluoro-4-methoxy-4-oxobutan-2-yl)hydrazin-1-ium trifluoromethanesulfonate 
172 
172
N
H
NH3
F3C
O
O
SO3CF3
 
To a solution of crude (RS)-5-(trifluoromethyl)pyrazolidin-3-one 84 (90.0 mg, 0.570 mmol) in 
methanol (1 mL) was added triflic acid (101 µL, 1.14 mmol) and the mixture stirred at rt 
overnight. The resulting solution was then concentrated in vacuo for 4 h to remove excess triflic 
acid to give the title compound as a colourless solid (175 mg, 91 %). 
"max (film)/ cm
#1
 3300 (N-H), 3144 (N-H), 2990 (C-H), 2968 (C-H) and 1717 (C=O); mp 73–77 
ºC; !F (375 MHz, CD3OD) &77.3 (3F, d, J 7.7, CHCF3) and –80.7 (3F, s, SO3CF3); !H (400 
MHz, CD3OD) 4.06 (1H, dqd, J 10.1, 6.9, 3.5, CHCF3), 3.77 (3H, s, OCH3), 2.91 (1H, dd, ABX 
system, JAB 17.5, JAX 3.5, C(O)HAHB) and 2.69 (1H, dd, ABX system, JBA 17.5, JBX 10.1, 
C(O)HAHB); !C (75 MHz, CD3OD) 172.0 (C(O)OCH3), 126.4 (q, J 281, CF3), 121.8 (q, J 320, 
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SO3CF3), 58.2 (q, J 30.1, CHCF3), 53.0 (OCH3) and 33.2 (C(O)CH2); m/z HRMS (ESI
+
) 
C5H10F3N2O2 ([M–OTf]
+
) requires 187.0689, found 187.0686 (-1.5 ppm). 
 
4,5-Dimethyl-2-phenyl-5-pyrazolin-3-one 198 (and 4,5-dimethyl-2-phenyl-4-pyrazolin-3-
one 198´) 
N
H
N
O
Ph
198
N
N
O
Ph
+
198'  
Ethyl 2-methylacetoacetate 197 (4.00 mL, 28.3 mmol) and phenylhydrazine (3.00 mL, 
31.1 mmol) were combined according to general procedure G. The resultant yellow oil was 
solidified upon trituration in petrol and a small volume of diethyl ether to give the title 
compound as an off-white solid, with spectroscopic data in accordance with the literature 
(4.95 g, 93 %).
152
 
mp 122–127 ˚C; !H (300 MHz, CDCl3, 5:1 198:198´) 7.91–7.86 (198, 2H, m, ArH), 7.71–7.69 
(198´, 2H, m, ArH), 7.43–7.34 (198, 2H, m, ArH & 198´, 2H, m, ArH), 7.21–7.13 (198, 1H, m, 
ArH & 198´, 1H, m, ArH), 3.24 (198, 1H, q, J 7.9, CH), 2.16 (198, 3H, s, C(5)CH3 & 198´, 3H, 
s, C(5)CH3), 1.83 (198´, 3H, s, C(4)CH3) and 1.44 (198, 3H, d, J 7.9, C(4)CH3). 
 
4,5-Dimethyl-2-phenyl-2H-pyrazol-3-yl phenyl carbonate 199 
N
N
O
OPh
O
Ph
199  
4,5-Dimethyl-2-phenyl-5-pyrazolin-3-one 198 (1.00 g, 5.31 mmol), triethylamine (0.810 mL, 
5.84 mmol) and phenyl chloroformate (0.790 mL, 5.58 mmol) were combined according to 
general procedure H to give the title compound as a colourless solid (1.60 g, 97 %). 
"max (KBr disc)/ cm
-1
 3061 (Ar-H), 2944 (C-H), 2918 (C-H), 1787 (C=O), 1620 (C=N) and 
1595 (C=C); mp 57–59 ˚C; !H (300 MHz, CDCl3) 7.60–7.56 (2H, m, ArH), 7.50–7.44 (2H, m, 
ArH), 7.40–7.33 (2H, m, ArH), 7.31–7.23 (2H, m, ArH), 7.17–7.10 (2H, m, ArH), 2.28 (3H, s, 
C(5)CH3) and 2.00 (3H, s, C(4)CH3); !C (75 MHz, CDCl3) 150.8 (OCAripso), 149.9 (C(O)O), 
148.5 (C(5)CH3), 141.6 (C(3)O), 138.1 (NCAripso), 129.8 (CAr), 129.4 (CAr), 127.2 (CAr), 
126.8 (CAr), 122.6 (CAr), 120.6 (CAr), 104.3 (C(4)CH3), 12.9 (C(5)CH3) and 7.14 (C(4)CH3); 
m/z HRMS (ESI
+
) C18H17N2O3 ([M+H]
+
) requires 309.1234, found 309.1229 (–1.5 ppm). 
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(RS)-Phenyl (4,5-dimethyl-2-phenyl-5-pyrazolin-3-one)-4-carboxylate 200 
N
N
O
Ph
PhO O
200  
4,5-Dimethyl-2-phenyl-2H-pyrazol-3-yl phenyl carbonate 199 (31.0 mg, 0.100 mmol), 
triazolium salt 176 (5.50 mg, 20.0 'mol) and KHMDS (0.5 M solution in toluene, 36.0 'L, 
18.0 'mol) were combined according to general procedure J. The crude material was purified 
by column chromatography on silica gel, eluting with 15 % diethyl ether in petrol to give the 
title compound as a colourless oil (20 mg, 65 %). 
"max (KBr disc)/ cm
-1
 3065 (Ar-H), 2988 (C-H), 2936 (C-H), 1764 (C=O), 1713 (C=O), 
1621 (Ar C=C) and 1596 (C=N); !H (300 MHz, CDCl3) 7.96–7.93 (2H, m, ArH), 7.45–7.35 
(4H, m, ArH), 7.27–7.19 (2H, m, ArH), 7.09–7.05 (2H, m, ArH), 2.26 (3H, s, C(5)CH3) and 
1.73 (3H, s, C(4)CH3); !C (75 MHz, CDCl3) 170.4 (C(3)O), 164.9 (C(O)O), 158.3 (C(5)CH3), 
150.3 (OCAripso), 137.8 (NCAripso), 129.7 (CAr), 129.1 (CAr), 126.7 (CAr), 125.6 (CAr), 
121.2 (CAr), 119.0 (CAr), 61.6 (C(4)CH3), 17.3 (C(4)CH3) and 14.4 (C(5)CH3); m/z HRMS 
(ESI
+
) C18H17N2O3 ([M+H]
+
) requires 309.1234, found 309.1233 (–0.2 ppm). 
 
(–)-Phenyl (4,5-dimethyl-2-phenyl-5-pyrazolin-3-one)-4-carboxylate (–)-200 
(!)-200
N
N
O
Ph
PhO O
 
4,5-Dimethyl-2-phenyl-2H-pyrazol-3-yl phenyl carbonate 199 (31.0 mg, 0.100 mmol), 
triazolium salt 185 (3.50 mg, 10.0 'mol) and KHMDS (18.0 'L, 0.5 M solution in toluene, 9.00 
'mol) were combined according to general procedure K. The crude material was purified by 
column chromatography on silica gel, eluting with 15 % diethyl ether in petrol to give the title 
compound as a colourless oil with an enantiomeric excess of 46 % (23 mg, 74 %).  
Enantiomeric excess was determined by HPLC with ChiralPax AS-H column 
(1 % isopropanol:hexane, flow rate = 1.0 mL min
-1
, 254 nm), tR(+) 13.3 min and tR(–) 14.7 min. 
When reaction was carried out with triazolium salt 217, an enantiomeric excess of 62 % was 
obtained in 61 % yield.  
[$]20D –108 (c 0.3, chloroform). 
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Phenyl (4,5-dimethyl-2-phenyl-4-pyrazolin-3-one)-1-carboxylate 201 
201
N
N
O
Ph
O OPh
 
4,5-Dimethyl-2-phenyl-2H-pyrazol-3-yl phenyl carbonate 199 (200 mg, 0.650 mmol) and 
DMAP (15.9 mg, 0.130 mmol) were combined according to general procedure I. The crude 
material was purified by column chromatography on silica gel, eluting with 50 % diethyl ether 
in petrol to give the title compound as a colourless solid (112 mg, 56 %).  
"max (KBr disc)/ cm
-1
 3074 (Ar-H), 3045 (Ar-H), 2924 (C-H), 1753 (C=O), 1686 (C=O), 
1649 and 1589 (C=C); mp 140–141 ˚C; !H (300 MHz, CDCl3) 7.47–7.40 (4H, m, ArH),     
7.32–7.26 (3H, m, ArH), 7.19 (1H, tt, J 7.4, 1.2, ArH), 6.83–6.79 (2H, m, ArH), 2.58 (3H, d, 
J 0.8, C(5)CH3) and 1.93 (3H, d, J 0.8, C(4)CH3); !C (75 MHz, CDCl3) 167.9 (C(3)O), 
149.9 (C(5)CH3), 149.4 (OCAripso), 148.6 (C(O)O), 139.2 (NCAripso), 129.6 (CAr), 
129.1 (CAr), 126.8 (CAr), 126.6 (CAr), 123.2 (CAr), 120.9 (CAr), 111.0 (C(4)CH3), 
13.9 (C(5)CH3) and 7.3 (C(4)CH3); m/z HRMS (ESI
+
) C18H17N2O3 ([M+H]
+
) requires 
309.1234, found 309.1235 (+0.4 ppm). 
 
Ethyl 2-methyl-3-oxo-3-phenylpropanoate 202 
Ph
O
OEt
O
202  
Based upon a procedure by Hii and co-workers,
133
 (ethyl 3-oxo-3-phenylpropanoate 63 (10.0 
mL, 58.0 mmol), potassium carbonate (12.0 g, 87.0 mmol) and iodomethane (5.40 mL, 87.0 
mmol) were combined in acetonitrile (200 mL) and refluxed for 3 days. Reaction was diluted 
with water (300 mL) and extracted with diethyl ether (2 x 250 mL). The combined organic 
layers were dried (MgSO4), filtered and concentrated in vacuo. The crude material was purified 
by column chromatography on silica gel, eluting with 5 % ethyl acetate in petrol to give the title 
compound as a colourless oil, with spectroscopic data in accordance with the literature (5.14 g, 
42 %).
133
  
!H (300 MHz, CDCl3) 8.00–7.96 (2H, m, ArH), 7.61–7.56 (1H, m, ArH), 7.51–7.45 (2H, m, 
ArH), 4.37 (1H, q, J 7.0, CH), 4.15 (2H, q, J 7.1, OCH2), 1.50 (3H, d, J 7.0, CHCH3) and 
1.17 (3H, t, J 7.1, OCH2CH3). 
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2,4,5-Trimethyl-5-pyrazolin-3-one 203 (and 2,4,5-trimethyl-4-pyrazolin-3-one 203´ and 
2,4,5-trimethyl-2H-pyrazol-3-one 203˝) 
N
H
N
O
203
N
N
O
+
N
N
OH
+
203' 203''  
Ethyl 2-methylacetoacetate 197 (2.00 mL, 14.2 mmol) and methylhydrazine (0.820 mL, 
15.6 mmol) were combined according to general procedure G. The resultant yellow oil was 
solidified upon trituration in diethyl ether to give the title compound as a colourless solid 
(1.52 g, 85 %). 
"max (KBr disc)/ cm
-1
 (203˝ only) 3150–2000 (O-H), 2917 (C-H), 2723 (C-H), 2576 (C-H), 
1614 (C=N) and 1587 (C=C); mp 128–131 ˚C; !H (300 MHz, CDCl3, 1.1:1 203:203´) 
3.34 (203´, 3H, s, NCH3), 3.26 (203, 3H, s, NCH3), 2.97 (203, 1H, q, J 8.0, CH), 2.07 (203´, 
3H, s, C(5)CH3), 2.04 (203, 3H, s, C(5)CH3), 1.75 (203´, 3H, s, C(4)CH3) and 1.32 (203, 3H, d, 
J 8.0, CHCH3); !C (75 MHz, CDCl3) 175.7 (203, C(O)), 163.1 (203´, C(O)), 160.4 (203, 
CCH3), 144.1 (203´, C(5)CH3), 100.0 (203´, C(4)CH3), 45.8 (203, CH), 31.2 (203, NCH3), 
31.0 (203´, NCH3), 15.3 (203, CCH3), 12.1 (203, CHCH3), 11.1 (203´, C(5)CH3) and 6.8 (203´, 
C(4)CH3); m/z  HRMS (ESI
+
) C6H10N2O ([M]
+
) requires 126.0788, found 126.0787 (–0.5 ppm). 
 
2,4-Dimethyl-5-phenyl-5-pyrazolin-3-one 204 (and 2,4-dimethyl-5-phenyl-4-pyrazolin-3-
one 204´) 
N
H
N
O
Ph
204
N
N
O
Ph
+
204'  
Ethyl 2-methyl-3-oxo-3-phenylpropanoate 202 (2.00 g, 9.70 mmol) and methylhydrazine (0.560 
mL, 10.7 mmol) were combined according to general procedure G. The resultant yellow oil was 
solidified upon trituration in a mixture of petrol, diethyl ether and a small volume of 
dichloromethane to give the title compound as a colourless solid, with spectroscopic data in 
accordance with the literature (1.17 g, 64 %).
130
  
mp 101–105 ˚C; !H (300 MHz, CDCl3, 9:1 204:204´) 7.68–7.65 (204, 2H, m, ArH), 7.57–7.54 
(204´, 1H, m, ArH), 7.50–7.47 (204´, 2H, m, ArH), 7.48–7.41 (204, 3H, m, ArH), 7.34–7.31 
(204´, 2H, m, ArH), 3.61 (204´, 3H, s, NCH3), 3.63 (204, 1H, q, J 7.9, CHCH3), 3.41 (204, 3H, 
s, NCH3), 1.92 (204´, 3H, s, CCH3) and 1.48 (204, 3H, s, CHCH3). 
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4-Methyl-2,5-diphenyl-5-pyrazolin-3-one 205 (and 4-methyl-2,5-diphenyl-4-pyrazolin-3-
one 205´) 
N
H
N
O
Ph Ph
205
N
N
O
Ph Ph
+
205'  
Ethyl 2-methyl-3-oxo-3-phenylpropanoate 202 (2.00 g, 9.70 mmol) and phenylhydrazine 
(1.05 mL, 10.7 mmol) were combined according to general procedure G. The resultant brown 
oil was taken up in toluene (10 mL) and subjected to a further reflux overnight before being 
concentrated in vacuo. The resultant oil solidified upon trituration in diethyl ether to give the 
title compound as a light brown solid (1.48 g, 81 %). 
"max (KBr disc)/ cm
-1
 (205 only) 3063 (Ar-H), 2982 (C-H), 2938 (C-H), 1711 (C=O) and 
1598 (C=N); mp 112–114 ˚C; !H (300 MHz, CDCl3, 11:1 205:205´) 8.03–8.00 (205, 2H, m, 
ArH), 7.84–7.81 (205´, 2H, m, ArH), 7.80–7.75 (205, 2H, m, ArH), 7.67–7.63 (205´, 2H, m, 
ArH), 7.51–7.39 (205, 5H, m, ArH & 205´, 1H, m, ArH), 7.25–7.18 (205, 1H, m, ArH), 
3.80 (205, 1H, q, J 7.9, CH), 2.09 (205´, 3H, s, CH3) and 1.59 (205, 3H, d, J 7.9, CH3); 
!C (125 MHz, CDCl3) 174.4 (205, C(O)), 164.0 (205´, C(O)), 159.7 (205, CPh), 149.3 (205´, 
CPh), 138.3 (205, NCAripso), 130.7 (205, CAr), 130.6 (205, CCAripso), 129.7 (205´, CAr), 
129.1 (205, CAr), 129.0 (205, CAr), 127.5 (205´, CAr), 126.7 (205, CAr), 125.3 (205, CAr), 
119.5 (205´, CAr), 119.1 (205, CAr), 107.5 (205´, C(4)), 44.7 (205, CH), 15.1 (205, CH3) and 
8.1 (205´, CH3); m/z  HRMS (ESI
+
) C16H15N2O ([M+H]
+
) requires 251.1179, found 251.1181 
(+0.8 ppm). 
 
2,4,5-Trimethyl-2H-pyrazol-3-yl phenyl carbonate 206 
N
N
O
OPh
O
206  
2,4,5-Trimethyl-5-pyrazolin-3-one 203 (500 mg, 3.96 mmol), triethylamine (0.600 mL, 
4.33 mmol) and phenyl chloroformate (0.520 mL, 4.15 mmol) were combined according to 
general procedure H. The crude material was purified by column chromatography on silica gel, 
eluting with 50 % diethyl ether in petrol to give the title compound as a colourless solid 
(571 mg, 59 %). 
"max (KBr disc)/ cm
-1
 2948 (C-H), 2925 (C-H), 1793 (C=O), 1607 (C=N) and 1593 (C=C); 
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mp 38–40 ˚C; !H (500 MHz, CDCl3) 7.38–7.35 (2H, m, ArH), 7.25–7.19 (3H, m, ArH), 
3.62 (3H, s, NCH3), 2.10 (3H, s, C(5)CH3) and 1.84 (3H, s, C(4)CH3); !C (125 MHz, CDCl3) 
150.9 (OCAripso), 150.1 (C(O)O), 146.4 (C(5)CH3), 142.2 (C(3)O), 129.9 (CAr), 126.9 (CAr), 
120.6 (CAr), 101.9 (C(4)CH3), 34.6 (NCH3), 12.7 (C(5)CH3) and 7.15 (C(4)CH3); m/z HRMS 
(ESI
+
) C13H15N2O3 ([M+H]
+
) requires 247.1077, found 247.1080 (+1.1 ppm). 
 
2,4-Dimethyl-5-phenyl-2H-pyrazol-3-yl phenyl carbonate 207 
N
N
O
Ph
OPh
O
207  
2,4-Dimethyl-5-phenyl-5-pyrazolin-3-one 204 (500 mg, 2.67 mmol), triethylamine (0.400 mL, 
2.89 mmol) and phenyl chloroformate (0.350 mL, 2.80 mmol) were combined according to 
general procedure H. The crude material was purified by column chromatography on silica gel, 
eluting with 25 % diethyl ether in petrol to give the title compound as a colourless solid 
(740 mg, 90 %). 
"max (KBr disc)/ cm
-1
 3094 (Ar-H), 3066 (Ar-H), 2945 (C-H), 2875 (C-H), 1783 (C=O), 
1600 (C=N) and 1572 (C=C); mp 57–58 ˚C; !H (500 MHz, CDCl3) 7.67–7.66 (2H, m, ArH), 
7.47–7.41 (4H, m, ArH), 7.35–7.30 (4H, m, ArH), 3.83 (3H, s, NCH3) and 2.16 (3H, s, CCH3); 
!C (125 MHz, CDCl3) 150.9 (OCAripso), 150.2 (C(O)O), 148.8 (CPh), 142.9 (C(3)O), 
134.0 (CCAripso), 129.9 (CAr), 128.6 (CAr), 127.7 (CAr), 127.4 (CAr), 126.9 (CAr), 
120.6 (CAr), 102.0 (CCH3), 35.1 (NCH3) and 8.59 (CCH3); m/z HRMS (ESI
+
) C18H17N2O3 
([M+H]
+
) requires 309.1234, found 309.1237 (+1.1 ppm). 
 
4-Methyl-2,5-diphenyl-2H-pyrazol-3-yl phenyl carbonate 208 
N
N
O
Ph
OPh
O
Ph
208  
4-Methyl-2,5-diphenyl-5-pyrazolin-3-one 205 (668 mg, 2.67 mmol), triethylamine (0.400 mL, 
2.89 mmol) and phenyl chloroformate (0.350 mL, 2.80 mmol) were combined according to 
general procedure H to give the title compound as a colourless solid (880 mg, 89 %). 
"max (KBr disc)/ cm
-1
 3063 (Ar-H), 2959 (C-H), 2921 (C-H), 1779 (C=O), 1604 (C=N) and 
1575 (C=C); mp 75–78 ˚C; !H (500 MHz, CDCl3) 7.77 (2H, d, J 7.2, ArH), 7.69 (2H, d, J 7.9, 
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ArH), 7.51 (2H, t, J 7.9, ArH), 7.46 (2H, t, J 7.7, ArH), 7.40–7.37 (4H, m, ArH), 7.28 (1H, dd, 
J 7.1, 3.1, ArH), 7.10 (2H, d, J 7.7, ArH) and 2.25 (3H, s, CCH3); !C (125 MHz, CDCl3) 
150.8 (OCAripso), 150.3 (CPh), 149.9 (C(O)O), 142.3 (C(3)O), 138.1 (NCAripso), 
133.7 (CCAripso), 129.8 (CAr), 129.5 (CAr), 128.6 (CAr), 128.1 (CAr), 127.7 (CAr), 
127.6 (CAr), 126.9 (CAr), 122.9 (CAr), 120.6 (CAr), 104.2 (CCH3) and 8.62 (CCH3); 
m/z HRMS (ESI
+
) C23H19N2O3 ([M+H]
+
) requires 371.1390, found 371.1391 (+0.2 ppm). 
 
Phenyl (2,4,5-trimethyl-4-pyrazolin-3-one)-1-carboxylate 209 
209
N
N
O
O OPh
 
2,4,5-Trimethyl-2H-pyrazol-3-yl phenyl carbonate 211 (24.6 mg, 0.100 mmol) and DMAP 
(2.40 mg, 20.0 'mol) were combined according to general procedure I. The crude material was 
purified by trituration in diethyl ether give the title compound as a colourless solid (19 mg, 
77 %). 
"max (KBr disc)/ cm
-1
 3068 (Ar-H), 2927 (C-H), 1748 (C=O), 1677 (C=O), 1646 and 
1590 (C=C); mp 90–91 ˚C; !H (300 MHz, CDCl3) 7.44 (2H, app t, J 7.8, m-ArH), 7.31 (1H, t, 
J 7.5, p-ArH), 7.20 (2H, d, J 8.0, o-ArH), 3.55 (3H, s, NCH3), 2.46 (3H, s, C(5)CH3) and 
1.88 (3H, s, C(4)CH3); !C (75 MHz, CDCl3) 169.3 (C(3)O), 149.9 (OCAripso), 148.5 (C(O)O), 
147.4 (C(5)CH3), 129.9 (CAr), 126.9 (CAr), 121.3 (CAr), 111.5 (C(4)CH3), 35.1 (NCH3), 
14.1 (C(5)CH3) and 7.3 (C(4)CH3); m/z HRMS (ESI
+
) C13H15N2O3 ([M+H]
+
) requires 
247.1077, found 247.1080 (+0.4 ppm). 
  
2,5-Diphenyl-2H-pyrazol-3-yl phenyl carbonate 210 
N
N
O
Ph
OPh
O
Ph
210  
2,5-Diphenyl-5-pyrazolin-3-one 65 (200 mg, 0.850 mmol), triethylamine (0.130 mL, 
0.930 mmol) and phenyl chloroformate (0.110 mL, 0.89 mmol) were combined according to 
general procedure H. The crude material was purified by column chromatography on silica gel, 
eluting with a gradient of 10 % diethyl ether in petrol to give the title compound as a brown 
solid (170 mg, 56 %). 
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"max (KBr disc)/ cm
-1
 3057 (Ar-H), 1784 (C=O) and 1593 (C=N); mp 79–80 ˚C; !H (300 MHz, 
CDCl3) 7.90–7.87 (2H, m, ArH), 7.75–7.72 (2H, m, ArH), 7.55–7.50 (2H, m, ArH), 7.46–7.30 
(7H, m, ArH), 7.19–7.16 (2H, m, ArH) and 6.75 (1H, s, C(4)H); !C (75 MHz, CDCl3) 
151.0 (C(5)Ph), 150.7 (OCAripso), 149.2 (C(O)O), 145.0 (C(3)O), 137.9 (NCAripso), 
132.9 (CCAripso), 129.8 (CAr), 129.4 (CAr), 128.7 (CAr), 128.4 (CAr), 127.7 (CAr), 
126.9 (CAr), 125.6 (CAr), 123.3 (CAr), 120.7 (CAr) and 93.0 (C(4)H); m/z  HRMS (ESI
+
) 
C22H17N2O3 ([M+H]
+
) requires 357.1234, found 357.1229 (–1.3 ppm). 
 
(RS)-Phenyl (2,4,5-trimethyl-5-pyrazolin-3-one)-4-carboxylate 211 
211
N
N
O
PhO O
 
2,4,5-Trimethyl-2H-pyrazol-3-yl phenyl carbonate 206 (24.6 mg, 0.100 mmol), triazolium salt 
175 (5.50 mg, 20.0 'mol) and KHMDS (0.5 M solution in toluene, 36.0 'L, 18.0 'mol) were 
combined according to general procedure J. The crude material was purified by column 
chromatography on silica gel, eluting with 25 % diethyl ether in petrol to give the title 
compound as a colourless solid (11 mg, 45 %). 
"max (KBr disc)/ cm
-1
 3059 (Ar-H), 2985 (C-H), 2941 (C-H), 1762 (C=O), 1708 (C=O), 
1607 (Ar C=C) and 1592 (C=N); mp 80–82 ˚C; !H (300 MHz, CDCl3) 7.40–7.34 (2H, m, ArH), 
7.24 (1H, tt, J 7.4, 1.2, ArH), 7.07–7.03 (2H, m, ArH), 3.36 (3H, s, NCH3), 2.14 (3H, s, 
C(5)CH3) and 1.61 (3H, s, C(4)CH3); !C (75 MHz, CDCl3) 172.1 (C(3)O), 165.2 (C(O)O), 
157.6 (C(5)CH3), 150.3 (CAripso), 129.7 (CAr), 126.6 (CAr), 121.3 (CAr), 59.9 (C(4)CH3), 
31.6 (NCH3), 19.9 (C(4)CH3) and 14.2 (C(5)CH3); m/z HRMS (ESI
+
) C13H15N2O3 ([M+H]
+
) 
requires 247.1077, found 247.1082 (+1.9 ppm). 
 
(–)-Phenyl (2,4,5-trimethyl-5-pyrazolin-3-one)-4-carboxylate (–)-211 
(!)-211
N
N
O
PhO O
 
2,4,5-Trimethyl-2H-pyrazol-3-yl phenyl carbonate 206 (24.6 mg, 0.100 mmol), triazolium salt 
217 (4.70 mg, 10.0 'mol) and KHMDS (0.5 M solution in toluene, 18.0 'L, 9.00 'mol) were 
combined according to general procedure K. The crude material was purified by column 
chromatography on silica gel, eluting with 40 % diethyl ether in petrol to give the title 
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compound as a colourless solid with an enantiomeric excess of 86 % (15 mg, 61 %).  
[$]20D –116.9 (c 0.1, chloroform); mp 94–95 ˚C. 
Enantiomeric excess was determined by HPLC with ChiralPax AS-H column 
(1 % isopropanol:hexane, flow rate = 1.0 mL min
-1
, 254 nm), tR(+) 17.3 min and tR(–) 24.0 min. 
 
(RS)-Phenyl (2,4-dimethyl-5-phenyl-5-pyrazolin-3-one)-4-carboxylate 212 
212
N
N
O
Ph
PhO O
 
2,4-Dimethyl-5-phenyl-2H-pyrazol-3-yl phenyl carbonate 207 (31.0 mg, 0.100 mmol), 
triazolium salt 175 (5.50 mg, 20.0 'mol) and KHMDS (0.5 M solution in toluene, 36.0 'L, 
18.0 'mol) were combined according to general procedure J. The crude material was purified 
by column chromatography on silica gel, eluting with 10 % diethyl ether in petrol to give the 
title compound as a colourless solid (17 mg, 55 %). 
"max (KBr disc)/ cm
-1
 2921 (C-H), 2852 (C-H), 1759 (C=O), 1710 (C=O) and 1596 (C=N); 
mp 92 ˚C; !H (300 MHz, CDCl3) 7.78–7.75 (2H, m, ArH), 7.45–7.44 (3H, m, ArH), 7.34–7.18 
(3H, m, ArH), 6.94–6.90 (2H, m, ArH), 3.51 (3H, s, NCH3) and 1.79 (3H, s, CCH3); 
!C (75 MHz, CDCl3) 172.4 (C(3)O), 166.2 (C(O)O), 156.5 (CPh), 150.3 (OCAripso), 130.8 
(CAr), 129.8 (CCAripso), 129.6 (CAr), 129.3 (CAr), 126.6 (CAr), 126.0 (CAr), 121.3 (CAr), 
58.4 (CCH3), 32.0 (NCH3) and 18.8 (CCH3); m/z HRMS (ESI
+
) C18H17N2O3 ([M+H]
+
) requires 
309.1234, found 309.1238 (+1.4 ppm). 
 
(–)-Phenyl (2,4-dimethyl-5-phenyl-5-pyrazolin-3-one)-4-carboxylate (–)-212 
(!)-212
N
N
O
Ph
PhO O
 
2,4-Dimethyl-5-phenyl-2H-pyrazol-3-yl phenyl carbonate 207 (31.0 mg, 0.100 mmol), 
triazolium salt 216 (3.80 mg, 10.0 'mol) and KHMDS (0.5 M solution in toluene, 18.0 'L, 
9.00 'mol) were combined according to general procedure K. The crude material was purified 
by column chromatography on silica gel, eluting with 10 % diethyl ether in petrol to give the 
title compound as a colourless solid with an enantiomeric excess of 10 % (3.2 mg, 10 %).  
Enantiomeric excess was determined by HPLC with ChiralPax AS-H column 
(1 % isopropanol:hexane, flow rate = 1.0 mL min
-1
, 211 nm), tR(+) 15.1 min and tR(–) 19.2 min. 
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[$]20D –1.0 (c 0.1, chloroform); mp 87–89 ºC.  
 
(RS)-Phenyl (4-methyl-2,5-diphenyl-5-pyrazolin-3-one)-4-carboxylate 213 
213
N
N
O
Ph Ph
PhO O
 
4-Methyl-2,5-diphenyl-2H-pyrazol-3-yl phenyl carbonate 208 (37.0 mg, 0.100 mmol), and 
DMAP (2.40 mg, 20.0 'mol) were combined according to general procedure J. The crude 
material was purified by column chromatography on silica gel, eluting with 10 % then 20 % 
diethyl ether in petrol to give the title compound as a colourless oil (9 mg, 24 %). 
 "max (KBr disc)/ cm
-1
 3064 (Ar-H), 2931 (C-H), 2857 (C-H), 1764 (C=O), 1715 (C=O) and 
1594 (C=N); !H (300 MHz, C6D6) 8.37–8.32 (2H, m, ArH), 7.92–7.88 (2H, m, ArH), 7.25–7.19 
(2H, m, ArH), 7.09–7.05 (3H, m, ArH), 6.98 (1H, tt, J, 7.4, 1.3, ArH), 6.82–6.70 (5H, m, ArH), 
and 1.69 (3H, s, CH3); !C (75 MHz, C6D6) 171.0 (C(3)O), 166.2 (C(O)O), 156.9 (CPh), 
150.8 (OCAripso), 138.7 (NCAripso), 131.0 (CAr), 130.2 (CCAripso), 129.6 (CAr), 129.4 (CAr), 
129.3 (CAr), 126.5 (CAr), 126.4 (CAr), 125.8 (CAr), 121.5 (CAr), 119.3 (CAr), 60.4 (CCH3) 
and 18.9 (CCH3); m/z HRMS (ESI
+
) C23H19N2O3 ([M+H]
+
) requires 371.1390, found 371.1389                
(–0.3 ppm). 
 
(+)-Phenyl (4-methyl-2,5-diphenyl-5-pyrazolin-3-one)-4-carboxylate (+)-213 
(+)-213
N
N
O
Ph Ph
PhO O
 
4-Methyl-2,5-diphenyl-2H-pyrazol-3-yl phenyl carbonate 208 (37.0 mg, 0.100 mmol), 
triazolium salt 217 (4.70 mg, 10.0 'mol) and KHMDS (0.5 M solution in toluene, 18.0 'L, 
9.00 'mol) were combined according to general procedure K. The crude material was purified 
by column chromatography on silica gel, eluting with 10 % diethyl ether in petrol to give the 
title compound as a colourless oil with an enantiomeric excess of 20 % (18 mg, 48 %).  
[$]20D +12.7 (c 0.9, chloroform). 
Enantiomeric excess was determined by HPLC with ChiralPax IB column 
(1 % isopropanol:hexane, flow rate = 1.0 mL min
-1
, 254 nm), tR(+) 9.86 min and tR(–) 12.1 min. 
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Phenyl (2,4-dimethyl-5-phenyl-4-pyrazolin-3-one)-1-carboxylate 214 
N
N
O
Ph
O OPh
214  
2,4-Dimethyl-5-phenyl-2H-pyrazol-3-yl phenyl carbonate 207 (31.0 mg, 0.100 mmol) and 
DMAP (2.40 mg, 20.0 'mol) were combined according to general procedure I. The crude 
material was purified by column chromatography on silica gel, eluting with 20 % diethyl ether 
in petrol then 50 % diethyl ether in petrol to give the title compound as a colourless solid 
(4.4 mg, 14 %) and residual starting material (10 mg, 32 %).  
"max (KBr disc)/ cm
-1
 3054 (Ar-H), 3020 (Ar-H), 2961 (C-H), 2921 (C-H), 1754 (C=O), 
1680 (C=O), 1646 and 1597 (C=C); mp 83–85 ˚C; !H (300 MHz, CDCl3) 7.44 (5H, app s, 
ArH), 7.30–7.25 (2H, m, ArH), 7.17 (1H, tt, J 6.4, 1.2, ArH), 6.86–6.82 (2H, m, ArH), 
3.67 (3H, s, NCH3) and 1.87 (3H, s, CCH3); !C (75 MHz, CDCl3) 168.4 (C(3)O), 
149.8 (OCAripso), 149.7 (CPh), 149.1 (C(O)O), 130.4 (CCAripso), 129.8 (CAr), 129.6 (CAr), 
129.4 (CAr), 128.4 (CAr), 126.5 (CAr), 120.7 (CAr), 113.9 (CCH3), 34.8 (NCH3) and 
8.0 (CCH3); m/z HRMS (ESI
+
) C18H17N2O3 ([M+H]
+
) requires 309.1234, found 309.1236 
(+0.7 ppm). 
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Appendix 1: Resolution of rotamers by variable temperature 
1
H NMR 
spectroscopy 
 
All reactions were carried out in a Bruker Avance 500 (500 MHz) spectrometer in the specified 
solvent. 
 
(S)-1-(2’-(6-Methoxynaphthalen-2-yl)propanoyl)pyrazolidin-3-one 149 
 
N
NH
O
149 (CD3CN)
O
O
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(S)-2-((S)-1'-((benzyloxy)carbonyl)pyrrolidine-2'-carbonyl)-5-phenylpyrazolidin-3-one 
(5S)-142 
 
N
H
N
O
Ph
O
N
(5S)-142 (CD3)2S(O))
O
OBn
  
 
Consistent with, but not conclusive for, rotamers 
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(R)-2-((S)-1'-((benzyloxy)carbonyl)pyrrolidine-2'-carbonyl)-5-(trifluoromethyl)-
pyrazolidin-3-one (5R)-163 
(5R)-163 (CD3)2S(O))
N
H
N
O
F3C
O
N
O
OBn
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Appendix 2: Data for 
1
H and 
19
F NMR spectroscopy monitoring experiments  
 
Reactions were carried out on a a Bruker Avance 300 (282 MHz 
19
F) or Bruker Avance 500 
(500 MHz 
1
H) spectrometer in CD3OD. All chemical shift values are quoted in parts per million 
(ppm). 
 
19
F NMR spectroscopic monitoring of methanolysis of catalyst (5R)-163 
N
H
H
N
O
N
CO2Bn
F3C
O
OCD3
N
H
NH
O
F3C
HSO3CF3
CD3OD
N
H
N
O
F3C
O
N
CO2Bn
(5R)-163
!F = –79.88 & –80.00
(Rotamers B & A)
HSO3CF3
CD3OD
d3-170
!F = –76.67 & –76.76
(Rotamers B & A)
HSO3CF3
CD3OD
(R)-84
!F = (–79.94)-(–80.33)
d3-(R)-172
!F = –77.24
D3CO
O
N
CO2Bn
d3-171
D3CO
O
N
CO2Bn
d3-171
HSO3CF3
CD3OD
N
H
NH2
F3C
O
OCD3
 
Catalyst (5R)-163 (37.0 mg, 95.0 µmol) and triflic acid (0.190 M solution in CD3OD, 0.5 mL, 
95.0 µmol) were combined in an NMR tube at t = 0 and the NMR spectrometer was locked and 
shimmed to this solution. Reaction was monitored by 
1
H decoupled 
19
F NMR spectroscopy with 
a delay between spectrum acquisition of 30 min for the first 4.82 h and 60 min thereafter, up to 
16.42 h. 
Integrals were determined manually and scaled to the triflate anion peak (%F –80.57, 
integral= 1). 
The chemical shift corresponding to (R)-84 drifted slightly over the course of the reaction from 
%F = –79.94 to –80.33. At timepoint t = 1.28 h, this led to complete overlap of the (R)-84 peak 
with the A rotamer of (5R)-163 (%F = –80.00). Hence, a single integral is given for these two 
compounds at this timepoint. 
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19
F NMR spectroscopy integral values 
 
Time 
(h) 
170 
B 
(-76.67) 
170 
A 
(-76.76) 
d3-(R)-172 
(-77.24) 
(5R)-163 
B 
(-79.88) 
(5R)-163  
A 
(-80.00) 
(R)-84 
((-79.94)- 
(–80.33)) 
(5R)-163 
Total 
(A+B) 
170 
Total 
(A+B) 
Integral 
Sum 
0.22 0.031 0.039 0.003 0.437 0.505 0.119 0.942 0.07 1.134 
0.27 0.040 0.050 0.005 0.423 0.470 0.118 0.893 0.09 1.106 
0.78 0.095 0.113 0.026 0.327 0.324 0.231 0.651 0.208 1.116 
1.28 0.133 0.156 0.055 0.249 - 0.517
a
 - 0.289 1.11 
1.78 0.162 0.193 0.092 0.186 0.198 0.260 0.384 0.355 1.091 
2.30 0.185 0.216 0.129 0.141 0.170 0.263 0.311 0.401 1.104 
2.80 0.195 0.237 0.161 0.107 0.118 0.253 0.225 0.432 1.071 
3.30 0.213 0.257 0.198 0.086 0.096 0.252 0.182 0.47 1.102 
3.82 0.223 0.266 0.229 0.070 0.080 0.239 0.15 0.489 1.107 
4.32 0.228 0.273 0.258 0.052 0.063 0.219 0.115 0.501 1.093 
4.82 0.240 0.277 0.285 0.043 0.052 0.210 0.095 0.517 1.107 
5.83 0.253 0.295 0.337 0.031 0.036 0.184 0.067 0.548 1.136 
6.83 0.258 0.304 0.375 0.020 0.023 0.156 0.043 0.562 1.136 
7.85 0.253 0.305 0.409 0.015 0.016 0.134 0.031 0.558 1.132 
8.85 0.264 0.310 0.438 0.010 0.011 0.111 0.021 0.574 1.144 
9.87 0.266 0.320 0.467 0.008 0.009 0.098 0.017 0.586 1.168 
10.88 0.269 0.320 0.488 0.005 0.006 0.082 0.011 0.589 1.17 
11.88 0.268 0.320 0.505 0.004 0.004 0.067 0.008 0.588 1.168 
12.90 0.273 0.321 0.521 0.003 0.003 0.059 0.006 0.594 1.180 
13.90 0.269 0.326 0.534 0.002 0.003 0.050 0.005 0.595 1.184 
14.92 0.275 0.330 0.546 0.002 0.002 0.045 0.004 0.605 1.200 
15.92 0.274 0.328 0.553 0.001 0.001 0.035 0.002 0.602 1.192 
16.42 0.273 0.330 0.560 0.001 0.001 0.032 0.002 0.603 1.197 
a) Combined integral of (5R)-163 A and (R)-84 
Appendix 2 
 
 
 
205 
Integral values as percentage composition 
 
Time 
(h) 
170 
Total 
(A+B) 
(5R)-163 
Total 
(A+B) 
d3-(R)-172 (R)-84 
0.22 6 83 0 10 
0.27 8 81 0 11 
0.78 19 58 2 21 
1.28 26 - 5 - 
1.78 33 35 8 24 
2.30 36 28 12 24 
2.80 40 21 15 24 
3.30 43 17 18 23 
3.82 44 14 21 22 
4.32 46 11 24 20 
4.82 47 9 26 19 
5.83 48 6 30 16 
6.83 49 4 33 14 
7.85 49 3 36 12 
8.85 50 2 38 10 
9.87 50 1 40 8 
10.88 50 1 42 7 
11.88 50 1 43 6 
12.90 50 1 44 5 
13.90 50 0 45 4 
14.92 50 0 46 4 
15.92 51 0 46 3 
16.42 50 0 47 3 
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1
H NMR spectroscopic monitoring of Diels-Alder reaction of (E)-cinnamaldehyde 37 and 
cyclopentadiene catalysed by (5R)-163 or 170 
170
(2 mol%, 38 mM)
N
H
H
N
O
N
CO2Bn
F3C
O
O
N
H
N
O
F3C
O
N
CO2Bn
(5R)-163
(4 mol%, 76 mM)
Ph
O
H
37
Ph
d6-110
OCD3
OCD3
!H = 6.65 
(1H, d, J 16.0, CHPh)
!H = 9.52 
(1H, d, J 7.8, CHO)
!H = 4.85 
(1H, dd, J 5.0, 1.0, CH(OCD3)2)
!H = 6.65 
(1H, dd, J 15.9, 7.8, CHPh)
CD3OD
Ph
+
d6-exo-(2R)-111 d6-endo-(2R)-111
Ph
OCD3
OCD3
OCD3D3CO
Ph
O
H +
37
(10 mol%)
CD3OD
CF3SO3H
catalyst
!H = 4.30 
(1H, d, J 8.3, CH(OCD3)2)
!H = 3.89 
(1H, d, J 9.1, CH(OCD3)2)
 
 
Reaction with (5R)-163 
(E)-Cinnamaldehyde 37 (0.120 mL, 0.950 mmol), triflic acid (76.0 mM solution in CD3OD, 
0.5 mL, 38.0 µmol), cyclopentadiene (94.0 mg, 1.43 mmol) and 1-methylnaphthalene (26.0 µL, 
0.190 mmol) were combined in an NMR tube and the NMR spectrometer was locked and 
shimmed to this solution. Catalyst (5R)-163 (4 mol%, 14.6 mg, 38.0 µmol) was added at t = 0 
and reaction monitored by 
1
H NMR spectroscopy with a delay between spectrum acquisition of 
5 min for the first 17 min and 10 min thereafter, up to 256 min. Integrals were determined 
manually and scaled to 1-methylnaphthalene (%H 7.78, integral=1). 
 
Reaction with 170 
(E)-Cinnamaldehyde 37 (0.120 mL, 0.950 mmol), triflic acid (38.0 mM solution in CD3OD, 
0.5 mL, 19.0 µmol), cyclopentadiene (94.0 mg, 1.43 mmol) and 1-methylnaphthalene (26.0 µL, 
0.190 mmol) were combined in an NMR tube and the NMR spectrometer was locked and 
shimmed to this solution. Catalyst 170 (2 mol%, 7.90 mg, 19.0 µmol) was added at t = 0 and 
reaction monitored by 
1
H NMR spectroscopy with a delay between spectrum acquisition of 
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5 min for the first 17 min and 10 min thereafter, up to 256 min. Integrals were determined 
manually and scaled to 1-methylnaphthalene (%H 7.78, integral= 1). 
From the timepoint t = 87 min onwards, the acetal peak at %H = 4.85 was obscured by a peak 
due to residual water. Hence, integral values are given only up to this timepoint.  
 
 
Reaction with (5R)-163-
 1
H NMR spectroscopy integral values 
 
Time 
(min) 
37 
(9.52) 
37+110 
(6.65) 
110 
(4.85) 
exo-111 
(4.30) 
exo-111 
(3.89) 
111 Com 
(4.30+3.89) 
% 
conversion  
5 2.58 5.89 2.84 0.15 0.21 0.36 5.9 
7 2.60 5.76 2.80 0.19 0.26 0.45 7.4 
12 2.50 5.43 2.66 0.25 0.37 0.62 10.2 
17 2.42 5.12 2.44 0.30 0.47 0.77 12.6 
28 2.34 4.91 2.39 0.45 0.72 1.17 19.2 
38 2.13 4.40 2.04 0.52 0.87 1.39 22.8 
48 2.06 4.24 1.97 0.66 1.09 1.75 28.7 
59 1.90 3.80 1.70 0.70 1.19 1.89 31.0 
69 1.83 3.77 1.70 0.85 1.45 2.30 37.7 
79 1.74 3.50 1.59 0.91 1.59 2.50 41.0 
89 1.63 3.20 1.42 0.97 1.68 2.65 43.4 
100 1.53 3.02 1.33 1.03 1.82 2.85 46.7 
110 1.44 2.82 1.24 1.09 1.92 3.01 49.3 
121 1.36 2.72 1.18 1.17 2.08 3.25 53.3 
131 1.27 2.56 1.10 1.23 2.18 3.41 55.9 
142 1.22 2.35 1.02 1.25 2.21 3.46 56.7 
152 1.15 2.32 1.00 1.37 2.41 3.78 62.0 
163 1.09 2.11 0.91 1.35 2.41 3.76 61.6 
173 1.00 2.00 0.86 1.4 2.49 3.89 63.8 
184 0.98 1.88 0.8 1.42 2.53 3.95 64.8 
194 0.92 1.79 0.77 1.48 2.64 4.12 67.5 
204 0.82 1.66 0.69 1.46 2.62 4.08 66.9 
214 0.82 1.57 0.67 1.51 2.69 4.20 68.9 
225 0.72 1.52 0.64 1.56 2.8 4.36 71.5 
235 0.71 1.42 0.6 1.56 2.82 4.38 71.8 
246 0.69 1.35 0.58 1.6 2.87 4.47 73.3 
256 0.66 1.31 0.53 1.65 2.97 4.62 75.7 
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Reaction with 170-
 1
H NMR spectroscopy integral values 
 
Time 
(min) 
37 
(9.52) 
37+110 
(6.65) 
110 
(4.85) 
exo-111 
(4.30) 
exo-111 
(3.89) 
111 Com 
(4.30+3.89) 
% 
conversion  
8 2.21 4.6 2.21 0.17 0.21 0.38 7.8 
10 2.13 4.42 2.08 0.2 0.26 0.46 9.4 
15 1.93 3.84 1.86 0.33 0.46 0.79 16.1 
25 1.70 3.37 1.56 0.57 0.91 1.48 30.2 
35 1.41 2.65 1.17 0.71 1.18 1.89 38.6 
46 1.22 2.22 0.96 0.85 1.45 2.30 46.9 
56 1.08 2.01 0.86 1.04 1.80 2.84 58.0 
67 0.94 1.69 0.69 1.11 1.95 3.06 62.4 
78 0.83 1.47 0.65 1.20 2.12 3.32 67.8 
87 0.73 1.30 - 1.28 2.27 3.55 72.4 
98 0.66 1.13 - 1.31 2.37 3.68 75.1 
108 0.56 1.02 - 1.39 2.50 3.89 79.4 
113 0.53 0.95 - 1.39 2.51 3.90 79.6 
119 0.50 0.89 - 1.39 2.52 3.91 79.8 
124 0.48 0.86 - 1.44 2.62 4.06 82.9 
129 0.45 0.83 - 1.49 2.71 4.20 85.7 
139 0.40 0.75 - 1.52 2.77 4.29 87.6 
160 0.33 0.59 - 1.52 2.80 4.32 88.2 
181 0.28 0.49 - 1.57 2.89 4.46 91.0 
202 0.23 0.41 - 1.59 2.92 4.51 92.0 
223 0.18 0.35 - 1.65 3.04 4.69 95.7 
243 0.14 0.3 - 1.67 3.09 4.76 97.1 
259 0.12 0.26 - 1.67 3.09 4.76 97.1 
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Appendix 3: HPLC chromatograms of relevant compounds  
 
Chiral HPLC was performed on Gilson apparatus, using a ChiralPak AD-H, AS-H, OD-H, or 
OJ-H or IB silica column, 0.46 cm ' x 25 cm, using hexane and isopropanol as eluents.  
 
endo-(1S,2R,3R,4R)-3-Phenylbicyclo[2.2.2]oct-5-en-2-yl)methyl benzoate endo-(2R)-164 
Ph
OBz  
ChiralCel OJ-H column, 0.5% isopropanol:hexane, flow rate = 1.0 mL min
-1
, 211 nm, 85 % ee.!
!
!
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(–)-Phenyl (4,5-dimethyl-2-phenyl-5-pyrazolin-3-one)-4-carboxylate (–)-200 
(!)-200
N
N
O
Ph
PhO O
 
ChiralPax AS-H column, 1 % isopropanol:hexane, flow rate = 1.0 mL min
-1
, 254 nm, 62 % ee. 
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211 
(–)-Phenyl (2,4,5-trimethyl-5-pyrazolin-3-one)-4-carboxylate (–)-211 
(!)-211
N
N
O
PhO O
 
ChiralPax AS-H column, 1 % isopropanol:hexane, flow rate = 1.0 mL min
-1
, 254 nm, 86 % ee. 
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212 
(–)-Phenyl (2,4-dimethyl-5-phenyl-5-pyrazolin-3-one)-4-carboxylate (–)-212 
(!)-212
N
N
O
Ph
PhO O
 
ChiralPax AS-H column, 1 % isopropanol:hexane, flow rate = 1.0 mL min
-1
, 211 nm, 10 % ee. 
 
 
 
Appendix 3 
 
 
 
213 
(+)-Phenyl (4-methyl-2,5-diphenyl-5-pyrazolin-3-one)-4-carboxylate (+)-213 
(+)-213
N
N
O
Ph Ph
PhO O
 
ChiralPax IB column, 1 % isopropanol:hexane, flow rate = 1.0 mL min
-1
, 254 nm, 20 % ee. 
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